data_1oqk_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1oqk _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.499 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.403 ' N ' HG21 ' A' ' 19' ' ' ILE . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.418 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' HG13 ' A' ' 27' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.418 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.443 HG23 ' HB ' ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.435 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.723 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.568 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.433 ' N ' HG12 ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.447 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.408 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.408 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.447 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.477 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.583 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.723 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.584 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.507 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.503 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.491 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.491 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.428 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.41 ' CD2' ' HB2' ' A' ' 72' ' ' GLU . 45.4 m170 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.425 ' CD1' ' N ' ' A' ' 63' ' ' PHE . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.41 ' HB2' ' CD2' ' A' ' 62' ' ' HIS . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.428 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.659 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.458 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HB2' ' CZ ' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 30' ' ' ILE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.422 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.432 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 49.9 m170 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.432 HG13 ' HB3' ' A' ' 22' ' ' SER . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.414 HG21 HD11 ' A' ' 30' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.71 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.656 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.804 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.475 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.475 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.804 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.678 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.71 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.627 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.442 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.442 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.427 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.424 ' CG2' ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.45 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.423 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.436 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.689 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.604 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.422 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.43 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.493 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.484 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.484 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.43 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.418 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.604 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.689 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.815 0.34 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.469 HD12 ' CD2' ' A' ' 63' ' ' PHE . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 51.7 m170 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.483 HD13 HG23 ' A' ' 27' ' ' ILE . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.832 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.819 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.527 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.527 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.534 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.771 ' C ' HG13 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.686 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.832 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.567 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.443 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.451 ' CG2' HG23 ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.403 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.438 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.558 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.628 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.478 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.469 ' CD2' HD12 ' A' ' 15' ' ' LEU . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.466 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.466 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.478 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.628 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.586 ' O ' ' HG ' ' A' ' 15' ' ' LEU . 11.2 tp . . . . . 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.586 ' HG ' ' O ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.524 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.448 HG12 ' CD2' ' A' ' 61' ' ' PHE . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.405 ' N ' ' CG1' ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.472 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.453 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 52.2 m170 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.477 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.522 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.573 ' CD1' ' HG2' ' A' ' 55' ' ' PRO . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.472 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.4 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.71 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.643 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.693 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.612 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.688 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.71 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.688 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.434 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.491 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.573 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.693 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.441 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.625 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.714 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.409 ' CG1' ' NH1' ' A' ' 76' ' ' ARG . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.518 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.483 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.464 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.483 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.714 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 . . . . . 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.489 ' CD1' ' N ' ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.479 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.42 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.485 HD13 HG22 ' A' ' 27' ' ' ILE . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.41 ' OE1' ' C ' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.675 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.572 ' C ' ' H ' ' A' ' 45' ' ' GLU . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.732 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.438 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.61 ' C ' HG13 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.675 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.732 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.542 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.438 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.504 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.428 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.494 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.632 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.446 ' CZ ' ' HE3' ' A' ' 56' ' ' LYS . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.479 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.409 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.43 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.424 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.632 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.527 ' C ' ' H ' ' A' ' 15' ' ' LEU . 18.0 tt . . . . . 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.527 ' H ' ' C ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.486 HG11 HD12 ' A' ' 19' ' ' ILE . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.416 ' N ' HG11 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.49 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.475 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.532 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.481 HG23 HD11 ' A' ' 27' ' ' ILE . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD11 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.699 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.723 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.703 ' HB ' ' HB2' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.46 ' N ' HG12 ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.421 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.582 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.564 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.723 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.703 ' HB2' ' HB ' ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.691 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . 0.468 ' C ' ' H ' ' A' ' 49' ' ' GLY . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.486 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.426 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.582 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.485 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.707 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.49 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.479 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.423 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.429 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.707 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.43 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.583 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.56 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.583 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.426 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.73 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.643 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.711 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.528 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.528 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.583 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.711 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.63 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.73 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.729 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.408 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.465 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.405 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.583 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.466 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.466 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.725 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.445 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.464 ' CE1' ' CG2' ' A' ' 71' ' ' VAL . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.462 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.449 ' HB ' ' CG ' ' A' ' 69' ' ' GLU . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.449 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.462 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.557 ' N ' HD12 ' A' ' 73' ' ' ILE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.725 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.415 ' O ' HD11 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.473 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.402 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG23 ' A' ' 27' ' ' ILE . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.903 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.54 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.817 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.506 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.401 ' N ' HG22 ' A' ' 38' ' ' THR . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.506 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.722 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.679 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.903 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.522 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.404 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.445 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.441 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.66 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.446 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.418 ' CD2' ' HA ' ' A' ' 72' ' ' GLU . 48.9 m170 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.422 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' HIS . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.418 ' HA ' ' CD2' ' A' ' 62' ' ' HIS . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.445 HG13 ' CE1' ' A' ' 63' ' ' PHE . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.66 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 . . . . . 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.421 HG23 HD11 ' A' ' 13' ' ' ILE . 58.6 mt . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 111.078 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.427 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.475 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.424 ' N ' ' HD3' ' A' ' 21' ' ' ARG . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.432 ' CB ' HG13 ' A' ' 27' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.51 ' HB3' HG12 ' A' ' 27' ' ' ILE . 18.5 t-160 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.409 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.831 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.611 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 45' ' ' GLU . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.447 ' N ' ' OE1' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.507 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.507 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 56' ' ' LYS . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.619 ' HG2' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.643 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.831 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.541 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.41 ' HB2' ' HE3' ' A' ' 46' ' ' MET . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.433 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.569 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.469 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.468 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.435 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.429 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 72' ' ' GLU . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.468 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.435 HD13 ' CD1' ' A' ' 63' ' ' PHE . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.569 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.643 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 . . . . . 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.782 0.325 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.427 HG21 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.458 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.45 HG21 ' CD2' ' A' ' 24' ' ' HIS . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.45 ' CD2' HG21 ' A' ' 23' ' ' VAL . 53.7 m170 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.418 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 27' ' ' ILE . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.418 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.711 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.537 ' C ' ' H ' ' A' ' 45' ' ' GLU . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.822 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.477 ' NE ' ' HA ' ' A' ' 39' ' ' ARG . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.471 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.588 ' HB2' ' HG2' ' A' ' 56' ' ' LYS . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.67 ' C ' HG13 ' A' ' 35' ' ' VAL . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.711 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.822 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.637 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.442 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.419 ' CG2' HG22 ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.588 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.495 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.606 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.733 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.478 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.478 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.476 ' OD1' ' HG2' ' A' ' 76' ' ' ARG . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.733 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.606 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 . . . . . 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 14' ' ' GLY . 2.0 mp . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . 0.419 ' N ' ' CG2' ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.449 ' HD2' ' N ' ' A' ' 21' ' ' ARG . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.453 HD11 HG22 ' A' ' 27' ' ' ILE . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.836 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.477 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.606 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.611 ' O ' HG13 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.776 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.836 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.612 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.538 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.4 HG23 HG22 ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.429 ' CD ' HG13 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.711 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.487 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.507 ' CZ ' ' CD1' ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.52 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.401 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.433 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.506 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.487 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.486 HD12 HG22 ' A' ' 13' ' ' ILE . 50.0 mt . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.813 0.339 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.475 ' O ' HG11 ' A' ' 34' ' ' VAL . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.435 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.491 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.422 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 59' ' ' ALA . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.422 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.75 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.504 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.469 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.418 ' N ' HG21 ' A' ' 38' ' ' THR . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.499 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.543 ' HG2' HG13 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.75 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.681 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.638 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.429 ' CG1' ' HD2' ' A' ' 55' ' ' PRO . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.429 ' HD2' ' CG1' ' A' ' 54' ' ' VAL . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.499 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.523 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.757 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.48 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.435 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.48 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.757 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.58 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.864 0.364 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.446 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.402 ' HB3' ' CG1' ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.476 ' CB ' HG13 ' A' ' 27' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.423 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.48 ' HB2' HG12 ' A' ' 27' ' ' ILE . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 24' ' ' HIS . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.814 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.574 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.465 ' C ' ' HD3' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.522 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.548 ' HB2' ' HG3' ' A' ' 56' ' ' LYS . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.774 ' HB3' HG22 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.697 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.843 ' HB2' HG21 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.584 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.423 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.548 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.478 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.758 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.583 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.402 ' CG1' ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.493 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.407 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . 0.462 ' N ' ' OE1' ' A' ' 67' ' ' GLN . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.441 ' OE1' ' N ' ' A' ' 72' ' ' GLU . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.758 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 . . . . . 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 56.6 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.441 HD13 ' CD2' ' A' ' 63' ' ' PHE . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.404 ' C ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.413 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 ' N ' ' A' ' 27' ' ' ILE . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.661 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.568 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.842 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.448 ' CG2' ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.448 ' HD2' ' CG2' ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.477 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.703 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.751 ' C ' HG11 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.661 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.842 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.559 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.437 ' CG2' HG21 ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.435 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.703 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.658 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.523 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.418 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' A' ' 15' ' ' LEU . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.413 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.427 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . 0.427 ' HG2' ' CG2' ' A' ' 65' ' ' THR . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.411 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.409 HG11 ' N ' ' A' ' 72' ' ' GLU . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.418 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.523 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.464 HD12 HG23 ' A' ' 13' ' ' ILE . 43.6 mt . . . . . 0 N--CA 1.456 -0.143 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.462 HD13 ' CD2' ' A' ' 63' ' ' PHE . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.459 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.417 ' CB ' HG13 ' A' ' 27' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.425 HG11 ' CD2' ' A' ' 24' ' ' HIS . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.478 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 46.5 m170 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.478 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.486 HD13 HG22 ' A' ' 27' ' ' ILE . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . 0.466 ' CD1' ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 1.067 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.523 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.405 ' N ' HG21 ' A' ' 38' ' ' THR . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.432 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.526 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.602 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.698 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 1.067 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.609 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.453 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.46 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.526 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.41 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.65 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.661 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.539 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.444 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.514 ' CE1' ' CE1' ' A' ' 61' ' ' PHE . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.422 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.444 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.539 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . 0.426 ' OD1' ' O ' ' A' ' 74' ' ' ASP . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.661 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.732 0.301 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.421 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.411 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.41 ' CD2' HG12 ' A' ' 23' ' ' VAL . 90.2 m-70 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.485 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.448 HD11 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.425 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 4.9 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.425 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.737 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.488 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.502 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.502 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.551 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.567 ' HG2' HG13 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.737 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.669 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.58 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.492 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.463 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.436 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.646 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.428 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.42 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . 0.407 ' HB3' HG21 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.42 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.431 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.428 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.646 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.473 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.3 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.716 0.293 . . . . 0.0 110.926 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.451 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.424 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.465 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.467 ' CD2' ' HB3' ' A' ' 26' ' ' ASP . 40.0 t60 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.467 ' HB3' ' CD2' ' A' ' 24' ' ' HIS . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.424 HG13 ' OG ' ' A' ' 22' ' ' SER . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.418 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 5.7 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.418 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.919 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.858 HG22 ' N ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 39' ' ' ARG . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.444 ' N ' HG23 ' A' ' 38' ' ' THR . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.444 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.501 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.699 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.65 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.919 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.578 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.457 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.407 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.465 ' HB ' ' HB ' ' A' ' 23' ' ' VAL . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.451 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.423 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.437 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 16.1 tpp85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.1 mm . . . . . 0 CA--C 1.527 0.06 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.417 HD11 ' CD2' ' A' ' 63' ' ' PHE . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.504 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.474 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.409 ' CB ' HG13 ' A' ' 27' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.421 HG11 ' CD2' ' A' ' 24' ' ' HIS . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.465 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 88.1 m-70 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . 0.465 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.433 HG21 HD12 ' A' ' 27' ' ' ILE . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.891 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.686 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.811 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.401 ' HG2' ' N ' ' A' ' 40' ' ' ASN . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.401 ' N ' ' HG2' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.432 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.65 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.811 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.641 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.891 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.656 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.459 ' HB2' ' HE3' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . 0.442 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.65 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.413 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.413 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.606 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 70' ' ' LEU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.53 ' CE1' ' CE1' ' A' ' 61' ' ' PHE . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.488 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.606 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? . . . . . 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.7 mm . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.831 0.348 . . . . 0.0 111.375 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.491 HG12 ' HB3' ' A' ' 61' ' ' PHE . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.409 ' HB3' ' NH2' ' A' ' 76' ' ' ARG . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.493 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.426 HG11 ' CD2' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.426 ' CD2' HG11 ' A' ' 23' ' ' VAL . 90.7 m-70 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.493 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 1.036 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.556 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.707 HG22 ' HB2' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.407 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.468 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.417 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . 0.417 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.468 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.623 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.656 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.672 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 1.036 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.68 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.444 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.558 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.52 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.438 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.569 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.421 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.52 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.688 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 54.8 mt . . . . . 0 CA--C 1.53 0.174 0 CA-C-O 120.693 0.282 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.419 ' O ' ' CG1' ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.427 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.422 HG11 ' CD2' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.422 ' CD2' HG11 ' A' ' 23' ' ' VAL . 90.4 m-70 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.438 ' CD1' ' HD2' ' A' ' 55' ' ' PRO . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.699 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.549 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.762 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.414 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . 0.404 ' N ' HG22 ' A' ' 38' ' ' THR . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.414 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.556 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.637 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.699 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.762 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.54 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.469 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.438 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.446 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.682 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.427 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' HG2' ' A' ' 72' ' ' GLU . 46.9 m170 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.428 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.478 ' HB ' ' CZ ' ' A' ' 63' ' ' PHE . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.456 ' HG2' ' CE1' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.682 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.4 mm . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.707 0.289 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.541 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.416 ' O ' ' HA ' ' A' ' 59' ' ' ALA . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.421 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.453 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . 0.421 ' CD2' HG12 ' A' ' 23' ' ' VAL . 43.8 m170 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . 0.468 ' N ' ' HD3' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.421 ' CD1' ' HB3' ' A' ' 22' ' ' SER . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.679 ' HG2' ' HA ' ' A' ' 46' ' ' MET . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.517 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.715 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.446 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.449 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.712 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.602 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.677 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.715 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.679 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.45 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . 0.414 ' CG1' ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HD2' ' CG1' ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.712 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . 0.451 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.574 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.555 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.511 ' HB2' ' NH1' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.425 ' CD1' ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.438 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.555 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.574 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 . . . . . 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.5 mm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.855 0.359 . . . . 0.0 111.028 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.409 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.451 ' HB3' HG13 ' A' ' 27' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.431 ' HA ' HD11 ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.451 HG13 ' HB3' ' A' ' 22' ' ' SER . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.409 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 50.8 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.674 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . 0.544 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.818 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' THR . . . . . 0.406 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' THR . . . . . 0.401 ' N ' ' CD ' ' A' ' 56' ' ' LYS . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.643 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ARG . . . . . 0.724 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' ILE . . . . . 0.674 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' GLU . . . . . 0.818 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.593 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' ARG . . . . . 0.505 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' LYS . . . . . 0.643 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' ILE . . . . . 0.804 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' ALA . . . . . 0.662 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' PHE . . . . . 0.531 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' HD22 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' CG ' ' A' ' 69' ' ' GLU . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' GLU . . . . . 0.441 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' LEU . . . . . 0.445 HD22 ' HD3' ' A' ' 64' ' ' ARG . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.531 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 75' ' ' GLY . . . . . 0.662 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 76' ' ' ARG . . . . . 0.804 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 . . . . . 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.746 0.308 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 20.7 t-160 64.04 130.76 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.535 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -50.74 -175.91 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 111.282 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.431 HD13 ' CE2' ' A' ' 63' ' ' PHE . 1.9 pt? -127.99 29.61 5.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.183 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.21 102.79 8.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.499 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.403 ' N ' HG21 ' A' ' 19' ' ' ILE . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.418 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.471 ' HB2' HG13 ' A' ' 27' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.405 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 91.1 m-70 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.471 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.418 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.443 HG23 ' HB ' ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.435 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.723 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.568 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.433 ' N ' HG12 ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.447 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.408 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.408 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.447 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.477 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.583 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.723 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.584 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.507 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.503 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.491 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.491 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.659 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.428 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.41 ' CD2' ' HB2' ' A' ' 72' ' ' GLU . 45.4 m170 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.431 ' CE2' HD13 ' A' ' 12' ' ' LEU . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.426 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.41 ' HB2' ' CD2' ' A' ' 62' ' ' HIS . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.428 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.46 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.659 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.458 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 -98.38 -49.03 4.82 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.18 -16.58 16.97 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.46 ' HB2' ' O ' ' A' ' 74' ' ' ASP . 78.4 mt -111.15 32.57 5.21 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.4 p -73.66 100.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.46 152.45 25.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.178 0.513 . . . . 0.0 112.082 -178.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.478 ' HB2' ' HB3' ' A' ' 84' ' ' GLU . 2.1 ptp180 -117.49 94.84 46.46 Favored Pre-proline 0 CA--C 1.532 0.268 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.469 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.69 -88.86 0.0 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.588 2.192 . . . . 0.0 113.652 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mm-40 -50.85 -25.47 4.56 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.478 ' HB3' ' HB2' ' A' ' 81' ' ' ARG . 40.7 tp10 -84.12 1.76 42.65 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.43 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 63.53 152.09 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.868 0.366 . . . . 0.0 111.069 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.474 ' CD1' ' N ' ' A' ' 86' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.906 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -167.91 110.71 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.902 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -142.81 -69.23 0.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.598 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.457 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 45.3 tp -139.14 9.45 2.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.367 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 13' ' ' ILE . 1.6 mp -91.11 158.6 2.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.416 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.415 ' HB2' ' CZ ' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.403 ' HB ' ' O ' ' A' ' 30' ' ' ILE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.422 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.432 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 49.9 m170 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.432 HG13 ' HB3' ' A' ' 22' ' ' SER . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.414 HG21 HD11 ' A' ' 30' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.71 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.656 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.804 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.475 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.456 ' O ' ' HD3' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.475 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.804 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.678 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.71 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.627 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.442 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.442 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.427 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.424 ' CG2' ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.45 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.423 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.436 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.689 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.604 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.422 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.418 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.43 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.493 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.484 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.484 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.43 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.418 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.434 ' OD1' ' O ' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.604 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.689 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? -71.96 -64.89 0.85 Allowed 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.29 -24.67 14.19 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -178.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.409 ' CB ' ' O ' ' A' ' 74' ' ' ASP . 3.2 tm? -59.83 -28.97 67.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.816 0.341 . . . . 0.0 111.198 -179.171 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.3 p -53.49 100.48 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.034 0.445 . . . . 0.0 111.164 -179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.58 149.32 29.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.177 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.443 ' N ' ' HD3' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -56.9 155.08 16.24 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.737 179.746 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -47.74 149.5 5.04 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.73 2.287 . . . . 0.0 112.194 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.401 ' OE1' ' N ' ' A' ' 83' ' ' GLU . 52.9 mp0 -69.28 -13.98 62.69 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.319 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.4 ' HG3' ' N ' ' A' ' 85' ' ' ARG . 16.6 pt-20 -90.07 -47.25 7.94 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.2 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.409 ' NE ' ' HA ' ' A' ' 85' ' ' ARG . 4.6 mmp_? -136.37 173.13 12.04 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.005 0.431 . . . . 0.0 111.278 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.428 HG12 ' HG3' ' A' ' 81' ' ' ARG . 45.5 mt . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.298 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 79.6 ttt180 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.671 0.272 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 27.0 p-80 -122.71 118.26 27.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.377 . . . . 0.0 111.179 -179.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.41 ' HG3' HD13 ' A' ' 12' ' ' LEU . 5.2 tp10 -168.13 -46.33 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.642 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.414 ' N ' HD13 ' A' ' 12' ' ' LEU . 5.1 mp -117.16 -34.55 4.33 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.994 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm -79.74 120.26 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.939 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.469 HD12 ' CD2' ' A' ' 63' ' ' PHE . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 51.7 m170 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.483 HD13 HG23 ' A' ' 27' ' ' ILE . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.832 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.525 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.819 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.527 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.527 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.534 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.771 ' C ' HG13 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.686 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.832 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.567 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.443 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.451 ' CG2' HG23 ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.403 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.534 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.438 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.558 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.628 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.478 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.469 ' CD2' HD12 ' A' ' 15' ' ' LEU . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.466 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.466 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.41 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.478 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.526 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.628 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 -88.7 -67.04 0.86 Allowed 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -86.69 -12.32 48.7 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.526 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 22.0 tp -107.69 34.06 3.74 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.681 -0.408 . . . . 0.0 111.16 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.7 138.43 22.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.73 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -86.44 138.29 31.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.349 -179.854 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 39.6 mtm-85 -117.14 153.55 49.78 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_exo -55.86 169.27 1.39 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.515 2.144 . . . . 0.0 112.287 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -74.14 -20.14 60.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.993 179.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -63.82 -46.72 83.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.901 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 -130.58 101.94 5.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.3 mt . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.76 179.756 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 . . . . . 0 N--CA 1.457 -0.119 0 CA-C-O 120.862 0.363 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.481 ' CB ' ' HA ' ' A' ' 47' ' ' ASP . 16.9 m80 -127.96 -70.7 0.68 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.891 ' C ' ' O ' ' A' ' 15' ' ' LEU . 44.8 mt-10 -48.38 118.11 2.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.216 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.99 ' HA ' ' HB ' ' A' ' 34' ' ' VAL . 0.8 OUTLIER 30.88 -144.15 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.258 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.586 ' O ' ' HG ' ' A' ' 15' ' ' LEU . 11.2 tp -90.74 94.75 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 173.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.891 ' O ' ' C ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.524 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.448 HG12 ' CD2' ' A' ' 61' ' ' PHE . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.405 ' N ' ' CG1' ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.472 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.453 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.522 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 52.2 m170 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.477 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.522 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.573 ' CD1' ' HG2' ' A' ' 55' ' ' PRO . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.472 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.4 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.71 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.99 ' HB ' ' HA ' ' A' ' 12' ' ' LEU . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.669 ' HB ' ' HB2' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.693 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.612 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.688 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.71 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.688 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.481 ' HA ' ' CB ' ' A' ' 10' ' ' HIS . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.434 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.491 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.573 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.693 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.441 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.625 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.714 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.409 ' CG1' ' NH1' ' A' ' 76' ' ' ARG . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.518 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.483 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.464 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.483 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.714 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.625 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 -70.86 -42.38 70.19 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.24 0.21 37.0 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.978 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.489 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -75.84 -1.86 27.28 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 120.829 0.347 . . . . 0.0 111.238 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 49.8 t -48.86 100.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 120.923 0.392 . . . . 0.0 111.294 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.445 ' HB3' HD12 ' A' ' 86' ' ' ILE . . . -102.97 101.88 11.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.739 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.62 ' HB3' ' HB3' ' A' ' 84' ' ' GLU . 48.5 ttt-85 -118.67 142.39 31.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.845 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.415 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 50.6 Cg_exo -53.85 -31.63 63.17 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.542 2.161 . . . . 0.0 113.511 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -110.74 -19.48 12.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.62 ' HB3' ' HB3' ' A' ' 81' ' ' ARG . 5.3 tp10 -85.86 -50.4 7.15 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.754 -0.379 . . . . 0.0 111.953 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 ttp85 -139.44 -78.94 0.32 Allowed 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.818 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.445 HD12 ' HB3' ' A' ' 80' ' ' ALA . 24.0 mt . . . . . 0 C--N 1.332 -0.193 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.337 -179.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' HD2' ' N ' ' A' ' 9' ' ' ARG . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.766 0.317 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -111.15 82.48 1.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.972 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -131.94 143.01 49.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.438 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 39.5 tp -135.38 10.69 3.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.489 ' CD1' ' N ' ' A' ' 13' ' ' ILE . 1.6 mp -91.08 157.38 2.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.479 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.438 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.42 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 48.1 m170 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.485 HD13 HG22 ' A' ' 27' ' ' ILE . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.41 ' OE1' ' C ' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.675 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.572 ' C ' ' H ' ' A' ' 45' ' ' GLU . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.732 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.438 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.438 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.494 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.61 ' C ' HG13 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.675 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.732 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.542 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.438 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.504 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.428 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.494 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.632 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.446 ' CZ ' ' HE3' ' A' ' 56' ' ' LYS . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.479 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.409 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.409 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.43 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.455 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.424 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.549 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.632 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -67.63 -58.64 4.33 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.53 -31.47 10.86 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.549 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 30.0 tp -61.32 -13.9 22.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.322 0.489 . . . . 0.0 112.322 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.404 ' O ' ' CG1' ' A' ' 79' ' ' VAL . 10.8 p -48.83 100.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 121.081 0.467 . . . . 0.0 111.204 -179.623 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.28 127.61 54.42 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.087 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.409 ' HD2' ' HA ' ' A' ' 86' ' ' ILE . 99.4 mtt180 -106.41 155.1 39.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.737 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -56.43 -163.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.75 2.3 . . . . 0.0 112.586 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.5 mt-10 -56.39 -18.77 12.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.451 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.456 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 4.5 mm-40 -56.68 -17.34 8.52 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.424 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.456 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 81.4 mtm180 75.52 153.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.88 0.371 . . . . 0.0 110.914 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.489 ' CD1' ' N ' ' A' ' 86' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.193 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 41.2 ptt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.819 0.342 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.548 ' HB2' ' HA ' ' A' ' 47' ' ' ASP . 90.6 m-70 -77.95 -51.42 10.42 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.503 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.585 ' HA ' ' HB3' ' A' ' 33' ' ' ARG . 85.3 mt-10 -50.88 176.8 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.556 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.791 ' HB3' ' O ' ' A' ' 15' ' ' LEU . 1.4 tp -51.21 137.96 21.49 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.588 ' C ' ' O ' ' A' ' 12' ' ' LEU . 18.0 tt -30.84 97.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -175.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 12' ' ' LEU . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.791 ' O ' ' HB3' ' A' ' 12' ' ' LEU . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.488 HG21 HD23 ' A' ' 12' ' ' LEU . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.416 ' N ' HG11 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.49 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.475 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.532 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.532 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.481 HG23 HD11 ' A' ' 27' ' ' ILE . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD11 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.434 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.699 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.784 ' HB ' ' CB ' ' A' ' 12' ' ' LEU . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.703 ' HB ' ' HB2' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.46 ' N ' HG12 ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.421 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.407 ' HD2' ' CD ' ' A' ' 82' ' ' PRO . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.582 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.564 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.723 ' HA ' ' HA ' ' A' ' 34' ' ' VAL . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.703 ' HB2' ' HB ' ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.691 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.548 ' HA ' ' HB2' ' A' ' 10' ' ' HIS . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.468 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.486 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.426 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.582 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.485 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.55 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.707 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.475 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.49 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.479 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.425 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.425 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.423 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.429 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.492 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.707 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.55 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 -98.55 -47.95 5.18 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.78 -13.53 17.68 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.492 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 2.5 tm? -98.8 -35.46 10.12 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.222 -178.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 12.2 p -52.21 100.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.076 0.465 . . . . 0.0 111.351 -179.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.57 110.66 21.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.113 179.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.413 ' NH2' ' HA2' ' A' ' 57' ' ' GLY . 54.2 mtt85 -87.67 110.49 35.03 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.524 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.407 ' CD ' ' HD2' ' A' ' 39' ' ' ARG . 65.3 Cg_endo -73.09 -12.14 25.61 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.375 2.05 . . . . 0.0 112.607 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -81.51 -27.31 34.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.896 0.379 . . . . 0.0 111.121 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -107.11 -5.16 18.19 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 76.3 mtt-85 63.85 132.22 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.858 0.361 . . . . 0.0 110.815 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 45.0 mm . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.008 -179.896 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.666 0.27 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -122.11 159.7 26.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.046 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -178.78 35.47 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.262 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.448 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 30.1 tp -167.75 27.74 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.802 0.334 . . . . 0.0 111.053 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt -91.39 163.13 2.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.43 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.426 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.583 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.56 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.583 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.426 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.73 ' CB ' ' O ' ' A' ' 45' ' ' GLU . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.643 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.711 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.528 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.591 ' HD3' HG12 ' A' ' 86' ' ' ILE . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.414 ' HB3' ' HA ' ' A' ' 80' ' ' ALA . 0.1 OUTLIER -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.528 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.583 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.711 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.63 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.73 ' O ' ' CB ' ' A' ' 33' ' ' ARG . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.729 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.408 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.465 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.405 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.583 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.466 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.466 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.725 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.445 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.464 ' CE1' ' CG2' ' A' ' 71' ' ' VAL . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.462 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.449 ' HB ' ' CG ' ' A' ' 69' ' ' GLU . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.449 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.462 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.557 ' N ' HD12 ' A' ' 73' ' ' ILE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.725 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.454 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 -70.91 -21.96 62.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -98.48 0.16 44.6 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.697 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.409 ' N ' ' CD2' ' A' ' 78' ' ' LEU . 3.1 mm? -94.14 25.56 3.7 Favored 'General case' 0 C--N 1.334 -0.075 0 CA-C-O 120.784 0.326 . . . . 0.0 111.423 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.405 ' CG2' ' N ' ' A' ' 80' ' ' ALA . 11.4 p -48.69 163.1 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.227 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.597 ' CB ' HG13 ' A' ' 86' ' ' ILE . . . -46.78 163.53 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.506 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.53 ' N ' HG13 ' A' ' 86' ' ' ILE . 75.5 mtp180 -117.16 115.09 38.47 Favored Pre-proline 0 N--CA 1.461 0.076 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.461 ' HA ' ' HB ' ' A' ' 86' ' ' ILE . 88.9 Cg_endo -77.59 2.33 7.91 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.627 2.218 . . . . 0.0 113.057 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -100.4 -13.66 18.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.709 -0.223 . . . . 0.0 111.367 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -107.09 -31.07 8.43 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.418 ' NE ' ' HA ' ' A' ' 85' ' ' ARG . 7.3 tpm_? -177.09 -28.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.597 HG13 ' CB ' ' A' ' 80' ' ' ALA . 48.6 mm . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 111.268 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.409 ' HB2' ' CZ ' ' A' ' 9' ' ' ARG . 17.3 ttm105 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.979 0.419 . . . . 0.0 111.023 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.454 ' ND1' ' HG2' ' A' ' 11' ' ' GLU . 35.4 t-80 -127.59 81.14 2.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.508 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.454 ' HG2' ' ND1' ' A' ' 10' ' ' HIS . 22.3 pt-20 46.69 -173.91 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.277 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.418 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 27.5 tp -137.56 15.6 2.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.159 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -91.06 147.93 4.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.415 ' O ' HD11 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.473 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.501 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.402 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.439 HD12 HG23 ' A' ' 27' ' ' ILE . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.903 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.54 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.817 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.506 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.401 ' N ' HG22 ' A' ' 38' ' ' THR . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.506 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.722 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.679 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.903 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.522 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.404 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.445 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.441 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.595 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.66 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.446 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.418 ' CD2' ' HA ' ' A' ' 72' ' ' GLU . 48.9 m170 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.422 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.411 ' O ' ' HB3' ' A' ' 62' ' ' HIS . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.418 ' HA ' ' CD2' ' A' ' 62' ' ' HIS . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.445 HG13 ' CE1' ' A' ' 63' ' ' PHE . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.433 ' O ' ' CB ' ' A' ' 78' ' ' LEU . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.66 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.595 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 -72.95 -62.57 1.41 Allowed 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.06 -35.08 9.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -177.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.433 ' CB ' ' O ' ' A' ' 74' ' ' ASP . 2.5 tm? -49.34 -29.48 6.18 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.5 p -59.04 111.09 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.082 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.78 144.13 37.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.085 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 52.8 mtp85 -115.05 115.61 43.0 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.85 -2.29 12.51 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.475 2.116 . . . . 0.0 112.797 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 tp10 -97.47 -30.7 12.75 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.919 0.39 . . . . 0.0 111.01 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -107.04 10.17 30.35 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.457 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 62.86 144.62 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 110.813 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 57.7 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.993 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.647 0.26 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -178.48 142.99 0.25 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.79 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -128.55 152.59 48.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.456 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 36.1 tp -125.13 17.82 8.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.421 HG23 HD11 ' A' ' 13' ' ' ILE . 58.6 mt -91.04 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.078 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.427 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.475 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.424 ' N ' ' HD3' ' A' ' 21' ' ' ARG . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.432 ' CB ' HG13 ' A' ' 27' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.51 ' HB3' HG12 ' A' ' 27' ' ' ILE . 18.5 t-160 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.51 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.409 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.831 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.611 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.663 HG22 ' HB2' ' A' ' 45' ' ' GLU . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.447 ' N ' ' OE1' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.507 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.507 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.432 ' HB2' ' HB2' ' A' ' 56' ' ' LYS . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.619 ' HG2' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.643 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.831 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.541 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.41 ' HB2' ' HE3' ' A' ' 46' ' ' MET . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.432 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.433 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.643 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.569 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.469 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.468 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.435 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.429 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.416 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.41 HG12 ' N ' ' A' ' 72' ' ' GLU . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.468 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.435 HD13 ' CD1' ' A' ' 63' ' ' PHE . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.418 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.569 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.643 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 -93.93 -66.93 0.88 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -79.79 -11.23 59.84 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.446 ' N ' HD21 ' A' ' 78' ' ' LEU . 2.9 mm? -130.8 45.99 2.73 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.802 0.334 . . . . 0.0 111.77 -179.47 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.0 p -64.15 101.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.439 . . . . 0.0 110.556 179.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -51.5 131.0 28.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.752 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.46 ' HG3' ' HA ' ' A' ' 86' ' ' ILE . 0.0 OUTLIER -117.48 137.3 24.01 Favored Pre-proline 0 N--CA 1.454 -0.249 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.416 179.455 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.93 171.74 17.29 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.465 2.11 . . . . 0.0 112.512 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -70.88 -20.51 62.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.091 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -81.0 -30.38 34.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.991 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.412 ' HD2' ' C ' ' A' ' 85' ' ' ARG . 3.7 tmm_? -144.04 98.95 3.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.572 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.46 ' HA ' ' HG3' ' A' ' 81' ' ' ARG . 59.4 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.599 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.755 0.312 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -168.45 -59.72 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -61.17 158.3 14.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.993 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.1 tp -177.34 -39.39 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.017 179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm -61.98 137.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.968 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.427 HG21 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.458 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.477 ' CB ' HG13 ' A' ' 27' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.45 HG21 ' CD2' ' A' ' 24' ' ' HIS . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.45 ' CD2' HG21 ' A' ' 23' ' ' VAL . 53.7 m170 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.418 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.489 HD11 HG21 ' A' ' 27' ' ' ILE . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.418 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.711 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.537 ' C ' ' H ' ' A' ' 45' ' ' GLU . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.822 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.477 ' NE ' ' HA ' ' A' ' 39' ' ' ARG . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.471 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.588 ' HB2' ' HG2' ' A' ' 56' ' ' LYS . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.67 ' C ' HG13 ' A' ' 35' ' ' VAL . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.711 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.822 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.637 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.442 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.419 ' CG2' HG22 ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.442 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.588 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.495 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.606 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.733 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.478 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.478 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.476 ' OD1' ' HG2' ' A' ' 76' ' ' ARG . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.733 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.606 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 -89.75 -37.25 14.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -77.89 0.81 22.64 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.948 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.443 HD22 ' N ' ' A' ' 78' ' ' LEU . 2.9 mm? -122.16 48.24 1.77 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.548 0.69 . . . . 0.0 110.222 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.41 ' CG1' ' N ' ' A' ' 80' ' ' ALA . 47.4 t -47.6 163.26 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 114.68 -1.146 . . . . 0.0 111.561 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.487 ' HB2' HG13 ' A' ' 86' ' ' ILE . . . -46.18 164.34 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.214 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.622 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -70.34 115.63 36.72 Favored Pre-proline 0 CA--C 1.529 0.151 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.321 -178.016 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.49 -64.17 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.85 2.366 . . . . 0.0 114.371 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -105.34 -17.33 14.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.622 ' HB2' ' HB2' ' A' ' 81' ' ' ARG . 69.2 mt-10 -57.25 -43.12 82.67 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.773 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.45 ' HD3' ' NH2' ' A' ' 81' ' ' ARG . 59.6 ttt-85 -170.41 -53.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.12 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.487 HG13 ' HB2' ' A' ' 80' ' ' ALA . 47.2 mm . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 121.082 0.468 . . . . 0.0 111.038 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 14.7 ptp180 . . . . . 0 CA--C 1.528 0.118 0 CA-C-O 120.776 0.322 . . . . 0.0 110.624 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 49.4 m170 -117.77 142.37 47.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.319 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 64.28 -75.01 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.611 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 65.3 tp -177.55 -24.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.565 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.419 ' CG2' ' N ' ' A' ' 14' ' ' GLY . 2.0 mp -57.02 156.77 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.419 ' N ' ' CG2' ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.48 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.449 ' HD2' ' N ' ' A' ' 21' ' ' ARG . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.453 HD11 HG22 ' A' ' 27' ' ' ILE . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.836 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.477 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.606 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.421 ' CB ' ' CZ ' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.711 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.611 ' O ' HG13 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.776 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.836 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.612 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.538 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.4 HG23 HG22 ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.429 ' CD ' HG13 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.711 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.487 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.487 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.507 ' CZ ' ' CD1' ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.52 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.401 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.433 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.52 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.506 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.487 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 -97.92 -37.77 9.67 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.33 -12.96 18.23 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -179.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.488 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -103.33 32.27 3.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.537 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 48.2 t -79.76 100.8 4.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.71 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -105.69 101.86 11.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.421 ' CZ ' ' CB ' ' A' ' 40' ' ' ASN . 21.1 mmt85 -117.28 94.73 45.87 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.773 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -66.14 -11.36 30.87 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.623 2.215 . . . . 0.0 112.786 -179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 17.7 tp10 -106.96 -22.76 12.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.765 0.316 . . . . 0.0 111.524 -179.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' A' ' 85' ' ' ARG . 61.8 mm-40 -94.78 10.6 34.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.364 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.436 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.7 ptp85 48.43 109.05 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.184 0.516 . . . . 0.0 111.637 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.985 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 . . . . . 0 CA--C 1.526 0.048 0 CA-C-O 120.87 0.367 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -106.43 -39.62 5.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -71.18 146.44 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.786 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 59.5 tp -178.53 -35.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.486 HD12 HG22 ' A' ' 13' ' ' ILE . 50.0 mt -53.28 157.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.134 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.475 ' O ' HG11 ' A' ' 34' ' ' VAL . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.435 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.491 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.422 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.406 ' HA ' ' HA ' ' A' ' 59' ' ' ALA . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 90.0 m-70 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.422 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.75 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.504 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.469 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.545 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.443 ' HB3' ' H ' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.499 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.543 ' HG2' HG13 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.75 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.681 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.638 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.429 ' CG1' ' HD2' ' A' ' 55' ' ' PRO . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.429 ' HD2' ' CG1' ' A' ' 54' ' ' VAL . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.499 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.523 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.757 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.48 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.435 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.41 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.41 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.48 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.757 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.58 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 -74.56 -18.38 60.59 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.79 -2.57 34.76 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.764 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.409 ' N ' ' CD2' ' A' ' 78' ' ' LEU . 2.5 mm? -100.92 33.14 2.91 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.076 0.465 . . . . 0.0 110.522 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.4 p -48.39 162.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.225 179.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . 0.404 ' CB ' ' HA ' ' A' ' 84' ' ' GLU . . . -47.32 163.5 0.04 OUTLIER 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.111 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.801 ' O ' ' N ' ' A' ' 84' ' ' GLU . 96.1 mtt180 -62.88 157.24 61.74 Favored Pre-proline 0 C--O 1.219 -0.546 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.55 ' C ' ' H ' ' A' ' 84' ' ' GLU . 99.3 Cg_exo -38.79 -32.64 0.3 Allowed 'Trans proline' 0 C--N 1.359 1.082 0 C-N-CA 121.608 1.539 . . . . 0.0 109.126 177.318 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 85' ' ' ARG . 4.6 mm-40 -76.22 25.67 0.13 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 112.54 -2.118 . . . . 0.0 108.803 174.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.801 ' N ' ' O ' ' A' ' 81' ' ' ARG . 47.5 mt-10 -38.33 -13.56 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 -172.394 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.541 ' N ' ' O ' ' A' ' 83' ' ' GLU . 4.5 mmp_? -68.25 76.38 0.25 Allowed 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 173.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.572 ' N ' ' O ' ' A' ' 84' ' ' GLU . 3.8 mp . . . . . 0 C--O 1.23 0.06 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.33 -175.357 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.4 mtp180 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.787 0.327 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -138.49 159.84 41.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.772 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -135.89 140.25 43.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.792 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.446 ' CD1' ' N ' ' A' ' 12' ' ' LEU . 4.4 mp -98.47 30.37 3.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm -83.43 145.83 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.767 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.446 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.431 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.449 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.402 ' HB3' ' CG1' ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.476 ' CB ' HG13 ' A' ' 27' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.423 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.48 ' HB2' HG12 ' A' ' 27' ' ' ILE . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.48 HG12 ' HB2' ' A' ' 24' ' ' HIS . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.449 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.814 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.574 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.843 HG21 ' HB2' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.465 ' C ' ' HD3' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.522 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.548 ' HB2' ' HG3' ' A' ' 56' ' ' LYS . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.774 ' HB3' HG22 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.697 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.843 ' HB2' HG21 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.584 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.446 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.423 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.404 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.403 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.548 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.478 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.758 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.583 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.402 ' CG1' ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.493 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.407 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . 0.462 ' N ' ' OE1' ' A' ' 67' ' ' GLN . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.493 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.441 ' OE1' ' N ' ' A' ' 72' ' ' GLU . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.471 ' HB2' HD21 ' A' ' 78' ' ' LEU . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.583 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.758 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 -98.18 -36.87 9.91 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -98.52 -5.04 32.99 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.471 HD21 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.25 43.19 3.14 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.833 -179.736 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 7.9 p -76.88 100.83 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.354 . . . . 0.0 110.325 179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -97.68 150.88 20.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.697 -179.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.489 ' HD2' ' N ' ' A' ' 81' ' ' ARG . 6.5 mpt_? -117.01 155.2 49.64 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.435 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.409 ' HD3' ' HG3' ' A' ' 39' ' ' ARG . 9.8 Cg_endo -50.97 142.31 34.29 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.599 2.199 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -58.44 -21.08 49.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.351 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -87.5 -37.21 17.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.883 0.373 . . . . 0.0 111.084 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -127.7 109.53 11.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.909 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--N 1.331 -0.227 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.075 -179.814 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 13.1 tpt180 . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.409 ' CG ' ' CD1' ' A' ' 13' ' ' ILE . 34.0 m170 -90.89 172.03 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.682 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -173.64 -37.32 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.402 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.3 pt? -118.8 22.11 12.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.704 0.288 . . . . 0.0 111.287 -179.973 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.409 ' CD1' ' CG ' ' A' ' 10' ' ' HIS . 56.6 mt -91.08 156.5 3.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.885 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.441 HD13 ' CD2' ' A' ' 63' ' ' PHE . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.404 ' C ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.413 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.416 HD11 ' N ' ' A' ' 27' ' ' ILE . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.661 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.568 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.842 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.448 ' CG2' ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.448 ' HD2' ' CG2' ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.43 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.477 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.703 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.751 ' C ' HG11 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.661 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.842 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.559 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.437 ' CG2' HG21 ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.435 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.703 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.658 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.523 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.418 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.441 ' CD2' HD13 ' A' ' 15' ' ' LEU . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.413 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.427 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . 0.427 ' HG2' ' CG2' ' A' ' 65' ' ' THR . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.411 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.409 HG11 ' N ' ' A' ' 72' ' ' GLU . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.418 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.523 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.541 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.658 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 -91.7 -36.92 13.33 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.18 -2.46 31.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.991 0.737 . . . . 0.0 112.991 -178.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.541 ' HB2' ' O ' ' A' ' 74' ' ' ASP . 61.1 mt -130.14 44.01 3.03 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.657 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 8.1 p -73.19 100.65 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.911 0.386 . . . . 0.0 110.669 179.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.94 105.59 15.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -179.679 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.43 ' HG2' ' HB3' ' A' ' 40' ' ' ASN . 75.3 mtp180 -117.16 140.12 26.76 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.948 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.402 ' CD ' ' HG3' ' A' ' 39' ' ' ARG . 93.4 Cg_endo -78.96 -15.75 12.96 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.55 2.166 . . . . 0.0 112.647 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -90.78 -24.44 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.095 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 41.5 tp10 -100.01 -18.06 17.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.049 179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 83.5 mtm180 63.88 67.32 0.62 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.855 0.359 . . . . 0.0 111.016 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 52.3 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.847 179.853 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.783 0.325 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . 0.423 ' CE1' HD13 ' A' ' 12' ' ' LEU . 7.5 p80 -119.89 -19.91 7.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.511 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 60.81 158.7 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.755 0.312 . . . . 0.0 111.181 179.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.423 HD13 ' CE1' ' A' ' 10' ' ' HIS . 5.1 mp -127.34 25.54 6.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.38 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.464 HD12 HG23 ' A' ' 13' ' ' ILE . 43.6 mt -86.42 144.23 9.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.462 HD13 ' CD2' ' A' ' 63' ' ' PHE . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.459 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.417 ' CB ' HG13 ' A' ' 27' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.425 HG11 ' CD2' ' A' ' 24' ' ' HIS . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.478 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 46.5 m170 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.478 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.486 HD13 HG22 ' A' ' 27' ' ' ILE . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . 0.466 ' CD1' ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 1.067 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.523 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.405 ' N ' HG21 ' A' ' 38' ' ' THR . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.432 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.526 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.602 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.698 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 1.067 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.609 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.453 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.46 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.526 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.41 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.65 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.661 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.539 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.444 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.514 ' CE1' ' CE1' ' A' ' 61' ' ' PHE . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.47 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.422 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.444 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.539 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.426 ' OD1' ' O ' ' A' ' 74' ' ' ASP . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.661 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.65 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER -98.46 -30.05 12.76 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.5 -1.78 32.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.024 -0.534 . . . . 0.0 112.139 -179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.499 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -116.71 40.44 2.93 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.105 0.478 . . . . 0.0 110.411 -179.646 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.419 ' CG1' ' CZ ' ' A' ' 81' ' ' ARG . 42.6 t -79.66 100.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.33 125.83 52.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.766 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.427 ' HD2' ' N ' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -94.06 140.77 23.0 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.373 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.539 ' HG2' ' HG2' ' A' ' 84' ' ' GLU . 9.8 Cg_endo -54.1 -163.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 122.909 2.406 . . . . 0.0 112.609 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 8.4 mp0 -85.51 -1.32 56.96 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.539 ' HG2' ' HG2' ' A' ' 82' ' ' PRO . 12.4 pt-20 -81.7 -41.7 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.774 0.321 . . . . 0.0 110.763 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.471 ' NE ' ' HA ' ' A' ' 85' ' ' ARG . 3.3 tpm_? -132.39 94.36 3.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.504 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.474 ' CD1' ' N ' ' A' ' 86' ' ' ILE . 1.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.896 0.379 . . . . 0.0 111.11 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.78 0.324 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -114.44 -175.65 2.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.913 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.27 -41.82 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.942 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.0 tp -133.11 -45.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.94 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm -75.68 133.38 31.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.983 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.421 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.411 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.41 ' CD2' HG12 ' A' ' 23' ' ' VAL . 90.2 m-70 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.485 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.448 ' OD1' HD11 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.448 HD11 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.425 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 4.9 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.425 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.737 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.488 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.502 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.502 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.551 ' HB2' ' CG ' ' A' ' 56' ' ' LYS . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.567 ' HG2' HG13 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.737 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.669 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.58 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.492 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.466 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.463 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.436 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.646 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.428 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD1' ' N ' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.42 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . 0.407 ' HB3' HG21 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.42 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.431 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.438 ' HB3' ' CD2' ' A' ' 62' ' ' HIS . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.428 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' HB2' HD23 ' A' ' 78' ' ' LEU . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.646 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.473 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 -98.53 -34.53 10.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.21 -7.06 23.43 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.467 HD23 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.17 44.47 2.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.915 0.388 . . . . 0.0 111.506 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 36.1 t -66.47 117.95 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.778 179.539 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -63.88 110.61 2.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.816 0.341 . . . . 0.0 110.704 179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 77.2 mtt-85 -117.23 155.32 49.9 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.283 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.432 ' HA ' HG13 ' A' ' 86' ' ' ILE . 88.5 Cg_endo -81.39 11.67 2.98 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.864 2.376 . . . . 0.0 113.091 -179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 51.6 mm-40 -58.92 -44.41 91.31 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.045 0.45 . . . . 0.0 110.729 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.491 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 95.2 mt-10 -107.81 -50.54 3.04 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.673 179.38 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.491 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 39.8 ttm180 167.49 132.26 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.432 HG13 ' HA ' ' A' ' 82' ' ' PRO . 54.8 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' N ' ' NE ' ' A' ' 9' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.829 0.347 . . . . 0.0 110.867 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 65.58 74.34 0.38 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.686 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -179.7 81.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.764 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.436 ' CD1' ' N ' ' A' ' 12' ' ' LEU . 5.2 mp -100.76 26.31 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 44.3 mm -91.24 143.07 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.926 179.681 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.451 ' HA ' ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.424 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.465 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.467 ' CD2' ' HB3' ' A' ' 26' ' ' ASP . 40.0 t60 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.467 ' HB3' ' CD2' ' A' ' 24' ' ' HIS . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.424 HG13 ' OG ' ' A' ' 22' ' ' SER . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.418 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 5.7 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.418 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.919 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.506 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.858 HG22 ' N ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.444 HG23 ' N ' ' A' ' 39' ' ' ARG . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.444 ' N ' HG23 ' A' ' 38' ' ' THR . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.444 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.501 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.699 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.65 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.919 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.578 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.457 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.407 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.501 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.428 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.465 ' HB ' ' HB ' ' A' ' 23' ' ' VAL . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.663 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.451 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.412 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.463 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.463 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.423 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.412 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.437 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.663 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.437 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 16.1 tpp85 -77.12 -67.02 0.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.61 -54.85 2.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -178.005 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . . . . . . . . . 71.2 mt -49.52 -23.56 1.66 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.832 -178.748 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.404 ' CG1' ' O ' ' A' ' 79' ' ' VAL . 9.8 p -57.57 101.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.924 0.392 . . . . 0.0 111.037 179.761 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -57.05 154.43 9.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.917 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.768 ' O ' ' N ' ' A' ' 84' ' ' GLU . 54.0 mtp85 -117.0 157.86 45.51 Favored Pre-proline 0 N--CA 1.468 0.434 0 CA-C-O 119.058 -0.496 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.637 ' C ' ' H ' ' A' ' 84' ' ' GLU . 59.1 Cg_exo -30.49 -35.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.366 1.484 0 C-N-CA 122.74 2.293 . . . . 0.0 110.168 178.41 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.552 ' N ' ' O ' ' A' ' 81' ' ' ARG . 56.5 mt-10 -69.03 24.23 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 112.935 -1.938 . . . . 0.0 109.258 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.768 ' N ' ' O ' ' A' ' 81' ' ' ARG . 55.9 mt-10 -39.19 -17.01 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.741 0.816 . . . . 0.0 112.837 -173.747 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 83' ' ' GLU . 63.3 mtt85 -74.31 66.73 1.34 Allowed 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 173.395 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.483 ' N ' ' O ' ' A' ' 84' ' ' GLU . 50.3 mm . . . . . 0 N--CA 1.454 -0.242 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.536 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 75.4 mtt-85 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.801 0.334 . . . . 0.0 110.987 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 63.42 87.14 0.11 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.087 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -105.21 32.0 4.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.768 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.418 ' CD2' ' OE1' ' A' ' 37' ' ' GLU . 61.0 tp -82.87 -22.01 34.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.273 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.1 mm -82.39 158.22 3.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.417 HD11 ' CD2' ' A' ' 63' ' ' PHE . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.504 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.474 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.409 ' CB ' HG13 ' A' ' 27' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.421 HG11 ' CD2' ' A' ' 24' ' ' HIS . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.465 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 88.1 m-70 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . 0.465 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.433 HG21 HD12 ' A' ' 27' ' ' ILE . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.891 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.686 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.811 ' HB ' ' HB3' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.418 ' OE1' ' CD2' ' A' ' 12' ' ' LEU . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.604 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.401 ' N ' ' HG2' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.432 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.65 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.811 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.641 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.891 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.656 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.459 ' HB2' ' HE3' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . 0.442 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.65 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.413 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.413 ' CD1' ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.606 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.402 ' CE1' ' HB2' ' A' ' 70' ' ' LEU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.53 ' CE1' ' CE1' ' A' ' 61' ' ' PHE . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.488 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.606 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.406 ' O ' ' CD2' ' A' ' 78' ' ' LEU . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.422 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? -92.1 -34.29 14.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -93.54 0.11 56.51 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.531 179.322 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.429 HD23 ' N ' ' A' ' 78' ' ' LEU . 4.2 mm? -109.14 38.02 2.41 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.134 0.492 . . . . 0.0 110.808 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 10.8 p -47.95 162.28 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.107 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -47.45 162.59 0.06 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.007 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.604 ' HG2' ' HB3' ' A' ' 39' ' ' ARG . 40.4 mmt-85 -58.44 115.36 11.26 Favored Pre-proline 0 N--CA 1.455 -0.177 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.3 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -82.44 -14.18 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.366 2.044 . . . . 0.0 112.863 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -110.37 -25.13 10.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.746 -179.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.413 ' HB2' ' HB3' ' A' ' 81' ' ' ARG . 88.7 mt-10 -92.8 10.45 30.87 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.594 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 38.9 ttm180 65.9 159.61 0.12 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.777 0.323 . . . . 0.0 110.762 -179.89 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 37.7 mm . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 -179.749 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 46.9 ttt85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.689 0.281 . . . . 0.0 110.705 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 9.7 p80 -51.41 162.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.119 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -114.86 -66.15 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.62 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.421 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 22.9 tp 55.17 23.1 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.012 179.6 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.7 mm -91.52 160.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.375 -179.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.453 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.491 HG12 ' HB3' ' A' ' 61' ' ' PHE . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.409 ' HB3' ' NH2' ' A' ' 76' ' ' ARG . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.493 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.426 HG11 ' CD2' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.426 ' CD2' HG11 ' A' ' 23' ' ' VAL . 90.7 m-70 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.493 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.453 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 1.036 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.556 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.707 HG22 ' HB2' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.407 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.468 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.417 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . 0.417 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.468 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.623 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.656 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.672 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 1.036 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.68 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.461 ' O ' ' HA ' ' A' ' 45' ' ' GLU . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . 0.441 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.444 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.558 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.688 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.52 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.438 ' N ' ' HD3' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.569 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 32.0 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.569 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' C ' ' CD1' ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.52 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.688 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.558 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 -93.41 -43.16 8.89 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.14 -7.39 23.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.402 ' O ' ' HG ' ' A' ' 78' ' ' LEU . 26.4 tp -119.85 40.47 3.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.748 0.309 . . . . 0.0 111.187 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 7.8 p -59.12 100.88 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.895 0.379 . . . . 0.0 110.674 179.621 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -58.69 124.78 20.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.279 -179.569 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.564 ' O ' ' HD2' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -95.76 155.25 38.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 121.057 0.456 . . . . 0.0 111.566 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -90.0 -155.02 0.05 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.041 2.494 . . . . 0.0 112.333 -179.679 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -55.43 -17.72 5.6 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.692 0.282 . . . . 0.0 111.317 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 84' ' ' GLU . 39.7 tt0 -78.13 10.55 2.86 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.416 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.466 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.9 ptp85 49.49 -177.66 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.844 0.354 . . . . 0.0 111.427 -179.733 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.439 ' N ' ' HG2' ' A' ' 81' ' ' ARG . 31.7 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.265 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.417 ' C ' ' HD3' ' A' ' 9' ' ' ARG . 2.1 tmt_? . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -112.38 -29.81 7.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.472 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 42.58 30.53 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.455 -0.338 . . . . 0.0 111.719 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 6.2 tt -77.14 -28.93 54.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.88 0.371 . . . . 0.0 110.674 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . 0.468 ' HA ' HG12 ' A' ' 34' ' ' VAL . 54.8 mt -56.46 154.58 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.125 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.419 ' O ' ' CG1' ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.427 ' HB2' ' CG1' ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.422 HG11 ' CD2' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.422 ' CD2' HG11 ' A' ' 23' ' ' VAL . 90.4 m-70 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.438 ' CD1' ' HD2' ' A' ' 55' ' ' PRO . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.699 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.549 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.762 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.414 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . 0.411 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.414 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.556 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.637 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.699 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.762 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.54 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.469 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.438 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.446 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.479 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.682 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.427 ' CG1' ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . 0.456 ' CE1' ' HG2' ' A' ' 72' ' ' GLU . 46.9 m170 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.478 ' CZ ' ' HB ' ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.428 ' C ' ' CD2' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.478 ' HB ' ' CZ ' ' A' ' 63' ' ' PHE . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.456 ' HG2' ' CE1' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.436 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.682 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.479 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 -94.44 -48.91 5.92 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.83 -20.97 14.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.436 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 3.0 tm? -78.11 -29.48 48.96 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 59.3 t -54.63 99.96 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.927 0.394 . . . . 0.0 111.222 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.98 109.96 20.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.182 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.45 ' O ' ' HG3' ' A' ' 81' ' ' ARG . 37.8 ptt180 -117.37 94.74 46.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.789 0.328 . . . . 0.0 111.647 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 85' ' ' ARG . 88.3 Cg_endo -76.07 -125.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 122.507 2.138 . . . . 0.0 111.636 179.46 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . 0.413 ' H ' ' HB2' ' A' ' 82' ' ' PRO . 50.3 mt-10 -110.35 -25.56 10.03 Favored 'General case' 0 C--O 1.231 0.104 0 O-C-N 122.041 -0.412 . . . . 0.0 111.934 -179.636 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -87.0 -50.31 6.74 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.889 0.376 . . . . 0.0 111.354 -179.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . 0.451 ' O ' ' HD2' ' A' ' 82' ' ' PRO . 47.5 ttt85 -174.83 -74.0 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.413 HG12 ' HG2' ' A' ' 85' ' ' ARG . 28.4 mm . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.202 178.643 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 59.6 ttp85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.764 0.316 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -64.62 174.29 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.966 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -115.34 135.47 54.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.792 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 5.4 tt -79.0 -33.21 45.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.473 -179.814 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 45.4 mm -66.53 159.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.795 179.709 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.541 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.456 ' CG1' ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . 0.494 ' CD1' ' N ' ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.416 ' O ' ' HA ' ' A' ' 59' ' ' ALA . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.421 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.453 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . 0.421 ' CD2' HG12 ' A' ' 23' ' ' VAL . 43.8 m170 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . 0.468 ' N ' ' HD3' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.421 ' CD1' ' HB3' ' A' ' 22' ' ' SER . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.679 ' HG2' ' HA ' ' A' ' 46' ' ' MET . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.517 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.715 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.446 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.449 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.712 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.602 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.677 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.715 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.679 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.45 ' CB ' ' HE3' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . 0.414 ' CG1' ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.414 ' HD2' ' CG1' ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.712 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . 0.451 ' C ' ' CD1' ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.574 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.555 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . 0.456 ' CE1' ' CG1' ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.511 ' HB2' ' NH1' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.54 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.54 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.425 ' CD1' ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.438 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.555 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.456 ' HB3' ' CD2' ' A' ' 78' ' ' LEU . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.574 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 -82.88 -66.97 0.83 Allowed 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.22 -42.69 6.24 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.456 ' CD2' ' HB3' ' A' ' 74' ' ' ASP . 4.3 mm? -54.26 -20.39 6.94 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -178.635 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 60.4 t -59.6 100.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 179.775 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -96.67 111.29 23.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.027 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 81' ' ' ARG . 15.6 ptp180 -100.03 103.89 25.46 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.985 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -80.5 52.87 4.51 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.565 2.177 . . . . 0.0 112.773 -179.632 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -110.02 -40.94 4.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.159 0.504 . . . . 0.0 110.654 179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -107.31 -50.06 3.15 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.598 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 56.0 ttp180 179.77 152.35 0.43 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.744 179.8 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 51.2 mm . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.983 -179.951 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.9 mtp85 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.705 0.288 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.1 m80 -110.64 141.91 43.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 179.903 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 62.44 120.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.007 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 61.0 tp -82.3 -25.31 34.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.998 179.901 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.5 mm -66.6 137.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.028 -179.98 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.409 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.451 ' HB3' HG13 ' A' ' 27' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.431 ' HA ' HD11 ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.451 HG13 ' HB3' ' A' ' 22' ' ' SER . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.409 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 50.8 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.674 ' O ' ' CG2' ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . 0.544 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.818 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' ASP . . . . . 0.427 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' THR . . . . . 0.406 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' THR . . . . . 0.401 ' N ' ' CD ' ' A' ' 56' ' ' LYS . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.643 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ARG . . . . . 0.724 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' ILE . . . . . 0.674 ' CG2' ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' GLU . . . . . 0.818 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.593 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' ARG . . . . . 0.505 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ILE . . . . . . . . . . . . . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' LYS . . . . . 0.643 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' ILE . . . . . 0.804 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . 0.662 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . 0.531 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' HD22 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' CG ' ' A' ' 69' ' ' GLU . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' GLU . . . . . 0.441 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' LEU . . . . . 0.445 HD22 ' HD3' ' A' ' 64' ' ' ARG . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.531 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ASP . . . . . 0.471 ' HB2' ' CD1' ' A' ' 78' ' ' LEU . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' GLY . . . . . 0.662 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' ARG . . . . . 0.804 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 -78.81 -64.33 1.21 Allowed 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.85 0.31 38.34 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -177.403 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' LEU . . . . . 0.471 ' CD1' ' HB2' ' A' ' 74' ' ' ASP . 7.1 mp -97.8 3.76 49.91 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -179.47 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.01 110.37 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.93 179.544 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -102.11 110.42 22.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.036 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' ARG . . . . . 0.411 ' CB ' ' HB2' ' A' ' 84' ' ' GLU . 99.2 mtt180 -85.72 152.88 57.59 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.06 -179.77 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -81.23 -92.78 0.0 OUTLIER 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.667 2.245 . . . . 0.0 113.346 -179.513 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -50.81 -25.64 4.71 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' GLU . . . . . 0.411 ' HB2' ' CB ' ' A' ' 81' ' ' ARG . 8.6 mp0 -74.09 -16.63 61.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.121 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 62.45 171.15 0.13 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.979 179.864 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.974 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.632 ' O ' HG23 ' A' ' 34' ' ' VAL . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.818 HD13 HG23 ' A' ' 30' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.455 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.65 ' OG ' HG21 ' A' ' 19' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.469 ' N ' HG13 ' A' ' 23' ' ' VAL . 40.1 m80 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.504 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.455 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.818 HG23 HD13 ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.46 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.06 ' O ' HG23 ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 15' ' ' LEU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.768 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.421 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 48.8 p30 -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.665 HD13 ' N ' ' A' ' 43' ' ' ARG . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.665 ' N ' HD13 ' A' ' 42' ' ' LEU . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.06 HG23 ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.768 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.609 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.612 HG21 HD12 ' A' ' 44' ' ' ILE . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' HD13 ' A' ' 27' ' ' ILE . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.517 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.87 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.87 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.665 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.417 ' CG1' ' HG2' ' A' ' 21' ' ' ARG . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.45 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.593 ' CE1' ' HB2' ' A' ' 72' ' ' GLU . 2.3 m-70 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.425 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.563 HG22 ' H ' ' A' ' 67' ' ' GLN . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.563 ' H ' HG22 ' A' ' 65' ' ' THR . 84.6 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.434 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.644 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.593 ' HB2' ' CE1' ' A' ' 62' ' ' HIS . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.461 HD13 ' O ' ' A' ' 72' ' ' GLU . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.665 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.568 HD22 ' HA ' ' A' ' 65' ' ' THR . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.425 ' CZ ' ' HB2' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.452 HD13 ' HB3' ' A' ' 61' ' ' PHE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.887 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.913 ' HB2' HG12 ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.591 ' HA ' HD11 ' A' ' 30' ' ' ILE . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.591 HD11 ' HA ' ' A' ' 27' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.901 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.727 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.95 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.477 ' HD3' ' O ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.532 ' O ' HG23 ' A' ' 41' ' ' THR . 50.4 p30 -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' ASN . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.789 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.95 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.901 HG23 ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.934 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.633 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' ASP . . . . . 0.407 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.473 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.443 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.709 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.789 ' HD2' HD23 ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.796 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.796 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.612 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.913 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.452 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.635 ' CZ ' HG11 ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.492 ' HD3' HD13 ' A' ' 70' ' ' LEU . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.568 ' HA ' HD22 ' A' ' 15' ' ' LEU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.438 ' OE1' HG22 ' A' ' 65' ' ' THR . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.492 HD13 ' HD3' ' A' ' 64' ' ' ARG . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 73' ' ' ILE . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.559 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.716 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.815 0.34 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.614 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.692 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.608 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.914 ' HB3' HG12 ' A' ' 60' ' ' VAL . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.427 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 24' ' ' HIS . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.489 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.6 m-70 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.809 HD12 ' HD2' ' A' ' 55' ' ' PRO . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD13 ' A' ' 19' ' ' ILE . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.425 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.128 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.865 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.441 ' N ' HG13 ' A' ' 35' ' ' VAL . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.484 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.484 ' O ' HG23 ' A' ' 41' ' ' THR . 49.2 p30 -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.484 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.598 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.865 ' C ' HG12 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.128 HG23 ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.874 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.576 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.518 ' HB2' ' HE2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.629 HG23 ' HB ' ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.809 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HD2' HD23 ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.811 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.811 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.636 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.914 HG12 ' HB3' ' A' ' 21' ' ' ARG . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.502 ' CE1' ' HB2' ' A' ' 72' ' ' GLU . 2.3 m-70 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.442 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.504 HG22 ' H ' ' A' ' 67' ' ' GLN . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.504 ' H ' HG22 ' A' ' 65' ' ' THR . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.502 ' HB2' ' CE1' ' A' ' 62' ' ' HIS . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.636 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.586 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 13' ' ' ILE . 11.2 tp . . . . . 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.585 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.517 HG12 ' N ' ' A' ' 18' ' ' ARG . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.517 ' N ' HG12 ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.455 HG21 ' OG ' ' A' ' 22' ' ' SER . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.455 ' OG ' HG21 ' A' ' 19' ' ' ILE . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.49 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.545 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 2.7 m-70 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.494 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.545 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.697 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.494 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.697 HD12 ' HA ' ' A' ' 27' ' ' ILE . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.411 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.053 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.697 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.947 HG23 ' OE1' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.636 ' CD ' HD22 ' A' ' 42' ' ' LEU . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 41' ' ' THR . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.752 ' O ' HD23 ' A' ' 42' ' ' LEU . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.752 HD23 ' O ' ' A' ' 41' ' ' THR . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.618 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.053 HG23 ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.947 ' OE1' HG23 ' A' ' 35' ' ' VAL . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.693 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.513 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 1.021 HG21 HD12 ' A' ' 44' ' ' ILE . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.69 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.728 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 60' ' ' VAL . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.575 ' CE2' HD12 ' A' ' 42' ' ' LEU . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.496 ' CD2' HD11 ' A' ' 73' ' ' ILE . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.477 ' HG3' HD13 ' A' ' 70' ' ' LEU . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 64' ' ' ARG . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.491 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.728 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.668 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 . . . . . 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.702 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.777 HG23 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.708 HG21 ' OG ' ' A' ' 22' ' ' SER . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.581 ' HB3' HG11 ' A' ' 60' ' ' VAL . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.708 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 27' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.4 m-70 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.577 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.41 ' C ' ' OE1' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.607 ' O ' HG23 ' A' ' 30' ' ' ILE . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.126 ' O ' HG23 ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.709 HG21 ' CE2' ' A' ' 63' ' ' PHE . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.733 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.49 ' HB ' HG22 ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.5 p30 -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.49 HG22 ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.63 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.636 ' C ' HG12 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.126 HG23 ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.733 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.566 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.451 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.519 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.577 ' HD2' HD12 ' A' ' 27' ' ' ILE . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.801 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.801 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.581 HG11 ' HB3' ' A' ' 20' ' ' ALA . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.444 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.417 ' CD2' ' HB2' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.777 ' CE1' HG23 ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.424 HH11 HD12 ' A' ' 70' ' ' LEU . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.536 ' H ' HG22 ' A' ' 65' ' ' THR . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 71' ' ' VAL . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 70' ' ' LEU . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.444 ' N ' HG22 ' A' ' 73' ' ' ILE . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.657 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 13' ' ' ILE . 18.0 tt . . . . . 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.519 HG12 ' N ' ' A' ' 18' ' ' ARG . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.519 ' N ' HG12 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.56 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.683 ' HB2' HG12 ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 24' ' ' HIS . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.53 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.53 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.923 HD12 HG13 ' A' ' 54' ' ' VAL . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.4 ' CB ' ' HA ' ' A' ' 18' ' ' ARG . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.023 ' O ' HG23 ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.762 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.926 HG23 ' OE1' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.442 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.6 p30 -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.655 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.57 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.023 HG23 ' O ' ' A' ' 33' ' ' ARG . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.926 ' OE1' HG23 ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.715 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' ASP . . . . . 0.449 ' C ' ' H ' ' A' ' 49' ' ' GLY . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 52' ' ' ILE . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.923 HG13 HD12 ' A' ' 27' ' ' ILE . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.761 ' HD2' HD13 ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.84 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.84 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.713 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.515 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.524 ' CD2' HD12 ' A' ' 15' ' ' LEU . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.538 ' H ' HG22 ' A' ' 65' ' ' THR . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.647 HD23 ' N ' ' A' ' 71' ' ' VAL . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.647 ' N ' HD23 ' A' ' 70' ' ' LEU . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.629 ' O ' HD13 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.629 HD13 ' O ' ' A' ' 72' ' ' GLU . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.713 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.579 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 65' ' ' THR . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.413 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.477 HD13 ' CB ' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.998 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.591 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.562 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.591 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.444 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.897 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.697 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.963 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.487 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 47.4 p30 -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.487 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.963 ' C ' HG23 ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.897 HG23 ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.896 ' N ' HG22 ' A' ' 35' ' ' VAL . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.745 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.715 HG23 ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.517 ' HD2' HD12 ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.612 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.826 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.826 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.738 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.998 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.477 ' CB ' HD13 ' A' ' 19' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.664 ' CD2' HD11 ' A' ' 73' ' ' ILE . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.472 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.537 ' H ' HG22 ' A' ' 65' ' ' THR . 66.4 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.429 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.472 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.472 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.449 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.664 HD11 ' CD2' ' A' ' 63' ' ' PHE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.738 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.497 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.491 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.628 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.484 ' HB3' HG12 ' A' ' 60' ' ' VAL . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.403 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.492 ' N ' HG13 ' A' ' 23' ' ' VAL . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.436 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.406 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.07 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.836 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.439 ' N ' HG13 ' A' ' 35' ' ' VAL . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.458 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.458 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.588 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.836 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.07 HG23 ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.935 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.527 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.4 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.485 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' HD12 ' A' ' 27' ' ' ILE . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.809 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.809 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.667 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.48 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.448 ' CD2' HD11 ' A' ' 70' ' ' LEU . 2.4 m-70 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.47 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.417 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.519 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.519 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.581 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.511 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.609 ' O ' HD13 ' A' ' 73' ' ' ILE . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.609 HD13 ' O ' ' A' ' 72' ' ' GLU . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.64 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 . . . . . 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.666 HD22 ' OG1' ' A' ' 65' ' ' THR . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.572 HG22 ' CD2' ' A' ' 63' ' ' PHE . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.436 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.75 ' NH2' HG11 ' A' ' 60' ' ' VAL . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.518 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.51 HG13 ' N ' ' A' ' 24' ' ' HIS . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.512 ' HB3' HG12 ' A' ' 27' ' ' ILE . 1.1 t60 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.428 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.978 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.625 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.999 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.447 ' OE1' ' N ' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.43 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 48.5 p30 -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.528 ' C ' HD13 ' A' ' 42' ' ' LEU . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.999 ' C ' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.978 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.981 ' N ' HG22 ' A' ' 35' ' ' VAL . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.557 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 50' ' ' ARG . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.419 ' HD3' ' HB2' ' A' ' 48' ' ' ASP . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.61 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.925 HG21 HD12 ' A' ' 44' ' ' ILE . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.788 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.788 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.571 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.75 HG11 ' NH2' ' A' ' 21' ' ' ARG . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.479 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.472 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.733 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.666 ' OG1' HD22 ' A' ' 15' ' ' LEU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.507 ' H ' HG22 ' A' ' 65' ' ' THR . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.433 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.634 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.568 HG12 HD11 ' A' ' 73' ' ' ILE . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.824 ' C ' HD12 ' A' ' 73' ' ' ILE . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.824 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.67 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 . . . . . 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.782 0.325 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.846 HD22 ' OG1' ' A' ' 65' ' ' THR . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.591 HD13 ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.77 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB3' HG12 ' A' ' 60' ' ' VAL . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.782 HG12 ' HB ' ' A' ' 58' ' ' ILE . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.486 ' N ' HG23 ' A' ' 23' ' ' VAL . 2.7 m-70 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.435 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.48 HG13 ' CB ' ' A' ' 22' ' ' SER . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.435 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.149 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.708 HG21 ' CE2' ' A' ' 63' ' ' PHE . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.831 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' HG22 ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HA ' ' NE ' ' A' ' 39' ' ' ARG . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.414 ' H ' HG22 ' A' ' 38' ' ' THR . 52.5 p-10 -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.427 HG22 ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.891 HD13 ' N ' ' A' ' 43' ' ' ARG . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.891 ' N ' HD13 ' A' ' 42' ' ' LEU . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.149 HG23 ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.831 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.648 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' ASP . . . . . 0.414 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.537 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.556 ' CG2' HD12 ' A' ' 44' ' ' ILE . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.6 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.866 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.866 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.745 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.591 ' HB3' HD13 ' A' ' 19' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HG21 ' A' ' 34' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.846 ' OG1' HD22 ' A' ' 15' ' ' LEU . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.568 ' H ' HG22 ' A' ' 65' ' ' THR . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.553 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.489 ' OD1' ' HG2' ' A' ' 76' ' ' ARG . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.745 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.648 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 . . . . . 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.573 ' N ' HD12 ' A' ' 13' ' ' ILE . 2.0 mp . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.407 ' O ' HG12 ' A' ' 34' ' ' VAL . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.453 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.678 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.747 ' HB2' HG12 ' A' ' 60' ' ' VAL . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.994 HG21 HG13 ' A' ' 54' ' ' VAL . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 27' ' ' ILE . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.418 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.139 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.541 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.626 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 41' ' ' THR . 48.5 p30 -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 40' ' ' ASN . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.723 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.627 ' O ' HG12 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.139 HG23 ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.872 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.635 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.556 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.415 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 27' ' ' ILE . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.545 ' HD2' HG21 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.723 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.857 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.857 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.747 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.541 ' CZ ' HD11 ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.532 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.402 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.614 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.509 ' O ' HD13 ' A' ' 73' ' ' ILE . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.513 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.581 ' HA ' HG13 ' A' ' 34' ' ' VAL . 50.0 mt . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.813 0.339 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.762 HD22 ' OG1' ' A' ' 65' ' ' THR . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.445 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.829 HD13 HG23 ' A' ' 30' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.519 ' HB2' HG12 ' A' ' 60' ' ' VAL . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.769 HG21 ' HD2' ' A' ' 55' ' ' PRO . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.829 HG23 HD13 ' A' ' 19' ' ' ILE . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.409 ' N ' HG12 ' A' ' 30' ' ' ILE . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.15 ' O ' HG23 ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.581 HG13 ' HA ' ' A' ' 13' ' ' ILE . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.621 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.5 ' HG3' ' HZ1' ' A' ' 56' ' ' LYS . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.493 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.514 ' O ' HG23 ' A' ' 41' ' ' THR . 47.4 p30 -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 40' ' ' ASN . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.641 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.538 ' HG2' HG11 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.15 HG23 ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.689 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.643 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.481 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.408 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.556 HG13 HG21 ' A' ' 27' ' ' ILE . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.769 ' HD2' HG21 ' A' ' 27' ' ' ILE . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.6 ' NZ ' HD23 ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.896 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.772 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.519 HG12 ' HB2' ' A' ' 21' ' ' ARG . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.485 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.762 ' OG1' HD22 ' A' ' 15' ' ' LEU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.547 ' H ' HG22 ' A' ' 65' ' ' THR . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.543 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.772 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.864 0.364 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.404 ' CD2' ' HD2' ' A' ' 66' ' ' PRO . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.576 HG21 ' OG ' ' A' ' 22' ' ' SER . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.799 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.814 ' HB3' HG12 ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.576 ' OG ' HG21 ' A' ' 19' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.686 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.686 ' ND1' HG13 ' A' ' 23' ' ' VAL . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.557 ' OD1' HG23 ' A' ' 27' ' ' ILE . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.557 HG23 ' OD1' ' A' ' 26' ' ' ASP . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 21.1 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.618 ' O ' HG23 ' A' ' 30' ' ' ILE . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.95 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.619 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 1.014 HG22 ' N ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.496 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.482 ' HD3' ' C ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.52 ' O ' HG23 ' A' ' 41' ' ' THR . 49.5 p30 -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.52 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.622 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 1.008 ' C ' HG23 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.95 HG23 ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 1.014 ' N ' HG22 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.602 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.818 HG21 HD12 ' A' ' 44' ' ' ILE . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.56 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.841 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.841 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.589 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.814 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.551 ' HB3' HD13 ' A' ' 19' ' ' ILE . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.502 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.421 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.509 HG22 ' H ' ' A' ' 67' ' ' GLN . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.509 ' H ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 71' ' ' VAL . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 60' ' ' VAL . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.589 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.777 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 . . . . . 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.455 HG22 ' N ' ' A' ' 14' ' ' GLY . 56.6 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.455 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.596 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 18' ' ' ARG . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.493 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.414 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.768 ' HB2' HG12 ' A' ' 60' ' ' VAL . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.437 ' HA ' ' HB2' ' A' ' 59' ' ' ALA . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.42 ' HB2' ' CD1' ' A' ' 27' ' ' ILE . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.92 ' OD1' HG23 ' A' ' 27' ' ' ILE . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.92 HG23 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.409 ' C ' HD12 ' A' ' 30' ' ' ILE . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.661 ' N ' HD12 ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.123 ' O ' HG23 ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.655 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.864 HG12 ' C ' ' A' ' 43' ' ' ARG . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.458 ' N ' HG13 ' A' ' 35' ' ' VAL . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.762 HG22 ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.54 ' O ' HG23 ' A' ' 41' ' ' THR . 51.4 p30 -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.54 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.982 HD11 ' CE2' ' A' ' 61' ' ' PHE . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.864 ' C ' HG12 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.123 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.855 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.593 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.638 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.437 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.715 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.778 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.778 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.768 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.982 ' CE2' HD11 ' A' ' 42' ' ' LEU . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.44 ' CD1' HG13 ' A' ' 17' ' ' VAL . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.415 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.431 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.454 ' HG3' ' HG2' ' A' ' 69' ' ' GLU . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.454 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.589 HG12 HD11 ' A' ' 73' ' ' ILE . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.795 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.795 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.675 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.6 mt . . . . . 0 N--CA 1.456 -0.143 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.704 HG23 ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.583 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.844 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.83 ' HB3' HG12 ' A' ' 60' ' ' VAL . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.458 ' OG ' HG21 ' A' ' 19' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.5 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 2.4 m-70 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.5 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.698 HD12 ' HD2' ' A' ' 55' ' ' PRO . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.661 HD13 ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.544 ' N ' HD13 ' A' ' 30' ' ' ILE . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.106 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.599 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 39' ' ' ARG . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.469 ' O ' HG23 ' A' ' 41' ' ' THR . 48.9 p30 -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 40' ' ' ASN . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.707 HD23 ' HD3' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.61 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.106 HG23 ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 1.081 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.621 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.407 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.701 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.698 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.707 ' HD3' HD23 ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.828 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.828 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.844 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.583 ' HB3' HD13 ' A' ' 19' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.434 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.704 ' CE1' HG23 ' A' ' 17' ' ' VAL . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.758 ' HE ' HD23 ' A' ' 70' ' ' LEU . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.442 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 65' ' ' THR . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.758 HD23 ' HE ' ' A' ' 64' ' ' ARG . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 72' ' ' GLU . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.673 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.732 0.301 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.433 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.592 HD13 ' HB3' ' A' ' 61' ' ' PHE . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.667 ' HB2' HG12 ' A' ' 60' ' ' VAL . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.516 ' OG ' HD11 ' A' ' 27' ' ' ILE . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.688 ' O ' HD13 ' A' ' 27' ' ' ILE . 39.2 m80 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.41 ' OD1' HG23 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.688 HD13 ' O ' ' A' ' 24' ' ' HIS . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.084 ' O ' HG23 ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.563 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.601 HG11 ' HG2' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 49.7 p30 -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.461 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.601 ' HG2' HG11 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.084 HG23 ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.705 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.599 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.478 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.648 HG21 HD12 ' A' ' 44' ' ' ILE . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.573 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.667 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.592 ' HB3' HD13 ' A' ' 19' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.46 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 67' ' ' GLN . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.525 ' H ' HG22 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.462 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.607 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 72' ' ' GLU . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.656 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.5 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.479 ' HA ' HG11 ' A' ' 34' ' ' VAL . 44.3 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.716 0.293 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.74 HD13 ' OG1' ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.527 HD13 ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.851 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.653 ' HB3' HG12 ' A' ' 60' ' ' VAL . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.41 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.488 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.481 ' N ' HG13 ' A' ' 23' ' ' VAL . 10.5 t-80 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HB3' ' A' ' 28' ' ' GLN . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.423 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 25' ' ' ARG . 1.2 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 27' ' ' ILE . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.426 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.035 ' O ' HG23 ' A' ' 44' ' ' ILE . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.517 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 1.102 HG22 ' CB ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.429 ' O ' HD22 ' A' ' 42' ' ' LEU . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 40' ' ' ASN . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.515 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 40' ' ' ASN . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.619 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.724 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.035 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 1.102 ' CB ' HG22 ' A' ' 35' ' ' VAL . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.595 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.681 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.624 HG21 HD12 ' A' ' 44' ' ' ILE . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.413 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.673 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.851 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.527 ' HB3' HD13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.409 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.498 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.74 ' OG1' HD13 ' A' ' 15' ' ' LEU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.5 ' H ' HG22 ' A' ' 65' ' ' THR . 66.4 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.636 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.498 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.614 ' O ' HD13 ' A' ' 73' ' ' ILE . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.614 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.673 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HD3' HG23 ' A' ' 58' ' ' ILE . 16.1 tpp85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 14' ' ' GLY . 43.1 mm . . . . . 0 CA--C 1.527 0.06 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.496 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.563 ' O ' HD12 ' A' ' 15' ' ' LEU . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.743 HG23 ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.706 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.799 ' HB3' HG12 ' A' ' 60' ' ' VAL . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.486 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 37.5 m80 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.486 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' HB2' ' A' ' 24' ' ' HIS . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.984 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.702 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 1.038 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.424 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.417 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.42 ' HD3' ' H ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.402 ' N ' ' HG2' ' A' ' 39' ' ' ARG . 52.2 p-10 -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 40' ' ' ASN . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.994 HD11 ' CE2' ' A' ' 61' ' ' PHE . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 1.038 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 0.984 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.971 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.723 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.471 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.672 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 27' ' ' ILE . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.668 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.775 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.775 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.799 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.994 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.424 ' ND1' ' HG2' ' A' ' 72' ' ' GLU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.743 ' CE1' HG23 ' A' ' 17' ' ' VAL . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 70' ' ' LEU . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.605 HG22 ' H ' ' A' ' 67' ' ' GLN . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.605 ' H ' HG22 ' A' ' 65' ' ' THR . 84.9 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.748 HD22 ' C ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG2' ' ND1' ' A' ' 62' ' ' HIS . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.622 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.43 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? . . . . . 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 48.7 mm . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.831 0.348 . . . . 0.0 111.375 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.458 ' CD2' HG23 ' A' ' 65' ' ' THR . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 60' ' ' VAL . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.599 ' HB2' HG12 ' A' ' 60' ' ' VAL . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.514 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.487 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.487 ' N ' HG13 ' A' ' 23' ' ' VAL . 39.3 m80 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASP . . . . . 0.408 ' OD1' HG23 ' A' ' 27' ' ' ILE . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.514 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.079 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 1.035 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' ' O ' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.445 ' O ' HG23 ' A' ' 41' ' ' THR . 49.0 p30 -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 40' ' ' ASN . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.954 HD11 ' CE2' ' A' ' 61' ' ' PHE . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 1.035 ' C ' HG23 ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.013 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 1.079 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.697 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.548 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.434 HG21 HD12 ' A' ' 44' ' ' ILE . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.459 ' HD2' HD12 ' A' ' 27' ' ' ILE . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.82 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.82 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.695 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.699 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.954 ' CE2' HD11 ' A' ' 42' ' ' LEU . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.415 ' H ' HG22 ' A' ' 65' ' ' THR . 25.6 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.635 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.536 ' N ' HD13 ' A' ' 70' ' ' LEU . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.534 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.593 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 14' ' ' GLY . 54.8 mt . . . . . 0 CA--C 1.53 0.174 0 CA-C-O 120.693 0.282 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.716 ' H ' HG13 ' A' ' 34' ' ' VAL . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.914 ' O ' HG12 ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 63' ' ' PHE . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.531 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.644 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB2' HG12 ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 39.5 m80 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.711 ' HA ' HD12 ' A' ' 30' ' ' ILE . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.711 HD12 ' HA ' ' A' ' 27' ' ' ILE . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.122 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.914 HG12 ' O ' ' A' ' 15' ' ' LEU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 40' ' ' ASN . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.506 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.685 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.643 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.122 HG23 ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.549 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.511 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.499 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.447 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.685 ' HD2' HD23 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.822 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.822 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.696 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.712 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.531 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.573 ' CD2' ' HG2' ' A' ' 72' ' ' GLU . 2.8 m-70 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.562 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.67 ' HA ' HD22 ' A' ' 15' ' ' LEU . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.475 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.633 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.628 ' N ' HD23 ' A' ' 70' ' ' LEU . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.573 ' HG2' ' CD2' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 45.4 mm . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.707 0.289 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.67 ' CD2' HG23 ' A' ' 65' ' ' THR . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.57 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.731 HG13 ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD2' ' HB2' ' A' ' 31' ' ' SER . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.671 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.421 ' HB2' HG12 ' A' ' 60' ' ' VAL . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.48 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.3 m-70 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' ARG . . . . . 0.46 ' HD3' ' N ' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.557 ' C ' HD12 ' A' ' 27' ' ' ILE . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 19' ' ' ILE . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 18' ' ' ARG . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.074 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.608 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.714 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.433 ' HB ' HG22 ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 49.9 p30 -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.468 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.853 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.63 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.074 HG23 ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.714 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.714 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.463 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.587 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.507 ' HD2' HG13 ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.732 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.464 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.853 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 63' ' ' PHE . . . . . 0.731 ' CE1' HG13 ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.514 ' NH1' ' HB2' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.67 HG23 ' CD2' ' A' ' 15' ' ' LEU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.433 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.495 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.436 HD13 ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.694 HG12 HD11 ' A' ' 73' ' ' ILE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.779 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.779 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 . . . . . 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 35' ' ' VAL . 46.5 mm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.855 0.359 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.645 ' O ' HG23 ' A' ' 34' ' ' VAL . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.407 ' HB2' ' HB2' ' A' ' 64' ' ' ARG . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 34' ' ' VAL . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ARG . . . . . 0.435 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.646 ' CD1' HG11 ' A' ' 54' ' ' VAL . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.738 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.949 ' HB3' HG12 ' A' ' 60' ' ' VAL . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.482 ' OG ' HG21 ' A' ' 19' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.652 HG22 ' CD1' ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' HIS . . . . . 0.563 ' H ' HD11 ' A' ' 27' ' ' ILE . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ILE . . . . . 0.756 HD12 ' HD2' ' A' ' 55' ' ' PRO . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 16.0 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 30' ' ' ILE . . . . . 0.643 HD12 ' HA ' ' A' ' 27' ' ' ILE . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 1.088 ' O ' HG23 ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 15' ' ' LEU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.873 HG23 ' OE1' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' N ' HG13 ' A' ' 35' ' ' VAL . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 41' ' ' THR . 47.6 p30 -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' THR . . . . . 0.507 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.728 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ARG . . . . . 0.844 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' ILE . . . . . 1.088 HG23 ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' GLU . . . . . 0.873 ' OE1' HG23 ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.601 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ILE . . . . . 0.419 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' VAL . . . . . 0.745 HG21 HD12 ' A' ' 44' ' ' ILE . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 27' ' ' ILE . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 56' ' ' LYS . . . . . 0.687 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 58' ' ' ILE . . . . . 0.849 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' ALA . . . . . 0.672 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.949 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 61' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 42' ' ' LEU . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 62' ' ' HIS . . . . . 0.73 ' HB3' HD21 ' A' ' 70' ' ' LEU . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.676 ' HD3' HD23 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' H ' ' A' ' 67' ' ' GLN . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 67' ' ' GLN . . . . . 0.493 ' H ' HG22 ' A' ' 65' ' ' THR . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' GLU . . . . . 0.416 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' LEU . . . . . 0.73 HD21 ' HB3' ' A' ' 62' ' ' HIS . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.624 HG12 HD11 ' A' ' 73' ' ' ILE . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.763 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.763 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 75' ' ' GLY . . . . . 0.672 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 76' ' ' ARG . . . . . 0.849 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 . . . . . 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.746 0.308 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 1.1 t60 64.04 130.76 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.535 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -50.74 -175.91 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 111.282 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.795 HD23 ' H ' ' A' ' 12' ' ' LEU . 1.9 pt? -127.99 29.61 5.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.183 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.21 102.79 8.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.632 ' O ' HG23 ' A' ' 34' ' ' VAL . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.818 HD13 HG23 ' A' ' 30' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.455 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.65 ' OG ' HG21 ' A' ' 19' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.469 ' N ' HG13 ' A' ' 23' ' ' VAL . 40.1 m80 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.504 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.455 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.818 HG23 HD13 ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.46 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.06 ' O ' HG23 ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 15' ' ' LEU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.768 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 48.8 p30 -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.665 HD13 ' N ' ' A' ' 43' ' ' ARG . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.665 ' N ' HD13 ' A' ' 42' ' ' LEU . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.06 HG23 ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.768 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.609 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.612 HG21 HD12 ' A' ' 44' ' ' ILE . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' HD13 ' A' ' 27' ' ' ILE . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.517 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.87 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.87 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.665 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.417 ' CG1' ' HG2' ' A' ' 21' ' ' ARG . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.45 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.593 ' CE1' ' HB2' ' A' ' 72' ' ' GLU . 2.3 m-70 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HD12 ' A' ' 12' ' ' LEU . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.563 HG22 ' H ' ' A' ' 67' ' ' GLN . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.563 ' H ' HG22 ' A' ' 65' ' ' THR . 84.6 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.434 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.644 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.593 ' HB2' ' CE1' ' A' ' 62' ' ' HIS . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.461 HD13 ' O ' ' A' ' 72' ' ' GLU . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.665 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 -98.38 -49.03 4.82 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.18 -16.58 16.97 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.467 ' HB2' ' O ' ' A' ' 74' ' ' ASP . 78.4 mt -111.15 32.57 5.21 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.4 p -73.66 100.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.46 152.45 25.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.178 0.513 . . . . 0.0 112.082 -178.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HB2' ' HB3' ' A' ' 84' ' ' GLU . 2.1 ptp180 -117.49 94.84 46.46 Favored Pre-proline 0 CA--C 1.532 0.268 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.469 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.69 -88.86 0.0 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.588 2.192 . . . . 0.0 113.652 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mm-40 -50.85 -25.47 4.56 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.494 ' HB3' ' HB2' ' A' ' 81' ' ' ARG . 40.7 tp10 -84.12 1.76 42.65 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.43 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 63.53 152.09 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.868 0.366 . . . . 0.0 111.069 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 86' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.906 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -167.91 110.71 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.902 179.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -142.81 -69.23 0.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.598 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.758 HD12 HD12 ' A' ' 15' ' ' LEU . 45.3 tp -139.14 9.45 2.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.367 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp -91.11 158.6 2.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.758 HD12 HD12 ' A' ' 12' ' ' LEU . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.425 ' CZ ' ' HB2' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.452 HD13 ' HB3' ' A' ' 61' ' ' PHE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.887 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.913 ' HB2' HG12 ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.591 ' HA ' HD11 ' A' ' 30' ' ' ILE . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.591 HD11 ' HA ' ' A' ' 27' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.901 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.727 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.95 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.654 ' NH1' HG22 ' A' ' 79' ' ' VAL . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.532 ' O ' HG23 ' A' ' 41' ' ' THR . 50.4 p30 -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' ASN . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.789 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.95 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.901 HG23 ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.934 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.633 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.407 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.473 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.443 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.709 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.789 ' HD2' HD23 ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.796 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.796 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.612 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.913 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.452 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.635 ' CZ ' HG11 ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.492 ' HD3' HD13 ' A' ' 70' ' ' LEU . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.568 ' HA ' HD22 ' A' ' 15' ' ' LEU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.438 ' OE1' HG22 ' A' ' 65' ' ' THR . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.492 HD13 ' HD3' ' A' ' 64' ' ' ARG . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 73' ' ' ILE . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.818 HG23 ' HG ' ' A' ' 78' ' ' LEU . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.716 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? -71.96 -64.89 0.85 Allowed 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.29 -24.67 14.19 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -178.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.889 HD13 ' O ' ' A' ' 78' ' ' LEU . 3.2 tm? -59.83 -28.97 67.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.816 0.341 . . . . 0.0 111.198 -179.171 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.654 HG22 ' NH1' ' A' ' 39' ' ' ARG . 8.3 p -53.49 100.48 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.034 0.445 . . . . 0.0 111.164 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.58 149.32 29.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.177 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.681 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -56.9 155.08 16.24 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.737 179.746 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -47.74 149.5 5.04 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.73 2.287 . . . . 0.0 112.194 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.401 ' OE1' ' N ' ' A' ' 83' ' ' GLU . 52.9 mp0 -69.28 -13.98 62.69 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.319 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.413 ' HG3' ' N ' ' A' ' 85' ' ' ARG . 16.6 pt-20 -90.07 -47.25 7.94 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.2 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.413 ' N ' ' HG3' ' A' ' 84' ' ' GLU . 4.6 mmp_? -136.37 173.13 12.04 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.005 0.431 . . . . 0.0 111.278 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.681 HG23 ' HG3' ' A' ' 81' ' ' ARG . 45.5 mt . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.298 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.406 ' HG2' ' N ' ' A' ' 10' ' ' HIS . 79.6 ttt180 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.671 0.272 . . . . 0.0 110.405 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.406 ' N ' ' HG2' ' A' ' 9' ' ' ARG . 27.0 p-80 -122.71 118.26 27.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.377 . . . . 0.0 111.179 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.412 ' HB3' HD12 ' A' ' 12' ' ' LEU . 5.2 tp10 -168.13 -46.33 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.642 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.521 ' N ' HD12 ' A' ' 12' ' ' LEU . 5.1 mp -117.16 -34.55 4.33 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.994 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm -79.74 120.26 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.939 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.614 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.692 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.608 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.914 ' HB3' HG12 ' A' ' 60' ' ' VAL . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.427 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 24' ' ' HIS . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.489 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.6 m-70 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.809 HD12 ' HD2' ' A' ' 55' ' ' PRO . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 20.4 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD13 ' A' ' 19' ' ' ILE . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.425 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.128 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.865 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.441 ' N ' HG13 ' A' ' 35' ' ' VAL . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.414 ' OE2' HD22 ' A' ' 12' ' ' LEU . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.484 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.65 ' HA ' ' HB3' ' A' ' 80' ' ' ALA . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.484 ' O ' HG23 ' A' ' 41' ' ' THR . 49.2 p30 -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.484 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.598 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.865 ' C ' HG12 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.128 HG23 ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.874 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.576 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.518 ' HB2' ' HE2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.629 HG23 ' HB ' ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.809 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HD2' HD23 ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.811 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.811 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.636 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.914 HG12 ' HB3' ' A' ' 21' ' ' ARG . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.502 ' CE1' ' HB2' ' A' ' 72' ' ' GLU . 2.3 m-70 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.442 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.504 HG22 ' H ' ' A' ' 67' ' ' GLN . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.504 ' H ' HG22 ' A' ' 65' ' ' THR . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.502 ' HB2' ' CE1' ' A' ' 62' ' ' HIS . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.544 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.636 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.586 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 -88.7 -67.04 0.86 Allowed 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -86.69 -12.32 48.7 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.544 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 22.0 tp -107.69 34.06 3.74 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.681 -0.408 . . . . 0.0 111.16 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.7 138.43 22.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.73 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.65 ' HB3' ' HA ' ' A' ' 39' ' ' ARG . . . -86.44 138.29 31.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.349 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 39.6 mtm-85 -117.14 153.55 49.78 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' HG3' ' HD2' ' A' ' 39' ' ' ARG . 45.2 Cg_exo -55.86 169.27 1.39 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.515 2.144 . . . . 0.0 112.287 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.462 ' HA ' HD11 ' A' ' 86' ' ' ILE . 95.1 mt-10 -74.14 -20.14 60.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.993 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -63.82 -46.72 83.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.901 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 -130.58 101.94 5.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.462 HD11 ' HA ' ' A' ' 83' ' ' GLU . 62.3 mt . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.76 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 . . . . . 0 N--CA 1.457 -0.119 0 CA-C-O 120.862 0.363 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.49 ' CB ' ' HA ' ' A' ' 47' ' ' ASP . 16.9 m80 -127.96 -70.7 0.68 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.891 ' C ' ' O ' ' A' ' 15' ' ' LEU . 44.8 mt-10 -48.38 118.11 2.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.216 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 1.027 ' HA ' ' HB ' ' A' ' 34' ' ' VAL . 0.8 OUTLIER 30.88 -144.15 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.258 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.752 ' H ' HD22 ' A' ' 12' ' ' LEU . 11.2 tp -90.74 94.75 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 173.24 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.891 ' O ' ' C ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.585 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.56 HG22 HD12 ' A' ' 12' ' ' LEU . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.517 ' N ' HG12 ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.455 HG21 ' OG ' ' A' ' 22' ' ' SER . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.455 ' OG ' HG21 ' A' ' 19' ' ' ILE . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.49 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.545 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 2.7 m-70 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.494 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.545 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.697 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.494 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.697 HD12 ' HA ' ' A' ' 27' ' ' ILE . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.411 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.053 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 1.027 ' HB ' ' HA ' ' A' ' 12' ' ' LEU . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.947 HG23 ' OE1' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.636 ' CD ' HD22 ' A' ' 42' ' ' LEU . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 41' ' ' THR . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.752 ' O ' HD23 ' A' ' 42' ' ' LEU . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.752 HD23 ' O ' ' A' ' 41' ' ' THR . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.618 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.053 HG23 ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.947 ' OE1' HG23 ' A' ' 35' ' ' VAL . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.693 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.49 ' HA ' ' CB ' ' A' ' 10' ' ' HIS . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.513 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 1.021 HG21 HD12 ' A' ' 44' ' ' ILE . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.69 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.728 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 60' ' ' VAL . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.575 ' CE2' HD12 ' A' ' 42' ' ' LEU . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.496 ' CD2' HD11 ' A' ' 73' ' ' ILE . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.477 ' HG3' HD13 ' A' ' 70' ' ' LEU . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 64' ' ' ARG . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.491 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.728 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.668 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 -70.86 -42.38 70.19 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.24 0.21 37.0 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.978 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.611 HD13 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -75.84 -1.86 27.28 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 120.829 0.347 . . . . 0.0 111.238 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 49.8 t -48.86 100.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 120.923 0.392 . . . . 0.0 111.294 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.822 ' CB ' HD12 ' A' ' 86' ' ' ILE . . . -102.97 101.88 11.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.739 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.675 ' HB3' ' HB3' ' A' ' 84' ' ' GLU . 48.5 ttt-85 -118.67 142.39 31.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.845 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.486 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 50.6 Cg_exo -53.85 -31.63 63.17 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.542 2.161 . . . . 0.0 113.511 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -110.74 -19.48 12.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' ARG . 5.3 tp10 -85.86 -50.4 7.15 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.754 -0.379 . . . . 0.0 111.953 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 ttp85 -139.44 -78.94 0.32 Allowed 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.818 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.822 HD12 ' CB ' ' A' ' 80' ' ' ALA . 24.0 mt . . . . . 0 C--N 1.332 -0.193 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.337 -179.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.401 ' HD2' ' N ' ' A' ' 9' ' ' ARG . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.766 0.317 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -111.15 82.48 1.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.972 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -131.94 143.01 49.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.688 HD12 HD21 ' A' ' 15' ' ' LEU . 39.5 tp -135.38 10.69 3.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.702 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp -91.08 157.38 2.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.688 HD21 HD12 ' A' ' 12' ' ' LEU . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.777 HG23 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.708 HG21 ' OG ' ' A' ' 22' ' ' SER . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.581 ' HB3' HG11 ' A' ' 60' ' ' VAL . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.708 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 27' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.4 m-70 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.577 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.41 ' C ' ' OE1' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.607 ' O ' HG23 ' A' ' 30' ' ' ILE . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.126 ' O ' HG23 ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.709 HG21 ' CE2' ' A' ' 63' ' ' PHE . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.733 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.49 ' HB ' HG22 ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.5 p30 -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.49 HG22 ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.63 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.636 ' C ' HG12 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.126 HG23 ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.733 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.566 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.451 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.519 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.577 ' HD2' HD12 ' A' ' 27' ' ' ILE . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.801 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.801 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.581 HG11 ' HB3' ' A' ' 20' ' ' ALA . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.444 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.417 ' CD2' ' HB2' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.777 ' CE1' HG23 ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.424 HH11 HD12 ' A' ' 70' ' ' LEU . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.536 ' H ' HG22 ' A' ' 65' ' ' THR . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 71' ' ' VAL . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 70' ' ' LEU . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.657 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -67.63 -58.64 4.33 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.53 -31.47 10.86 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.58 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 30.0 tp -61.32 -13.9 22.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.322 0.489 . . . . 0.0 112.322 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.651 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.8 p -48.83 100.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 121.081 0.467 . . . . 0.0 111.204 -179.623 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.28 127.61 54.42 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.087 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.428 ' HD2' ' HA ' ' A' ' 86' ' ' ILE . 99.4 mtt180 -106.41 155.1 39.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.737 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -56.43 -163.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.75 2.3 . . . . 0.0 112.586 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.5 mt-10 -56.39 -18.77 12.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.451 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 4.5 mm-40 -56.68 -17.34 8.52 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.424 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.451 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 81.4 mtm180 75.52 153.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.88 0.371 . . . . 0.0 110.914 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.707 ' N ' HD12 ' A' ' 86' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.193 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 41.2 ptt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.819 0.342 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.575 ' HB2' ' HA ' ' A' ' 47' ' ' ASP . 90.6 m-70 -77.95 -51.42 10.42 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.503 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.62 ' HA ' ' HB3' ' A' ' 33' ' ' ARG . 85.3 mt-10 -50.88 176.8 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.556 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.934 HD22 HG22 ' A' ' 17' ' ' VAL . 1.4 tp -51.21 137.96 21.49 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 13' ' ' ILE . 18.0 tt -30.84 97.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -175.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 12' ' ' LEU . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.805 ' O ' ' HB3' ' A' ' 12' ' ' LEU . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.934 HG22 HD22 ' A' ' 12' ' ' LEU . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.519 ' N ' HG12 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.56 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.683 ' HB2' HG12 ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 24' ' ' HIS . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.53 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.53 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.923 HD12 HG13 ' A' ' 54' ' ' VAL . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.4 ' CB ' ' HA ' ' A' ' 18' ' ' ARG . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.023 ' O ' HG23 ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.829 ' H ' ' CA ' ' A' ' 12' ' ' LEU . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.926 HG23 ' OE1' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.442 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' HD2' ' CD ' ' A' ' 82' ' ' PRO . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.6 p30 -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.655 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.57 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.023 HG23 ' O ' ' A' ' 33' ' ' ARG . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.926 ' OE1' HG23 ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.715 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.575 ' HA ' ' HB2' ' A' ' 10' ' ' HIS . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 52' ' ' ILE . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.923 HG13 HD12 ' A' ' 27' ' ' ILE . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.761 ' HD2' HD13 ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.84 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.84 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.713 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.515 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.788 ' CD2' HD21 ' A' ' 12' ' ' LEU . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.538 ' H ' HG22 ' A' ' 65' ' ' THR . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.647 HD23 ' N ' ' A' ' 71' ' ' VAL . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.647 ' N ' HD23 ' A' ' 70' ' ' LEU . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.629 ' O ' HD13 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.629 HD13 ' O ' ' A' ' 72' ' ' GLU . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.507 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.713 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.579 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 -98.55 -47.95 5.18 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.78 -13.53 17.68 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.847 HD13 ' O ' ' A' ' 78' ' ' LEU . 2.5 tm? -98.8 -35.46 10.12 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.222 -178.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 79' ' ' VAL . 12.2 p -52.21 100.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.076 0.465 . . . . 0.0 111.351 -179.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.441 ' HA ' HD11 ' A' ' 86' ' ' ILE . . . -109.57 110.66 21.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.113 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.431 ' NH2' ' HA2' ' A' ' 57' ' ' GLY . 54.2 mtt85 -87.67 110.49 35.03 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.524 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.409 ' CD ' ' HD2' ' A' ' 39' ' ' ARG . 65.3 Cg_endo -73.09 -12.14 25.61 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.375 2.05 . . . . 0.0 112.607 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -81.51 -27.31 34.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.896 0.379 . . . . 0.0 111.121 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -107.11 -5.16 18.19 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 76.3 mtt-85 63.85 132.22 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.858 0.361 . . . . 0.0 110.815 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.441 HD11 ' HA ' ' A' ' 80' ' ' ALA . 45.0 mm . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.008 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.666 0.27 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -122.11 159.7 26.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.046 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -178.78 35.47 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.262 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 30.1 tp -167.75 27.74 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.802 0.334 . . . . 0.0 111.053 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt -91.39 163.13 2.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 65' ' ' THR . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.413 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.477 HD13 ' CB ' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.998 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.591 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.562 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.591 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.444 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.897 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.697 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.963 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.487 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.63 ' HD3' HG12 ' A' ' 86' ' ' ILE . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB3' ' HA ' ' A' ' 80' ' ' ALA . 47.4 p30 -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.487 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.963 ' C ' HG23 ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.897 HG23 ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.896 ' N ' HG22 ' A' ' 35' ' ' VAL . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.745 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.715 HG23 ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.517 ' HD2' HD12 ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.612 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.826 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.826 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.738 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.998 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.477 ' CB ' HD13 ' A' ' 19' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.664 ' CD2' HD11 ' A' ' 73' ' ' ILE . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.472 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.537 ' H ' HG22 ' A' ' 65' ' ' THR . 66.4 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.429 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.472 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.472 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.449 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.664 HD11 ' CD2' ' A' ' 63' ' ' PHE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HD23 ' A' ' 78' ' ' LEU . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.761 ' HA2' HD23 ' A' ' 78' ' ' LEU . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 -70.91 -21.96 62.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -98.48 0.16 44.6 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.697 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.761 HD23 ' HA2' ' A' ' 75' ' ' GLY . 3.1 mm? -94.14 25.56 3.7 Favored 'General case' 0 C--N 1.334 -0.075 0 CA-C-O 120.784 0.326 . . . . 0.0 111.423 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.566 HG22 ' N ' ' A' ' 80' ' ' ALA . 11.4 p -48.69 163.1 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.227 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.946 ' HB1' HG13 ' A' ' 86' ' ' ILE . . . -46.78 163.53 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.506 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.556 ' N ' HG13 ' A' ' 86' ' ' ILE . 75.5 mtp180 -117.16 115.09 38.47 Favored Pre-proline 0 N--CA 1.461 0.076 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.423 ' HA ' ' HB ' ' A' ' 86' ' ' ILE . 88.9 Cg_endo -77.59 2.33 7.91 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.627 2.218 . . . . 0.0 113.057 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -100.4 -13.66 18.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.709 -0.223 . . . . 0.0 111.367 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -107.09 -31.07 8.43 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.418 ' HA ' ' NE ' ' A' ' 85' ' ' ARG . 7.3 tpm_? -177.09 -28.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.946 HG13 ' HB1' ' A' ' 80' ' ' ALA . 48.6 mm . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 111.268 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.425 ' NH1' ' HB2' ' A' ' 9' ' ' ARG . 17.3 ttm105 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.979 0.419 . . . . 0.0 111.023 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.473 ' ND1' ' HG2' ' A' ' 11' ' ' GLU . 35.4 t-80 -127.59 81.14 2.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.508 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.473 ' HG2' ' ND1' ' A' ' 10' ' ' HIS . 22.3 pt-20 46.69 -173.91 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.277 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.596 ' CD1' HD21 ' A' ' 15' ' ' LEU . 27.5 tp -137.56 15.6 2.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.159 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -91.06 147.93 4.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.596 HD21 ' CD1' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.491 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.628 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.484 ' HB3' HG12 ' A' ' 60' ' ' VAL . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.403 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.492 ' N ' HG13 ' A' ' 23' ' ' VAL . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.436 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.406 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.07 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.836 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.439 ' N ' HG13 ' A' ' 35' ' ' VAL . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.458 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 48.2 p30 -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.458 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.588 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.836 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.07 HG23 ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.935 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.527 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.4 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.485 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' HD12 ' A' ' 27' ' ' ILE . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.809 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.809 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.667 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.48 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.448 ' CD2' HD11 ' A' ' 70' ' ' LEU . 2.4 m-70 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.47 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.417 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.519 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.519 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.581 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.511 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.609 ' O ' HD13 ' A' ' 73' ' ' ILE . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.609 HD13 ' O ' ' A' ' 72' ' ' GLU . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.433 ' O ' ' CB ' ' A' ' 78' ' ' LEU . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.64 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 -72.95 -62.57 1.41 Allowed 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.06 -35.08 9.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -177.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.892 HD13 ' O ' ' A' ' 78' ' ' LEU . 2.5 tm? -49.34 -29.48 6.18 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.56 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.5 p -59.04 111.09 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.082 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.78 144.13 37.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.085 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 52.8 mtp85 -115.05 115.61 43.0 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.85 -2.29 12.51 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.475 2.116 . . . . 0.0 112.797 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 tp10 -97.47 -30.7 12.75 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.919 0.39 . . . . 0.0 111.01 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -107.04 10.17 30.35 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.457 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 62.86 144.62 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 110.813 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 57.7 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.993 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.647 0.26 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -178.48 142.99 0.25 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.79 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -128.55 152.59 48.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.598 HD12 HD12 ' A' ' 15' ' ' LEU . 36.1 tp -125.13 17.82 8.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -91.04 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.078 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.666 HD22 ' OG1' ' A' ' 65' ' ' THR . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.572 HG22 ' CD2' ' A' ' 63' ' ' PHE . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.436 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.75 ' NH2' HG11 ' A' ' 60' ' ' VAL . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.518 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.51 HG13 ' N ' ' A' ' 24' ' ' HIS . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.512 ' HB3' HG12 ' A' ' 27' ' ' ILE . 1.1 t60 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.428 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.978 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.625 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.999 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.447 ' OE1' ' N ' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.43 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 48.5 p30 -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.528 ' C ' HD13 ' A' ' 42' ' ' LEU . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.999 ' C ' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.978 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.981 ' N ' HG22 ' A' ' 35' ' ' VAL . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.557 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 50' ' ' ARG . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.419 ' HD3' ' HB2' ' A' ' 48' ' ' ASP . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.61 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.925 HG21 HD12 ' A' ' 44' ' ' ILE . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.788 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.788 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.571 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.75 HG11 ' NH2' ' A' ' 21' ' ' ARG . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.479 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.472 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.733 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.666 ' OG1' HD22 ' A' ' 15' ' ' LEU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.507 ' H ' HG22 ' A' ' 65' ' ' THR . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.433 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.634 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.568 HG12 HD11 ' A' ' 73' ' ' ILE . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.824 ' C ' HD12 ' A' ' 73' ' ' ILE . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.824 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.785 ' HB2' HD23 ' A' ' 78' ' ' LEU . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.67 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 -93.93 -66.93 0.88 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.845 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -79.79 -11.23 59.84 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.646 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.845 HD22 ' C ' ' A' ' 77' ' ' ALA . 2.9 mm? -130.8 45.99 2.73 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.802 0.334 . . . . 0.0 111.77 -179.47 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.0 p -64.15 101.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.439 . . . . 0.0 110.556 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -51.5 131.0 28.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.752 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.728 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -117.48 137.3 24.01 Favored Pre-proline 0 N--CA 1.454 -0.249 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.416 179.455 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.93 171.74 17.29 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.465 2.11 . . . . 0.0 112.512 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -70.88 -20.51 62.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.091 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -81.0 -30.38 34.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.991 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.405 ' C ' ' HD2' ' A' ' 85' ' ' ARG . 3.7 tmm_? -144.04 98.95 3.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.572 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.728 HG23 ' HG3' ' A' ' 81' ' ' ARG . 59.4 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.599 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.755 0.312 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -168.45 -59.72 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -61.17 158.3 14.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.993 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.597 HD11 ' CE2' ' A' ' 63' ' ' PHE . 59.1 tp -177.34 -39.39 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.017 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm -61.98 137.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.968 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.846 HD22 ' OG1' ' A' ' 65' ' ' THR . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.591 HD13 ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.77 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB3' HG12 ' A' ' 60' ' ' VAL . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.782 HG12 ' HB ' ' A' ' 58' ' ' ILE . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.486 ' N ' HG23 ' A' ' 23' ' ' VAL . 2.7 m-70 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.435 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.48 HG13 ' CB ' ' A' ' 22' ' ' SER . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.435 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.149 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.708 HG21 ' CE2' ' A' ' 63' ' ' PHE . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.831 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' HG22 ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.954 ' NH2' HD12 ' A' ' 78' ' ' LEU . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.582 ' OD1' HD11 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.427 HG22 ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.891 HD13 ' N ' ' A' ' 43' ' ' ARG . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.891 ' N ' HD13 ' A' ' 42' ' ' LEU . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.149 HG23 ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.831 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.648 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.414 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.537 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.556 ' CG2' HD12 ' A' ' 44' ' ' ILE . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.6 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.866 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.866 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.745 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.591 ' HB3' HD13 ' A' ' 19' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HG21 ' A' ' 34' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.846 ' OG1' HD22 ' A' ' 15' ' ' LEU . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.568 ' H ' HG22 ' A' ' 65' ' ' THR . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.553 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.93 ' O ' HD23 ' A' ' 78' ' ' LEU . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.745 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.648 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 -89.75 -37.25 14.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.753 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -77.89 0.81 22.64 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.948 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.954 HD12 ' NH2' ' A' ' 39' ' ' ARG . 2.9 mm? -122.16 48.24 1.77 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.548 0.69 . . . . 0.0 110.222 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 80' ' ' ALA . 47.4 t -47.6 163.26 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 114.68 -1.146 . . . . 0.0 111.561 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.927 ' CB ' HG21 ' A' ' 86' ' ' ILE . . . -46.18 164.34 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.214 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.64 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -70.34 115.63 36.72 Favored Pre-proline 0 CA--C 1.529 0.151 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.321 -178.016 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.49 -64.17 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.85 2.366 . . . . 0.0 114.371 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -105.34 -17.33 14.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.64 ' HB2' ' HB2' ' A' ' 81' ' ' ARG . 69.2 mt-10 -57.25 -43.12 82.67 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.773 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.475 ' HD3' ' NH2' ' A' ' 81' ' ' ARG . 59.6 ttt-85 -170.41 -53.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.12 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.927 HG21 ' CB ' ' A' ' 80' ' ' ALA . 47.2 mm . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 121.082 0.468 . . . . 0.0 111.038 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' O ' ' HG3' ' A' ' 9' ' ' ARG . 14.7 ptp180 . . . . . 0 CA--C 1.528 0.118 0 CA-C-O 120.776 0.322 . . . . 0.0 110.624 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 2.5 m-70 -117.77 142.37 47.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.319 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 64.28 -75.01 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.611 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 65.3 tp -177.55 -24.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.565 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.573 ' N ' HD12 ' A' ' 13' ' ' ILE . 2.0 mp -57.02 156.77 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.407 ' O ' HG12 ' A' ' 34' ' ' VAL . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.453 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.678 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.747 ' HB2' HG12 ' A' ' 60' ' ' VAL . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.994 HG21 HG13 ' A' ' 54' ' ' VAL . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 27' ' ' ILE . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.418 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.139 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.541 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.626 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.41 ' HD2' ' HD2' ' A' ' 82' ' ' PRO . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 41' ' ' THR . 48.5 p30 -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 40' ' ' ASN . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.723 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.627 ' O ' HG12 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.139 HG23 ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.872 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.635 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.556 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.415 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 27' ' ' ILE . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.545 ' HD2' HG21 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.723 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.857 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.857 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.747 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.541 ' CZ ' HD11 ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.532 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.402 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.614 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.509 ' O ' HD13 ' A' ' 73' ' ' ILE . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.513 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.712 ' OD2' ' HB3' ' A' ' 77' ' ' ALA . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 -97.92 -37.77 9.67 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB3' ' OD2' ' A' ' 74' ' ' ASP . . . -101.33 -12.96 18.23 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.488 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -103.33 32.27 3.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.537 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 48.2 t -79.76 100.8 4.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.71 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -105.69 101.86 11.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.421 ' CZ ' ' CB ' ' A' ' 40' ' ' ASN . 21.1 mmt85 -117.28 94.73 45.87 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.773 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.41 ' HD2' ' HD2' ' A' ' 39' ' ' ARG . 19.9 Cg_exo -66.14 -11.36 30.87 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.623 2.215 . . . . 0.0 112.786 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 17.7 tp10 -106.96 -22.76 12.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.765 0.316 . . . . 0.0 111.524 -179.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' A' ' 85' ' ' ARG . 61.8 mm-40 -94.78 10.6 34.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.364 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.436 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.7 ptp85 48.43 109.05 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.184 0.516 . . . . 0.0 111.637 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.985 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 . . . . . 0 CA--C 1.526 0.048 0 CA-C-O 120.87 0.367 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -106.43 -39.62 5.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -71.18 146.44 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.786 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.719 HD12 HD12 ' A' ' 15' ' ' LEU . 59.5 tp -178.53 -35.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.581 ' HA ' HG13 ' A' ' 34' ' ' VAL . 50.0 mt -53.28 157.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.134 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.762 HD22 ' OG1' ' A' ' 65' ' ' THR . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.445 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.829 HD13 HG23 ' A' ' 30' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.519 ' HB2' HG12 ' A' ' 60' ' ' VAL . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 39.0 m80 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.769 HG21 ' HD2' ' A' ' 55' ' ' PRO . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.829 HG23 HD13 ' A' ' 19' ' ' ILE . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.409 ' N ' HG12 ' A' ' 30' ' ' ILE . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.15 ' O ' HG23 ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.581 HG13 ' HA ' ' A' ' 13' ' ' ILE . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.621 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.5 ' HG3' ' HZ1' ' A' ' 56' ' ' LYS . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.493 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.554 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.514 ' O ' HG23 ' A' ' 41' ' ' THR . 47.4 p30 -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 40' ' ' ASN . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.641 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.538 ' HG2' HG11 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.15 HG23 ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.689 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.643 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.481 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.408 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.556 HG13 HG21 ' A' ' 27' ' ' ILE . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.769 ' HD2' HG21 ' A' ' 27' ' ' ILE . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.6 ' NZ ' HD23 ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.896 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.772 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.519 HG12 ' HB2' ' A' ' 21' ' ' ARG . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.485 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.762 ' OG1' HD22 ' A' ' 15' ' ' LEU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.547 ' H ' HG22 ' A' ' 65' ' ' THR . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.543 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.772 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 -74.56 -18.38 60.59 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.79 -2.57 34.76 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.764 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.593 HD22 ' N ' ' A' ' 78' ' ' LEU . 2.5 mm? -100.92 33.14 2.91 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.076 0.465 . . . . 0.0 110.522 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 80' ' ' ALA . 10.4 p -48.39 162.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.225 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.53 ' N ' HG22 ' A' ' 79' ' ' VAL . . . -47.32 163.5 0.04 OUTLIER 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.111 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.801 ' O ' ' N ' ' A' ' 84' ' ' GLU . 96.1 mtt180 -62.88 157.24 61.74 Favored Pre-proline 0 C--O 1.219 -0.546 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.506 ' C ' ' H ' ' A' ' 84' ' ' GLU . 99.3 Cg_exo -38.79 -32.64 0.3 Allowed 'Trans proline' 0 C--N 1.359 1.082 0 C-N-CA 121.608 1.539 . . . . 0.0 109.126 177.318 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 85' ' ' ARG . 4.6 mm-40 -76.22 25.67 0.13 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 112.54 -2.118 . . . . 0.0 108.803 174.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.801 ' N ' ' O ' ' A' ' 81' ' ' ARG . 47.5 mt-10 -38.33 -13.56 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 -172.394 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.541 ' N ' ' O ' ' A' ' 83' ' ' GLU . 4.5 mmp_? -68.25 76.38 0.25 Allowed 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 173.682 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.585 HD12 ' O ' ' A' ' 84' ' ' GLU . 3.8 mp . . . . . 0 C--O 1.23 0.06 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.33 -175.357 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.4 mtp180 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.787 0.327 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -138.49 159.84 41.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.772 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -135.89 140.25 43.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.792 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.633 ' N ' HD12 ' A' ' 12' ' ' LEU . 4.4 mp -98.47 30.37 3.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm -83.43 145.83 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.767 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.404 ' CD2' ' HD2' ' A' ' 66' ' ' PRO . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.576 HG21 ' OG ' ' A' ' 22' ' ' SER . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.799 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.814 ' HB3' HG12 ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.576 ' OG ' HG21 ' A' ' 19' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.686 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.686 ' ND1' HG13 ' A' ' 23' ' ' VAL . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.557 ' OD1' HG23 ' A' ' 27' ' ' ILE . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.557 HG23 ' OD1' ' A' ' 26' ' ' ASP . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 21.1 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.618 ' O ' HG23 ' A' ' 30' ' ' ILE . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.95 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.619 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 1.014 HG22 ' N ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.496 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.482 ' HD3' ' C ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.52 ' O ' HG23 ' A' ' 41' ' ' THR . 49.5 p30 -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.52 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.622 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 1.008 ' C ' HG23 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.95 HG23 ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 1.014 ' N ' HG22 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.602 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.818 HG21 HD12 ' A' ' 44' ' ' ILE . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.56 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.841 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.841 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.589 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.814 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.551 ' HB3' HD13 ' A' ' 19' ' ' ILE . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.502 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.421 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.509 HG22 ' H ' ' A' ' 67' ' ' GLN . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.509 ' H ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 71' ' ' VAL . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.877 ' HB2' HD23 ' A' ' 78' ' ' LEU . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.589 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.777 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 -98.18 -36.87 9.91 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.771 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -98.52 -5.04 32.99 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.877 HD23 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.25 43.19 3.14 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.833 -179.736 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.631 HG13 ' O ' ' A' ' 79' ' ' VAL . 7.9 p -76.88 100.83 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.354 . . . . 0.0 110.325 179.148 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -97.68 150.88 20.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.697 -179.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.5 ' N ' ' HD2' ' A' ' 81' ' ' ARG . 6.5 mpt_? -117.01 155.2 49.64 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.435 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HD3' ' HG3' ' A' ' 39' ' ' ARG . 9.8 Cg_endo -50.97 142.31 34.29 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.599 2.199 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -58.44 -21.08 49.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.351 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -87.5 -37.21 17.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.883 0.373 . . . . 0.0 111.084 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -127.7 109.53 11.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.909 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--N 1.331 -0.227 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.075 -179.814 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 13.1 tpt180 . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.885 ' CG ' HD12 ' A' ' 13' ' ' ILE . 34.0 m170 -90.89 172.03 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.682 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -173.64 -37.32 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.402 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.812 HD23 ' H ' ' A' ' 12' ' ' LEU . 2.3 pt? -118.8 22.11 12.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.704 0.288 . . . . 0.0 111.287 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.885 HD12 ' CG ' ' A' ' 10' ' ' HIS . 56.6 mt -91.08 156.5 3.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.885 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.455 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.596 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 18' ' ' ARG . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.493 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.414 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.768 ' HB2' HG12 ' A' ' 60' ' ' VAL . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.437 ' HA ' ' HB2' ' A' ' 59' ' ' ALA . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.42 ' HB2' ' CD1' ' A' ' 27' ' ' ILE . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.92 ' OD1' HG23 ' A' ' 27' ' ' ILE . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.92 HG23 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.409 ' C ' HD12 ' A' ' 30' ' ' ILE . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.661 ' N ' HD12 ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.123 ' O ' HG23 ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.655 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.864 HG12 ' C ' ' A' ' 43' ' ' ARG . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.458 ' N ' HG13 ' A' ' 35' ' ' VAL . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.762 HG22 ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.54 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.54 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.982 HD11 ' CE2' ' A' ' 61' ' ' PHE . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.864 ' C ' HG12 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.123 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.855 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.593 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.638 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.437 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.715 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.778 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.778 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.768 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.982 ' CE2' HD11 ' A' ' 42' ' ' LEU . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.44 ' CD1' HG13 ' A' ' 17' ' ' VAL . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.415 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.431 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.454 ' HG3' ' HG2' ' A' ' 69' ' ' GLU . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.454 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.589 HG12 HD11 ' A' ' 73' ' ' ILE . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.795 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.795 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.545 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.675 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 -91.7 -36.92 13.33 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.566 ' O ' HD23 ' A' ' 78' ' ' LEU . . . -101.18 -2.46 31.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.991 0.737 . . . . 0.0 112.991 -178.68 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 77' ' ' ALA . 61.1 mt -130.14 44.01 3.03 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.657 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.1 p -73.19 100.65 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.911 0.386 . . . . 0.0 110.669 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.94 105.59 15.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -179.679 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.443 ' HG2' ' HB3' ' A' ' 40' ' ' ASN . 75.3 mtp180 -117.16 140.12 26.76 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.948 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.416 ' CD ' ' HG3' ' A' ' 39' ' ' ARG . 93.4 Cg_endo -78.96 -15.75 12.96 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.55 2.166 . . . . 0.0 112.647 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -90.78 -24.44 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.095 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HG2' HD11 ' A' ' 86' ' ' ILE . 41.5 tp10 -100.01 -18.06 17.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.049 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 83.5 mtm180 63.88 67.32 0.62 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.855 0.359 . . . . 0.0 111.016 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.532 HD11 ' HG2' ' A' ' 84' ' ' GLU . 52.3 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.847 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.783 0.325 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.661 ' HE1' HD11 ' A' ' 12' ' ' LEU . 7.5 p80 -119.89 -19.91 7.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.511 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.792 ' C ' HD12 ' A' ' 12' ' ' LEU . 56.2 mt-10 60.81 158.7 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.755 0.312 . . . . 0.0 111.181 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.792 HD12 ' C ' ' A' ' 11' ' ' GLU . 5.1 mp -127.34 25.54 6.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.38 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.6 mt -86.42 144.23 9.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.704 HG23 ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.583 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.844 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.83 ' HB3' HG12 ' A' ' 60' ' ' VAL . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.458 ' OG ' HG21 ' A' ' 19' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.5 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 2.4 m-70 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.5 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.698 HD12 ' HD2' ' A' ' 55' ' ' PRO . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.661 HD13 ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.544 ' N ' HD13 ' A' ' 30' ' ' ILE . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.106 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.599 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 39' ' ' ARG . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.469 ' O ' HG23 ' A' ' 41' ' ' THR . 48.9 p30 -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 40' ' ' ASN . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.707 HD23 ' HD3' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.61 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.106 HG23 ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 1.081 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.621 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.407 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.701 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.698 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.707 ' HD3' HD23 ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.828 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.828 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.844 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.583 ' HB3' HD13 ' A' ' 19' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.434 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.704 ' CE1' HG23 ' A' ' 17' ' ' VAL . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.758 ' HE ' HD23 ' A' ' 70' ' ' LEU . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.442 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 65' ' ' THR . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.758 HD23 ' HE ' ' A' ' 64' ' ' ARG . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 72' ' ' GLU . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.718 ' CG ' ' HB3' ' A' ' 77' ' ' ALA . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.673 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER -98.46 -30.05 12.76 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' CG ' ' A' ' 74' ' ' ASP . . . -101.5 -1.78 32.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.024 -0.534 . . . . 0.0 112.139 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.499 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -116.71 40.44 2.93 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.105 0.478 . . . . 0.0 110.411 -179.646 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 57' ' ' GLY . 42.6 t -79.66 100.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.33 125.83 52.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.766 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.444 ' N ' ' HD2' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -94.06 140.77 23.0 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.373 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.56 ' HG2' ' HG2' ' A' ' 84' ' ' GLU . 9.8 Cg_endo -54.1 -163.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 122.909 2.406 . . . . 0.0 112.609 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.777 ' HA ' HD11 ' A' ' 86' ' ' ILE . 8.4 mp0 -85.51 -1.32 56.96 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.56 ' HG2' ' HG2' ' A' ' 82' ' ' PRO . 12.4 pt-20 -81.7 -41.7 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.774 0.321 . . . . 0.0 110.763 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.486 ' HA ' ' NE ' ' A' ' 85' ' ' ARG . 3.3 tpm_? -132.39 94.36 3.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.504 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.777 HD11 ' HA ' ' A' ' 83' ' ' GLU . 1.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.896 0.379 . . . . 0.0 111.11 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.78 0.324 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -114.44 -175.65 2.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.913 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.27 -41.82 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.942 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.0 tp -133.11 -45.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.94 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm -75.68 133.38 31.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.983 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.433 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.592 HD13 ' HB3' ' A' ' 61' ' ' PHE . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.667 ' HB2' HG12 ' A' ' 60' ' ' VAL . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.516 ' OG ' HD11 ' A' ' 27' ' ' ILE . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.688 ' O ' HD13 ' A' ' 27' ' ' ILE . 39.2 m80 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.41 ' OD1' HG23 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.688 HD13 ' O ' ' A' ' 24' ' ' HIS . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 1.1 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.084 ' O ' HG23 ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.563 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.601 HG11 ' HG2' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.867 ' HA ' ' HB3' ' A' ' 80' ' ' ALA . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 49.7 p30 -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.461 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.601 ' HG2' HG11 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.084 HG23 ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.705 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.599 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.478 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.648 HG21 HD12 ' A' ' 44' ' ' ILE . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.573 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.667 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.592 ' HB3' HD13 ' A' ' 19' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.46 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 67' ' ' GLN . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.525 ' H ' HG22 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.462 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.607 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 72' ' ' GLU . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.91 ' HB2' HD23 ' A' ' 78' ' ' LEU . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.656 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.5 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 -98.53 -34.53 10.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.747 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -101.21 -7.06 23.43 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.492 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.91 HD23 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.17 44.47 2.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.915 0.388 . . . . 0.0 111.506 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 57' ' ' GLY . 36.1 t -66.47 117.95 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.778 179.539 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.867 ' HB3' ' HA ' ' A' ' 39' ' ' ARG . . . -63.88 110.61 2.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.816 0.341 . . . . 0.0 110.704 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 77.2 mtt-85 -117.23 155.32 49.9 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.283 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -81.39 11.67 2.98 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.864 2.376 . . . . 0.0 113.091 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 51.6 mm-40 -58.92 -44.41 91.31 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.045 0.45 . . . . 0.0 110.729 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.505 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 95.2 mt-10 -107.81 -50.54 3.04 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.673 179.38 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.505 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 39.8 ttm180 167.49 132.26 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.707 HD13 ' HB3' ' A' ' 39' ' ' ARG . 54.8 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' NE ' ' N ' ' A' ' 9' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.829 0.347 . . . . 0.0 110.867 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 65.58 74.34 0.38 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.686 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -179.7 81.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.764 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.586 ' N ' HD12 ' A' ' 12' ' ' LEU . 5.2 mp -100.76 26.31 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.479 ' HA ' HG11 ' A' ' 34' ' ' VAL . 44.3 mm -91.24 143.07 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.926 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.74 HD13 ' OG1' ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.527 HD13 ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.851 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.653 ' HB3' HG12 ' A' ' 60' ' ' VAL . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.41 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.488 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.481 ' N ' HG13 ' A' ' 23' ' ' VAL . 10.5 t-80 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HB3' ' A' ' 28' ' ' GLN . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.423 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 25' ' ' ARG . 1.2 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 27' ' ' ILE . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.426 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.035 ' O ' HG23 ' A' ' 44' ' ' ILE . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.517 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 1.102 HG22 ' CB ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.429 ' O ' HD22 ' A' ' 42' ' ' LEU . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 40' ' ' ASN . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.413 ' NH1' ' HA ' ' A' ' 82' ' ' PRO . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.515 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 40' ' ' ASN . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.619 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.724 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.035 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 1.102 ' CB ' HG22 ' A' ' 35' ' ' VAL . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.595 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.681 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.624 HG21 HD12 ' A' ' 44' ' ' ILE . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.413 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.942 ' HA2' HG21 ' A' ' 79' ' ' VAL . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.673 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.851 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.527 ' HB3' HD13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.409 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.498 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.74 ' OG1' HD13 ' A' ' 15' ' ' LEU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.5 ' H ' HG22 ' A' ' 65' ' ' THR . 66.4 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.636 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.498 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.614 ' O ' HD13 ' A' ' 73' ' ' ILE . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.614 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.472 ' H ' HD12 ' A' ' 78' ' ' LEU . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.673 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HD3' HG23 ' A' ' 58' ' ' ILE . 16.1 tpp85 -77.12 -67.02 0.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.61 -54.85 2.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -178.005 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.472 HD12 ' H ' ' A' ' 74' ' ' ASP . 71.2 mt -49.52 -23.56 1.66 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.832 -178.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.942 HG21 ' HA2' ' A' ' 57' ' ' GLY . 9.8 p -57.57 101.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.924 0.392 . . . . 0.0 111.037 179.761 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -57.05 154.43 9.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.917 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.768 ' O ' ' N ' ' A' ' 84' ' ' GLU . 54.0 mtp85 -117.0 157.86 45.51 Favored Pre-proline 0 N--CA 1.468 0.434 0 CA-C-O 119.058 -0.496 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.612 ' C ' ' H ' ' A' ' 84' ' ' GLU . 59.1 Cg_exo -30.49 -35.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.366 1.484 0 C-N-CA 122.74 2.293 . . . . 0.0 110.168 178.41 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLU . . . . . 0.552 ' N ' ' O ' ' A' ' 81' ' ' ARG . 56.5 mt-10 -69.03 24.23 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 112.935 -1.938 . . . . 0.0 109.258 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.768 ' N ' ' O ' ' A' ' 81' ' ' ARG . 55.9 mt-10 -39.19 -17.01 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.741 0.816 . . . . 0.0 112.837 -173.747 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 83' ' ' GLU . 63.3 mtt85 -74.31 66.73 1.34 Allowed 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 173.395 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.483 ' N ' ' O ' ' A' ' 84' ' ' GLU . 50.3 mm . . . . . 0 N--CA 1.454 -0.242 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.536 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 75.4 mtt-85 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.801 0.334 . . . . 0.0 110.987 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 63.42 87.14 0.11 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.087 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -105.21 32.0 4.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.768 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.512 HD22 ' OE1' ' A' ' 37' ' ' GLU . 61.0 tp -82.87 -22.01 34.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.273 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 14' ' ' GLY . 43.1 mm -82.39 158.22 3.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.496 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.563 ' O ' HD12 ' A' ' 15' ' ' LEU . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.743 HG23 ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.706 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.799 ' HB3' HG12 ' A' ' 60' ' ' VAL . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.486 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 37.5 m80 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.486 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' HB2' ' A' ' 24' ' ' HIS . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.984 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.702 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 1.038 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.512 ' OE1' HD22 ' A' ' 12' ' ' LEU . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.417 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.647 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.47 ' ND2' ' HB2' ' A' ' 80' ' ' ALA . 52.2 p-10 -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 40' ' ' ASN . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.994 HD11 ' CE2' ' A' ' 61' ' ' PHE . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 1.038 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 0.984 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.971 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.723 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.471 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.672 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 27' ' ' ILE . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.668 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.775 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.775 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.799 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.994 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.424 ' ND1' ' HG2' ' A' ' 72' ' ' GLU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.743 ' CE1' HG23 ' A' ' 17' ' ' VAL . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 70' ' ' LEU . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.605 HG22 ' H ' ' A' ' 67' ' ' GLN . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.605 ' H ' HG22 ' A' ' 65' ' ' THR . 84.9 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.748 HD22 ' C ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG2' ' ND1' ' A' ' 62' ' ' HIS . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.622 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.715 ' O ' HD23 ' A' ' 78' ' ' LEU . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.43 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? -92.1 -34.29 14.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.453 ' HB3' ' HB2' ' A' ' 74' ' ' ASP . . . -93.54 0.11 56.51 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.531 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 74' ' ' ASP . 4.2 mm? -109.14 38.02 2.41 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.134 0.492 . . . . 0.0 110.808 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.527 HG22 ' N ' ' A' ' 80' ' ' ALA . 10.8 p -47.95 162.28 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.107 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.527 ' N ' HG22 ' A' ' 79' ' ' VAL . . . -47.45 162.59 0.06 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.007 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.647 ' HG2' ' HB3' ' A' ' 39' ' ' ARG . 40.4 mmt-85 -58.44 115.36 11.26 Favored Pre-proline 0 N--CA 1.455 -0.177 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.3 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -82.44 -14.18 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.366 2.044 . . . . 0.0 112.863 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -110.37 -25.13 10.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.746 -179.528 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.426 ' HB2' ' HB3' ' A' ' 81' ' ' ARG . 88.7 mt-10 -92.8 10.45 30.87 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.594 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.407 ' HG2' ' N ' ' A' ' 86' ' ' ILE . 38.9 ttm180 65.9 159.61 0.12 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.777 0.323 . . . . 0.0 110.762 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.524 HD12 ' CB ' ' A' ' 80' ' ' ALA . 37.7 mm . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.416 ' HG2' ' N ' ' A' ' 10' ' ' HIS . 46.9 ttt85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.689 0.281 . . . . 0.0 110.705 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' HIS . . . . . 0.416 ' N ' ' HG2' ' A' ' 9' ' ' ARG . 9.7 p80 -51.41 162.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.119 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.402 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.9 tt0 -114.86 -66.15 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.62 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.439 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 22.9 tp 55.17 23.1 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.012 179.6 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 48.7 mm -91.52 160.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.375 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.458 ' CD2' HG23 ' A' ' 65' ' ' THR . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 60' ' ' VAL . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.599 ' HB2' HG12 ' A' ' 60' ' ' VAL . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.514 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.487 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.487 ' N ' HG13 ' A' ' 23' ' ' VAL . 39.3 m80 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASP . . . . . 0.408 ' OD1' HG23 ' A' ' 27' ' ' ILE . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.514 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.079 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 1.035 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' ' O ' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 80' ' ' ALA . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.445 ' O ' HG23 ' A' ' 41' ' ' THR . 49.0 p30 -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 40' ' ' ASN . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.954 HD11 ' CE2' ' A' ' 61' ' ' PHE . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 1.035 ' C ' HG23 ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.013 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 1.079 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.697 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.548 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.434 HG21 HD12 ' A' ' 44' ' ' ILE . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.459 ' HD2' HD12 ' A' ' 27' ' ' ILE . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.82 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.82 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.695 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.699 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.954 ' CE2' HD11 ' A' ' 42' ' ' LEU . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.415 ' H ' HG22 ' A' ' 65' ' ' THR . 25.6 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.635 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.536 ' N ' HD13 ' A' ' 70' ' ' LEU . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.671 HG23 HD23 ' A' ' 78' ' ' LEU . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.693 ' OD2' ' HB3' ' A' ' 77' ' ' ALA . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.593 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 -93.41 -43.16 8.89 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.693 ' HB3' ' OD2' ' A' ' 74' ' ' ASP . . . -101.14 -7.39 23.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.671 HD23 HG23 ' A' ' 73' ' ' ILE . 26.4 tp -119.85 40.47 3.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.748 0.309 . . . . 0.0 111.187 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 79' ' ' VAL . 7.8 p -59.12 100.88 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.895 0.379 . . . . 0.0 110.674 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ALA . . . . . 0.6 ' HB3' ' O ' ' A' ' 39' ' ' ARG . . . -58.69 124.78 20.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.279 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.593 ' HD2' ' O ' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -95.76 155.25 38.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 121.057 0.456 . . . . 0.0 111.566 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -90.0 -155.02 0.05 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.041 2.494 . . . . 0.0 112.333 -179.679 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -55.43 -17.72 5.6 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.692 0.282 . . . . 0.0 111.317 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.49 ' HG2' ' O ' ' A' ' 84' ' ' GLU . 39.7 tt0 -78.13 10.55 2.86 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.416 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.466 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.9 ptp85 49.49 -177.66 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.844 0.354 . . . . 0.0 111.427 -179.733 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.437 ' N ' ' HG2' ' A' ' 81' ' ' ARG . 31.7 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.265 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.435 ' HD3' ' C ' ' A' ' 9' ' ' ARG . 2.1 tmt_? . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -112.38 -29.81 7.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.472 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 42.58 30.53 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.455 -0.338 . . . . 0.0 111.719 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.873 HD23 ' O ' ' A' ' 12' ' ' LEU . 6.2 tt -77.14 -28.93 54.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.88 0.371 . . . . 0.0 110.674 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 14' ' ' GLY . 54.8 mt -56.46 154.58 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.125 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.716 ' H ' HG13 ' A' ' 34' ' ' VAL . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.914 ' O ' HG12 ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 63' ' ' PHE . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.531 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.644 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB2' HG12 ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 39.5 m80 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.711 ' HA ' HD12 ' A' ' 30' ' ' ILE . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.9 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.711 HD12 ' HA ' ' A' ' 27' ' ' ILE . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.122 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.914 HG12 ' O ' ' A' ' 15' ' ' LEU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 40' ' ' ASN . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.506 ' O ' HG23 ' A' ' 41' ' ' THR . 48.8 p30 -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.643 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.122 HG23 ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.549 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.511 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.499 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.447 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.685 ' HD2' HD23 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.822 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.822 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.696 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.712 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.531 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.573 ' CD2' ' HG2' ' A' ' 72' ' ' GLU . 2.8 m-70 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.562 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.67 ' HA ' HD22 ' A' ' 15' ' ' LEU . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.475 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.633 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.628 ' N ' HD23 ' A' ' 70' ' ' LEU . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.573 ' HG2' ' CD2' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.402 HG23 ' HG ' ' A' ' 78' ' ' LEU . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.453 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 -94.44 -48.91 5.92 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 76' ' ' ARG . . . -101.83 -20.97 14.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.497 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.887 HD13 ' O ' ' A' ' 78' ' ' LEU . 3.0 tm? -78.11 -29.48 48.96 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.436 HG21 ' HA2' ' A' ' 57' ' ' GLY . 59.3 t -54.63 99.96 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.927 0.394 . . . . 0.0 111.222 -179.724 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.98 109.96 20.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.182 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.45 ' O ' ' HG3' ' A' ' 81' ' ' ARG . 37.8 ptt180 -117.37 94.74 46.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.789 0.328 . . . . 0.0 111.647 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.464 ' HD2' ' O ' ' A' ' 85' ' ' ARG . 88.3 Cg_endo -76.07 -125.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 122.507 2.138 . . . . 0.0 111.636 179.46 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -110.35 -25.56 10.03 Favored 'General case' 0 C--O 1.231 0.104 0 O-C-N 122.041 -0.412 . . . . 0.0 111.934 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -87.0 -50.31 6.74 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.889 0.376 . . . . 0.0 111.354 -179.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ARG . . . . . 0.464 ' O ' ' HD2' ' A' ' 82' ' ' PRO . 47.5 ttt85 -174.83 -74.0 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.409 ' CD1' ' HA ' ' A' ' 39' ' ' ARG . 28.4 mm . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.202 178.643 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 59.6 ttp85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.764 0.316 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -64.62 174.29 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.966 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -115.34 135.47 54.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.792 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.847 HD23 ' O ' ' A' ' 12' ' ' LEU . 5.4 tt -79.0 -33.21 45.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.473 -179.814 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 45.4 mm -66.53 159.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.795 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.67 ' CD2' HG23 ' A' ' 65' ' ' THR . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.57 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.731 HG13 ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD2' ' HB2' ' A' ' 31' ' ' SER . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.671 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.421 ' HB2' HG12 ' A' ' 60' ' ' VAL . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.48 ' N ' HG13 ' A' ' 23' ' ' VAL . 2.3 m-70 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' ARG . . . . . 0.46 ' HD3' ' N ' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.557 ' C ' HD12 ' A' ' 27' ' ' ILE . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 19' ' ' ILE . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 18' ' ' ARG . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.074 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.608 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.714 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.527 ' OE2' HD13 ' A' ' 12' ' ' LEU . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.433 ' HB ' HG22 ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' ARG . . . . . 0.411 ' O ' HG13 ' A' ' 79' ' ' VAL . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 49.9 p30 -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.468 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.853 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.63 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.074 HG23 ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.714 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.714 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.463 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.587 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.507 ' HD2' HG13 ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.732 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.464 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.853 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 63' ' ' PHE . . . . . 0.731 ' CE1' HG13 ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.514 ' NH1' ' HB2' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.67 HG23 ' CD2' ' A' ' 15' ' ' LEU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.433 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.495 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.436 HD13 ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.694 HG12 HD11 ' A' ' 73' ' ' ILE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.779 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.779 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.857 ' HB3' HD23 ' A' ' 78' ' ' LEU . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 -82.88 -66.97 0.83 Allowed 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.22 -42.69 6.24 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.857 HD23 ' HB3' ' A' ' 74' ' ' ASP . 4.3 mm? -54.26 -20.39 6.94 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -178.635 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 39' ' ' ARG . 60.4 t -59.6 100.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 179.775 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -96.67 111.29 23.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.027 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 81' ' ' ARG . 15.6 ptp180 -100.03 103.89 25.46 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.985 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -80.5 52.87 4.51 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.565 2.177 . . . . 0.0 112.773 -179.632 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -110.02 -40.94 4.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.159 0.504 . . . . 0.0 110.654 179.542 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -107.31 -50.06 3.15 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.598 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 56.0 ttp180 179.77 152.35 0.43 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.744 179.8 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 51.2 mm . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.983 -179.951 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.9 mtp85 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.705 0.288 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.1 m80 -110.64 141.91 43.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 179.903 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 62.44 120.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.007 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.738 HD12 HD12 ' A' ' 15' ' ' LEU . 61.0 tp -82.3 -25.31 34.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.998 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 35' ' ' VAL . 46.5 mm -66.6 137.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.028 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.738 HD12 HD12 ' A' ' 12' ' ' LEU . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.407 ' HB2' ' HB2' ' A' ' 64' ' ' ARG . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 34' ' ' VAL . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.435 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.646 ' CD1' HG11 ' A' ' 54' ' ' VAL . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.738 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.949 ' HB3' HG12 ' A' ' 60' ' ' VAL . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.482 ' OG ' HG21 ' A' ' 19' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.652 HG22 ' CD1' ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' HIS . . . . . 0.563 ' H ' HD11 ' A' ' 27' ' ' ILE . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ILE . . . . . 0.756 HD12 ' HD2' ' A' ' 55' ' ' PRO . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 16.0 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 30' ' ' ILE . . . . . 0.643 HD12 ' HA ' ' A' ' 27' ' ' ILE . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 1.088 ' O ' HG23 ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 15' ' ' LEU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.873 HG23 ' OE1' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' N ' HG13 ' A' ' 35' ' ' VAL . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' GLU . . . . . 0.579 ' HG2' HD23 ' A' ' 12' ' ' LEU . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 41' ' ' THR . 47.6 p30 -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' THR . . . . . 0.507 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.728 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ARG . . . . . 0.844 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' ILE . . . . . 1.088 HG23 ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' GLU . . . . . 0.873 ' OE1' HG23 ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.601 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ILE . . . . . 0.419 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' VAL . . . . . 0.745 HG21 HD12 ' A' ' 44' ' ' ILE . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 27' ' ' ILE . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 56' ' ' LYS . . . . . 0.687 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 57' ' ' GLY . . . . . 0.485 ' O ' HG21 ' A' ' 79' ' ' VAL . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' ILE . . . . . 0.849 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' ALA . . . . . 0.672 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.949 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 61' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 42' ' ' LEU . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 62' ' ' HIS . . . . . 0.73 ' HB3' HD21 ' A' ' 70' ' ' LEU . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.676 ' HD3' HD23 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' H ' ' A' ' 67' ' ' GLN . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 67' ' ' GLN . . . . . 0.493 ' H ' HG22 ' A' ' 65' ' ' THR . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' GLU . . . . . 0.416 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' LEU . . . . . 0.73 HD21 ' HB3' ' A' ' 62' ' ' HIS . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.624 HG12 HD11 ' A' ' 73' ' ' ILE . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.763 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.763 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ASP . . . . . 0.791 ' HB2' HD13 ' A' ' 78' ' ' LEU . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' GLY . . . . . 0.672 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' ARG . . . . . 0.849 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 -78.81 -64.33 1.21 Allowed 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.85 0.31 38.34 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -177.403 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' LEU . . . . . 0.791 HD13 ' HB2' ' A' ' 74' ' ' ASP . 7.1 mp -97.8 3.76 49.91 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -179.47 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 57' ' ' GLY . 41.0 t -76.01 110.37 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.93 179.544 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -102.11 110.42 22.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.036 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 81' ' ' ARG . . . . . 0.422 ' CB ' ' HB2' ' A' ' 84' ' ' GLU . 99.2 mtt180 -85.72 152.88 57.59 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.06 -179.77 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -81.23 -92.78 0.0 OUTLIER 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.667 2.245 . . . . 0.0 113.346 -179.513 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -50.81 -25.64 4.71 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 84' ' ' GLU . . . . . 0.422 ' HB2' ' CB ' ' A' ' 81' ' ' ARG . 8.6 mp0 -74.09 -16.63 61.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.121 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 62.45 171.15 0.13 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.979 179.864 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.974 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt . . . . . 0 C--O 1.232 0.141 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.632 ' O ' HG23 ' A' ' 34' ' ' VAL . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.818 HD13 HG23 ' A' ' 30' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.455 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.65 ' OG ' HG21 ' A' ' 19' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.469 ' N ' HG13 ' A' ' 23' ' ' VAL . 91.1 m-70 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.504 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.455 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.818 HG23 HD13 ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.46 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.06 ' O ' HG23 ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 15' ' ' LEU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.768 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.421 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.665 HD13 ' N ' ' A' ' 43' ' ' ARG . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.665 ' N ' HD13 ' A' ' 42' ' ' LEU . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.06 HG23 ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.768 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.609 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.612 HG21 HD12 ' A' ' 44' ' ' ILE . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' HD13 ' A' ' 27' ' ' ILE . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.517 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.87 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.87 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.665 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.417 ' CG1' ' HG2' ' A' ' 21' ' ' ARG . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.45 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.427 ' CD2' ' HB2' ' A' ' 72' ' ' GLU . 45.4 m170 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.425 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.563 HG22 ' H ' ' A' ' 67' ' ' GLN . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.563 ' H ' HG22 ' A' ' 65' ' ' THR . 26.0 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.434 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.644 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.461 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.461 HD13 ' O ' ' A' ' 72' ' ' GLU . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.665 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 . . . . . 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.568 HD22 ' HA ' ' A' ' 65' ' ' THR . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.425 ' CZ ' ' HB2' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.452 HD13 ' HB3' ' A' ' 61' ' ' PHE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.887 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.913 ' HB2' HG12 ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 49.9 m170 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.591 ' HA ' HD11 ' A' ' 30' ' ' ILE . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.591 HD11 ' HA ' ' A' ' 27' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.901 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.727 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.95 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.477 ' HD3' ' O ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.532 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' ASN . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.789 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.95 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.901 HG23 ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.934 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.633 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . 0.407 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.473 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.443 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.709 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.789 ' HD2' HD23 ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.796 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.796 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.612 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.913 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.452 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.635 ' CZ ' HG11 ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.492 ' HD3' HD13 ' A' ' 70' ' ' LEU . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.568 ' HA ' HD22 ' A' ' 15' ' ' LEU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.438 ' OE1' HG22 ' A' ' 65' ' ' THR . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.492 HD13 ' HD3' ' A' ' 64' ' ' ARG . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 73' ' ' ILE . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.559 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.716 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm . . . . . 0 N--CA 1.458 -0.068 0 CA-C-O 120.815 0.34 . . . . 0.0 110.939 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.614 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.692 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.608 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.914 ' HB3' HG12 ' A' ' 60' ' ' VAL . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.427 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 24' ' ' HIS . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.489 ' N ' HG13 ' A' ' 23' ' ' VAL . 51.7 m170 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.809 HD12 ' HD2' ' A' ' 55' ' ' PRO . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD13 ' A' ' 19' ' ' ILE . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.425 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.128 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.865 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.441 ' N ' HG13 ' A' ' 35' ' ' VAL . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.484 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.484 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.484 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.598 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.865 ' C ' HG12 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.128 HG23 ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.874 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.576 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.518 ' HB2' ' HE2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.629 HG23 ' HB ' ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.809 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HD2' HD23 ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.811 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.811 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.636 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.914 HG12 ' HB3' ' A' ' 21' ' ' ARG . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.442 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.504 HG22 ' H ' ' A' ' 67' ' ' GLN . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.504 ' H ' HG22 ' A' ' 65' ' ' THR . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.636 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.586 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.688 HG23 ' O ' ' A' ' 13' ' ' ILE . 11.2 tp . . . . . 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.596 ' HG ' ' O ' ' A' ' 13' ' ' ILE . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.585 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.517 HG12 ' N ' ' A' ' 18' ' ' ARG . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.517 ' N ' HG12 ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.455 HG21 ' OG ' ' A' ' 22' ' ' SER . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.455 ' OG ' HG21 ' A' ' 19' ' ' ILE . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.49 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.545 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 52.2 m170 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.494 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.545 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.697 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.494 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.697 HD12 ' HA ' ' A' ' 27' ' ' ILE . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.411 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.053 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.697 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.947 HG23 ' OE1' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.636 ' CD ' HD22 ' A' ' 42' ' ' LEU . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 41' ' ' THR . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.752 ' O ' HD23 ' A' ' 42' ' ' LEU . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.752 HD23 ' O ' ' A' ' 41' ' ' THR . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.618 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.053 HG23 ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.947 ' OE1' HG23 ' A' ' 35' ' ' VAL . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.693 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.513 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 1.021 HG21 HD12 ' A' ' 44' ' ' ILE . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.69 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.728 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 60' ' ' VAL . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.575 ' CE2' HD12 ' A' ' 42' ' ' LEU . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.496 ' CD2' HD11 ' A' ' 73' ' ' ILE . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.477 ' HG3' HD13 ' A' ' 70' ' ' LEU . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 64' ' ' ARG . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.491 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.728 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.668 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 . . . . . 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.702 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.777 HG23 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.708 HG21 ' OG ' ' A' ' 22' ' ' SER . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.581 ' HB3' HG11 ' A' ' 60' ' ' VAL . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.708 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 27' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 48.1 m170 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.577 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.41 ' C ' ' OE1' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.607 ' O ' HG23 ' A' ' 30' ' ' ILE . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.126 ' O ' HG23 ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.709 HG21 ' CE2' ' A' ' 63' ' ' PHE . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.733 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.49 ' HB ' HG22 ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.49 HG22 ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.63 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.636 ' C ' HG12 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.126 HG23 ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.733 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.566 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.451 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.519 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.577 ' HD2' HD12 ' A' ' 27' ' ' ILE . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.801 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.801 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.581 HG11 ' HB3' ' A' ' 20' ' ' ALA . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.444 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.417 ' CD2' ' HB2' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.777 ' CE1' HG23 ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.424 HH11 HD12 ' A' ' 70' ' ' LEU . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.536 ' H ' HG22 ' A' ' 65' ' ' THR . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 71' ' ' VAL . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 70' ' ' LEU . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.444 ' N ' HG22 ' A' ' 73' ' ' ILE . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.657 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER . . . . . 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 13' ' ' ILE . 18.0 tt . . . . . 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.527 ' HG ' ' O ' ' A' ' 13' ' ' ILE . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.519 HG12 ' N ' ' A' ' 18' ' ' ARG . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.519 ' N ' HG12 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.56 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.683 ' HB2' HG12 ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 24' ' ' HIS . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.53 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.53 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.923 HD12 HG13 ' A' ' 54' ' ' VAL . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.4 ' CB ' ' HA ' ' A' ' 18' ' ' ARG . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.023 ' O ' HG23 ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.762 ' HA ' ' HA ' ' A' ' 44' ' ' ILE . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.926 HG23 ' OE1' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.457 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.442 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.655 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.57 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.023 HG23 ' O ' ' A' ' 33' ' ' ARG . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.926 ' OE1' HG23 ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.715 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . 0.449 ' C ' ' H ' ' A' ' 49' ' ' GLY . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 52' ' ' ILE . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.923 HG13 HD12 ' A' ' 27' ' ' ILE . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.761 ' HD2' HD13 ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.84 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.84 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.713 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.515 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.524 ' CD2' HD12 ' A' ' 15' ' ' LEU . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.538 ' H ' HG22 ' A' ' 65' ' ' THR . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.647 HD23 ' N ' ' A' ' 71' ' ' VAL . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.647 ' N ' HD23 ' A' ' 70' ' ' LEU . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.629 ' O ' HD13 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.629 HD13 ' O ' ' A' ' 72' ' ' GLU . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.713 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.579 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 . . . . . 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 65' ' ' THR . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.413 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.477 HD13 ' CB ' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.998 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.591 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.562 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.591 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.444 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.897 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.697 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.963 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.487 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.487 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.963 ' C ' HG23 ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.897 HG23 ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.896 ' N ' HG22 ' A' ' 35' ' ' VAL . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.745 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.715 HG23 ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.517 ' HD2' HD12 ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.612 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.826 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.826 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.738 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.998 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.477 ' CB ' HD13 ' A' ' 19' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.664 ' CD2' HD11 ' A' ' 73' ' ' ILE . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.472 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.537 ' H ' HG22 ' A' ' 65' ' ' THR . 8.3 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.429 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.472 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.472 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.449 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.664 HD11 ' CD2' ' A' ' 63' ' ' PHE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.738 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 . . . . . 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.497 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.491 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.628 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.484 ' HB3' HG12 ' A' ' 60' ' ' VAL . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.403 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.492 ' N ' HG13 ' A' ' 23' ' ' VAL . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.436 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.406 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.07 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.621 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.836 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.439 ' N ' HG13 ' A' ' 35' ' ' VAL . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.458 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.458 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.588 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.836 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.07 HG23 ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.935 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.527 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.4 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.485 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' HD12 ' A' ' 27' ' ' ILE . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.809 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.809 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.667 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.48 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 72' ' ' GLU . 48.9 m170 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.47 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.417 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.519 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.519 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.581 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.511 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.609 ' O ' HD13 ' A' ' 73' ' ' ILE . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.609 HD13 ' O ' ' A' ' 72' ' ' GLU . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.64 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 . . . . . 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt . . . . . 0 C--O 1.231 0.084 0 CA-C-O 120.848 0.356 . . . . 0.0 111.078 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.666 HD22 ' OG1' ' A' ' 65' ' ' THR . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.572 HG22 ' CD2' ' A' ' 63' ' ' PHE . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.436 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.75 ' NH2' HG11 ' A' ' 60' ' ' VAL . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.518 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.51 HG13 ' N ' ' A' ' 24' ' ' HIS . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.512 ' HB3' HG12 ' A' ' 27' ' ' ILE . 18.5 t-160 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.428 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.978 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.625 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.999 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.447 ' OE1' ' N ' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.43 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.528 ' C ' HD13 ' A' ' 42' ' ' LEU . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.999 ' C ' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.978 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.981 ' N ' HG22 ' A' ' 35' ' ' VAL . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.557 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 50' ' ' ARG . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.419 ' HD3' ' HB2' ' A' ' 48' ' ' ASP . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.61 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.925 HG21 HD12 ' A' ' 44' ' ' ILE . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.788 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.788 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.571 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.75 HG11 ' NH2' ' A' ' 21' ' ' ARG . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.479 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.472 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.733 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.666 ' OG1' HD22 ' A' ' 15' ' ' LEU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.507 ' H ' HG22 ' A' ' 65' ' ' THR . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.433 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.634 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.568 HG12 HD11 ' A' ' 73' ' ' ILE . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.824 ' C ' HD12 ' A' ' 73' ' ' ILE . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.824 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.67 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 . . . . . 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.782 0.325 . . . . 0.0 110.968 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.846 HD22 ' OG1' ' A' ' 65' ' ' THR . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.591 HD13 ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.77 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB3' HG12 ' A' ' 60' ' ' VAL . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.782 HG12 ' HB ' ' A' ' 58' ' ' ILE . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.486 ' N ' HG23 ' A' ' 23' ' ' VAL . 53.7 m170 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.435 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.48 HG13 ' CB ' ' A' ' 22' ' ' SER . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.435 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.149 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.708 HG21 ' CE2' ' A' ' 63' ' ' PHE . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.831 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' HG22 ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.472 ' HA ' ' NE ' ' A' ' 39' ' ' ARG . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.414 ' H ' HG22 ' A' ' 38' ' ' THR . 0.0 OUTLIER -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.427 HG22 ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.891 HD13 ' N ' ' A' ' 43' ' ' ARG . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.891 ' N ' HD13 ' A' ' 42' ' ' LEU . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.149 HG23 ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.831 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.648 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . 0.414 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.537 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.556 ' CG2' HD12 ' A' ' 44' ' ' ILE . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.6 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.866 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.866 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.745 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.591 ' HB3' HD13 ' A' ' 19' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HG21 ' A' ' 34' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.846 ' OG1' HD22 ' A' ' 15' ' ' LEU . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.568 ' H ' HG22 ' A' ' 65' ' ' THR . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.553 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.489 ' OD1' ' HG2' ' A' ' 76' ' ' ARG . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.745 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.648 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 . . . . . 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.573 ' N ' HD12 ' A' ' 13' ' ' ILE . 2.0 mp . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.407 ' O ' HG12 ' A' ' 34' ' ' VAL . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.453 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.678 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.747 ' HB2' HG12 ' A' ' 60' ' ' VAL . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.994 HG21 HG13 ' A' ' 54' ' ' VAL . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 27' ' ' ILE . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.418 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.139 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.541 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.626 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 40' ' ' ASN . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.723 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.627 ' O ' HG12 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.139 HG23 ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.872 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.635 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.556 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.415 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 27' ' ' ILE . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.545 ' HD2' HG21 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.723 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.857 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.857 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.747 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.541 ' CZ ' HD11 ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.532 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.402 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.614 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.509 ' O ' HD13 ' A' ' 73' ' ' ILE . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.513 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 . . . . . 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.581 ' HA ' HG13 ' A' ' 34' ' ' VAL . 50.0 mt . . . . . 0 CA--C 1.528 0.129 0 CA-C-O 120.813 0.339 . . . . 0.0 111.134 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.762 HD22 ' OG1' ' A' ' 65' ' ' THR . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.445 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.829 HD13 HG23 ' A' ' 30' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.519 ' HB2' HG12 ' A' ' 60' ' ' VAL . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.566 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.566 ' CD2' HG13 ' A' ' 23' ' ' VAL . 90.0 m-70 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.769 HG21 ' HD2' ' A' ' 55' ' ' PRO . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.829 HG23 HD13 ' A' ' 19' ' ' ILE . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.409 ' N ' HG12 ' A' ' 30' ' ' ILE . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.15 ' O ' HG23 ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.581 HG13 ' HA ' ' A' ' 13' ' ' ILE . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.621 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.5 ' HG3' ' HZ1' ' A' ' 56' ' ' LYS . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.493 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.514 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 40' ' ' ASN . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.641 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.538 ' HG2' HG11 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.15 HG23 ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.689 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.643 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.481 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.408 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.556 HG13 HG21 ' A' ' 27' ' ' ILE . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.769 ' HD2' HG21 ' A' ' 27' ' ' ILE . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.6 ' NZ ' HD23 ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.896 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.772 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.519 HG12 ' HB2' ' A' ' 21' ' ' ARG . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.485 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.762 ' OG1' HD22 ' A' ' 15' ' ' LEU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.547 ' H ' HG22 ' A' ' 65' ' ' THR . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.543 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.772 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.864 0.364 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.404 ' CD2' ' HD2' ' A' ' 66' ' ' PRO . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.576 HG21 ' OG ' ' A' ' 22' ' ' SER . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.799 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.814 ' HB3' HG12 ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.576 ' OG ' HG21 ' A' ' 19' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.686 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.686 ' ND1' HG13 ' A' ' 23' ' ' VAL . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.557 ' OD1' HG23 ' A' ' 27' ' ' ILE . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.557 HG23 ' OD1' ' A' ' 26' ' ' ASP . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.618 ' O ' HG23 ' A' ' 30' ' ' ILE . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.95 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.619 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 1.014 HG22 ' N ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.496 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.482 ' HD3' ' C ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.52 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.52 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.622 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 1.008 ' C ' HG23 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.95 HG23 ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 1.014 ' N ' HG22 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.602 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.818 HG21 HD12 ' A' ' 44' ' ' ILE . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.56 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.841 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.841 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.589 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.814 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.551 ' HB3' HD13 ' A' ' 19' ' ' ILE . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.502 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.421 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.509 HG22 ' H ' ' A' ' 67' ' ' GLN . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.509 ' H ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 71' ' ' VAL . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.457 ' OD1' HG23 ' A' ' 60' ' ' VAL . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.589 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.777 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 . . . . . 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.455 HG22 ' N ' ' A' ' 14' ' ' GLY . 56.6 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.73 0.3 . . . . 0.0 110.885 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.455 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.596 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 18' ' ' ARG . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.493 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.414 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.768 ' HB2' HG12 ' A' ' 60' ' ' VAL . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.437 ' HA ' ' HB2' ' A' ' 59' ' ' ALA . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.42 ' HB2' ' CD1' ' A' ' 27' ' ' ILE . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.92 ' OD1' HG23 ' A' ' 27' ' ' ILE . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.92 HG23 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.409 ' C ' HD12 ' A' ' 30' ' ' ILE . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.661 ' N ' HD12 ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.123 ' O ' HG23 ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.655 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.864 HG12 ' C ' ' A' ' 43' ' ' ARG . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.458 ' N ' HG13 ' A' ' 35' ' ' VAL . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.762 HG22 ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.54 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.54 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.982 HD11 ' CE2' ' A' ' 61' ' ' PHE . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.864 ' C ' HG12 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.123 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.855 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.593 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.638 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.437 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.715 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.778 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.778 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.768 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.982 ' CE2' HD11 ' A' ' 42' ' ' LEU . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.44 ' CD1' HG13 ' A' ' 17' ' ' VAL . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.415 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.431 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.454 ' HG3' ' HG2' ' A' ' 69' ' ' GLU . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.454 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.589 HG12 HD11 ' A' ' 73' ' ' ILE . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.795 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.795 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.675 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 . . . . . 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.6 mt . . . . . 0 N--CA 1.456 -0.143 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.704 HG23 ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.583 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.844 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.83 ' HB3' HG12 ' A' ' 60' ' ' VAL . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.458 ' OG ' HG21 ' A' ' 19' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.496 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.5 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 46.5 m170 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.5 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.698 HD12 ' HD2' ' A' ' 55' ' ' PRO . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.661 HD13 ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.544 ' N ' HD13 ' A' ' 30' ' ' ILE . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.106 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.599 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 39' ' ' ARG . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.469 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 40' ' ' ASN . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.707 HD23 ' HD3' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.61 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.106 HG23 ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 1.081 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.621 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.407 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.701 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.698 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.707 ' HD3' HD23 ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.828 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.828 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.844 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.583 ' HB3' HD13 ' A' ' 19' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.434 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.704 ' CE1' HG23 ' A' ' 17' ' ' VAL . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.758 ' HE ' HD23 ' A' ' 70' ' ' LEU . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.442 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 65' ' ' THR . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.758 HD23 ' HE ' ' A' ' 64' ' ' ARG . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 72' ' ' GLU . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.673 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm . . . . . 0 N--CA 1.456 -0.132 0 CA-C-O 120.732 0.301 . . . . 0.0 110.983 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.433 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.592 HD13 ' HB3' ' A' ' 61' ' ' PHE . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.667 ' HB2' HG12 ' A' ' 60' ' ' VAL . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.516 ' OG ' HD11 ' A' ' 27' ' ' ILE . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.688 ' O ' HD13 ' A' ' 27' ' ' ILE . 90.2 m-70 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.503 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.41 ' OD1' HG23 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.688 HD13 ' O ' ' A' ' 24' ' ' HIS . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.425 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 4.9 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.425 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.084 ' O ' HG23 ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.563 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.601 HG11 ' HG2' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.461 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.601 ' HG2' HG11 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.084 HG23 ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.705 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.599 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.478 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.648 HG21 HD12 ' A' ' 44' ' ' ILE . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.573 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.667 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.592 ' HB3' HD13 ' A' ' 19' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.46 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 67' ' ' GLN . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.525 ' H ' HG22 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.462 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.607 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 72' ' ' GLU . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.656 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.5 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 . . . . . 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.479 ' HA ' HG11 ' A' ' 34' ' ' VAL . 44.3 mm . . . . . 0 C--O 1.231 0.118 0 CA-C-O 120.716 0.293 . . . . 0.0 110.926 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.74 HD13 ' OG1' ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.527 HD13 ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.851 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.653 ' HB3' HG12 ' A' ' 60' ' ' VAL . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.41 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.488 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.495 ' CD2' ' HB3' ' A' ' 26' ' ' ASP . 40.0 t60 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HB3' ' A' ' 28' ' ' GLN . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.495 ' HB3' ' CD2' ' A' ' 24' ' ' HIS . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.423 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 25' ' ' ARG . 5.7 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.418 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 27' ' ' ILE . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.426 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.035 ' O ' HG23 ' A' ' 44' ' ' ILE . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.517 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 1.102 HG22 ' CB ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.429 ' O ' HD22 ' A' ' 42' ' ' LEU . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 40' ' ' ASN . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.515 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 40' ' ' ASN . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.619 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.724 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.035 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 1.102 ' CB ' HG22 ' A' ' 35' ' ' VAL . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.595 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.681 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.624 HG21 HD12 ' A' ' 44' ' ' ILE . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.413 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.673 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.851 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.527 ' HB3' HD13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.409 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.498 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.74 ' OG1' HD13 ' A' ' 15' ' ' LEU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.5 ' H ' HG22 ' A' ' 65' ' ' THR . 8.3 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.636 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.498 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.614 ' O ' HD13 ' A' ' 73' ' ' ILE . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.614 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.673 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HD3' HG23 ' A' ' 58' ' ' ILE . 16.1 tpp85 . . . . . 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 14' ' ' GLY . 43.1 mm . . . . . 0 CA--C 1.527 0.06 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.496 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.563 ' O ' HD12 ' A' ' 15' ' ' LEU . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.743 HG23 ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.706 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.799 ' HB3' HG12 ' A' ' 60' ' ' VAL . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.498 HG13 ' CD2' ' A' ' 24' ' ' HIS . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.498 ' CD2' HG13 ' A' ' 23' ' ' VAL . 88.1 m-70 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.486 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' HB2' ' A' ' 24' ' ' HIS . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.984 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.702 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 1.038 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.424 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.417 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.42 ' HD3' ' H ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.402 ' N ' ' HG2' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 40' ' ' ASN . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.994 HD11 ' CE2' ' A' ' 61' ' ' PHE . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 1.038 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 0.984 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.971 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.723 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.471 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.672 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 27' ' ' ILE . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.668 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.775 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.775 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.799 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.994 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.424 ' ND1' ' HG2' ' A' ' 72' ' ' GLU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.743 ' CE1' HG23 ' A' ' 17' ' ' VAL . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 70' ' ' LEU . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.605 HG22 ' H ' ' A' ' 67' ' ' GLN . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.605 ' H ' HG22 ' A' ' 65' ' ' THR . 26.0 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.748 HD22 ' C ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG2' ' ND1' ' A' ' 62' ' ' HIS . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.622 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.43 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? . . . . . 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 48.7 mm . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.831 0.348 . . . . 0.0 111.375 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.458 ' CD2' HG23 ' A' ' 65' ' ' THR . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 60' ' ' VAL . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.599 ' HB2' HG12 ' A' ' 60' ' ' VAL . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.514 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.487 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.487 ' N ' HG13 ' A' ' 23' ' ' VAL . 90.7 m-70 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . 0.408 ' OD1' HG23 ' A' ' 27' ' ' ILE . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.514 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.079 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.623 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 1.035 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' ' O ' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.445 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 40' ' ' ASN . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.954 HD11 ' CE2' ' A' ' 61' ' ' PHE . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 1.035 ' C ' HG23 ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.013 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 1.079 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.697 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.548 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.434 HG21 HD12 ' A' ' 44' ' ' ILE . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.459 ' HD2' HD12 ' A' ' 27' ' ' ILE . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.82 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.82 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.695 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.699 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.954 ' CE2' HD11 ' A' ' 42' ' ' LEU . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.415 ' H ' HG22 ' A' ' 65' ' ' THR . 32.0 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.635 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.536 ' N ' HD13 ' A' ' 70' ' ' LEU . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.534 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.593 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 . . . . . 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 14' ' ' GLY . 54.8 mt . . . . . 0 CA--C 1.53 0.174 0 CA-C-O 120.693 0.282 . . . . 0.0 111.125 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.716 ' H ' HG13 ' A' ' 34' ' ' VAL . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.914 ' O ' HG12 ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 63' ' ' PHE . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.531 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.644 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB2' HG12 ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 90.4 m-70 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.711 ' HA ' HD12 ' A' ' 30' ' ' ILE . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.711 HD12 ' HA ' ' A' ' 27' ' ' ILE . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.122 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.914 HG12 ' O ' ' A' ' 15' ' ' LEU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 40' ' ' ASN . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.506 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.685 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.643 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.122 HG23 ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.549 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.511 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.499 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.447 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.685 ' HD2' HD23 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.822 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.822 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.696 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.712 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.531 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.45 ' CE1' ' HG2' ' A' ' 72' ' ' GLU . 46.9 m170 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.562 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.67 ' HA ' HD22 ' A' ' 15' ' ' LEU . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.475 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.633 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.628 ' N ' HD23 ' A' ' 70' ' ' LEU . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.45 ' HG2' ' CE1' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 . . . . . 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 45.4 mm . . . . . 0 CA--C 1.527 0.095 0 CA-C-O 120.707 0.289 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.67 ' CD2' HG23 ' A' ' 65' ' ' THR . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.57 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.731 HG13 ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD2' ' HB2' ' A' ' 31' ' ' SER . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.671 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.421 ' HB2' HG12 ' A' ' 60' ' ' VAL . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.48 ' N ' HG13 ' A' ' 23' ' ' VAL . 43.8 m170 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . 0.46 ' HD3' ' N ' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.557 ' C ' HD12 ' A' ' 27' ' ' ILE . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 19' ' ' ILE . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 18' ' ' ARG . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.074 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.608 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.714 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.433 ' HB ' HG22 ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.468 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.853 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.63 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.074 HG23 ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.714 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.714 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.463 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.587 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.507 ' HD2' HG13 ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.732 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.464 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.853 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . 0.731 ' CE1' HG13 ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.514 ' NH1' ' HB2' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.67 HG23 ' CD2' ' A' ' 15' ' ' LEU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.433 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.495 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.436 HD13 ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.694 HG12 HD11 ' A' ' 73' ' ' ILE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.779 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.779 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 . . . . . 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 35' ' ' VAL . 46.5 mm . . . . . 0 C--O 1.231 0.08 0 CA-C-O 120.855 0.359 . . . . 0.0 111.028 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.645 ' O ' HG23 ' A' ' 34' ' ' VAL . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.407 ' HB2' ' HB2' ' A' ' 64' ' ' ARG . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 34' ' ' VAL . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ARG . . . . . 0.435 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.646 ' CD1' HG11 ' A' ' 54' ' ' VAL . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.738 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.949 ' HB3' HG12 ' A' ' 60' ' ' VAL . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.482 ' OG ' HG21 ' A' ' 19' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.652 HG22 ' CD1' ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . 0.563 ' H ' HD11 ' A' ' 27' ' ' ILE . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . 0.756 HD12 ' HD2' ' A' ' 55' ' ' PRO . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 50.8 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' ILE . . . . . 0.643 HD12 ' HA ' ' A' ' 27' ' ' ILE . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 1.088 ' O ' HG23 ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 15' ' ' LEU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.873 HG23 ' OE1' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' ASP . . . . . 0.435 ' N ' HG13 ' A' ' 35' ' ' VAL . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' GLU . . . . . 0.427 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' THR . . . . . 0.507 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.728 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ARG . . . . . 0.844 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' ILE . . . . . 1.088 HG23 ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' GLU . . . . . 0.873 ' OE1' HG23 ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.601 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ILE . . . . . 0.419 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' VAL . . . . . 0.745 HG21 HD12 ' A' ' 44' ' ' ILE . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 27' ' ' ILE . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' LYS . . . . . 0.687 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' ILE . . . . . 0.849 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' ALA . . . . . 0.672 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.949 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 42' ' ' LEU . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' HIS . . . . . 0.73 ' HB3' HD21 ' A' ' 70' ' ' LEU . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.676 ' HD3' HD23 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' H ' ' A' ' 67' ' ' GLN . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' GLN . . . . . 0.493 ' H ' HG22 ' A' ' 65' ' ' THR . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' GLU . . . . . 0.416 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' LEU . . . . . 0.73 HD21 ' HB3' ' A' ' 62' ' ' HIS . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.624 HG12 HD11 ' A' ' 73' ' ' ILE . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.763 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.763 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 75' ' ' GLY . . . . . 0.672 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 76' ' ' ARG . . . . . 0.849 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 . . . . . 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 99.2 mtt180 . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.746 0.308 . . . . 0.0 111.033 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 20.7 t-160 64.04 130.76 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.535 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -50.74 -175.91 0.0 OUTLIER 'General case' 0 N--CA 1.463 0.178 0 CA-C-O 120.912 0.387 . . . . 0.0 111.282 -179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.795 HD23 ' H ' ' A' ' 12' ' ' LEU . 1.9 pt? -127.99 29.61 5.38 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.183 -179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 57.2 mt -82.21 102.79 8.54 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-O 120.811 0.339 . . . . 0.0 110.71 179.759 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.08 -23.62 9.81 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.478 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.632 ' O ' HG23 ' A' ' 34' ' ' VAL . 73.4 mt -58.49 165.97 1.94 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.811 0.339 . . . . 0.0 111.029 179.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.1 m -89.82 147.57 23.71 Favored 'General case' 0 C--N 1.329 -0.287 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 6.3 p -147.36 135.5 15.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.896 0.379 . . . . 0.0 111.362 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 76.3 mtp180 -122.8 134.08 54.43 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.11 -179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.818 HD13 HG23 ' A' ' 30' ' ' ILE . 1.3 mp -98.55 136.72 28.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.102 -179.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -98.66 -30.63 12.36 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.099 0.476 . . . . 0.0 110.7 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.455 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 39.1 ptt180 -168.14 130.93 1.51 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.551 179.51 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.65 ' OG ' HG21 ' A' ' 19' ' ' ILE . 70.7 m -128.62 164.29 23.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.022 0.439 . . . . 0.0 111.546 -179.238 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.469 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.5 p -52.74 -46.44 50.68 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.857 -0.61 . . . . 0.0 111.437 179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.469 ' N ' HG13 ' A' ' 23' ' ' VAL . 91.1 m-70 -97.4 137.08 36.92 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.788 0.328 . . . . 0.0 110.975 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 99.0 mtt180 -68.03 -26.47 65.9 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.196 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.8 m-20 -62.66 -25.9 68.37 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.981 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.504 HG13 ' HB2' ' A' ' 22' ' ' SER . 21.7 pt -112.52 -18.7 7.43 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.335 179.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.455 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 52.7 tt0 -50.4 126.12 14.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.379 -179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.9 17.65 79.95 Favored Glycine 0 N--CA 1.451 -0.363 0 C-N-CA 120.93 -0.653 . . . . 0.0 113.066 179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.818 HG23 HD13 ' A' ' 19' ' ' ILE . 14.3 tt -74.36 157.58 6.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.859 0.361 . . . . 0.0 110.934 179.995 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.46 ' N ' HG12 ' A' ' 30' ' ' ILE . 80.1 p -142.69 138.83 30.87 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.202 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.63 -161.72 27.83 Favored Glycine 0 N--CA 1.449 -0.473 0 C-N-CA 120.138 -1.029 . . . . 0.0 112.712 -179.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.06 ' O ' HG23 ' A' ' 44' ' ' ILE . 94.1 mtt180 -102.06 172.19 7.06 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 121.587 0.708 . . . . 0.0 112.111 -179.711 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.632 HG23 ' O ' ' A' ' 15' ' ' LEU . 41.6 t -100.56 154.45 4.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.063 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -175.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.768 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.2 p -136.94 -47.6 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.169 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.226 177.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.421 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 35.9 t70 -158.62 162.57 37.3 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.664 179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -128.05 131.45 49.12 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.873 179.76 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.3 m -122.81 155.69 36.05 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.809 0.338 . . . . 0.0 111.063 -179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.419 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 5.8 ptp85 -44.6 -44.19 8.7 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.023 -0.535 . . . . 0.0 112.05 -179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.419 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -131.45 29.31 4.58 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.986 0.365 . . . . 0.0 111.986 -179.465 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.461 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 87.7 m -157.19 131.2 8.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.005 0.431 . . . . 0.0 111.134 179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.665 HD13 ' N ' ' A' ' 43' ' ' ARG . 1.9 tm? -106.16 124.82 50.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.716 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.665 ' N ' HD13 ' A' ' 42' ' ' LEU . 10.2 tpp180 -101.99 126.68 48.96 Favored 'General case' 0 N--CA 1.45 -0.469 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.06 HG23 ' O ' ' A' ' 33' ' ' ARG . 45.2 mt -111.64 115.41 49.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.635 0 N-CA-C 114.465 1.283 . . . . 0.0 114.465 -176.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.768 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -131.38 144.19 51.04 Favored 'General case' 0 C--O 1.258 1.506 0 CA-C-O 121.135 0.493 . . . . 0.0 110.51 176.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.609 ' CA ' ' HB2' ' A' ' 33' ' ' ARG . 1.9 ptp -118.88 135.77 54.39 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.636 -1.62 . . . . 0.0 110.321 178.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.5 t70 -42.31 -26.29 0.1 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 115.222 -0.899 . . . . 0.0 112.459 -178.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 62.6 t0 -58.76 -16.09 15.19 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 120.983 0.421 . . . . 0.0 110.094 179.187 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.64 16.82 25.51 Favored Glycine 0 N--CA 1.448 -0.548 0 CA-C-N 115.971 -0.559 . . . . 0.0 111.966 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 87.4 mtm180 -105.67 125.37 50.91 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.852 0.358 . . . . 0.0 111.472 179.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -119.02 149.69 41.23 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.152 -179.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.59 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -159.3 138.69 3.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.469 179.748 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -92.52 154.24 18.57 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.969 0.414 . . . . 0.0 112.006 -179.305 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.612 HG21 HD12 ' A' ' 44' ' ' ILE . 45.9 t -152.16 105.15 2.79 Favored Pre-proline 0 CA--C 1.533 0.292 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.116 179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.418 ' HD2' HD13 ' A' ' 27' ' ' ILE . 84.3 Cg_exo -47.55 140.83 15.86 Favored 'Trans proline' 0 C--N 1.35 0.637 0 C-N-CA 123.099 2.533 . . . . 0.0 113.58 -179.556 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.517 ' NZ ' ' HB3' ' A' ' 56' ' ' LYS . 10.0 mtpm? -100.62 -1.74 34.59 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.405 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.87 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -36.62 19.87 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.222 -0.99 . . . . 0.0 112.927 -178.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.87 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.7 mp -156.11 63.3 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.665 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -138.33 110.47 7.33 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -178.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.417 ' CG1' ' HG2' ' A' ' 21' ' ' ARG . 12.5 p -89.6 132.58 33.96 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.247 178.023 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.45 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 1.7 p90 -156.03 151.18 26.55 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.097 0.475 . . . . 0.0 111.87 -179.343 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.427 ' CD2' ' HB2' ' A' ' 72' ' ' GLU . 45.4 m170 -116.67 144.57 44.26 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.104 179.722 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HD12 ' A' ' 12' ' ' LEU . 1.7 m-85 -101.53 155.14 18.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.952 0.406 . . . . 0.0 111.086 -179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.8 mmm-85 -131.09 129.21 41.6 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.879 -0.601 . . . . 0.0 110.612 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.563 HG22 ' H ' ' A' ' 67' ' ' GLN . 68.1 m -106.83 130.56 22.71 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.574 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -50.32 -29.67 24.16 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.728 2.285 . . . . 0.0 112.163 179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.563 ' H ' HG22 ' A' ' 65' ' ' THR . 26.0 mt-30 -62.35 -16.51 54.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.697 179.398 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 47.11 1.35 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.337 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.434 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 45.2 mt-10 -121.05 151.95 39.21 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.93 0.395 . . . . 0.0 111.169 -179.97 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.644 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -125.43 110.72 14.27 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.596 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.406 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 48.9 t -114.09 149.03 16.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.856 179.826 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.461 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -127.55 140.31 52.2 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.299 -179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.461 HD13 ' O ' ' A' ' 72' ' ' GLU . 47.0 mm -138.24 138.73 42.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.184 179.481 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.467 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.1 m-20 -109.12 122.43 47.28 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.388 0.613 . . . . 0.0 111.76 -179.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.665 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.12 -11.96 59.38 Favored Glycine 0 N--CA 1.447 -0.607 0 CA-C-N 115.396 -0.82 . . . . 0.0 112.323 179.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.482 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 78.4 ttt180 -98.38 -49.03 4.82 Favored 'General case' 0 N--CA 1.451 -0.405 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -178.227 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.18 -16.58 16.97 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.741 1.015 . . . . 0.0 113.741 -177.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.467 ' HB2' ' O ' ' A' ' 74' ' ' ASP . 78.4 mt -111.15 32.57 5.21 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 112.56 0.578 . . . . 0.0 112.56 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.634 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.4 p -73.66 100.31 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 N-CA-C 109.925 -0.398 . . . . 0.0 109.925 178.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.46 152.45 25.38 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.178 0.513 . . . . 0.0 112.082 -178.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.494 ' HB2' ' HB3' ' A' ' 84' ' ' GLU . 2.1 ptp180 -117.49 94.84 46.46 Favored Pre-proline 0 CA--C 1.532 0.268 0 CA-C-N 115.569 -0.742 . . . . 0.0 110.469 179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -68.69 -88.86 0.0 OUTLIER 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.588 2.192 . . . . 0.0 113.652 -178.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 54.1 mm-40 -50.85 -25.47 4.56 Favored 'General case' 0 C--N 1.329 -0.305 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.494 ' HB3' ' HB2' ' A' ' 81' ' ' ARG . 40.7 tp10 -84.12 1.76 42.65 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.43 -179.978 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 63.53 152.09 0.04 OUTLIER 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.868 0.366 . . . . 0.0 111.069 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 86' ' ' ILE . 1.6 mp . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.906 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 15.9 ptp180 . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.807 0.337 . . . . 0.0 110.861 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 14.6 t-160 -167.91 110.71 0.62 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.902 179.992 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.0 tm-20 -142.81 -69.23 0.34 Allowed 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.598 179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.758 HD12 HD12 ' A' ' 15' ' ' LEU . 45.3 tp -139.14 9.45 2.53 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.367 179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.719 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp -91.11 158.6 2.87 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-O 120.793 0.33 . . . . 0.0 110.818 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.514 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 84.62 6.67 85.37 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.841 -0.695 . . . . 0.0 112.626 -179.925 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.758 HD12 HD12 ' A' ' 12' ' ' LEU . 57.3 mt -106.48 166.03 10.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.826 0.346 . . . . 0.0 110.963 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.434 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.5 m -93.98 158.25 15.72 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.019 179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 27.5 t -144.75 148.3 18.21 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 CA-C-O 120.923 0.392 . . . . 0.0 111.569 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.425 ' CZ ' ' HB2' ' A' ' 18' ' ' ARG . 16.8 ttm105 -131.12 118.69 20.86 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.664 179.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.452 HD13 ' HB3' ' A' ' 61' ' ' PHE . 49.2 mm -82.24 118.86 30.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.235 -179.85 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.887 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -97.14 -31.96 12.2 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.077 0.465 . . . . 0.0 110.668 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.913 ' HB2' HG12 ' A' ' 60' ' ' VAL . 59.5 mmt-85 -148.64 145.63 27.83 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.186 179.364 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.453 ' HB3' HG13 ' A' ' 27' ' ' ILE . 38.5 m -139.28 164.12 30.66 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.96 0.41 . . . . 0.0 111.34 -179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.412 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.2 p -73.94 -35.38 42.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.889 179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 49.9 m170 -116.51 137.1 52.43 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.8 179.833 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 39.2 ptt180 -62.43 -26.63 68.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.212 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -66.77 -14.95 63.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.341 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.591 ' HA ' HD11 ' A' ' 30' ' ' ILE . 26.1 pt -124.14 21.51 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.308 0 CA-C-O 120.77 0.319 . . . . 0.0 111.514 -179.706 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.6 tp-100 -87.18 149.09 24.87 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.321 -0.4 . . . . 0.0 111.443 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 68.21 18.06 70.8 Favored Glycine 0 N--CA 1.453 -0.226 0 C-N-CA 120.917 -0.659 . . . . 0.0 113.446 179.251 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.591 HD11 ' HA ' ' A' ' 27' ' ' ILE . 56.3 mt -75.27 132.51 33.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 117.061 0.43 . . . . 0.0 111.193 179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.4 t -135.04 128.25 31.96 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.259 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.64 -161.85 27.17 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.22 -0.991 . . . . 0.0 112.765 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.901 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.2 mtt180 -99.07 172.03 7.65 Favored 'General case' 0 C--O 1.217 -0.626 0 CA-C-O 121.532 0.682 . . . . 0.0 111.961 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.727 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.2 p -100.29 155.44 4.28 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.891 0 N-CA-C 114.717 1.377 . . . . 0.0 114.717 -175.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.95 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.87 -49.64 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 176.808 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.474 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 8.2 t70 -159.88 161.82 34.45 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.365 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.474 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 39.1 tt0 -128.78 119.24 24.17 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.658 -0.247 . . . . 0.0 110.37 179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.445 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 90.4 m -122.89 159.9 27.25 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-O 121.028 0.442 . . . . 0.0 110.921 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.654 ' NH1' HG22 ' A' ' 79' ' ' VAL . 0.0 OUTLIER -48.32 -51.11 27.61 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.375 -179.747 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.532 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -108.74 18.06 21.21 Favored 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.559 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 40' ' ' ASN . 16.0 p -158.07 157.04 32.11 Favored 'General case' 0 CA--C 1.52 -0.189 0 C-N-CA 120.139 -0.625 . . . . 0.0 111.925 179.42 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.789 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.8 tm? -136.45 105.79 6.06 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.221 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.95 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.4 OUTLIER -78.51 126.32 30.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.684 179.97 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.901 HG23 ' O ' ' A' ' 33' ' ' ARG . 71.5 mt -109.5 103.51 15.6 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 115.778 -0.646 . . . . 0.0 112.236 -178.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.934 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.1 tt0 -121.32 143.14 49.34 Favored 'General case' 0 C--O 1.255 1.368 0 CA-C-O 121.036 0.446 . . . . 0.0 110.836 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.633 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 32.9 mtm -117.87 129.67 55.78 Favored 'General case' 0 C--O 1.234 0.245 0 O-C-N 125.827 1.954 . . . . 0.0 110.084 179.257 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.407 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 38.5 t70 -42.69 -27.36 0.17 Allowed 'General case' 0 N--CA 1.465 0.284 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 -178.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.473 ' OD2' ' HG2' ' A' ' 50' ' ' ARG . 12.7 p-10 -67.62 -7.29 25.32 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.874 -0.33 . . . . 0.0 111.337 -179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.14 20.06 14.95 Favored Glycine 0 C--N 1.334 0.468 0 C-N-CA 120.955 -0.64 . . . . 0.0 113.177 179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.473 ' HG2' ' OD2' ' A' ' 48' ' ' ASP . 40.7 mmt180 -104.95 121.75 44.4 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 120.715 0.293 . . . . 0.0 111.189 179.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.443 ' HG2' ' HG3' ' A' ' 45' ' ' GLU . 95.8 mt-10 -123.32 141.98 51.42 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.85 0.357 . . . . 0.0 111.581 -179.755 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.709 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.7 tp -155.69 136.61 4.98 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.707 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 10.2 t -94.97 143.45 26.47 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.872 0.368 . . . . 0.0 111.992 -179.043 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.461 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.3 t -152.49 125.65 4.16 Favored Pre-proline 0 CA--C 1.536 0.406 0 CA-C-N 116.037 -0.529 . . . . 0.0 111.013 179.573 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.427 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 23.9 Cg_exo -64.01 121.97 9.83 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.637 2.224 . . . . 0.0 112.652 -179.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.789 ' HD2' HD23 ' A' ' 42' ' ' LEU . 14.3 ptmm? -100.57 -2.02 34.0 Favored 'General case' 0 N--CA 1.463 0.188 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.796 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.05 -24.14 4.33 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 120.393 -0.908 . . . . 0.0 112.827 -179.173 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.796 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.12 60.04 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.534 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.612 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -146.15 110.9 5.2 Favored 'General case' 0 C--N 1.33 -0.279 0 N-CA-C 113.848 1.055 . . . . 0.0 113.848 -178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.913 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.7 p -73.45 132.55 33.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.142 0 CA-C-N 116.389 -0.368 . . . . 0.0 110.04 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.452 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -156.15 147.57 22.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 121.215 0.531 . . . . 0.0 111.633 -179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.426 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 64.9 m-70 -110.7 125.91 53.98 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.463 -0.789 . . . . 0.0 109.39 179.607 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.635 ' CZ ' HG11 ' A' ' 71' ' ' VAL . 6.4 p90 -107.6 134.84 50.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 121.17 0.51 . . . . 0.0 111.449 -179.248 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.492 ' HD3' HD13 ' A' ' 70' ' ' LEU . 48.7 mmm-85 -98.9 157.18 16.48 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.043 -179.638 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.568 ' HA ' HD22 ' A' ' 15' ' ' LEU . 62.3 m -115.7 136.72 22.89 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.226 179.194 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_exo -45.11 -37.68 13.24 Favored 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.074 2.516 . . . . 0.0 113.005 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.438 ' OE1' HG22 ' A' ' 65' ' ' THR . 14.3 mp0 -63.91 -15.79 59.91 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.013 179.708 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.93 50.1 1.11 Allowed Glycine 0 N--CA 1.45 -0.372 0 C-N-CA 120.874 -0.679 . . . . 0.0 112.204 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.446 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 57.4 mm-40 -122.73 156.07 35.19 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.99 0.424 . . . . 0.0 111.45 -179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.492 HD13 ' HD3' ' A' ' 64' ' ' ARG . 47.2 tp -124.65 129.62 50.89 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.848 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 63' ' ' PHE . 43.3 t -130.89 149.68 33.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.38 -0.373 . . . . 0.0 111.173 -179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.559 ' O ' HD13 ' A' ' 73' ' ' ILE . 43.2 tt0 -115.2 135.21 54.42 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.042 -0.526 . . . . 0.0 111.216 179.969 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.818 HG23 ' HG ' ' A' ' 78' ' ' LEU . 45.2 mm -144.14 102.9 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 115.958 -0.565 . . . . 0.0 109.891 179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.434 ' O ' ' OD1' ' A' ' 74' ' ' ASP . 1.8 p30 -76.21 99.09 4.61 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.372 0.606 . . . . 0.0 111.866 -179.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.612 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -55.07 -12.54 4.01 Favored Glycine 0 N--CA 1.449 -0.472 0 CA-C-N 115.319 -0.855 . . . . 0.0 112.966 179.023 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.716 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 2.5 tmt_? -71.96 -64.89 0.85 Allowed 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.187 0.494 . . . . 0.0 110.94 -178.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.29 -24.67 14.19 Favored 'General case' 0 C--N 1.322 -0.619 0 N-CA-C 112.89 0.7 . . . . 0.0 112.89 -178.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.889 HD13 ' O ' ' A' ' 78' ' ' LEU . 3.2 tm? -59.83 -28.97 67.94 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-O 120.816 0.341 . . . . 0.0 111.198 -179.171 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.654 HG22 ' NH1' ' A' ' 39' ' ' ARG . 8.3 p -53.49 100.48 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.034 0.445 . . . . 0.0 111.164 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.58 149.32 29.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.946 -0.57 . . . . 0.0 111.177 179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.681 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -56.9 155.08 16.24 Favored Pre-proline 0 C--N 1.331 -0.226 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.737 179.746 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_endo -47.74 149.5 5.04 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.73 2.287 . . . . 0.0 112.194 179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.401 ' OE1' ' N ' ' A' ' 83' ' ' GLU . 52.9 mp0 -69.28 -13.98 62.69 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.319 -179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.413 ' HG3' ' N ' ' A' ' 85' ' ' ARG . 16.6 pt-20 -90.07 -47.25 7.94 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.2 -179.846 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.413 ' N ' ' HG3' ' A' ' 84' ' ' GLU . 4.6 mmp_? -136.37 173.13 12.04 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.005 0.431 . . . . 0.0 111.278 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.681 HG23 ' HG3' ' A' ' 81' ' ' ARG . 45.5 mt . . . . . 0 C--N 1.331 -0.218 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.298 179.754 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.406 ' HG2' ' N ' ' A' ' 10' ' ' HIS . 79.6 ttt180 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 120.671 0.272 . . . . 0.0 110.405 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.406 ' N ' ' HG2' ' A' ' 9' ' ' ARG . 27.0 p-80 -122.71 118.26 27.66 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.891 0.377 . . . . 0.0 111.179 -179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.412 ' HB3' HD12 ' A' ' 12' ' ' LEU . 5.2 tp10 -168.13 -46.33 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.642 179.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.521 ' N ' HD12 ' A' ' 12' ' ' LEU . 5.1 mp -117.16 -34.55 4.33 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.994 179.574 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.0 mm -79.74 120.26 30.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.939 -179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 114.17 -26.18 10.02 Favored Glycine 0 N--CA 1.452 -0.239 0 C-N-CA 120.698 -0.763 . . . . 0.0 112.573 179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.614 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.2 pp -90.63 166.19 13.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.902 0.382 . . . . 0.0 111.137 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 52.9 m -89.08 158.5 17.94 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.954 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.439 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -132.6 123.6 49.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.892 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 79.2 ttt180 -105.63 123.76 48.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.174 -179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.692 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -95.18 121.56 45.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.0 -179.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.608 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -90.6 -20.55 22.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.15 179.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.914 ' HB3' HG12 ' A' ' 60' ' ' VAL . 22.2 tpp180 -160.63 150.31 17.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.324 179.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.427 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.64 164.19 30.57 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.287 -0.415 . . . . 0.0 111.231 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.489 HG13 ' N ' ' A' ' 24' ' ' HIS . 13.3 p -57.91 -45.58 87.62 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.222 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.094 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.489 ' N ' HG13 ' A' ' 23' ' ' VAL . 51.7 m170 -107.68 136.99 46.51 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.757 179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 -60.37 -21.16 61.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.485 -179.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 29.1 m-20 -77.63 -4.92 48.4 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.678 -179.771 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.809 HD12 ' HD2' ' A' ' 55' ' ' PRO . 23.5 pt -135.18 7.43 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 112.078 0.399 . . . . 0.0 112.078 -179.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.3 pt20 -86.92 147.14 25.9 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-O 120.849 0.357 . . . . 0.0 111.255 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.62 3.48 67.19 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.789 -0.72 . . . . 0.0 113.025 179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.4 ' O ' HD13 ' A' ' 19' ' ' ILE . 45.1 mm -87.11 121.47 37.87 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.334 0 CA-C-N 116.781 0.291 . . . . 0.0 111.092 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 50.1 m -92.67 159.44 15.45 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.133 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.425 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -172.1 -167.39 32.13 Favored Glycine 0 N--CA 1.449 -0.487 0 C-N-CA 119.955 -1.117 . . . . 0.0 112.817 -179.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.128 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.4 mpt_? -106.82 171.72 7.21 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.208 0.527 . . . . 0.0 111.451 -179.716 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.605 ' C ' ' H ' ' A' ' 45' ' ' GLU . 43.2 t -103.02 146.98 10.06 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 N-CA-C 114.157 1.169 . . . . 0.0 114.157 -176.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.865 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.1 p -138.47 -48.79 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 CA-C-O 120.726 0.298 . . . . 0.0 110.726 175.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.441 ' N ' HG13 ' A' ' 35' ' ' VAL . 59.8 m-20 -159.37 167.42 28.86 Favored 'General case' 0 C--N 1.342 0.241 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.969 179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.414 ' OE2' HD22 ' A' ' 12' ' ' LEU . 50.4 mt-10 -129.04 134.03 47.96 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.283 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.484 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 87.7 m -122.99 152.8 40.56 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 120.954 0.407 . . . . 0.0 111.118 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.65 ' HA ' ' HB3' ' A' ' 80' ' ' ALA . 24.4 ptt-85 -46.75 -41.9 15.97 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.858 -0.61 . . . . 0.0 111.646 -179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.484 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -127.58 21.98 6.47 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 112.498 0.555 . . . . 0.0 112.498 -179.342 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.484 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 13.2 p -156.97 156.64 33.34 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-O 121.203 0.525 . . . . 0.0 111.197 179.16 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.598 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -123.56 124.0 41.85 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.113 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.865 ' C ' HG12 ' A' ' 35' ' ' VAL . 12.4 ttt85 -98.27 138.62 35.26 Favored 'General case' 0 N--CA 1.447 -0.615 0 N-CA-C 109.427 -0.582 . . . . 0.0 109.427 -179.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.128 HG23 ' O ' ' A' ' 33' ' ' ARG . 62.7 mt -119.28 129.16 75.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.491 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -177.443 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.874 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.3 tt0 -131.13 133.84 45.99 Favored 'General case' 0 C--O 1.256 1.403 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 175.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.576 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 4.4 mpp? -102.81 127.93 49.77 Favored 'General case' 0 N--CA 1.453 -0.283 0 O-C-N 125.481 1.738 . . . . 0.0 110.112 179.971 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -43.63 -29.14 0.46 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.913 -179.573 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.74 -13.14 29.26 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.194 179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.19 22.39 10.68 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.122 -0.561 . . . . 0.0 112.119 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.518 ' HB2' ' HE2' ' A' ' 46' ' ' MET . 36.6 mmt180 -104.74 143.64 32.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.547 0.213 . . . . 0.0 110.865 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -126.91 139.39 53.1 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.95 0.405 . . . . 0.0 111.889 -179.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.629 HG23 ' HB ' ' A' ' 44' ' ' ILE . 12.2 tt -157.61 154.36 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.207 0 CA-C-N 115.884 -0.598 . . . . 0.0 110.426 179.325 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.3 m -115.85 154.26 30.02 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-O 121.036 0.446 . . . . 0.0 112.154 -179.035 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.43 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 49.4 t -152.25 140.59 13.55 Favored Pre-proline 0 CA--C 1.535 0.372 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.896 179.635 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.809 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.9 Cg_exo -76.09 117.77 4.77 Favored 'Trans proline' 0 C--N 1.349 0.593 0 C-N-CA 122.992 2.461 . . . . 0.0 113.065 -179.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.556 ' HD2' HD23 ' A' ' 42' ' ' LEU . 21.2 ptmt -100.77 -1.99 33.51 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 112.16 0.43 . . . . 0.0 112.16 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.811 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.81 -25.99 5.32 Favored Glycine 0 C--N 1.335 0.473 0 C-N-CA 120.17 -1.014 . . . . 0.0 112.323 -179.178 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.811 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -150.01 60.21 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.48 0 N-CA-C 109.458 -0.571 . . . . 0.0 109.458 178.725 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.636 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -143.55 111.03 5.86 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -178.552 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.914 HG12 ' HB3' ' A' ' 21' ' ' ARG . 10.2 p -75.7 128.01 37.21 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.0 177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.488 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 2.8 p90 -154.2 150.94 28.62 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.144 0.497 . . . . 0.0 111.833 -179.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 47.8 m170 -118.08 139.04 51.8 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.646 179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.442 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 4.1 m-30 -92.97 122.58 35.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.962 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 -106.37 113.07 26.36 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.768 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.504 HG22 ' H ' ' A' ' 67' ' ' GLN . 56.8 m -89.62 130.57 42.77 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.101 -179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_exo -50.0 -31.32 27.2 Favored 'Trans proline' 0 C--N 1.349 0.58 0 C-N-CA 122.76 2.306 . . . . 0.0 112.613 179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.504 ' H ' HG22 ' A' ' 65' ' ' THR . 12.9 mp0 -63.39 -13.41 39.28 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.214 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.25 44.69 1.68 Allowed Glycine 0 N--CA 1.449 -0.44 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.796 179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 44.6 mt-10 -122.87 144.55 49.14 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.741 0.305 . . . . 0.0 110.661 179.581 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.4 tp -121.72 109.63 14.95 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.154 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.442 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 55.2 t -112.52 147.74 16.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.532 179.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -122.39 146.83 46.98 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.989 0.423 . . . . 0.0 111.502 -179.506 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 58.1 mt -148.66 125.27 2.49 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.017 179.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.544 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 65.8 t0 -91.47 99.19 12.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.125 0.488 . . . . 0.0 111.831 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.636 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.46 -12.54 46.38 Favored Glycine 0 N--CA 1.449 -0.445 0 CA-C-N 115.871 -0.604 . . . . 0.0 112.709 178.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.586 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 79.1 ttt180 -88.7 -67.04 0.86 Allowed 'General case' 0 N--CA 1.453 -0.28 0 CA-C-O 121.056 0.455 . . . . 0.0 112.13 -178.612 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -86.69 -12.32 48.7 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 113.279 0.844 . . . . 0.0 113.279 -178.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.544 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 22.0 tp -107.69 34.06 3.74 Favored 'General case' 0 C--N 1.33 -0.264 0 C-N-CA 120.681 -0.408 . . . . 0.0 111.16 -179.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 9.3 p -61.7 138.43 22.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.73 179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.65 ' HB3' ' HA ' ' A' ' 39' ' ' ARG . . . -86.44 138.29 31.88 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.31 -0.405 . . . . 0.0 111.349 -179.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 39.6 mtm-85 -117.14 153.55 49.78 Favored Pre-proline 0 C--N 1.33 -0.271 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.952 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' HG3' ' HD2' ' A' ' 39' ' ' ARG . 45.2 Cg_exo -55.86 169.27 1.39 Allowed 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 122.515 2.144 . . . . 0.0 112.287 179.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.462 ' HA ' HD11 ' A' ' 86' ' ' ILE . 95.1 mt-10 -74.14 -20.14 60.34 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.993 179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -63.82 -46.72 83.82 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.295 -0.411 . . . . 0.0 110.901 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 -130.58 101.94 5.92 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.308 -0.405 . . . . 0.0 111.133 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.462 HD11 ' HA ' ' A' ' 83' ' ' GLU . 62.3 mt . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.76 179.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 . . . . . 0 N--CA 1.457 -0.119 0 CA-C-O 120.862 0.363 . . . . 0.0 110.985 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.49 ' CB ' ' HA ' ' A' ' 47' ' ' ASP . 16.9 m80 -127.96 -70.7 0.68 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.956 -179.952 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.891 ' C ' ' O ' ' A' ' 15' ' ' LEU . 44.8 mt-10 -48.38 118.11 2.3 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 116.438 -0.346 . . . . 0.0 110.216 179.624 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 1.027 ' HA ' ' HB ' ' A' ' 34' ' ' VAL . 0.8 OUTLIER 30.88 -144.15 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 N-CA-C 107.297 -1.372 . . . . 0.0 107.297 -179.258 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.752 ' H ' HD22 ' A' ' 12' ' ' LEU . 11.2 tp -90.74 94.75 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.038 0 N-CA-C 100.909 -3.737 . . . . 0.0 100.909 173.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 61.26 -2.72 0.65 Allowed Glycine 0 CA--C 1.549 2.176 0 C-N-CA 119.809 -1.186 . . . . 0.0 111.814 -174.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.891 ' O ' ' C ' ' A' ' 11' ' ' GLU . 0.2 OUTLIER -114.03 170.06 8.55 Favored 'General case' 0 N--CA 1.479 1.0 0 CA-C-N 117.592 0.696 . . . . 0.0 112.153 -178.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.585 ' HA ' ' HG3' ' A' ' 33' ' ' ARG . 51.9 m -115.77 158.69 22.49 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.56 HG22 HD12 ' A' ' 12' ' ' LEU . 46.5 t -125.94 157.42 35.83 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.121 0 N-CA-C 113.875 1.065 . . . . 0.0 113.875 -177.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.517 ' N ' HG12 ' A' ' 17' ' ' VAL . 55.7 ttp180 -143.58 110.6 5.68 Favored 'General case' 0 N--CA 1.455 -0.215 0 CA-C-N 114.407 -1.269 . . . . 0.0 109.144 178.971 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.455 HG21 ' OG ' ' A' ' 22' ' ' SER . 51.7 mt -88.15 142.01 13.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.97 0.414 . . . . 0.0 111.887 -178.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.28 -24.45 8.92 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.457 179.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HA ' ' HG3' ' A' ' 28' ' ' GLN . 79.6 mtt-85 -158.22 132.89 8.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.429 -0.351 . . . . 0.0 111.165 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.455 ' OG ' HG21 ' A' ' 19' ' ' ILE . 50.3 m -139.35 164.16 30.59 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.929 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.49 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.1 p -64.78 -47.14 89.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.899 179.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.545 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 52.2 m170 -92.56 137.32 32.47 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.562 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.494 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 0.4 OUTLIER -68.43 -26.48 65.54 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 112.226 -178.914 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.545 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.0 p-10 -73.98 -7.15 51.34 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 111.602 0.223 . . . . 0.0 111.602 -179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.697 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.0 pt -127.48 0.82 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.289 0 N-CA-C 111.741 0.275 . . . . 0.0 111.741 179.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.494 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 42.1 tt0 -83.88 147.15 27.68 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 121.0 0.428 . . . . 0.0 111.567 -179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.0 16.56 52.95 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 121.084 -0.579 . . . . 0.0 112.965 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.697 HD12 ' HA ' ' A' ' 27' ' ' ILE . 28.8 mt -104.0 131.41 52.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-O 120.896 0.379 . . . . 0.0 111.405 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.7 m -92.76 163.96 13.54 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 178.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.411 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 168.93 -176.23 43.16 Favored Glycine 0 N--CA 1.443 -0.877 0 C-N-CA 119.637 -1.268 . . . . 0.0 112.053 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.053 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -113.37 165.61 12.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.588 0.708 . . . . 0.0 111.482 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 1.027 ' HB ' ' HA ' ' A' ' 12' ' ' LEU . 1.4 t -103.59 157.78 5.15 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.374 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -178.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.947 HG23 ' OE1' ' A' ' 45' ' ' GLU . 4.3 p -123.72 -49.02 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.223 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 176.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 28.1 t70 -160.51 164.47 32.08 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.332 178.573 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.636 ' CD ' HD22 ' A' ' 42' ' ' LEU . 4.3 mm-40 -102.81 144.93 30.51 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 120.823 0.344 . . . . 0.0 110.879 179.776 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.432 ' HB ' ' O ' ' A' ' 41' ' ' THR . 85.3 m -123.11 155.06 37.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.965 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.8 ttm180 -40.67 -46.63 2.63 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.193 -179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.464 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -132.77 23.76 4.29 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 112.149 0.425 . . . . 0.0 112.149 -179.637 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.752 ' O ' HD23 ' A' ' 42' ' ' LEU . 28.0 p -158.27 171.28 20.48 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.117 0.484 . . . . 0.0 111.472 179.695 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.752 HD23 ' O ' ' A' ' 41' ' ' THR . 35.6 mt -133.85 115.09 14.06 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.276 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.618 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 45.1 ttt-85 -78.75 121.51 24.84 Favored 'General case' 0 N--CA 1.446 -0.638 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 178.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.053 HG23 ' O ' ' A' ' 33' ' ' ARG . 5.2 mt -95.51 115.86 35.61 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.623 0 N-CA-C 114.242 1.201 . . . . 0.0 114.242 -175.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.947 ' OE1' HG23 ' A' ' 35' ' ' VAL . 68.7 tt0 -114.87 136.86 52.64 Favored 'General case' 0 C--O 1.255 1.355 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 175.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.693 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 49.9 mtm -118.54 130.78 56.1 Favored 'General case' 0 C--O 1.236 0.348 0 O-C-N 125.377 1.673 . . . . 0.0 111.404 -179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.49 ' HA ' ' CB ' ' A' ' 10' ' ' HIS . 35.1 t70 -46.41 -27.54 1.1 Allowed 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.707 -0.679 . . . . 0.0 112.139 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 36.3 t70 -59.74 -12.19 6.66 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.877 179.625 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 99.49 20.94 15.88 Favored Glycine 0 N--CA 1.448 -0.546 0 N-CA-C 111.479 -0.648 . . . . 0.0 111.479 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . . . . . . . . . 88.3 mtm180 -104.73 159.98 15.34 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.848 0.356 . . . . 0.0 111.101 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -152.99 127.61 9.41 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.92 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.513 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 12.0 tt -155.78 153.1 7.89 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.509 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.787 179.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 86.3 m -93.96 153.96 17.93 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 120.851 0.358 . . . . 0.0 111.634 -179.557 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 1.021 HG21 HD12 ' A' ' 44' ' ' ILE . 39.9 t -152.16 111.51 2.85 Favored Pre-proline 0 CA--C 1.534 0.36 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.562 179.782 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HG2' ' CD1' ' A' ' 27' ' ' ILE . 11.1 Cg_endo -60.75 117.56 4.34 Favored 'Trans proline' 0 C--N 1.351 0.66 0 C-N-CA 122.542 2.161 . . . . 0.0 112.603 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.69 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.61 -1.58 35.01 Favored 'General case' 0 N--CA 1.464 0.254 0 N-CA-C 112.302 0.482 . . . . 0.0 112.302 -179.838 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.823 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.31 -25.38 4.21 Favored Glycine 0 C--N 1.333 0.374 0 C-N-CA 120.264 -0.969 . . . . 0.0 112.114 -179.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -150.11 61.07 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 178.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.728 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.5 117.41 8.24 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 113.973 1.101 . . . . 0.0 113.973 -178.025 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.459 ' O ' HG23 ' A' ' 60' ' ' VAL . 22.7 m -70.93 122.98 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 CA-C-O 120.698 0.285 . . . . 0.0 110.307 178.422 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.575 ' CE2' HD12 ' A' ' 42' ' ' LEU . 3.3 m-85 -111.85 147.51 35.61 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.242 0.544 . . . . 0.0 112.116 -178.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 27.0 m80 -137.95 103.61 5.02 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.229 178.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.496 ' CD2' HD11 ' A' ' 73' ' ' ILE . 6.0 p90 -105.96 140.27 39.23 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.312 0.577 . . . . 0.0 112.186 -178.503 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.477 ' HG3' HD13 ' A' ' 70' ' ' LEU . 0.9 OUTLIER -108.82 149.74 28.65 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.483 179.466 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . . . . . . . . . 91.1 m -106.4 137.37 19.41 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.55 179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_exo -44.66 -36.33 10.2 Favored 'Trans proline' 0 C--N 1.349 0.564 0 C-N-CA 122.825 2.35 . . . . 0.0 112.896 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -61.35 -16.17 43.41 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.306 -0.406 . . . . 0.0 111.163 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 46.64 1.41 Allowed Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.322 -179.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -126.14 156.12 40.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.871 0.367 . . . . 0.0 111.277 -179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.477 HD13 ' HG3' ' A' ' 64' ' ' ARG . 61.7 tp -127.11 140.43 52.27 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.733 179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.491 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 47.8 t -135.71 134.53 51.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.962 0.411 . . . . 0.0 111.105 -179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.3 mp0 -92.91 150.06 20.83 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.238 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.548 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 65.1 mt -144.11 133.89 20.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.717 -0.674 . . . . 0.0 110.064 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -108.04 99.42 8.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.123 0.487 . . . . 0.0 110.757 179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.728 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -69.98 -11.97 67.47 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.451 -0.795 . . . . 0.0 113.163 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.668 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 71.2 mtm-85 -70.86 -42.38 70.19 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 117.52 0.66 . . . . 0.0 110.622 -179.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.24 0.21 37.0 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.978 -179.869 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.611 HD13 ' O ' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -75.84 -1.86 27.28 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 120.829 0.347 . . . . 0.0 111.238 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 49.8 t -48.86 100.88 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.126 0 CA-C-O 120.923 0.392 . . . . 0.0 111.294 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.822 ' CB ' HD12 ' A' ' 86' ' ' ILE . . . -102.97 101.88 11.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.739 179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.675 ' HB3' ' HB3' ' A' ' 84' ' ' GLU . 48.5 ttt-85 -118.67 142.39 31.56 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.845 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.486 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 50.6 Cg_exo -53.85 -31.63 63.17 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.542 2.161 . . . . 0.0 113.511 -179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.3 mm-40 -110.74 -19.48 12.84 Favored 'General case' 0 C--N 1.323 -0.547 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -178.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.675 ' HB3' ' HB3' ' A' ' 81' ' ' ARG . 5.3 tp10 -85.86 -50.4 7.15 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.754 -0.379 . . . . 0.0 111.953 -178.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 59.1 ttp85 -139.44 -78.94 0.32 Allowed 'General case' 0 C--N 1.33 -0.277 0 C-N-CA 120.797 -0.361 . . . . 0.0 111.818 -179.46 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.822 HD12 ' CB ' ' A' ' 80' ' ' ALA . 24.0 mt . . . . . 0 C--N 1.332 -0.193 0 C-N-CA 120.597 -0.441 . . . . 0.0 111.337 -179.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.401 ' HD2' ' N ' ' A' ' 9' ' ' ARG . 0.3 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.766 0.317 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 25.6 t-80 -111.15 82.48 1.6 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.972 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -131.94 143.01 49.81 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.741 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.688 HD12 HD21 ' A' ' 15' ' ' LEU . 39.5 tp -135.38 10.69 3.49 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.238 -179.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.702 ' N ' HD12 ' A' ' 13' ' ' ILE . 1.6 mp -91.08 157.38 2.95 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-O 120.854 0.359 . . . . 0.0 110.93 179.933 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.485 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.06 -26.0 26.16 Favored Glycine 0 N--CA 1.452 -0.255 0 C-N-CA 120.815 -0.707 . . . . 0.0 112.679 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.688 HD21 HD12 ' A' ' 12' ' ' LEU . 0.5 OUTLIER -103.17 166.24 10.55 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.917 0.389 . . . . 0.0 111.227 -179.896 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.35 158.57 15.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.091 -0.504 . . . . 0.0 111.112 -179.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.777 HG23 ' CE1' ' A' ' 63' ' ' PHE . 7.6 p -130.69 152.91 38.29 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.068 -179.77 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.6 ttm180 -139.98 131.0 26.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.631 179.833 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.708 HG21 ' OG ' ' A' ' 22' ' ' SER . 46.5 mm -103.31 109.61 27.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.974 -0.557 . . . . 0.0 111.241 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.581 ' HB3' HG11 ' A' ' 60' ' ' VAL . . . -79.0 -19.44 51.56 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.927 0.394 . . . . 0.0 110.839 179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 29.7 tpt180 -158.64 145.58 17.48 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.558 179.424 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.708 ' OG ' HG21 ' A' ' 19' ' ' ILE . 57.6 m -139.7 164.32 30.24 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.402 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.464 HG12 HD11 ' A' ' 27' ' ' ILE . 9.9 p -58.2 -41.98 82.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.953 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 48.1 m170 -114.89 137.09 52.38 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.885 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 62.2 mtt85 -62.02 -24.28 66.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.155 -179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -68.23 -23.46 64.8 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.2 -179.805 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.577 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.6 pt -112.36 -17.47 8.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.516 -179.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.41 ' C ' ' OE1' ' A' ' 28' ' ' GLN . 1.0 OUTLIER -57.58 138.6 55.08 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.842 0.353 . . . . 0.0 110.795 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.28 18.14 72.31 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.386 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.607 ' O ' HG23 ' A' ' 30' ' ' ILE . 7.7 tp -77.74 103.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.888 0.375 . . . . 0.0 111.487 -179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.7 t -95.41 137.71 34.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.134 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.43 -161.65 27.82 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.246 -0.978 . . . . 0.0 112.371 -179.696 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.126 ' O ' HG23 ' A' ' 44' ' ' ILE . 68.5 mtt85 -102.52 170.62 7.93 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.631 0.729 . . . . 0.0 112.091 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.709 HG21 ' CE2' ' A' ' 63' ' ' PHE . 46.2 t -103.77 154.72 5.77 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.882 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -175.698 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.733 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -137.49 -50.19 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.341 0.202 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.083 175.248 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.473 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 57.9 m-20 -160.11 154.76 24.08 Favored 'General case' 0 N--CA 1.454 -0.23 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.349 179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.31 123.06 29.14 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 110.084 -0.339 . . . . 0.0 110.084 178.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.49 ' HB ' HG22 ' A' ' 41' ' ' THR . 26.7 m -110.97 156.27 21.47 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 121.06 0.457 . . . . 0.0 111.276 -179.397 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 54.9 mtm-85 -57.84 -19.47 29.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.934 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -122.06 -1.07 9.35 Favored 'General case' 0 CA--C 1.531 0.218 0 N-CA-C 112.509 0.559 . . . . 0.0 112.509 -179.757 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.49 HG22 ' HB ' ' A' ' 38' ' ' THR . 9.0 t -158.39 176.16 12.79 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-O 121.099 0.476 . . . . 0.0 111.314 179.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.63 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.5 tm? -142.95 113.68 7.51 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.731 -0.668 . . . . 0.0 109.376 -179.813 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.636 ' C ' HG12 ' A' ' 35' ' ' VAL . 10.2 tpt85 -92.77 145.65 24.24 Favored 'General case' 0 N--CA 1.45 -0.455 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 -179.388 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.126 HG23 ' O ' ' A' ' 33' ' ' ARG . 18.2 mt -120.53 129.73 75.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 N-CA-C 113.65 0.981 . . . . 0.0 113.65 -177.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.733 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.7 tt0 -131.51 143.11 50.15 Favored 'General case' 0 C--O 1.259 1.57 0 CA-C-O 121.095 0.474 . . . . 0.0 110.068 176.274 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.566 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 3.8 mpp? -116.14 124.41 50.26 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 125.487 1.742 . . . . 0.0 109.997 179.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 p-10 -44.81 -27.09 0.47 Allowed 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.985 -179.732 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.7 p30 -64.68 -8.38 14.3 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.498 179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.34 18.8 18.1 Favored Glycine 0 C--N 1.332 0.309 0 C-N-CA 120.886 -0.673 . . . . 0.0 113.194 179.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.451 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 84.1 mtm180 -104.7 154.69 19.65 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-O 120.584 0.231 . . . . 0.0 110.693 179.047 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.8 mt-10 -151.39 133.6 15.26 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 121.056 0.455 . . . . 0.0 111.896 -179.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.519 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -150.84 152.21 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.216 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.375 179.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 11.0 t -103.99 153.93 20.26 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-O 120.882 0.373 . . . . 0.0 111.93 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.431 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 48.6 t -152.29 133.91 8.26 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.028 179.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.577 ' HD2' HD12 ' A' ' 27' ' ' ILE . 6.9 Cg_exo -73.88 119.34 5.83 Favored 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 122.807 2.338 . . . . 0.0 112.836 -179.854 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.52 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 21.5 ptmt -100.54 -2.27 33.42 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 112.1 0.407 . . . . 0.0 112.1 179.853 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.801 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.06 -22.29 3.03 Favored Glycine 0 C--N 1.331 0.269 0 C-N-CA 120.368 -0.92 . . . . 0.0 113.062 -178.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.801 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.1 mp -148.33 58.71 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 109.624 -0.509 . . . . 0.0 109.624 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.576 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -145.71 137.18 25.02 Favored 'General case' 0 C--O 1.224 -0.247 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 -178.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.581 HG11 ' HB3' ' A' ' 20' ' ' ALA . 7.1 p -80.09 138.26 20.15 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.016 178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.444 ' HB2' ' HB ' ' A' ' 73' ' ' ILE . 3.1 m-85 -102.78 135.84 43.7 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 112.643 0.609 . . . . 0.0 112.643 -178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.417 ' CD2' ' HB2' ' A' ' 20' ' ' ALA . 90.7 m-70 -143.08 97.34 3.07 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.287 178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.777 ' CE1' HG23 ' A' ' 17' ' ' VAL . 1.3 m-85 -97.8 160.12 14.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.34 0.591 . . . . 0.0 112.205 -178.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.424 HH11 HD12 ' A' ' 70' ' ' LEU . 24.3 mmm180 -139.44 135.11 33.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.436 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.536 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.0 m -112.94 126.69 27.86 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.846 -179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 78.0 Cg_exo -47.95 -29.42 11.83 Favored 'Trans proline' 0 C--N 1.348 0.549 0 C-N-CA 122.653 2.235 . . . . 0.0 112.499 179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.536 ' H ' HG22 ' A' ' 65' ' ' THR . 10.6 mm100 -63.17 -15.31 56.49 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.981 179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.28 40.61 2.38 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.326 -179.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.9 mm-40 -126.12 152.45 45.89 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-O 120.883 0.373 . . . . 0.0 110.925 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 71' ' ' VAL . 4.7 tt -127.09 126.23 42.63 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.41 -179.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 70' ' ' LEU . 51.8 t -117.51 132.6 66.84 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.533 179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -125.34 137.83 54.05 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.003 0.43 . . . . 0.0 111.585 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.444 ' HB ' ' HB2' ' A' ' 61' ' ' PHE . 60.4 mt -145.92 157.29 12.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.819 179.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.58 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 21.9 m-20 -107.27 99.41 8.95 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.898 0.38 . . . . 0.0 111.627 -179.294 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.576 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -84.4 -11.79 77.15 Favored Glycine 0 CA--C 1.518 0.28 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.878 178.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.657 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.0 OUTLIER -67.63 -58.64 4.33 Favored 'General case' 0 C--N 1.326 -0.451 0 O-C-N 122.481 -0.423 . . . . 0.0 112.017 -178.793 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.53 -31.47 10.86 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.935 1.087 . . . . 0.0 113.935 -177.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.58 ' HB3' ' O ' ' A' ' 74' ' ' ASP . 30.0 tp -61.32 -13.9 22.89 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.322 0.489 . . . . 0.0 112.322 -178.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.651 HG13 ' O ' ' A' ' 79' ' ' VAL . 10.8 p -48.83 100.57 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-O 121.081 0.467 . . . . 0.0 111.204 -179.623 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.28 127.61 54.42 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.087 -179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.428 ' HD2' ' HA ' ' A' ' 86' ' ' ILE . 99.4 mtt180 -106.41 155.1 39.31 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.737 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_endo -56.43 -163.02 0.02 OUTLIER 'Trans proline' 0 C--N 1.344 0.307 0 C-N-CA 122.75 2.3 . . . . 0.0 112.586 -179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 55.5 mt-10 -56.39 -18.77 12.09 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.451 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.451 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 4.5 mm-40 -56.68 -17.34 8.52 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.475 -0.33 . . . . 0.0 111.424 179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.451 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 81.4 mtm180 75.52 153.35 0.14 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.88 0.371 . . . . 0.0 110.914 -179.89 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.707 ' N ' HD12 ' A' ' 86' ' ' ILE . 1.7 mp . . . . . 0 C--N 1.33 -0.247 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.193 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 41.2 ptt180 . . . . . 0 C--O 1.23 0.068 0 CA-C-O 120.819 0.342 . . . . 0.0 110.811 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.575 ' HB2' ' HA ' ' A' ' 47' ' ' ASP . 90.6 m-70 -77.95 -51.42 10.42 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.503 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.62 ' HA ' ' HB3' ' A' ' 33' ' ' ARG . 85.3 mt-10 -50.88 176.8 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.205 0 CA-C-N 116.568 -0.287 . . . . 0.0 110.556 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.934 HD22 HG22 ' A' ' 17' ' ' VAL . 1.4 tp -51.21 137.96 21.49 Favored 'General case' 0 CA--C 1.494 -1.197 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 178.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.671 HG23 ' O ' ' A' ' 13' ' ' ILE . 18.0 tt -30.84 97.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.439 -1.009 0 N-CA-C 108.9 -0.778 . . . . 0.0 108.9 -175.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.56 ' N ' ' O ' ' A' ' 12' ' ' LEU . . . 61.85 -18.61 0.06 OUTLIER Glycine 0 CA--C 1.541 1.687 0 CA-C-N 115.648 -0.705 . . . . 0.0 113.79 -177.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.805 ' O ' ' HB3' ' A' ' 12' ' ' LEU . 0.0 OUTLIER -115.07 172.13 7.24 Favored 'General case' 0 C--O 1.218 -0.579 0 CA-C-N 117.74 0.77 . . . . 0.0 112.055 -178.807 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.1 m -118.85 159.73 23.21 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.934 HG22 HD22 ' A' ' 12' ' ' LEU . 20.0 t -124.49 157.69 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-N 119.494 1.043 . . . . 0.0 113.692 -177.327 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.519 ' N ' HG12 ' A' ' 17' ' ' VAL . 99.2 mtt180 -143.24 100.3 3.6 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 114.742 -1.117 . . . . 0.0 109.889 178.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.56 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -71.04 141.39 16.9 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-O 121.244 0.545 . . . . 0.0 112.279 -178.881 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -114.23 -36.28 4.74 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.461 -0.791 . . . . 0.0 110.528 179.024 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.683 ' HB2' HG12 ' A' ' 60' ' ' VAL . 98.4 mtt180 -155.77 134.29 11.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.121 179.314 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 49.9 m -139.11 164.0 30.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.92 0.39 . . . . 0.0 111.204 -179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.46 HG13 ' N ' ' A' ' 24' ' ' HIS . 10.3 p -77.33 -43.65 30.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.026 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.53 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 59.8 t60 -88.25 137.13 32.6 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.341 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -66.17 -41.6 90.07 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 112.901 0.704 . . . . 0.0 112.901 -178.274 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.53 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -57.85 -19.86 32.12 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.464 -0.335 . . . . 0.0 111.828 -178.786 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.923 HD12 HG13 ' A' ' 54' ' ' VAL . 26.9 pt -110.83 -22.35 5.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-O 120.884 0.374 . . . . 0.0 111.646 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.4 tp60 -53.75 134.33 42.12 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.086 -0.507 . . . . 0.0 111.708 -179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.63 14.01 48.28 Favored Glycine 0 C--N 1.331 0.278 0 CA-C-N 115.887 -0.597 . . . . 0.0 113.074 179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.451 ' O ' HD13 ' A' ' 19' ' ' ILE . 50.5 mm -104.48 115.46 46.43 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.417 0 CA-C-N 116.839 0.32 . . . . 0.0 111.192 -179.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.4 ' CB ' ' HA ' ' A' ' 18' ' ' ARG . 56.2 m -92.26 165.79 12.93 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.405 ' O ' ' N ' ' A' ' 17' ' ' VAL . . . 163.92 -168.72 38.56 Favored Glycine 0 N--CA 1.438 -1.209 0 C-N-CA 119.486 -1.34 . . . . 0.0 111.907 -179.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.023 ' O ' HG23 ' A' ' 44' ' ' ILE . 11.0 mpt_? -103.49 169.77 8.34 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-O 121.452 0.644 . . . . 0.0 112.28 -179.064 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.829 ' H ' ' CA ' ' A' ' 12' ' ' LEU . 0.9 OUTLIER -101.3 156.77 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.189 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -178.387 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.926 HG23 ' OE1' ' A' ' 45' ' ' GLU . 5.6 p -115.06 -46.51 4.52 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 N-CA-C 106.982 -1.488 . . . . 0.0 106.982 176.209 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.457 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 3.0 p30 -159.36 148.0 17.94 Favored 'General case' 0 C--O 1.233 0.221 0 CA-C-N 114.979 -1.01 . . . . 0.0 109.806 177.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.421 ' OE1' ' C ' ' A' ' 37' ' ' GLU . 0.0 OUTLIER -116.19 125.29 52.08 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.839 0.352 . . . . 0.0 111.243 -179.378 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.442 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 30.9 m -122.96 151.73 41.54 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.236 179.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' HD2' ' CD ' ' A' ' 82' ' ' PRO . 68.3 mtm-85 -60.57 -9.28 3.57 Favored 'General case' 0 C--N 1.329 -0.324 0 N-CA-C 112.617 0.599 . . . . 0.0 112.617 -179.359 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -126.88 -3.04 6.53 Favored 'General case' 0 CA--C 1.532 0.261 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -179.962 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . . . . . . . . . 9.0 t -158.94 163.21 36.72 Favored 'General case' 0 C--O 1.232 0.184 0 CA-C-O 121.065 0.46 . . . . 0.0 111.739 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.655 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.6 tm? -137.5 105.83 5.77 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.61 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.57 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 76.7 ttt180 -96.23 124.85 40.38 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.228 0.537 . . . . 0.0 109.561 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.023 HG23 ' O ' ' A' ' 33' ' ' ARG . 13.6 mt -91.94 119.22 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 N-CA-C 115.086 1.513 . . . . 0.0 115.086 -176.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.926 ' OE1' HG23 ' A' ' 35' ' ' VAL . 71.3 tt0 -125.14 131.87 53.17 Favored 'General case' 0 C--O 1.255 1.379 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 175.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.715 ' HA ' ' HB2' ' A' ' 33' ' ' ARG . 14.0 ptp -120.49 145.84 46.87 Favored 'General case' 0 C--O 1.24 0.587 0 O-C-N 124.945 1.403 . . . . 0.0 111.976 -179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.575 ' HA ' ' HB2' ' A' ' 10' ' ' HIS . 7.7 t70 -42.66 -26.2 0.11 Allowed 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.461 -179.81 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 54.9 m-20 -70.21 10.91 0.37 Allowed 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.706 -0.224 . . . . 0.0 110.747 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 47' ' ' ASP . . . 67.74 22.45 73.63 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.781 -0.723 . . . . 0.0 111.66 -179.357 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.499 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 54.9 mtp85 -105.15 113.04 26.4 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.989 0.423 . . . . 0.0 111.252 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 2.1 pp20? -111.53 141.81 44.62 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.85 -0.613 . . . . 0.0 110.599 179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.464 ' O ' ' N ' ' A' ' 44' ' ' ILE . 12.5 tt -157.55 154.59 5.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.804 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.417 ' N ' HG12 ' A' ' 52' ' ' ILE . 87.4 m -93.56 151.95 19.36 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.878 0.371 . . . . 0.0 111.331 -179.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.923 HG13 HD12 ' A' ' 27' ' ' ILE . 59.0 t -151.95 104.54 2.83 Favored Pre-proline 0 CA--C 1.533 0.29 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.896 179.691 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.761 ' HD2' HD13 ' A' ' 27' ' ' ILE . 87.3 Cg_exo -50.19 140.97 32.21 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.935 2.423 . . . . 0.0 113.281 -179.837 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.604 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 57.3 mtpt -100.2 -2.06 34.9 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.047 179.513 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.84 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.32 -41.58 31.95 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 120.36 -0.924 . . . . 0.0 113.162 -178.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.84 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -155.56 63.03 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.713 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -129.4 109.8 11.37 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 113.351 0.871 . . . . 0.0 113.351 -178.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.683 HG12 ' HB2' ' A' ' 21' ' ' ARG . 15.0 p -89.82 129.39 40.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-O 120.81 0.338 . . . . 0.0 110.354 178.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.515 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.35 143.02 21.9 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 121.112 0.482 . . . . 0.0 111.378 -179.692 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -102.93 135.74 44.05 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.595 -179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.788 ' CD2' HD21 ' A' ' 12' ' ' LEU . 10.3 m-30 -95.97 154.57 17.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.21 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 47.6 mmt-85 -132.09 141.81 49.31 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.857 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.538 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.9 m -121.07 124.01 27.58 Favored Pre-proline 0 C--N 1.33 -0.278 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.641 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_exo -47.06 -28.12 6.99 Favored 'Trans proline' 0 C--N 1.35 0.653 0 C-N-CA 122.748 2.298 . . . . 0.0 112.634 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.538 ' H ' HG22 ' A' ' 65' ' ' THR . 73.4 mt-30 -64.56 -14.25 56.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.211 179.815 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 37.79 3.04 Favored Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.836 -0.697 . . . . 0.0 112.441 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 4.6 mm-40 -123.15 149.52 44.45 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.889 0.376 . . . . 0.0 110.953 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.647 HD23 ' N ' ' A' ' 71' ' ' VAL . 5.1 tt -126.34 125.21 41.88 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.467 -179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.647 ' N ' HD23 ' A' ' 70' ' ' LEU . 52.2 t -122.85 158.94 27.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.883 179.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.629 ' O ' HD13 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -125.89 149.61 48.56 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.269 -179.771 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.629 HD13 ' O ' ' A' ' 72' ' ' GLU . 42.6 mm -146.45 102.9 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.277 179.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.507 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 25.3 m-20 -79.5 99.4 7.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.139 0.495 . . . . 0.0 111.82 -179.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.713 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.97 -12.21 53.8 Favored Glycine 0 C--O 1.223 -0.579 0 CA-C-N 115.763 -0.653 . . . . 0.0 112.645 178.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.579 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt85 -98.55 -47.95 5.18 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-O 120.908 0.385 . . . . 0.0 111.869 -178.812 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.78 -13.53 17.68 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 113.772 1.027 . . . . 0.0 113.772 -178.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.847 HD13 ' O ' ' A' ' 78' ' ' LEU . 2.5 tm? -98.8 -35.46 10.12 Favored 'General case' 0 N--CA 1.467 0.382 0 C-N-CA 120.533 -0.467 . . . . 0.0 112.222 -178.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 79' ' ' VAL . 12.2 p -52.21 100.57 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.663 0 CA-C-O 121.076 0.465 . . . . 0.0 111.351 -179.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.441 ' HA ' HD11 ' A' ' 86' ' ' ILE . . . -109.57 110.66 21.8 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.113 179.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.431 ' NH2' ' HA2' ' A' ' 57' ' ' GLY . 54.2 mtt85 -87.67 110.49 35.03 Favored Pre-proline 0 C--N 1.328 -0.362 0 CA-C-N 116.433 -0.348 . . . . 0.0 110.524 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.409 ' CD ' ' HD2' ' A' ' 39' ' ' ARG . 65.3 Cg_endo -73.09 -12.14 25.61 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.375 2.05 . . . . 0.0 112.607 -179.961 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 64.5 mm-40 -81.51 -27.31 34.54 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.896 0.379 . . . . 0.0 111.121 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -107.11 -5.16 18.19 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.392 179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 76.3 mtt-85 63.85 132.22 0.02 OUTLIER 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.858 0.361 . . . . 0.0 110.815 179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.441 HD11 ' HA ' ' A' ' 80' ' ' ALA . 45.0 mm . . . . . 0 C--N 1.329 -0.314 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.008 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.088 0 CA-C-O 120.666 0.27 . . . . 0.0 111.047 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.6 OUTLIER -122.11 159.7 26.59 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.314 -0.403 . . . . 0.0 111.046 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -178.78 35.47 0.0 OUTLIER 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.262 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.465 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 30.1 tp -167.75 27.74 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 120.802 0.334 . . . . 0.0 111.053 179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 29.7 pt -91.39 163.13 2.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.754 0.311 . . . . 0.0 111.394 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 90.93 8.91 64.52 Favored Glycine 0 CA--C 1.519 0.322 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.555 -179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.519 HD22 ' HA ' ' A' ' 65' ' ' THR . 49.5 mt -110.06 166.08 11.23 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.783 0.325 . . . . 0.0 110.675 -179.848 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.413 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 53.2 m -97.33 141.77 30.02 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 109.846 -0.428 . . . . 0.0 109.846 179.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 21.5 t -125.42 140.79 47.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.833 0.349 . . . . 0.0 111.51 -179.128 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 46.8 ttt85 -121.2 98.63 6.07 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.449 179.683 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.477 HD13 ' CB ' ' A' ' 61' ' ' PHE . 45.3 mm -74.74 123.34 30.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.313 -179.509 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.998 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -84.09 -47.47 10.88 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.297 0.57 . . . . 0.0 110.335 179.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.444 ' HA ' ' CB ' ' A' ' 28' ' ' GLN . 25.6 ptt-85 -171.11 130.91 0.77 Allowed 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.558 179.134 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.591 ' HB2' HG13 ' A' ' 27' ' ' ILE . 31.8 m -114.79 164.67 13.76 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.118 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.7 p -35.22 -46.39 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.022 -0.535 . . . . 0.0 112.133 -179.761 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.562 ' CD2' ' HB2' ' A' ' 26' ' ' ASP . 63.3 t60 -86.0 137.04 33.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.826 0.345 . . . . 0.0 110.329 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 59.2 mtm-85 -73.39 -20.94 60.63 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 113.215 0.821 . . . . 0.0 113.215 -178.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.562 ' HB2' ' CD2' ' A' ' 24' ' ' HIS . 1.4 m-20 -86.71 8.49 22.28 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 111.927 0.343 . . . . 0.0 111.927 -179.283 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.591 HG13 ' HB2' ' A' ' 22' ' ' SER . 31.2 pt -133.64 10.43 1.34 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.201 0.445 . . . . 0.0 112.201 -179.576 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.444 ' CB ' ' HA ' ' A' ' 21' ' ' ARG . 23.3 pt20 -83.56 120.41 25.91 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.883 0.373 . . . . 0.0 111.289 -179.612 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 106.13 18.19 11.66 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.797 -0.716 . . . . 0.0 113.221 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 63.0 mt -79.23 130.77 35.63 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-O 120.964 0.412 . . . . 0.0 111.299 -179.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 47.8 t -124.34 127.96 48.38 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.286 179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.47 -161.69 26.82 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.362 -0.923 . . . . 0.0 112.173 -179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.897 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.7 mpt_? -98.93 171.42 8.07 Favored 'General case' 0 C--O 1.22 -0.469 0 CA-C-O 121.368 0.604 . . . . 0.0 111.651 -179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.697 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.5 p -100.82 155.74 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.79 0 N-CA-C 114.276 1.213 . . . . 0.0 114.276 -176.049 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.963 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -125.31 -49.75 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 N-CA-C 108.918 -0.771 . . . . 0.0 108.918 176.618 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.41 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.5 t70 -160.2 166.94 28.72 Favored 'General case' 0 CA--C 1.53 0.209 0 CA-C-N 115.284 -0.871 . . . . 0.0 111.383 -179.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.4 tt0 -119.1 126.69 52.23 Favored 'General case' 0 C--N 1.332 -0.17 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 178.76 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.487 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 88.9 m -123.34 155.28 37.62 Favored 'General case' 0 CA--C 1.53 0.185 0 CA-C-O 121.256 0.55 . . . . 0.0 112.382 -178.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.63 ' HD3' HG12 ' A' ' 86' ' ' ILE . 4.3 ptp85 -40.76 -43.42 1.99 Allowed 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.18 -0.918 . . . . 0.0 112.044 179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.402 ' HB3' ' HA ' ' A' ' 80' ' ' ALA . 0.1 OUTLIER -138.4 27.94 2.52 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 112.161 0.43 . . . . 0.0 112.161 -179.452 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.487 ' OG1' ' HB ' ' A' ' 38' ' ' THR . 4.2 p -153.29 147.09 25.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.066 0.46 . . . . 0.0 111.156 179.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.612 ' HB2' ' HB3' ' A' ' 56' ' ' LYS . 1.8 tm? -123.21 110.41 15.21 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.7 -0.682 . . . . 0.0 111.04 -179.207 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.963 ' C ' HG23 ' A' ' 35' ' ' VAL . 25.7 mtt180 -79.56 122.15 26.13 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.287 179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.897 HG23 ' O ' ' A' ' 33' ' ' ARG . 29.0 mm -106.5 104.56 17.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 CA-C-N 115.705 -0.68 . . . . 0.0 112.641 -178.333 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.896 ' N ' HG22 ' A' ' 35' ' ' VAL . 23.9 tt0 -125.23 143.09 51.12 Favored 'General case' 0 C--O 1.254 1.336 0 CA-C-O 120.839 0.352 . . . . 0.0 111.286 179.444 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.745 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 0.0 OUTLIER -108.57 134.6 51.11 Favored 'General case' 0 C--N 1.345 0.392 0 O-C-N 125.681 1.863 . . . . 0.0 109.937 178.871 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -48.87 -24.96 1.65 Allowed 'General case' 0 C--N 1.333 -0.128 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.45 179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.0 m-20 -64.75 -9.84 23.18 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.35 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.52 22.33 10.51 Favored Glycine 0 N--CA 1.449 -0.454 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.553 -179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.421 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.6 mtt-85 -104.66 148.45 26.54 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 110.36 -0.237 . . . . 0.0 110.36 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 86.9 mt-10 -147.02 143.42 28.39 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.051 0.453 . . . . 0.0 111.958 -179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.715 HG23 ' HB ' ' A' ' 44' ' ' ILE . 10.9 tt -159.2 139.31 3.78 Favored 'Isoleucine or valine' 0 C--O 1.225 -0.199 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.357 179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -91.76 150.08 21.28 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.874 0.368 . . . . 0.0 111.872 -179.288 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . . . . . . . . . 48.1 t -152.39 115.66 2.91 Favored Pre-proline 0 CA--C 1.537 0.447 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.308 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.517 ' HD2' HD12 ' A' ' 27' ' ' ILE . 41.3 Cg_exo -58.03 121.12 9.47 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 122.791 2.327 . . . . 0.0 112.895 -179.97 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.612 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 0.1 OUTLIER -100.92 -2.06 32.89 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -179.891 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.826 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.8 -26.99 6.0 Favored Glycine 0 CA--C 1.519 0.309 0 C-N-CA 120.199 -1.001 . . . . 0.0 112.527 -179.167 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.826 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -154.63 62.66 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.738 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -135.95 110.38 8.51 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 114.236 1.198 . . . . 0.0 114.236 -178.399 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.998 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.5 p -76.15 130.29 36.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.477 ' CB ' HD13 ' A' ' 19' ' ' ILE . 7.6 p90 -156.1 166.63 32.89 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.089 0.471 . . . . 0.0 111.226 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 10.8 m-70 -135.78 121.71 19.95 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.294 179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.664 ' CD2' HD11 ' A' ' 73' ' ' ILE . 4.0 p90 -97.09 144.24 27.14 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-O 121.147 0.499 . . . . 0.0 111.661 -178.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.472 ' HG2' ' CD2' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -109.66 117.51 34.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.122 179.925 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.537 HG22 ' H ' ' A' ' 67' ' ' GLN . 85.7 m -82.18 129.22 64.76 Favored Pre-proline 0 C--O 1.235 0.336 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.719 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 98.5 Cg_exo -43.93 -25.51 1.08 Allowed 'Trans proline' 0 C--N 1.351 0.708 0 C-N-CA 123.136 2.557 . . . . 0.0 112.956 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.537 ' H ' HG22 ' A' ' 65' ' ' THR . 8.3 tt0 -60.57 -15.69 30.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.768 0.318 . . . . 0.0 110.686 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.27 27.23 6.6 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.021 -0.609 . . . . 0.0 112.438 179.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.429 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.5 pt-20 -126.63 152.72 46.3 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.032 0.444 . . . . 0.0 111.492 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.472 ' CD2' ' HG2' ' A' ' 64' ' ' ARG . 23.3 mt -115.3 149.19 38.22 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.85 179.601 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.472 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 52.9 t -137.82 139.93 41.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.965 179.917 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.449 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -101.27 133.22 46.18 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.003 179.852 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.664 HD11 ' CD2' ' A' ' 63' ' ' PHE . 3.9 mp -132.79 137.14 54.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.449 -179.854 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.41 ' O ' HD23 ' A' ' 78' ' ' LEU . 26.3 m-20 -100.55 99.76 10.39 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.954 0.407 . . . . 0.0 110.984 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.761 ' HA2' HD23 ' A' ' 78' ' ' LEU . . . -57.49 -12.65 9.54 Favored Glycine 0 C--O 1.225 -0.41 0 CA-C-N 115.722 -0.672 . . . . 0.0 113.407 179.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 29.6 tpt180 -70.91 -21.96 62.31 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 117.287 0.543 . . . . 0.0 110.492 -179.797 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -98.48 0.16 44.6 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 116.082 -0.508 . . . . 0.0 111.697 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.761 HD23 ' HA2' ' A' ' 75' ' ' GLY . 3.1 mm? -94.14 25.56 3.7 Favored 'General case' 0 C--N 1.334 -0.075 0 CA-C-O 120.784 0.326 . . . . 0.0 111.423 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.566 HG22 ' N ' ' A' ' 80' ' ' ALA . 11.4 p -48.69 163.1 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.227 179.067 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.946 ' HB1' HG13 ' A' ' 86' ' ' ILE . . . -46.78 163.53 0.04 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.506 179.87 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.556 ' N ' HG13 ' A' ' 86' ' ' ILE . 75.5 mtp180 -117.16 115.09 38.47 Favored Pre-proline 0 N--CA 1.461 0.076 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -178.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.423 ' HA ' ' HB ' ' A' ' 86' ' ' ILE . 88.9 Cg_endo -77.59 2.33 7.91 Favored 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 122.627 2.218 . . . . 0.0 113.057 -179.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -100.4 -13.66 18.65 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.709 -0.223 . . . . 0.0 111.367 -179.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -107.09 -31.07 8.43 Favored 'General case' 0 C--N 1.331 -0.219 0 N-CA-C 111.755 0.28 . . . . 0.0 111.755 -179.64 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.418 ' HA ' ' NE ' ' A' ' 85' ' ' ARG . 7.3 tpm_? -177.09 -28.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.676 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.946 HG13 ' HB1' ' A' ' 80' ' ' ALA . 48.6 mm . . . . . 0 C--N 1.33 -0.266 0 CA-C-O 120.771 0.319 . . . . 0.0 111.268 -179.344 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.425 ' NH1' ' HB2' ' A' ' 9' ' ' ARG . 17.3 ttm105 . . . . . 0 N--CA 1.457 -0.105 0 CA-C-O 120.979 0.419 . . . . 0.0 111.023 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.473 ' ND1' ' HG2' ' A' ' 11' ' ' GLU . 35.4 t-80 -127.59 81.14 2.0 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.508 -179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.473 ' HG2' ' ND1' ' A' ' 10' ' ' HIS . 22.3 pt-20 46.69 -173.91 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.277 -179.429 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.596 ' CD1' HD21 ' A' ' 15' ' ' LEU . 27.5 tp -137.56 15.6 2.94 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.501 -0.318 . . . . 0.0 111.159 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.8 mm -91.06 147.93 4.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-O 120.744 0.307 . . . . 0.0 111.148 179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 109.33 -10.87 33.51 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.698 -0.763 . . . . 0.0 113.063 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.596 HD21 ' CD1' ' A' ' 12' ' ' LEU . 0.5 OUTLIER -110.03 166.24 11.1 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.03 0.443 . . . . 0.0 111.524 -179.74 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.3 m -88.45 158.56 18.32 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.94 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 22.8 t -133.01 109.04 13.65 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.749 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.491 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 1.0 OUTLIER -93.05 122.09 35.06 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.35 -0.386 . . . . 0.0 111.396 -179.642 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.685 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.3 mp -94.74 123.63 46.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.088 -0.506 . . . . 0.0 110.912 179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.628 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -87.75 -22.97 24.27 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.211 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.484 ' HB3' HG12 ' A' ' 60' ' ' VAL . 16.9 tpp85 -165.81 149.46 7.91 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.517 179.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.403 ' CB ' HG13 ' A' ' 27' ' ' ILE . 34.9 t -139.68 164.26 30.4 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.316 -179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.492 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.9 p -54.21 -46.03 67.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-N 116.036 -0.529 . . . . 0.0 111.475 179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.492 ' N ' HG13 ' A' ' 23' ' ' VAL . 4.3 t-80 -104.99 137.31 42.94 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.459 -0.337 . . . . 0.0 110.374 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.436 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 76.5 mtp180 -63.28 -14.63 51.74 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.564 0.579 . . . . 0.0 112.564 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 57.8 p30 -82.82 -3.59 56.93 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 111.719 0.266 . . . . 0.0 111.719 -179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.406 HD12 ' HD2' ' A' ' 55' ' ' PRO . 26.8 pt -135.18 1.87 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -179.719 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 18.3 pt20 -82.96 153.56 24.95 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.788 0.328 . . . . 0.0 111.347 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.81 17.92 55.59 Favored Glycine 0 N--CA 1.452 -0.269 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.673 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 43.4 mm -101.96 129.95 52.47 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.483 0 CA-C-O 120.802 0.334 . . . . 0.0 111.163 -179.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.5 p -92.66 142.66 27.12 Favored 'General case' 0 C--N 1.329 -0.308 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 179.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -154.09 178.62 30.86 Favored Glycine 0 N--CA 1.446 -0.639 0 C-N-CA 120.012 -1.089 . . . . 0.0 112.817 -179.367 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.07 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.6 mpt_? -98.68 170.66 8.63 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.056 0.455 . . . . 0.0 111.82 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.621 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.7 p -102.35 144.52 13.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -176.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.836 HG12 ' C ' ' A' ' 43' ' ' ARG . 9.3 p -138.45 -48.83 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.529 0.17 0 CA-C-O 120.665 0.269 . . . . 0.0 110.867 176.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.439 ' N ' HG13 ' A' ' 35' ' ' VAL . 57.0 m-20 -159.18 167.41 29.16 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-O 120.963 0.411 . . . . 0.0 111.18 -179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -129.06 126.6 39.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.09 179.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.458 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 31.0 m -116.21 149.31 39.34 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-O 121.018 0.437 . . . . 0.0 111.273 -179.475 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -52.78 -22.43 5.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.893 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -131.65 6.13 4.36 Favored 'General case' 0 CA--C 1.532 0.251 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.458 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 8.9 t -158.38 163.43 37.28 Favored 'General case' 0 C--N 1.332 -0.165 0 C-N-CA 120.595 -0.442 . . . . 0.0 111.352 179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.588 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -121.4 122.46 39.86 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.833 -179.747 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.836 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.1 tpt180 -95.44 137.88 33.9 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.07 HG23 ' O ' ' A' ' 33' ' ' ARG . 52.5 mt -117.51 125.96 74.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 N-CA-C 113.995 1.109 . . . . 0.0 113.995 -177.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.935 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.0 tt0 -131.35 136.63 48.24 Favored 'General case' 0 C--O 1.253 1.289 0 CA-C-O 120.944 0.402 . . . . 0.0 109.929 176.18 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.527 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 7.5 mtt -102.87 132.62 48.95 Favored 'General case' 0 C--O 1.234 0.268 0 O-C-N 125.15 1.531 . . . . 0.0 110.415 179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -46.04 -28.45 1.18 Allowed 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.587 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 56.7 m-20 -63.11 -12.97 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.21 179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.3 24.29 9.01 Favored Glycine 0 N--CA 1.45 -0.421 0 C-N-CA 121.01 -0.614 . . . . 0.0 112.096 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.4 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.2 mtt180 -104.61 147.69 27.36 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.528 0.204 . . . . 0.0 110.798 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -135.71 138.92 43.23 Favored 'General case' 0 N--CA 1.452 -0.333 0 CA-C-O 120.957 0.408 . . . . 0.0 111.835 -179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.485 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -159.19 148.59 7.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.419 179.399 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.7 t -102.58 154.48 19.08 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.853 0.359 . . . . 0.0 111.945 -179.064 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.632 HG21 HD12 ' A' ' 44' ' ' ILE . 47.8 t -152.34 119.71 3.16 Favored Pre-proline 0 CA--C 1.534 0.363 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.208 179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.406 ' HD2' HD12 ' A' ' 27' ' ' ILE . 34.7 Cg_exo -61.17 118.1 4.94 Favored 'Trans proline' 0 C--N 1.348 0.544 0 C-N-CA 122.722 2.281 . . . . 0.0 112.792 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.8 ptmt -100.62 -1.85 34.31 Favored 'General case' 0 N--CA 1.465 0.303 0 N-CA-C 112.521 0.563 . . . . 0.0 112.521 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.809 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.55 -24.46 3.93 Favored Glycine 0 C--N 1.332 0.308 0 C-N-CA 120.275 -0.964 . . . . 0.0 112.292 -179.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.809 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.22 61.06 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.477 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.667 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -142.05 110.73 6.15 Favored 'General case' 0 CA--C 1.53 0.188 0 N-CA-C 113.979 1.103 . . . . 0.0 113.979 -178.288 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.628 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.7 p -77.67 129.87 36.91 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.736 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.48 ' HB3' ' HA ' ' A' ' 19' ' ' ILE . 0.6 OUTLIER -151.55 154.85 37.28 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.476 0.655 . . . . 0.0 112.369 -179.231 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.414 ' CD2' ' HA ' ' A' ' 72' ' ' GLU . 48.9 m170 -118.22 136.46 53.64 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.016 -0.993 . . . . 0.0 110.104 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.47 ' CE1' HG13 ' A' ' 73' ' ' ILE . 1.8 m-85 -92.77 113.74 26.09 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.89 0.376 . . . . 0.0 111.036 -179.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.417 ' HD2' ' C ' ' A' ' 64' ' ' ARG . 4.7 tmm_? -98.64 105.47 17.62 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.459 -179.978 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.519 HG22 ' H ' ' A' ' 67' ' ' GLN . 88.5 m -80.08 134.2 56.47 Favored Pre-proline 0 C--N 1.33 -0.247 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.155 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.5 Cg_exo -47.28 -30.77 11.52 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.791 2.327 . . . . 0.0 112.66 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.519 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.77 -15.2 39.22 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.098 179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.22 39.4 2.64 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.308 -179.826 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 55.3 mt-10 -121.97 145.69 47.87 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.761 0.315 . . . . 0.0 110.505 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.581 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -126.98 110.04 12.55 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.816 -179.803 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.511 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -100.91 160.49 3.72 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.63 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.609 ' O ' HD13 ' A' ' 73' ' ' ILE . 7.0 mp0 -121.79 145.1 48.39 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-O 121.015 0.436 . . . . 0.0 111.736 -179.389 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.609 HD13 ' O ' ' A' ' 72' ' ' GLU . 46.8 mm -148.7 143.79 18.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.225 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.883 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.433 ' O ' ' CB ' ' A' ' 78' ' ' LEU . 24.1 m-20 -108.99 99.56 8.87 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.094 0.473 . . . . 0.0 111.966 -179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.667 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -64.41 -12.0 49.66 Favored Glycine 0 N--CA 1.448 -0.553 0 CA-C-N 115.76 -0.654 . . . . 0.0 112.95 178.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.64 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 65.7 mtt85 -72.95 -62.57 1.41 Allowed 'General case' 0 C--N 1.332 -0.163 0 N-CA-C 112.093 0.405 . . . . 0.0 112.093 -178.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.06 -35.08 9.81 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 113.344 0.868 . . . . 0.0 113.344 -177.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.892 HD13 ' O ' ' A' ' 78' ' ' LEU . 2.5 tm? -49.34 -29.48 6.18 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.919 0.39 . . . . 0.0 111.109 -178.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.56 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.5 p -59.04 111.09 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.082 179.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.78 144.13 37.03 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.085 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 52.8 mtp85 -115.05 115.61 43.0 Favored Pre-proline 0 C--N 1.33 -0.261 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.866 -179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_endo -76.85 -2.29 12.51 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.475 2.116 . . . . 0.0 112.797 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 42.0 tp10 -97.47 -30.7 12.75 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.919 0.39 . . . . 0.0 111.01 -179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -107.04 10.17 30.35 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.991 -0.549 . . . . 0.0 111.457 179.9 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 29.6 tpt180 62.86 144.62 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.85 0.357 . . . . 0.0 110.813 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 57.7 mt . . . . . 0 C--N 1.33 -0.277 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.993 -179.965 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.1 mtp180 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.647 0.26 . . . . 0.0 111.109 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 24.8 t-80 -178.48 142.99 0.25 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.323 -0.399 . . . . 0.0 110.79 179.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -128.55 152.59 48.13 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.947 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.598 HD12 HD12 ' A' ' 15' ' ' LEU . 36.1 tp -125.13 17.82 8.41 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.964 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 58.6 mt -91.04 148.95 4.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.078 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.35 8.93 58.35 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.842 -0.694 . . . . 0.0 112.951 179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.666 HD22 ' OG1' ' A' ' 65' ' ' THR . 84.7 mt -110.1 166.01 11.29 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.923 0.392 . . . . 0.0 110.984 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.4 t -101.54 158.97 15.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.485 179.742 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.572 HG22 ' CD2' ' A' ' 63' ' ' PHE . 15.9 t -137.18 149.29 26.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-O 121.037 0.446 . . . . 0.0 111.998 -179.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.436 ' O ' ' HG3' ' A' ' 18' ' ' ARG . 8.2 ptm180 -131.66 106.79 8.38 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.725 -0.671 . . . . 0.0 109.629 178.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.687 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -88.74 141.35 14.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.613 -178.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -110.52 -67.41 1.0 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.591 179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.75 ' NH2' HG11 ' A' ' 60' ' ' VAL . 1.0 OUTLIER -110.8 132.24 54.36 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 179.453 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.518 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.1 164.25 30.27 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.976 0.417 . . . . 0.0 111.446 -179.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.51 HG13 ' N ' ' A' ' 24' ' ' HIS . 11.1 p -58.1 -46.69 88.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 115.994 -0.548 . . . . 0.0 111.475 -179.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.512 ' HB3' HG12 ' A' ' 27' ' ' ILE . 18.5 t-160 -89.22 127.34 35.75 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.946 0.403 . . . . 0.0 110.533 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 21.2 tpp180 -61.67 -14.88 35.12 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.893 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 25.5 m-20 -94.1 -15.05 25.08 Favored 'General case' 0 C--N 1.329 -0.295 0 N-CA-C 112.805 0.669 . . . . 0.0 112.805 -178.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.512 HG12 ' HB3' ' A' ' 24' ' ' HIS . 18.2 pt -103.65 -23.55 4.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.3 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 17.8 pt20 -64.12 151.28 43.66 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.848 0.356 . . . . 0.0 111.121 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 73.83 4.01 65.41 Favored Glycine 0 CA--C 1.519 0.293 0 C-N-CA 120.822 -0.704 . . . . 0.0 113.08 179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.428 ' O ' ' HB ' ' A' ' 19' ' ' ILE . 47.8 mm -104.36 129.69 56.33 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.392 0 CA-C-N 116.878 0.339 . . . . 0.0 111.197 -179.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -92.63 155.12 17.96 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.18 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -164.58 178.4 39.81 Favored Glycine 0 N--CA 1.448 -0.539 0 C-N-CA 120.083 -1.056 . . . . 0.0 113.069 -179.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.978 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 mpt_? -98.52 172.64 7.38 Favored 'General case' 0 C--O 1.22 -0.463 0 C-N-CA 122.782 0.433 . . . . 0.0 111.312 -179.94 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.625 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 21.4 t -100.44 154.21 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 N-CA-C 114.961 1.467 . . . . 0.0 114.961 -175.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.999 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -135.95 -50.62 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.454 0 N-CA-C 108.501 -0.926 . . . . 0.0 108.501 175.09 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 57.5 m-20 -159.92 167.17 28.66 Favored 'General case' 0 N--CA 1.454 -0.225 0 CA-C-N 114.725 -1.125 . . . . 0.0 110.913 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.447 ' OE1' ' N ' ' A' ' 37' ' ' GLU . 49.1 mp0 -124.85 120.22 31.07 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.212 178.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 41' ' ' THR . 89.4 m -118.42 155.28 31.03 Favored 'General case' 0 C--O 1.232 0.171 0 CA-C-O 121.007 0.432 . . . . 0.0 111.61 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.43 ' HG3' ' N ' ' A' ' 40' ' ' ASN . 39.5 ptt180 -40.68 -45.58 2.41 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-N 115.653 -0.703 . . . . 0.0 112.101 -179.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.43 ' N ' ' HG3' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -136.89 28.54 2.89 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.404 -0.362 . . . . 0.0 111.703 -179.719 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.522 ' HB ' ' HB ' ' A' ' 38' ' ' THR . 90.8 m -148.68 131.18 15.77 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 120.974 0.416 . . . . 0.0 110.794 179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.528 ' C ' HD13 ' A' ' 42' ' ' LEU . 1.7 tm? -112.83 107.46 16.08 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.319 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.999 ' C ' HG23 ' A' ' 35' ' ' VAL . 22.5 ttt180 -83.16 121.47 27.11 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.635 -0.506 . . . . 0.0 109.635 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.978 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.8 mt -104.22 113.24 40.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 N-CA-C 113.188 0.81 . . . . 0.0 113.188 -178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.981 ' N ' HG22 ' A' ' 35' ' ' VAL . 31.3 tt0 -125.89 135.19 51.64 Favored 'General case' 0 C--O 1.252 1.203 0 CA-C-O 121.146 0.498 . . . . 0.0 110.307 178.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.557 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.2 mpp? -101.7 131.24 48.06 Favored 'General case' 0 N--CA 1.453 -0.324 0 O-C-N 125.77 1.919 . . . . 0.0 110.008 179.885 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 28.4 m-20 -43.93 -28.36 0.45 Allowed 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.897 -179.709 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.419 ' HB2' ' HD3' ' A' ' 50' ' ' ARG . 34.8 m-20 -62.86 -12.49 25.17 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.32 179.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 21.75 11.41 Favored Glycine 0 N--CA 1.45 -0.392 0 C-N-CA 121.019 -0.61 . . . . 0.0 112.469 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.419 ' HD3' ' HB2' ' A' ' 48' ' ' ASP . 1.1 mpt_? -104.83 126.25 51.71 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.54 0.21 . . . . 0.0 110.804 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -117.69 142.24 47.47 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 120.945 0.403 . . . . 0.0 111.7 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.61 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.4 tp -159.13 131.11 1.01 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.149 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.569 179.479 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.9 t -84.73 152.52 23.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.891 0.377 . . . . 0.0 111.767 -179.362 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.925 HG21 HD12 ' A' ' 44' ' ' ILE . 58.9 t -152.16 117.88 3.07 Favored Pre-proline 0 CA--C 1.534 0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.806 179.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.25 121.94 10.83 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.78 2.32 . . . . 0.0 113.147 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.473 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . 1.4 tttm -100.52 -9.22 22.28 Favored 'General case' 0 CA--C 1.532 0.279 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.556 179.534 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.788 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.69 -27.19 8.74 Favored Glycine 0 C--N 1.331 0.272 0 C-N-CA 120.744 -0.741 . . . . 0.0 113.236 -179.13 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.788 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.0 mp -149.66 59.31 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 CA-C-O 120.941 0.401 . . . . 0.0 110.269 179.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.571 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.24 118.2 7.18 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 112.99 0.737 . . . . 0.0 112.99 -179.145 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.75 HG11 ' NH2' ' A' ' 21' ' ' ARG . 8.3 p -86.02 132.4 32.16 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.162 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.0 178.4 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.479 ' HB3' HG13 ' A' ' 19' ' ' ILE . 0.5 OUTLIER -156.31 156.89 34.78 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.041 0.448 . . . . 0.0 111.352 -179.681 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.472 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 12.8 m-70 -124.27 136.78 54.39 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.311 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.733 ' CD1' HD13 ' A' ' 73' ' ' ILE . 1.7 m-85 -92.7 148.32 22.15 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.897 0.379 . . . . 0.0 110.358 179.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.445 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -132.56 118.1 18.81 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.05 -179.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.666 ' OG1' HD22 ' A' ' 15' ' ' LEU . 58.1 m -92.27 129.49 41.04 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.724 -179.836 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_exo -46.76 -27.87 6.07 Favored 'Trans proline' 0 C--N 1.349 0.583 0 C-N-CA 122.66 2.24 . . . . 0.0 112.627 -179.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.507 ' H ' HG22 ' A' ' 65' ' ' THR . 11.0 mp0 -67.94 -11.8 59.49 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.394 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.19 48.46 1.22 Allowed Glycine 0 N--CA 1.449 -0.438 0 C-N-CA 120.687 -0.768 . . . . 0.0 112.904 179.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.433 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 88.7 mt-10 -126.13 145.64 50.27 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.906 0.384 . . . . 0.0 110.808 179.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.634 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.03 110.84 13.39 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.623 -179.79 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.568 HG12 HD11 ' A' ' 73' ' ' ILE . 35.2 t -109.83 142.05 23.43 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.998 -179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.824 ' C ' HD12 ' A' ' 73' ' ' ILE . 33.3 tt0 -112.06 130.98 55.7 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.315 -179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.824 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -135.64 109.95 10.68 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.122 0 CA-C-O 120.791 0.329 . . . . 0.0 110.324 179.324 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.785 ' HB2' HD23 ' A' ' 78' ' ' LEU . 60.1 m-20 -83.48 99.59 10.21 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.167 0.508 . . . . 0.0 111.227 -179.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.571 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -77.41 -12.65 84.35 Favored Glycine 0 N--CA 1.45 -0.41 0 CA-C-N 115.673 -0.694 . . . . 0.0 112.215 179.321 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.67 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 56.2 ttp180 -93.93 -66.93 0.88 Allowed 'General case' 0 N--CA 1.453 -0.318 0 CA-C-O 121.089 0.471 . . . . 0.0 111.855 -178.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.845 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -79.79 -11.23 59.84 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 112.93 0.715 . . . . 0.0 112.93 -178.646 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.845 HD22 ' C ' ' A' ' 77' ' ' ALA . 2.9 mm? -130.8 45.99 2.73 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-O 120.802 0.334 . . . . 0.0 111.77 -179.47 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.0 p -64.15 101.04 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 121.023 0.439 . . . . 0.0 110.556 179.395 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -51.5 131.0 28.89 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.752 -179.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.728 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -117.48 137.3 24.01 Favored Pre-proline 0 N--CA 1.454 -0.249 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.416 179.455 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 66.5 Cg_endo -73.93 171.74 17.29 Favored 'Trans proline' 0 C--N 1.343 0.276 0 C-N-CA 122.465 2.11 . . . . 0.0 112.512 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 94.1 mt-10 -70.88 -20.51 62.5 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.091 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 64.8 mm-40 -81.0 -30.38 34.99 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.991 -179.95 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.405 ' C ' ' HD2' ' A' ' 85' ' ' ARG . 3.7 tmm_? -144.04 98.95 3.31 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.572 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.728 HG23 ' HG3' ' A' ' 81' ' ' ARG . 59.4 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.599 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 79.0 ttt180 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.755 0.312 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 14.9 t-160 -168.45 -59.72 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.283 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.942 -179.97 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.3 tt0 -61.17 158.3 14.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.993 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.597 HD11 ' CE2' ' A' ' 63' ' ' PHE . 59.1 tp -177.34 -39.39 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.017 179.996 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 46.1 mm -61.98 137.28 24.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.968 179.964 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.0 -28.02 16.48 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.557 179.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.846 HD22 ' OG1' ' A' ' 65' ' ' THR . 76.1 mt -65.92 159.21 26.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.784 0.326 . . . . 0.0 111.031 -179.965 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -97.99 155.0 17.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.209 -0.451 . . . . 0.0 109.817 178.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . . . . . . . . . 7.6 p -147.61 122.48 2.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.96 0.41 . . . . 0.0 111.409 -179.55 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 39.5 ptt85 -106.38 138.03 43.28 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.704 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.591 HD13 ' HB3' ' A' ' 61' ' ' PHE . 43.8 mm -87.13 124.13 40.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.487 -179.451 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.77 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.04 -29.9 19.1 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.516 179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB3' HG12 ' A' ' 60' ' ' VAL . 78.7 ttt180 -166.46 147.8 6.41 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.516 179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 52.2 m -139.67 164.33 30.21 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 115.835 -0.621 . . . . 0.0 111.253 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.782 HG12 ' HB ' ' A' ' 58' ' ' ILE . 27.2 m -58.22 -44.43 87.87 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-N 116.068 -0.514 . . . . 0.0 111.415 179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.486 ' N ' HG23 ' A' ' 23' ' ' VAL . 53.7 m170 -102.97 136.99 41.77 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.893 179.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.435 ' HA ' ' HG2' ' A' ' 28' ' ' GLN . 49.9 ttm-85 -64.36 -17.5 63.79 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.659 -179.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -83.98 -0.74 52.78 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 112.069 0.396 . . . . 0.0 112.069 -179.348 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.48 HG13 ' CB ' ' A' ' 22' ' ' SER . 22.1 pt -131.42 -15.68 1.52 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.224 0 N-CA-C 112.311 0.486 . . . . 0.0 112.311 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.435 ' HG2' ' HA ' ' A' ' 25' ' ' ARG . 3.0 pt20 -72.81 147.47 45.44 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.852 0.358 . . . . 0.0 111.307 -179.605 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 82.04 -3.84 78.59 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.862 -0.685 . . . . 0.0 113.299 179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.1 mm -76.22 147.08 8.07 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.858 0.361 . . . . 0.0 111.226 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.0 t -119.53 155.42 32.2 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.421 179.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.21 -161.83 26.93 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.303 -0.951 . . . . 0.0 112.838 -179.735 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.149 ' O ' HG23 ' A' ' 44' ' ' ILE . 99.6 mtt180 -116.07 172.37 7.21 Favored 'General case' 0 C--O 1.22 -0.467 0 CA-C-O 121.478 0.656 . . . . 0.0 111.682 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.708 HG21 ' CE2' ' A' ' 63' ' ' PHE . 40.1 t -101.54 153.14 5.09 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 N-CA-C 114.385 1.254 . . . . 0.0 114.385 -175.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.831 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 5.6 p -138.69 -48.71 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.283 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.588 176.704 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.436 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 51.7 t0 -159.74 164.45 33.84 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 116.075 -0.512 . . . . 0.0 110.462 179.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.436 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 56.2 mt-10 -129.41 133.53 47.4 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.689 -0.232 . . . . 0.0 110.696 179.403 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' HG22 ' A' ' 41' ' ' THR . 32.2 m -123.16 148.08 46.14 Favored 'General case' 0 C--O 1.231 0.086 0 CA-C-O 120.958 0.409 . . . . 0.0 111.077 -179.908 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.954 ' NH2' HD12 ' A' ' 78' ' ' LEU . 5.1 tpm_? -53.97 -19.26 4.42 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.806 -179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.582 ' OD1' HD11 ' A' ' 86' ' ' ILE . 0.0 OUTLIER -132.72 4.55 3.9 Favored 'General case' 0 CA--C 1.53 0.179 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -179.509 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.427 HG22 ' HB ' ' A' ' 38' ' ' THR . 13.6 t -158.28 159.15 35.65 Favored 'General case' 0 C--N 1.331 -0.198 0 C-N-CA 120.185 -0.606 . . . . 0.0 111.62 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.891 HD13 ' N ' ' A' ' 43' ' ' ARG . 2.8 tm? -115.33 139.62 49.83 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.151 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.891 ' N ' HD13 ' A' ' 42' ' ' LEU . 15.0 ttt-85 -116.78 126.02 52.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.428 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.149 HG23 ' O ' ' A' ' 33' ' ' ARG . 48.3 mt -110.75 120.87 62.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -176.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.831 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 35.8 tt0 -127.83 142.68 51.22 Favored 'General case' 0 C--O 1.259 1.579 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 175.777 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.648 ' CG ' ' HB2' ' A' ' 33' ' ' ARG . 35.1 mtm -114.46 127.69 55.95 Favored 'General case' 0 N--CA 1.455 -0.221 0 O-C-N 125.611 1.819 . . . . 0.0 110.341 -179.856 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.414 ' HB3' ' NH1' ' A' ' 33' ' ' ARG . 37.4 t70 -44.03 -27.65 0.4 Allowed 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.874 -179.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -61.46 -12.37 14.5 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.216 179.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 21.26 11.73 Favored Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.972 -0.632 . . . . 0.0 112.244 -179.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.401 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 36.0 mmt180 -104.61 160.26 15.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.523 0.202 . . . . 0.0 110.759 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -152.36 140.49 20.31 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.106 0.479 . . . . 0.0 111.67 -179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.537 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.5 tp -156.31 154.23 6.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.313 179.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.1 t -106.04 154.39 20.7 Favored 'General case' 0 CA--C 1.531 0.237 0 N-CA-C 112.259 0.466 . . . . 0.0 112.259 -178.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.556 ' CG2' HD12 ' A' ' 44' ' ' ILE . 60.7 t -146.16 136.44 12.08 Favored Pre-proline 0 CA--C 1.535 0.396 0 CA-C-N 115.879 -0.6 . . . . 0.0 110.813 179.47 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 23.5 Cg_exo -65.17 135.53 43.85 Favored 'Trans proline' 0 N--CA 1.478 0.57 0 C-N-CA 122.97 2.447 . . . . 0.0 113.857 -179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.6 ' HG2' ' HB2' ' A' ' 42' ' ' LEU . 4.4 mmmp? -100.85 -2.36 32.32 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 115.778 -0.647 . . . . 0.0 112.084 179.093 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.866 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.71 -48.59 36.11 Favored Glycine 0 CA--C 1.52 0.406 0 C-N-CA 120.552 -0.832 . . . . 0.0 113.574 -178.576 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.866 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -155.07 62.75 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 N-CA-C 109.78 -0.452 . . . . 0.0 109.78 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.745 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -124.66 110.48 14.45 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.77 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.1 p -84.4 127.8 39.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 N-CA-C 109.987 -0.375 . . . . 0.0 109.987 178.013 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.591 ' HB3' HD13 ' A' ' 19' ' ' ILE . 3.5 p90 -153.88 147.0 24.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.039 0.447 . . . . 0.0 111.397 -179.473 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 38.8 m-70 -116.22 145.06 43.41 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.714 -0.675 . . . . 0.0 110.9 -179.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.708 ' CE2' HG21 ' A' ' 34' ' ' VAL . 1.2 m-85 -95.64 152.69 18.22 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.59 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 65' ' ' THR . 0.0 OUTLIER -142.31 122.27 13.64 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.219 -179.923 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.846 ' OG1' HD22 ' A' ' 15' ' ' LEU . 51.9 m -98.75 133.35 22.52 Favored Pre-proline 0 C--N 1.33 -0.277 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.495 -179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.8 Cg_endo -50.53 -25.73 15.11 Favored 'Trans proline' 0 C--N 1.347 0.48 0 C-N-CA 122.614 2.209 . . . . 0.0 112.208 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.568 ' H ' HG22 ' A' ' 65' ' ' THR . 98.6 mm-40 -67.43 -13.04 61.67 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.12 -0.491 . . . . 0.0 111.062 179.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 45.96 1.51 Allowed Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.653 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 60.7 mm-40 -124.58 143.74 50.53 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.804 0.335 . . . . 0.0 111.013 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 62.3 tp -127.4 116.56 20.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.297 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.1 t -119.16 159.19 20.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.553 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -124.57 147.83 48.2 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.907 0.384 . . . . 0.0 111.669 -179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.553 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.7 mm -149.09 108.66 0.51 Allowed 'Isoleucine or valine' 0 CA--C 1.527 0.084 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.947 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.93 ' O ' HD23 ' A' ' 78' ' ' LEU . 51.2 t0 -77.95 133.13 38.1 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.551 -178.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.745 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -92.33 -12.19 58.85 Favored Glycine 0 C--O 1.224 -0.513 0 CA-C-N 115.87 -0.605 . . . . 0.0 114.002 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.648 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 40.4 ptt180 -89.75 -37.25 14.67 Favored 'General case' 0 C--N 1.333 -0.114 0 CA-C-N 117.754 0.777 . . . . 0.0 110.821 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.753 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -77.89 0.81 22.64 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.334 -0.848 . . . . 0.0 111.948 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.954 HD12 ' NH2' ' A' ' 39' ' ' ARG . 2.9 mm? -122.16 48.24 1.77 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 121.548 0.69 . . . . 0.0 110.222 -179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.556 HG12 ' N ' ' A' ' 80' ' ' ALA . 47.4 t -47.6 163.26 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.602 0 CA-C-N 114.68 -1.146 . . . . 0.0 111.561 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.927 ' CB ' HG21 ' A' ' 86' ' ' ILE . . . -46.18 164.34 0.03 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 115.912 -0.585 . . . . 0.0 111.214 -179.274 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.64 ' HB2' ' HB2' ' A' ' 84' ' ' GLU . 0.0 OUTLIER -70.34 115.63 36.72 Favored Pre-proline 0 CA--C 1.529 0.151 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.321 -178.016 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.49 -64.17 0.16 Allowed 'Trans proline' 0 C--N 1.344 0.333 0 C-N-CA 122.85 2.366 . . . . 0.0 114.371 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 4.5 mm-40 -105.34 -17.33 14.48 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -177.553 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.64 ' HB2' ' HB2' ' A' ' 81' ' ' ARG . 69.2 mt-10 -57.25 -43.12 82.67 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.532 -0.467 . . . . 0.0 110.773 -179.41 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.475 ' HD3' ' NH2' ' A' ' 81' ' ' ARG . 59.6 ttt-85 -170.41 -53.65 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.12 179.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.927 HG21 ' CB ' ' A' ' 80' ' ' ALA . 47.2 mm . . . . . 0 C--N 1.329 -0.299 0 CA-C-O 121.082 0.468 . . . . 0.0 111.038 -179.745 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' O ' ' HG3' ' A' ' 9' ' ' ARG . 14.7 ptp180 . . . . . 0 CA--C 1.528 0.118 0 CA-C-O 120.776 0.322 . . . . 0.0 110.624 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 49.4 m170 -117.77 142.37 47.35 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.319 -179.737 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 66.3 mm-40 64.28 -75.01 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.611 179.468 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 65.3 tp -177.55 -24.66 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.565 -179.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.573 ' N ' HD12 ' A' ' 13' ' ' ILE . 2.0 mp -57.02 156.77 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.21 0 CA-C-O 120.814 0.34 . . . . 0.0 110.796 -179.889 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.454 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 103.05 0.4 48.14 Favored Glycine 0 CA--C 1.519 0.328 0 C-N-CA 120.819 -0.705 . . . . 0.0 112.347 -179.607 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.407 ' O ' HG12 ' A' ' 34' ' ' VAL . 81.4 mt -109.99 166.35 11.01 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.892 0.377 . . . . 0.0 110.741 -179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 78.8 p -101.39 156.15 17.63 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 178.645 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.453 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 4.7 p -147.32 134.2 13.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-O 120.944 0.402 . . . . 0.0 111.502 -179.007 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 25.4 ptt-85 -116.38 130.86 56.99 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.125 -179.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.678 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -95.52 117.9 40.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.33 -179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -84.55 -63.6 1.31 Allowed 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.372 0.605 . . . . 0.0 110.151 179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.747 ' HB2' HG12 ' A' ' 60' ' ' VAL . 0.5 OUTLIER -110.66 139.44 45.93 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.291 179.105 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.4 t -137.67 164.08 29.71 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.071 0.463 . . . . 0.0 111.338 -179.502 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 6.3 p -75.03 -30.62 23.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.882 -0.599 . . . . 0.0 111.25 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 14.1 m80 -119.96 137.05 54.29 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.827 0.346 . . . . 0.0 111.008 179.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 16.4 ptm180 -63.36 -24.95 68.07 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.296 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -66.45 -26.64 67.3 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.865 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.994 HG21 HG13 ' A' ' 54' ' ' VAL . 18.9 mm -105.79 -24.11 4.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.741 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tp-100 -54.59 145.38 19.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.465 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.96 8.68 30.15 Favored Glycine 0 C--N 1.331 0.285 0 CA-C-N 115.812 -0.631 . . . . 0.0 113.48 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 27' ' ' ILE . 37.8 mt -104.13 121.8 56.19 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 CA-C-N 117.127 0.464 . . . . 0.0 111.301 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 80.6 p -103.74 177.64 4.78 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.16 179.57 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.418 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . 170.8 -169.45 42.41 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 119.979 -1.105 . . . . 0.0 113.067 179.955 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.139 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.7 OUTLIER -98.51 171.4 8.17 Favored 'General case' 0 C--O 1.217 -0.624 0 CA-C-O 121.232 0.539 . . . . 0.0 111.175 -179.722 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.541 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.3 p -101.59 154.21 4.92 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 113.767 1.025 . . . . 0.0 113.767 -176.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.627 HG12 ' O ' ' A' ' 43' ' ' ARG . 0.8 OUTLIER -137.33 -51.14 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.249 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.275 175.693 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.626 ' OD1' ' HB3' ' A' ' 43' ' ' ARG . 5.0 p-10 -161.23 167.45 26.01 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.997 178.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -117.08 139.12 51.1 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 116.284 -0.416 . . . . 0.0 110.318 178.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 53.3 m -121.31 150.23 41.74 Favored 'General case' 0 C--N 1.333 -0.117 0 CA-C-O 121.032 0.444 . . . . 0.0 111.354 -179.565 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.41 ' HD2' ' HD2' ' A' ' 82' ' ' PRO . 54.8 ttp180 -43.67 -34.98 1.62 Allowed 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.764 -0.653 . . . . 0.0 112.272 -179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.491 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -140.22 22.04 2.41 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -179.27 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 40' ' ' ASN . 23.4 p -158.3 169.51 24.32 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.19 0.519 . . . . 0.0 111.506 179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.723 ' HG ' ' HB3' ' A' ' 56' ' ' LYS . 92.3 mt -138.69 135.5 34.87 Favored 'General case' 0 CA--C 1.514 -0.427 0 CA-C-N 115.518 -0.765 . . . . 0.0 110.807 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.627 ' O ' HG12 ' A' ' 35' ' ' VAL . 35.6 ttm180 -113.35 124.75 53.21 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.139 HG23 ' O ' ' A' ' 33' ' ' ARG . 32.3 mt -96.46 123.4 48.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.296 -177.047 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.872 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.5 tt0 -131.2 140.52 49.91 Favored 'General case' 0 C--O 1.254 1.32 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.156 176.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.635 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.7 ptp -118.63 132.37 56.18 Favored 'General case' 0 C--O 1.241 0.656 0 O-C-N 125.21 1.569 . . . . 0.0 110.42 179.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -42.36 -26.05 0.1 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.404 -0.816 . . . . 0.0 112.388 -179.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -58.81 -14.75 9.66 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.23 16.4 25.3 Favored Glycine 0 C--N 1.335 0.489 0 C-N-CA 121.174 -0.536 . . . . 0.0 112.322 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.556 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 0.4 OUTLIER -105.41 158.21 16.81 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.716 0.293 . . . . 0.0 111.112 179.709 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 88.1 mt-10 -151.22 134.42 16.02 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.951 0.405 . . . . 0.0 111.747 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.415 HG23 ' HB ' ' A' ' 44' ' ' ILE . 7.9 tp -141.93 154.26 19.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.938 178.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 88.3 m -100.16 154.39 18.48 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 112.522 0.564 . . . . 0.0 112.522 -178.548 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.994 HG13 HG21 ' A' ' 27' ' ' ILE . 38.4 t -149.8 130.07 6.82 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.921 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.545 ' HD2' HG21 ' A' ' 27' ' ' ILE . 4.3 Cg_exo -74.93 128.56 11.63 Favored 'Trans proline' 0 C--N 1.351 0.673 0 C-N-CA 122.844 2.362 . . . . 0.0 112.658 -179.827 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.723 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 14.5 ptmm? -100.87 -2.54 31.8 Favored 'General case' 0 N--CA 1.463 0.183 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.857 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.07 -33.01 13.16 Favored Glycine 0 C--N 1.331 0.273 0 C-N-CA 120.156 -1.021 . . . . 0.0 112.362 -179.065 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.857 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -156.59 63.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 179.012 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.679 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -136.95 110.16 7.81 Favored 'General case' 0 C--N 1.332 -0.188 0 N-CA-C 114.074 1.139 . . . . 0.0 114.074 -178.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.747 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.7 p -82.99 134.13 27.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 177.515 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.541 ' CZ ' HD11 ' A' ' 42' ' ' LEU . 7.5 p90 -156.11 151.61 26.95 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.23 0.538 . . . . 0.0 111.8 -179.04 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 43.8 m-70 -119.5 143.19 47.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.237 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.532 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 1.3 m-85 -103.47 152.32 21.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.871 0.367 . . . . 0.0 110.448 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.402 ' NH1' ' HB2' ' A' ' 70' ' ' LEU . 24.3 mmm180 -125.16 138.89 54.14 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.753 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.441 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 77.9 m -117.35 132.7 23.4 Favored Pre-proline 0 C--O 1.234 0.271 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.54 179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_exo -44.65 -36.69 10.58 Favored 'Trans proline' 0 C--N 1.349 0.602 0 C-N-CA 123.082 2.521 . . . . 0.0 113.145 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 84.4 mt-30 -60.74 -16.89 44.84 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.493 -0.321 . . . . 0.0 111.025 179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.21 43.86 1.82 Allowed Glycine 0 N--CA 1.448 -0.518 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.217 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.441 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 58.8 mm-40 -114.23 152.49 31.19 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 120.925 0.393 . . . . 0.0 111.048 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.614 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.1 tt -127.12 108.28 10.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.577 -179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.532 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 41.7 t -96.58 157.0 3.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.789 179.586 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.509 ' O ' HD13 ' A' ' 73' ' ' ILE . 88.7 tt0 -131.89 140.51 49.1 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.959 0.409 . . . . 0.0 111.567 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.513 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 43.2 mm -148.56 125.82 2.8 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.172 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.251 179.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.712 ' OD2' ' HB3' ' A' ' 77' ' ' ALA . 7.8 p-10 -97.94 99.85 11.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.287 0.565 . . . . 0.0 111.81 -179.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.679 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.97 -12.24 59.73 Favored Glycine 0 C--O 1.225 -0.443 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.886 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 55.4 ttp180 -97.92 -37.77 9.67 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-O 120.914 0.388 . . . . 0.0 111.49 -178.823 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.712 ' HB3' ' OD2' ' A' ' 74' ' ' ASP . . . -101.33 -12.96 18.23 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 112.59 0.589 . . . . 0.0 112.59 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.488 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.2 OUTLIER -103.33 32.27 3.88 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 121.085 0.469 . . . . 0.0 110.585 -179.537 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 48.2 t -79.76 100.8 4.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.71 179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -105.69 101.86 11.35 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.899 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.421 ' CZ ' ' CB ' ' A' ' 40' ' ' ASN . 21.1 mmt85 -117.28 94.73 45.87 Favored Pre-proline 0 C--N 1.329 -0.291 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.773 -179.897 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.41 ' HD2' ' HD2' ' A' ' 39' ' ' ARG . 19.9 Cg_exo -66.14 -11.36 30.87 Favored 'Trans proline' 0 C--N 1.344 0.316 0 C-N-CA 122.623 2.215 . . . . 0.0 112.786 -179.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 17.7 tp10 -106.96 -22.76 12.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.765 0.316 . . . . 0.0 111.524 -179.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.436 ' O ' ' CG ' ' A' ' 85' ' ' ARG . 61.8 mm-40 -94.78 10.6 34.55 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.364 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.436 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.7 ptp85 48.43 109.05 0.0 OUTLIER 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 121.184 0.516 . . . . 0.0 111.637 -179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.985 -179.984 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.2 mtp180 . . . . . 0 CA--C 1.526 0.048 0 CA-C-O 120.87 0.367 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 16.4 m80 -106.43 -39.62 5.83 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.869 -179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 53.1 mm-40 -71.18 146.44 49.1 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.786 179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.719 HD12 HD12 ' A' ' 15' ' ' LEU . 59.5 tp -178.53 -35.6 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.095 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.581 ' HA ' HG13 ' A' ' 34' ' ' VAL . 50.0 mt -53.28 157.72 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.134 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.503 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 91.96 -6.63 79.24 Favored Glycine 0 CA--C 1.519 0.329 0 C-N-CA 120.662 -0.78 . . . . 0.0 112.794 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.762 HD22 ' OG1' ' A' ' 65' ' ' THR . 89.8 mt -97.43 162.41 13.33 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.901 0.381 . . . . 0.0 111.062 -179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.9 p -93.93 150.67 20.16 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 179.034 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.445 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 5.1 p -147.1 128.51 6.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-O 120.906 0.384 . . . . 0.0 111.134 -179.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -115.41 138.31 51.13 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.293 -179.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.829 HD13 HG23 ' A' ' 30' ' ' ILE . 1.4 mp -98.88 132.44 44.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.936 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -101.06 -28.38 12.74 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.851 179.664 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.519 ' HB2' HG12 ' A' ' 60' ' ' VAL . 56.1 mtp85 -158.58 130.98 6.91 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.697 -0.683 . . . . 0.0 110.489 179.556 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 48.0 t -124.92 157.45 35.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.23 -179.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.566 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.5 p -58.66 -26.68 32.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.915 179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.566 ' CD2' HG13 ' A' ' 23' ' ' VAL . 90.0 m-70 -125.53 125.3 43.01 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.275 -0.421 . . . . 0.0 110.732 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 79.3 ttt180 -57.95 -21.93 46.56 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.208 -179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.66 -25.16 68.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.0 -179.99 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.769 HG21 ' HD2' ' A' ' 55' ' ' PRO . 27.2 mm -115.0 -20.54 5.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.275 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.436 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 43.1 tt0 -55.62 151.03 11.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.852 0.358 . . . . 0.0 111.102 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 74.0 4.97 69.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.684 -0.769 . . . . 0.0 112.561 -179.618 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.829 HG23 HD13 ' A' ' 19' ' ' ILE . 13.0 tt -73.67 154.25 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 CA-C-O 120.86 0.362 . . . . 0.0 111.019 -179.913 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.409 ' N ' HG12 ' A' ' 30' ' ' ILE . 49.1 m -151.22 140.9 21.75 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.381 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.12 -161.71 30.29 Favored Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.198 -1.001 . . . . 0.0 112.697 -179.693 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.15 ' O ' HG23 ' A' ' 44' ' ' ILE . 32.0 ttm-85 -98.9 171.47 8.04 Favored 'General case' 0 CA--C 1.541 0.621 0 CA-C-O 120.964 0.411 . . . . 0.0 110.529 -179.787 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.581 HG13 ' HA ' ' A' ' 13' ' ' ILE . 13.4 p -100.51 156.42 4.21 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 N-CA-C 113.932 1.086 . . . . 0.0 113.932 -175.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.621 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.1 p -135.41 -48.97 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.338 0.075 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.469 177.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.494 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 55.8 m-20 -159.04 157.06 30.45 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-O 121.181 0.515 . . . . 0.0 112.224 -179.5 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.5 ' HG3' ' HZ1' ' A' ' 56' ' ' LYS . 87.0 tt0 -118.84 118.36 31.36 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.625 178.713 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.493 ' O ' ' HD2' ' A' ' 56' ' ' LYS . 40.2 m -114.75 150.88 34.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 121.081 0.467 . . . . 0.0 111.792 -178.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.554 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 39.0 ttm180 -55.44 -12.54 1.13 Allowed 'General case' 0 N--CA 1.463 0.182 0 CA-C-N 115.769 -0.651 . . . . 0.0 111.969 179.561 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.514 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -144.19 8.93 1.43 Allowed 'General case' 0 C--N 1.332 -0.161 0 N-CA-C 112.844 0.683 . . . . 0.0 112.844 179.946 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.514 HG23 ' O ' ' A' ' 40' ' ' ASN . 20.6 p -158.31 152.47 24.12 Favored 'General case' 0 CA--C 1.521 -0.157 0 CA-C-O 121.462 0.648 . . . . 0.0 112.5 179.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.641 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -128.06 113.05 15.29 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.45 178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.538 ' HG2' HG11 ' A' ' 35' ' ' VAL . 41.0 ttp180 -103.59 134.87 46.22 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.374 0.607 . . . . 0.0 110.73 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.15 HG23 ' O ' ' A' ' 33' ' ' ARG . 17.2 mt -99.95 122.53 51.94 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.315 0 CA-C-N 114.804 -1.089 . . . . 0.0 112.871 -177.495 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.689 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 31.2 tt0 -128.77 134.99 48.58 Favored 'General case' 0 C--O 1.262 1.716 0 CA-C-O 121.039 0.447 . . . . 0.0 109.811 176.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.643 ' HA ' ' HD2' ' A' ' 33' ' ' ARG . 14.2 ptp -119.81 138.59 53.27 Favored 'General case' 0 C--O 1.241 0.609 0 O-C-N 125.305 1.628 . . . . 0.0 110.744 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -42.21 -28.26 0.18 Allowed 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 115.43 -0.804 . . . . 0.0 112.639 -178.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.3 m-20 -59.27 -12.85 6.13 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.893 0.378 . . . . 0.0 110.52 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 94.25 19.04 34.28 Favored Glycine 0 N--CA 1.447 -0.606 0 N-CA-C 111.621 -0.592 . . . . 0.0 111.621 -179.387 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.481 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 22.1 mmt85 -105.61 117.7 34.69 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.735 0.303 . . . . 0.0 111.507 -179.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.48 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 16.7 pt-20 -117.91 114.99 24.03 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 116.303 -0.408 . . . . 0.0 111.056 179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.408 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -122.27 127.76 75.28 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.953 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -71.35 154.08 41.85 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.091 0.472 . . . . 0.0 112.152 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.556 HG13 HG21 ' A' ' 27' ' ' ILE . 52.5 t -146.88 139.02 13.77 Favored Pre-proline 0 CA--C 1.531 0.248 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.227 179.44 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.769 ' HD2' HG21 ' A' ' 27' ' ' ILE . 72.6 Cg_endo -75.96 139.57 22.0 Favored 'Trans proline' 0 C--N 1.346 0.419 0 C-N-CA 122.565 2.176 . . . . 0.0 113.789 -178.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.6 ' NZ ' HD23 ' A' ' 42' ' ' LEU . 58.1 mttm -100.64 -2.05 33.73 Favored 'General case' 0 N--CA 1.464 0.228 0 CA-C-N 115.488 -0.778 . . . . 0.0 112.533 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.896 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.02 -48.53 31.19 Favored Glycine 0 CA--C 1.518 0.255 0 C-N-CA 120.182 -1.008 . . . . 0.0 113.326 -178.354 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.9 mp -160.99 66.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 179.34 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.772 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -122.06 109.18 14.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -178.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.519 HG12 ' HB2' ' A' ' 21' ' ' ARG . 11.6 p -78.79 126.74 38.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.447 178.483 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.485 ' CE1' ' HB ' ' A' ' 73' ' ' ILE . 3.4 p90 -156.04 143.47 19.31 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.164 0.507 . . . . 0.0 111.833 -179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 41.8 m-70 -114.55 136.99 52.42 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.328 -179.815 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' CD2' ' HB ' ' A' ' 17' ' ' VAL . 2.0 m-85 -93.2 154.04 18.27 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.745 0.307 . . . . 0.0 110.758 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 17.8 mtm180 -141.57 136.81 31.45 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.108 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.762 ' OG1' HD22 ' A' ' 15' ' ' LEU . 68.1 m -112.11 134.62 21.41 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.554 179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.8 Cg_endo -49.09 -28.84 14.77 Favored 'Trans proline' 0 C--N 1.348 0.546 0 C-N-CA 122.899 2.399 . . . . 0.0 112.187 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.547 ' H ' HG22 ' A' ' 65' ' ' THR . 84.3 mt-30 -64.42 -15.31 60.34 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.904 179.633 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.35 46.1 1.48 Allowed Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.798 -0.715 . . . . 0.0 112.384 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 89.9 mt-10 -118.45 145.42 45.25 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.818 0.342 . . . . 0.0 110.986 179.979 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 60.7 tp -127.07 118.94 25.41 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.154 -179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.482 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.6 t -123.03 158.9 27.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.681 179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.543 ' O ' HD13 ' A' ' 73' ' ' ILE . 16.6 pt-20 -130.67 148.29 52.44 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.871 0.367 . . . . 0.0 111.317 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.543 HD13 ' O ' ' A' ' 72' ' ' GLU . 43.8 mm -148.51 107.72 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.412 179.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . . . . . . . . . 12.2 p-10 -75.3 102.91 5.23 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.478 -179.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.772 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -58.97 -12.53 15.54 Favored Glycine 0 C--O 1.226 -0.389 0 CA-C-N 115.61 -0.723 . . . . 0.0 113.458 179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.605 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 46.4 ttt85 -74.56 -18.38 60.59 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 117.065 0.433 . . . . 0.0 110.822 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.79 -2.57 34.76 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.296 -0.411 . . . . 0.0 111.764 -179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.593 HD22 ' N ' ' A' ' 78' ' ' LEU . 2.5 mm? -100.92 33.14 2.91 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.076 0.465 . . . . 0.0 110.522 179.706 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.53 HG22 ' N ' ' A' ' 80' ' ' ALA . 10.4 p -48.39 162.07 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.225 179.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.53 ' N ' HG22 ' A' ' 79' ' ' VAL . . . -47.32 163.5 0.04 OUTLIER 'General case' 0 C--O 1.232 0.155 0 CA-C-N 116.266 -0.424 . . . . 0.0 111.111 -179.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.801 ' O ' ' N ' ' A' ' 84' ' ' GLU . 96.1 mtt180 -62.88 157.24 61.74 Favored Pre-proline 0 C--O 1.219 -0.546 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 -179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.506 ' C ' ' H ' ' A' ' 84' ' ' GLU . 99.3 Cg_exo -38.79 -32.64 0.3 Allowed 'Trans proline' 0 C--N 1.359 1.082 0 C-N-CA 121.608 1.539 . . . . 0.0 109.126 177.318 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.541 ' O ' ' N ' ' A' ' 85' ' ' ARG . 4.6 mm-40 -76.22 25.67 0.13 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 112.54 -2.118 . . . . 0.0 108.803 174.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.801 ' N ' ' O ' ' A' ' 81' ' ' ARG . 47.5 mt-10 -38.33 -13.56 0.01 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 114.052 1.13 . . . . 0.0 114.052 -172.394 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.541 ' N ' ' O ' ' A' ' 83' ' ' GLU . 4.5 mmp_? -68.25 76.38 0.25 Allowed 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 173.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.585 HD12 ' O ' ' A' ' 84' ' ' GLU . 3.8 mp . . . . . 0 C--O 1.23 0.06 0 CA-C-N 115.437 -0.801 . . . . 0.0 111.33 -175.357 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 76.4 mtp180 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.787 0.327 . . . . 0.0 110.963 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -138.49 159.84 41.05 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.772 -179.928 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 12.4 pt-20 -135.89 140.25 43.95 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.792 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.633 ' N ' HD12 ' A' ' 12' ' ' LEU . 4.4 mp -98.47 30.37 3.25 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.022 179.967 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 49.2 mm -83.43 145.83 7.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.767 179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 73.35 15.8 78.89 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.597 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.404 ' CD2' ' HD2' ' A' ' 66' ' ' PRO . 78.1 mt -104.02 166.11 10.62 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.635 0.255 . . . . 0.0 110.628 179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.467 ' O ' ' HB2' ' A' ' 63' ' ' PHE . 81.0 p -104.09 147.18 27.71 Favored 'General case' 0 C--N 1.329 -0.293 0 N-CA-C 110.186 -0.301 . . . . 0.0 110.186 179.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 63' ' ' PHE . 7.0 p -147.03 131.43 10.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-O 121.078 0.466 . . . . 0.0 111.521 -179.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 39.4 ptt180 -116.46 122.42 44.72 Favored 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.693 -179.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.576 HG21 ' OG ' ' A' ' 22' ' ' SER . 45.3 mm -81.21 119.41 30.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.161 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.799 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -83.89 -34.29 24.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.092 0.472 . . . . 0.0 110.652 179.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.814 ' HB3' HG12 ' A' ' 60' ' ' VAL . 47.7 ttm-85 -157.33 149.05 22.23 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.619 -0.719 . . . . 0.0 110.631 179.502 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.576 ' OG ' HG21 ' A' ' 19' ' ' ILE . 53.9 m -139.9 164.24 30.5 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.931 -0.577 . . . . 0.0 111.173 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.686 HG13 ' ND1' ' A' ' 24' ' ' HIS . 7.1 p -63.36 -36.73 77.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.951 179.53 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.686 ' ND1' HG13 ' A' ' 23' ' ' VAL . 64.7 m80 -92.61 137.25 32.53 Favored 'General case' 0 C--O 1.23 0.078 0 CA-C-O 120.887 0.375 . . . . 0.0 110.326 179.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 25.3 mmm180 -75.36 -3.08 31.47 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.945 -179.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.557 ' OD1' HG23 ' A' ' 27' ' ' ILE . 54.8 p-10 -99.73 -20.82 16.07 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 112.232 0.456 . . . . 0.0 112.232 -179.183 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.557 HG23 ' OD1' ' A' ' 26' ' ' ASP . 20.3 pt -102.54 -22.5 4.74 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 111.711 0.263 . . . . 0.0 111.711 -179.448 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -47.23 144.89 2.53 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.83 0.348 . . . . 0.0 111.632 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 70.55 18.09 75.25 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.9 -0.667 . . . . 0.0 112.926 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.618 ' O ' HG23 ' A' ' 30' ' ' ILE . 11.7 tt -88.39 103.88 14.14 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.302 0 CA-C-O 120.767 0.318 . . . . 0.0 111.327 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 47.6 t -94.14 151.12 19.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.15 179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 176.28 -161.46 29.77 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 119.962 -1.113 . . . . 0.0 112.877 -179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.95 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.3 OUTLIER -98.71 170.77 8.55 Favored 'General case' 0 C--O 1.218 -0.585 0 CA-C-O 121.126 0.489 . . . . 0.0 111.545 -179.64 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.619 ' C ' ' H ' ' A' ' 45' ' ' GLU . 41.9 t -101.02 155.23 4.52 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 114.813 1.412 . . . . 0.0 114.813 -175.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 1.014 HG22 ' N ' ' A' ' 45' ' ' GLU . 0.1 OUTLIER -135.36 -50.37 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 176.478 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 -159.84 167.29 28.48 Favored 'General case' 0 C--O 1.231 0.122 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.48 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 8.6 mp0 -129.29 119.02 23.24 Favored 'General case' 0 C--O 1.232 0.157 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.884 178.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.496 ' HB ' ' OG1' ' A' ' 41' ' ' THR . 92.1 m -123.06 158.65 30.14 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-O 121.153 0.501 . . . . 0.0 111.601 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.482 ' HD3' ' C ' ' A' ' 39' ' ' ARG . 0.0 OUTLIER -44.4 -51.24 8.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.604 -0.725 . . . . 0.0 111.632 -179.975 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.52 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -120.35 25.5 9.78 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 112.881 0.697 . . . . 0.0 112.881 -178.794 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.52 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.2 p -157.86 153.61 26.62 Favored 'General case' 0 CA--C 1.518 -0.25 0 CA-C-O 121.132 0.492 . . . . 0.0 111.375 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.622 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.8 tm? -137.31 106.24 5.95 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.744 -179.431 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 1.008 ' C ' HG23 ' A' ' 35' ' ' VAL . 1.2 mpt_? -76.87 128.7 35.05 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.95 HG23 ' O ' ' A' ' 33' ' ' ARG . 64.6 mt -112.96 103.83 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-N 115.606 -0.724 . . . . 0.0 111.338 -179.507 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 1.014 ' N ' HG22 ' A' ' 35' ' ' VAL . 39.2 tt0 -126.52 143.69 51.12 Favored 'General case' 0 C--O 1.252 1.219 0 CA-C-O 121.12 0.486 . . . . 0.0 111.624 -179.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.602 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 2.7 ptp -118.09 140.83 49.19 Favored 'General case' 0 C--O 1.239 0.517 0 CA-C-N 113.543 -1.662 . . . . 0.0 110.176 179.211 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.4 m-20 -42.12 -27.63 0.14 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.403 -0.817 . . . . 0.0 112.521 -178.826 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -58.73 -16.86 18.57 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.05 0.452 . . . . 0.0 110.155 179.166 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.14 17.89 23.59 Favored Glycine 0 N--CA 1.449 -0.461 0 CA-C-N 115.899 -0.591 . . . . 0.0 111.764 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.478 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.59 115.12 29.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.653 0.263 . . . . 0.0 111.267 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 12.6 pt-20 -116.71 149.42 39.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.383 -0.371 . . . . 0.0 111.184 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.609 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.1 tp -158.15 123.08 0.47 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.274 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.269 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.417 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 9.0 t -72.09 153.73 41.53 Favored 'General case' 0 N--CA 1.464 0.252 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 -179.438 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.818 HG21 HD12 ' A' ' 44' ' ' ILE . 60.2 t -152.25 118.0 3.06 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.898 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -56.75 124.57 16.57 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.825 2.35 . . . . 0.0 113.395 -179.543 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.56 ' HG3' ' HB2' ' A' ' 42' ' ' LEU . 24.9 mtpt -100.3 -2.35 33.88 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.647 0.61 . . . . 0.0 112.647 179.656 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.841 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.88 -30.09 8.83 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.386 -179.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.841 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.5 mp -155.92 63.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 178.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.589 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.2 112.01 7.48 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -178.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.814 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -81.18 138.24 19.97 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.062 178.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.551 ' HB3' HD13 ' A' ' 19' ' ' ILE . 10.0 p90 -156.14 168.12 28.27 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.108 0.48 . . . . 0.0 111.716 -179.5 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.7 128.05 26.34 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.508 -0.769 . . . . 0.0 109.481 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.502 ' CE1' ' HB ' ' A' ' 71' ' ' VAL . 5.6 p90 -114.24 137.69 51.45 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.203 0.525 . . . . 0.0 112.006 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.421 ' CZ ' ' HB2' ' A' ' 70' ' ' LEU . 19.3 tpp180 -101.74 148.84 24.8 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 115.322 -0.853 . . . . 0.0 110.745 -179.786 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.509 HG22 ' H ' ' A' ' 67' ' ' GLN . 90.3 m -116.68 133.89 22.98 Favored Pre-proline 0 C--O 1.235 0.307 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.416 179.558 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 15' ' ' LEU . 3.8 Cg_endo -46.44 -31.71 10.09 Favored 'Trans proline' 0 C--N 1.351 0.662 0 C-N-CA 123.295 2.663 . . . . 0.0 112.706 -179.653 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.509 ' H ' HG22 ' A' ' 65' ' ' THR . 0.5 OUTLIER -60.96 -17.24 50.54 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.429 -0.351 . . . . 0.0 110.722 179.59 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 102.16 37.96 3.22 Favored Glycine 0 N--CA 1.448 -0.512 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.955 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -126.12 144.33 50.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.865 0.364 . . . . 0.0 111.464 -179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 64' ' ' ARG . 59.0 tp -123.97 124.57 42.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.704 179.638 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.502 ' HB ' ' CE1' ' A' ' 63' ' ' PHE . 42.0 t -116.81 155.39 18.32 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.094 179.966 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.443 ' N ' HG12 ' A' ' 71' ' ' VAL . 0.2 OUTLIER -125.38 140.82 52.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.246 -179.826 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 56.2 mt -146.62 114.94 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.253 179.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.877 ' HB2' HD23 ' A' ' 78' ' ' LEU . 58.8 m-20 -82.55 99.67 9.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.267 0.556 . . . . 0.0 111.595 -179.249 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.589 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -62.95 -12.45 43.01 Favored Glycine 0 N--CA 1.449 -0.437 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.726 179.088 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.777 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 8.3 ptm180 -98.18 -36.87 9.91 Favored 'General case' 0 N--CA 1.452 -0.364 0 CA-C-O 121.033 0.444 . . . . 0.0 111.764 -178.8 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.771 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -98.52 -5.04 32.99 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -178.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.877 HD23 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.25 43.19 3.14 Favored 'General case' 0 C--N 1.331 -0.212 0 C-N-CA 120.925 -0.31 . . . . 0.0 111.833 -179.736 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.631 HG13 ' O ' ' A' ' 79' ' ' VAL . 7.9 p -76.88 100.83 2.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.844 0.354 . . . . 0.0 110.325 179.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -97.68 150.88 20.7 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.697 -179.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.5 ' N ' ' HD2' ' A' ' 81' ' ' ARG . 6.5 mpt_? -117.01 155.2 49.64 Favored Pre-proline 0 C--N 1.329 -0.316 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.435 179.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.46 ' HD3' ' HG3' ' A' ' 39' ' ' ARG . 9.8 Cg_endo -50.97 142.31 34.29 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.599 2.199 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 89.3 tt0 -58.44 -21.08 49.85 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.351 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 89.1 tt0 -87.5 -37.21 17.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.883 0.373 . . . . 0.0 111.084 -179.934 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 57.0 ttp180 -127.7 109.53 11.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.909 -179.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 55.3 mt . . . . . 0 C--N 1.331 -0.227 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.075 -179.814 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 13.1 tpt180 . . . . . 0 CA--C 1.527 0.088 0 CA-C-O 120.755 0.312 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.885 ' CG ' HD12 ' A' ' 13' ' ' ILE . 34.0 m170 -90.89 172.03 8.89 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.682 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -173.64 -37.32 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.506 -0.315 . . . . 0.0 111.402 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.812 HD23 ' H ' ' A' ' 12' ' ' LEU . 2.3 pt? -118.8 22.11 12.13 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-O 120.704 0.288 . . . . 0.0 111.287 -179.973 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.885 HD12 ' CG ' ' A' ' 10' ' ' HIS . 56.6 mt -91.08 156.5 3.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.885 179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.455 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 97.68 -26.25 23.96 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.582 -179.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.596 ' O ' HD12 ' A' ' 15' ' ' LEU . 1.4 pp -84.08 166.1 17.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.748 0.309 . . . . 0.0 111.148 -179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.3 t -93.38 158.02 15.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.271 -0.422 . . . . 0.0 111.102 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.493 HG12 ' N ' ' A' ' 18' ' ' ARG . 41.2 t -122.74 158.98 26.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.953 179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.493 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.96 118.55 9.14 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.8 0.333 . . . . 0.0 110.734 -179.804 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.414 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 49.1 mm -87.02 136.67 22.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.78 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -113.9 -30.94 6.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.351 -0.386 . . . . 0.0 111.642 -179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.768 ' HB2' HG12 ' A' ' 60' ' ' VAL . 76.4 mtt-85 -157.61 132.23 8.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.82 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.437 ' HA ' ' HB2' ' A' ' 59' ' ' ALA . 53.5 m -138.87 164.07 30.63 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.944 0.402 . . . . 0.0 111.237 -179.758 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.433 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 6.3 p -62.12 -31.67 52.14 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.161 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.35 179.924 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.42 ' HB2' ' CD1' ' A' ' 27' ' ' ILE . 15.0 m80 -120.38 137.23 54.41 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-O 120.97 0.414 . . . . 0.0 110.719 179.444 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 98.9 mtt180 -66.24 -15.84 63.52 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.636 -179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.92 ' OD1' HG23 ' A' ' 27' ' ' ILE . 3.0 p30 -66.38 -14.76 62.59 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.55 0.214 . . . . 0.0 111.363 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.92 HG23 ' OD1' ' A' ' 26' ' ' ASP . 0.2 OUTLIER -135.26 12.14 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 CA-C-O 120.659 0.266 . . . . 0.0 111.45 179.142 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.42 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 54.0 tt0 -87.12 122.11 30.5 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-O 120.795 0.331 . . . . 0.0 111.448 -179.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.409 ' C ' HD12 ' A' ' 30' ' ' ILE . . . 82.47 13.77 77.73 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.859 -0.686 . . . . 0.0 113.034 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.661 ' N ' HD12 ' A' ' 30' ' ' ILE . 1.4 mp -99.13 122.15 50.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 CA-C-O 120.836 0.351 . . . . 0.0 111.007 179.921 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.1 t -92.87 147.94 22.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.341 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -158.95 -161.65 11.3 Favored Glycine 0 N--CA 1.451 -0.334 0 C-N-CA 120.31 -0.948 . . . . 0.0 112.965 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.123 ' O ' HG23 ' A' ' 44' ' ' ILE . 7.3 ttm180 -113.46 171.49 7.53 Favored 'General case' 0 CA--C 1.536 0.435 0 N-CA-C 110.274 -0.269 . . . . 0.0 110.274 -179.743 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.655 ' C ' ' H ' ' A' ' 45' ' ' GLU . 13.6 p -102.45 152.87 5.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -175.141 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.864 HG12 ' C ' ' A' ' 43' ' ' ARG . 8.7 p -138.29 -48.6 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.182 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.369 176.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.458 ' N ' HG13 ' A' ' 35' ' ' VAL . 37.2 t70 -159.76 165.8 31.71 Favored 'General case' 0 C--N 1.342 0.25 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.984 -179.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -126.36 128.7 47.48 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.295 179.119 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.762 HG22 ' HD2' ' A' ' 39' ' ' ARG . 26.0 m -118.63 148.42 42.73 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-O 120.824 0.345 . . . . 0.0 110.997 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.762 ' HD2' HG22 ' A' ' 38' ' ' THR . 0.3 OUTLIER -52.2 -21.7 3.63 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.219 -0.446 . . . . 0.0 112.104 -179.262 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.54 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -138.33 13.82 2.8 Favored 'General case' 0 C--N 1.33 -0.267 0 N-CA-C 112.734 0.642 . . . . 0.0 112.734 -179.536 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.54 HG23 ' O ' ' A' ' 40' ' ' ASN . 12.8 p -158.21 150.13 21.68 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.352 0.596 . . . . 0.0 112.354 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.982 HD11 ' CE2' ' A' ' 61' ' ' PHE . 15.5 mt -105.9 127.89 53.42 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.163 178.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.864 ' C ' HG12 ' A' ' 35' ' ' VAL . 16.9 ttt180 -104.03 129.88 51.68 Favored 'General case' 0 N--CA 1.445 -0.704 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 179.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.123 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.7 mt -114.81 123.42 70.48 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 N-CA-C 114.187 1.18 . . . . 0.0 114.187 -176.538 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.855 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 66.1 tt0 -131.25 140.92 49.92 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 175.448 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.593 ' HG3' ' HB2' ' A' ' 33' ' ' ARG . 3.6 mpp? -110.7 128.11 55.58 Favored 'General case' 0 C--O 1.234 0.271 0 O-C-N 125.486 1.741 . . . . 0.0 110.116 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -44.97 -26.96 0.48 Allowed 'General case' 0 N--CA 1.464 0.251 0 CA-C-O 120.821 0.343 . . . . 0.0 111.736 -179.874 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -62.7 -11.72 19.13 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.261 179.798 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.42 22.22 10.7 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.863 -0.684 . . . . 0.0 112.464 -179.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.487 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 4.9 mmp_? -104.46 161.79 13.79 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 120.567 0.222 . . . . 0.0 110.427 179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -151.77 141.46 21.81 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.17 0.51 . . . . 0.0 111.702 -179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.638 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.8 tp -159.14 154.44 4.83 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.532 179.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 85.2 m -115.81 154.23 30.03 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-O 120.893 0.377 . . . . 0.0 111.812 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.437 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 47.9 t -145.42 136.23 12.32 Favored Pre-proline 0 CA--C 1.534 0.345 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.03 179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 54' ' ' VAL . 3.0 Cg_exo -75.42 116.35 4.48 Favored 'Trans proline' 0 C--N 1.35 0.649 0 C-N-CA 122.989 2.459 . . . . 0.0 113.068 -179.513 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.715 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.4 ptmt -100.94 -2.25 32.36 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.998 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.778 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.76 -25.23 4.74 Favored Glycine 0 C--N 1.332 0.307 0 C-N-CA 120.443 -0.884 . . . . 0.0 113.151 -178.579 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.778 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.66 59.61 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.433 0 N-CA-C 109.631 -0.507 . . . . 0.0 109.631 179.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.538 ' O ' ' CA ' ' A' ' 75' ' ' GLY . . . -151.09 142.2 23.13 Favored 'General case' 0 C--O 1.226 -0.165 0 N-CA-C 113.498 0.925 . . . . 0.0 113.498 -178.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.768 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.2 p -99.56 144.05 12.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.631 178.169 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.982 ' CE2' HD11 ' A' ' 42' ' ' LEU . 17.8 p90 -156.32 160.75 40.0 Favored 'General case' 0 C--N 1.329 -0.286 0 C-N-CA 120.386 -0.526 . . . . 0.0 112.042 -179.151 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.438 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 11.9 m80 -128.05 130.69 48.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.755 -179.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.44 ' CD1' HG13 ' A' ' 17' ' ' VAL . 4.0 m-30 -93.04 122.54 35.51 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 179.737 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.415 ' HD2' ' N ' ' A' ' 65' ' ' THR . 3.9 tmm_? -116.09 118.83 33.96 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.31 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.431 ' CG2' ' HG2' ' A' ' 67' ' ' GLN . 30.5 m -88.08 136.73 31.8 Favored Pre-proline 0 C--N 1.33 -0.256 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.678 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -49.21 -30.4 19.23 Favored 'Trans proline' 0 C--N 1.347 0.483 0 C-N-CA 122.87 2.38 . . . . 0.0 113.147 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.454 ' HG3' ' HG2' ' A' ' 69' ' ' GLU . 2.9 pt20 -63.98 -12.1 34.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.669 -0.241 . . . . 0.0 111.42 -179.822 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.54 50.04 1.07 Allowed Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.573 -0.823 . . . . 0.0 112.869 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.454 ' HG2' ' HG3' ' A' ' 67' ' ' GLN . 53.5 mm-40 -126.13 146.81 49.79 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.81 0.338 . . . . 0.0 110.778 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . . . . . . . . . 58.6 tp -124.39 119.93 30.63 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.003 -179.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.589 HG12 HD11 ' A' ' 73' ' ' ILE . 41.2 t -121.66 142.03 39.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.603 179.838 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.795 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.6 OUTLIER -119.86 131.68 55.34 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.893 -179.867 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.795 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.4 mp -132.61 145.21 34.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.194 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.545 ' O ' ' HB2' ' A' ' 78' ' ' LEU . 56.7 m-20 -106.38 99.66 9.23 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.983 0.42 . . . . 0.0 111.308 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.538 ' CA ' ' O ' ' A' ' 59' ' ' ALA . . . -92.01 -13.14 58.12 Favored Glycine 0 N--CA 1.449 -0.439 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.81 179.218 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.675 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ptt180 -91.7 -36.92 13.33 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-O 120.989 0.423 . . . . 0.0 111.355 -179.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.566 ' O ' HD23 ' A' ' 78' ' ' LEU . . . -101.18 -2.46 31.29 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 112.991 0.737 . . . . 0.0 112.991 -178.68 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.566 HD23 ' O ' ' A' ' 77' ' ' ALA . 61.1 mt -130.14 44.01 3.03 Favored 'General case' 0 C--N 1.331 -0.205 0 C-N-CA 120.692 -0.403 . . . . 0.0 111.657 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.632 HG13 ' O ' ' A' ' 79' ' ' VAL . 8.1 p -73.19 100.65 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.911 0.386 . . . . 0.0 110.669 179.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -108.94 105.59 15.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.122 -179.679 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.443 ' HG2' ' HB3' ' A' ' 40' ' ' ASN . 75.3 mtp180 -117.16 140.12 26.76 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.948 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.416 ' CD ' ' HG3' ' A' ' 39' ' ' ARG . 93.4 Cg_endo -78.96 -15.75 12.96 Favored 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.55 2.166 . . . . 0.0 112.647 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -90.78 -24.44 20.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.095 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.532 ' HG2' HD11 ' A' ' 86' ' ' ILE . 41.5 tp10 -100.01 -18.06 17.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.049 179.834 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 83.5 mtm180 63.88 67.32 0.62 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-O 120.855 0.359 . . . . 0.0 111.016 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.532 HD11 ' HG2' ' A' ' 84' ' ' GLU . 52.3 mt . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.847 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.8 mtp85 . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.783 0.325 . . . . 0.0 111.156 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.661 ' HE1' HD11 ' A' ' 12' ' ' LEU . 7.5 p80 -119.89 -19.91 7.74 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.511 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.792 ' C ' HD12 ' A' ' 12' ' ' LEU . 56.2 mt-10 60.81 158.7 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.755 0.312 . . . . 0.0 111.181 179.8 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.792 HD12 ' C ' ' A' ' 11' ' ' GLU . 5.1 mp -127.34 25.54 6.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.38 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 43.6 mt -86.42 144.23 9.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-O 120.803 0.335 . . . . 0.0 110.693 179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 103.91 -9.07 50.99 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.348 -179.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.576 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.6 OUTLIER -110.54 166.33 11.09 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.821 0.343 . . . . 0.0 111.135 -179.993 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.7 m -87.2 158.22 19.18 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.526 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.704 HG23 ' CE1' ' A' ' 63' ' ' PHE . 3.5 p -130.42 121.32 50.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.281 -179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 71.3 mtm180 -114.01 125.46 54.03 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.46 179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.583 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.1 mm -88.88 136.34 23.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.12 -179.761 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.844 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -101.19 -24.16 14.31 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.877 179.531 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.83 ' HB3' HG12 ' A' ' 60' ' ' VAL . 28.8 tpt180 -164.58 147.11 8.66 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.103 179.418 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.458 ' OG ' HG21 ' A' ' 19' ' ' ILE . 56.5 m -139.64 164.22 30.49 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.021 -0.536 . . . . 0.0 111.437 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.496 HG13 ' CD2' ' A' ' 24' ' ' HIS . 7.7 p -60.03 -34.91 58.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.765 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.5 ' HB3' ' OD1' ' A' ' 26' ' ' ASP . 46.5 m170 -112.88 137.37 51.35 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.533 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 15.8 ptp180 -66.92 -22.81 65.94 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -178.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.5 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.4 p-10 -81.17 1.05 33.66 Favored 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 111.89 0.33 . . . . 0.0 111.89 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.698 HD12 ' HD2' ' A' ' 55' ' ' PRO . 25.1 pt -130.75 -15.83 1.69 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.202 0 N-CA-C 111.96 0.355 . . . . 0.0 111.96 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.8 pt20 -64.21 158.06 24.13 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.807 0.337 . . . . 0.0 111.1 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.82 18.14 56.13 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.585 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.661 HD13 ' C ' ' A' ' 30' ' ' ILE . 0.0 OUTLIER -81.79 111.83 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.297 0 CA-C-O 120.989 0.423 . . . . 0.0 111.326 -179.583 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.544 ' N ' HD13 ' A' ' 30' ' ' ILE . 45.1 t -97.12 136.2 38.0 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.615 178.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -169.0 -161.45 19.32 Favored Glycine 0 N--CA 1.448 -0.542 0 C-N-CA 119.662 -1.256 . . . . 0.0 113.498 -179.229 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.106 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.2 OUTLIER -105.55 171.1 7.51 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.235 -0.483 . . . . 0.0 111.071 -179.466 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.599 ' C ' ' H ' ' A' ' 45' ' ' GLU . 14.1 p -103.19 153.23 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.627 0 N-CA-C 114.954 1.464 . . . . 0.0 114.954 -175.798 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 1.2 p -138.88 -49.96 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.171 0 CA-C-O 121.084 0.469 . . . . 0.0 110.288 174.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.491 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 7.8 t70 -159.72 159.49 32.92 Favored 'General case' 0 C--O 1.232 0.172 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.989 -179.609 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.464 ' N ' ' OD1' ' A' ' 36' ' ' ASP . 8.3 mp0 -127.16 125.68 41.55 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.415 -0.357 . . . . 0.0 110.545 179.283 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . . . . . . . . . 28.3 m -121.68 152.57 39.21 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-O 120.924 0.392 . . . . 0.0 111.056 -179.822 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.416 ' HD2' ' N ' ' A' ' 39' ' ' ARG . 10.7 mpt_? -55.81 -23.92 33.12 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.943 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.469 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -126.77 8.42 6.88 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 -179.285 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 40' ' ' ASN . 30.2 p -157.67 163.53 38.11 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-O 121.536 0.684 . . . . 0.0 112.077 179.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.707 HD23 ' HD3' ' A' ' 56' ' ' LYS . 2.5 tm? -140.46 108.9 5.85 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.466 179.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.61 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 71.5 ttt180 -97.0 134.67 40.07 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-O 121.245 0.545 . . . . 0.0 110.197 -179.244 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.106 HG23 ' O ' ' A' ' 33' ' ' ARG . 40.1 mt -106.36 120.23 57.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.216 -0.902 . . . . 0.0 113.199 -177.32 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 1.081 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 27.6 tt0 -122.36 136.2 54.85 Favored 'General case' 0 C--O 1.259 1.599 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 176.56 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.621 ' HA ' ' CB ' ' A' ' 33' ' ' ARG . 3.3 mpp? -99.7 134.48 42.52 Favored 'General case' 0 C--O 1.234 0.285 0 O-C-N 125.542 1.776 . . . . 0.0 110.259 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -45.44 -28.57 0.91 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.787 -179.863 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -63.69 -12.86 37.82 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.085 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.27 23.64 9.5 Favored Glycine 0 N--CA 1.449 -0.459 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.139 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.461 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtt-85 -104.76 151.64 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.608 0.242 . . . . 0.0 110.827 179.759 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.407 ' OE1' ' N ' ' A' ' 51' ' ' GLU . 0.0 OUTLIER -137.04 144.49 43.24 Favored 'General case' 0 N--CA 1.454 -0.269 0 CA-C-O 120.888 0.375 . . . . 0.0 111.786 -179.355 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.701 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.4 tt -157.51 116.85 0.27 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.332 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.022 179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . 0.497 ' HA ' ' HA ' ' A' ' 43' ' ' ARG . 8.8 t -74.91 147.39 41.0 Favored 'General case' 0 N--CA 1.466 0.33 0 N-CA-C 112.444 0.535 . . . . 0.0 112.444 -179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.415 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 50.2 t -152.46 136.86 10.45 Favored Pre-proline 0 CA--C 1.536 0.415 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.871 179.396 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.698 ' HD2' HD12 ' A' ' 27' ' ' ILE . 2.8 Cg_endo -81.02 110.75 2.36 Favored 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 122.834 2.356 . . . . 0.0 113.027 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.707 ' HD3' HD23 ' A' ' 42' ' ' LEU . 23.1 pttm -100.87 -1.97 33.3 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 111.698 0.259 . . . . 0.0 111.698 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.828 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.56 -23.98 3.6 Favored Glycine 0 C--N 1.334 0.461 0 C-N-CA 120.382 -0.913 . . . . 0.0 112.307 -179.115 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.828 HD12 ' C ' ' A' ' 57' ' ' GLY . 2.9 mp -145.24 58.21 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 N-CA-C 108.963 -0.755 . . . . 0.0 108.963 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.666 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -145.36 116.99 8.1 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 114.013 1.116 . . . . 0.0 114.013 -178.025 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.844 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.2 p -75.2 137.24 23.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 177.324 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.583 ' HB3' HD13 ' A' ' 19' ' ' ILE . 5.1 p90 -154.86 160.91 41.54 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.227 0.537 . . . . 0.0 111.796 -179.348 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.434 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 87.3 m-70 -123.1 127.93 49.4 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.481 -0.782 . . . . 0.0 110.393 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.704 ' CE1' HG23 ' A' ' 17' ' ' VAL . 4.1 m-30 -92.77 125.83 37.57 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 111.576 -179.655 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.758 ' HE ' HD23 ' A' ' 70' ' ' LEU . 16.3 mmt85 -105.23 117.17 33.33 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.919 179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.442 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 56.1 m -82.64 139.15 43.88 Favored Pre-proline 0 C--N 1.331 -0.228 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.324 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.404 ' HD2' HG23 ' A' ' 65' ' ' THR . 5.0 Cg_endo -46.94 -38.37 23.53 Favored 'Trans proline' 0 C--N 1.348 0.51 0 C-N-CA 123.2 2.6 . . . . 0.0 112.591 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . . . . . . . . . 10.3 mm100 -62.07 -16.19 50.37 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.935 179.69 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.3 48.44 1.22 Allowed Glycine 0 N--CA 1.449 -0.475 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.248 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.442 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 53.8 mm-40 -113.82 156.14 24.43 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.75 0.309 . . . . 0.0 111.203 -179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.758 HD23 ' HE ' ' A' ' 64' ' ' ARG . 2.6 tm? -123.84 109.03 13.12 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.017 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.428 HG12 ' N ' ' A' ' 72' ' ' GLU . 54.2 t -107.98 156.24 8.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.504 179.527 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.434 ' HG3' ' CE1' ' A' ' 62' ' ' HIS . 37.3 tt0 -132.41 135.35 46.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.928 0.394 . . . . 0.0 111.586 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.552 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 59.7 mt -149.11 118.28 1.03 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.133 179.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.718 ' CG ' ' HB3' ' A' ' 77' ' ' ALA . 1.6 p30 -78.44 99.89 6.61 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.137 0.494 . . . . 0.0 112.153 -179.106 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -63.65 -12.88 49.05 Favored Glycine 0 N--CA 1.448 -0.554 0 CA-C-N 115.81 -0.632 . . . . 0.0 112.222 178.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.673 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 0.8 OUTLIER -98.46 -30.05 12.76 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-O 120.926 0.394 . . . . 0.0 110.922 -179.623 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.718 ' HB3' ' CG ' ' A' ' 74' ' ' ASP . . . -101.5 -1.78 32.26 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.024 -0.534 . . . . 0.0 112.139 -179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.499 ' O ' ' CD1' ' A' ' 78' ' ' LEU . 0.3 OUTLIER -116.71 40.44 2.93 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.105 0.478 . . . . 0.0 110.411 -179.646 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 57' ' ' GLY . 42.6 t -79.66 100.87 4.46 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.133 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.33 125.83 52.75 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.766 179.693 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.444 ' N ' ' HD2' ' A' ' 81' ' ' ARG . 0.1 OUTLIER -94.06 140.77 23.0 Favored Pre-proline 0 C--N 1.33 -0.265 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.373 -179.879 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.56 ' HG2' ' HG2' ' A' ' 84' ' ' GLU . 9.8 Cg_endo -54.1 -163.84 0.01 OUTLIER 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 122.909 2.406 . . . . 0.0 112.609 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.777 ' HA ' HD11 ' A' ' 86' ' ' ILE . 8.4 mp0 -85.51 -1.32 56.96 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 -179.371 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.56 ' HG2' ' HG2' ' A' ' 82' ' ' PRO . 12.4 pt-20 -81.7 -41.7 20.93 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.774 0.321 . . . . 0.0 110.763 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.486 ' HA ' ' NE ' ' A' ' 85' ' ' ARG . 3.3 tpm_? -132.39 94.36 3.42 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.504 179.994 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.777 HD11 ' HA ' ' A' ' 83' ' ' GLU . 1.8 mp . . . . . 0 C--N 1.329 -0.301 0 CA-C-O 120.896 0.379 . . . . 0.0 111.11 -179.722 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 22.1 mmt85 . . . . . 0 C--O 1.232 0.176 0 CA-C-O 120.78 0.324 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -114.44 -175.65 2.73 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.913 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -173.27 -41.82 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.942 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 63.0 tp -133.11 -45.89 0.85 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.94 -179.985 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . . . . . . . . . 48.4 mm -75.68 133.38 31.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.983 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.05 -26.15 8.45 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.576 179.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.561 ' O ' HD12 ' A' ' 15' ' ' LEU . 0.8 OUTLIER -98.07 166.03 11.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.894 0.378 . . . . 0.0 111.189 179.974 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.8 t -95.77 158.39 15.47 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.102 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.433 ' HB ' ' CD2' ' A' ' 63' ' ' PHE . 7.1 p -133.83 132.8 56.76 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.821 -179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -112.19 133.49 54.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.029 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.592 HD13 ' HB3' ' A' ' 61' ' ' PHE . 46.7 mm -92.97 129.34 43.64 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.876 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.496 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -105.08 -32.25 8.79 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.325 -0.398 . . . . 0.0 111.108 179.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.667 ' HB2' HG12 ' A' ' 60' ' ' VAL . 77.3 mtp180 -158.64 134.83 9.18 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.515 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.516 ' OG ' HD11 ' A' ' 27' ' ' ILE . 46.6 t -139.08 162.61 34.52 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.833 0.349 . . . . 0.0 111.182 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.477 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.3 p -60.14 -46.31 94.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.094 179.87 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.688 ' O ' HD13 ' A' ' 27' ' ' ILE . 90.2 m-70 -98.68 137.09 37.81 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.808 -179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.503 ' HD2' ' N ' ' A' ' 25' ' ' ARG . 1.0 OUTLIER -73.52 -7.8 53.34 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.306 -179.891 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.41 ' OD1' HG23 ' A' ' 27' ' ' ILE . 47.9 p-10 -76.92 -13.29 60.0 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 111.806 0.299 . . . . 0.0 111.806 -179.754 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.688 HD13 ' O ' ' A' ' 24' ' ' HIS . 0.2 OUTLIER -135.19 11.12 1.07 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.21 0 CA-C-O 120.649 0.261 . . . . 0.0 111.475 179.325 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.425 ' NE2' ' N ' ' A' ' 29' ' ' GLY . 4.9 tm0? -78.68 136.98 37.59 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-O 120.857 0.36 . . . . 0.0 110.77 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.425 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 69.11 17.38 71.85 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.768 179.767 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 48.8 mm -98.89 124.28 52.0 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 CA-C-O 120.779 0.323 . . . . 0.0 111.127 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.7 t -93.04 157.68 16.17 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.6 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 179.1 -161.78 28.22 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.519 -0.848 . . . . 0.0 112.213 -179.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.084 ' O ' HG23 ' A' ' 44' ' ' ILE . 54.1 mtt85 -114.71 171.67 7.5 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.459 0.647 . . . . 0.0 112.016 -179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.563 ' C ' ' H ' ' A' ' 45' ' ' GLU . 44.3 t -102.36 154.66 5.14 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 -175.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.601 HG11 ' HG2' ' A' ' 43' ' ' ARG . 0.9 OUTLIER -137.29 -49.82 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.126 0 CA-C-O 121.079 0.466 . . . . 0.0 109.976 175.709 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.506 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.99 161.74 34.18 Favored 'General case' 0 C--O 1.233 0.21 0 CA-C-N 115.67 -0.696 . . . . 0.0 111.137 -179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 54.6 mt-10 -120.13 129.36 54.12 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.361 179.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 41' ' ' THR . 47.9 m -118.8 150.82 39.16 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 121.074 0.464 . . . . 0.0 111.075 -179.713 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.867 ' HA ' ' HB3' ' A' ' 80' ' ' ALA . 40.5 ptt180 -48.46 -29.04 3.7 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.618 -0.719 . . . . 0.0 112.284 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -133.0 10.89 4.24 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 -178.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.461 ' CG2' ' HB ' ' A' ' 38' ' ' THR . 12.8 t -158.24 160.03 36.66 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-O 121.199 0.523 . . . . 0.0 111.388 179.414 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.69 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.2 tm? -131.9 115.38 15.82 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.887 -179.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.601 ' HG2' HG11 ' A' ' 35' ' ' VAL . 39.5 ttp180 -93.68 130.94 39.45 Favored 'General case' 0 N--CA 1.449 -0.521 0 CA-C-O 121.204 0.526 . . . . 0.0 109.71 179.781 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.084 HG23 ' O ' ' A' ' 33' ' ' ARG . 19.7 mt -99.92 124.73 53.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 115.24 -0.891 . . . . 0.0 113.04 -177.128 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.705 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 29.4 tt0 -129.2 137.14 50.96 Favored 'General case' 0 C--O 1.258 1.54 0 N-CA-C 109.325 -0.62 . . . . 0.0 109.325 176.285 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.599 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 10.2 ptp -118.8 135.29 54.6 Favored 'General case' 0 C--O 1.242 0.66 0 O-C-N 125.239 1.587 . . . . 0.0 110.99 -179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.9 p30 -42.46 -26.21 0.11 Allowed 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.489 -179.282 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -58.63 -15.21 10.61 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.07 17.18 23.49 Favored Glycine 0 N--CA 1.449 -0.493 0 C-N-CA 121.166 -0.54 . . . . 0.0 112.233 179.942 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.504 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.8 mmp_? -105.28 158.69 16.44 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.763 0.316 . . . . 0.0 110.941 179.674 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.486 ' HA ' ' O ' ' A' ' 44' ' ' ILE . 47.4 mt-10 -152.2 117.43 5.25 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.328 -0.396 . . . . 0.0 111.257 179.994 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.478 ' O ' ' HB ' ' A' ' 44' ' ' ILE . 11.0 tt -127.61 134.6 65.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.58 -0.282 . . . . 0.0 110.951 179.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.7 t -77.88 147.58 35.03 Favored 'General case' 0 N--CA 1.466 0.357 0 N-CA-C 112.213 0.449 . . . . 0.0 112.213 -179.317 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.648 HG21 HD12 ' A' ' 44' ' ' ILE . 44.0 t -152.44 118.62 3.05 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.993 179.702 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -64.26 117.69 4.7 Favored 'Trans proline' 0 C--N 1.349 0.589 0 C-N-CA 122.825 2.35 . . . . 0.0 113.039 -179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.573 ' CG ' ' HB2' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.83 -2.2 32.81 Favored 'General case' 0 N--CA 1.464 0.237 0 N-CA-C 112.492 0.553 . . . . 0.0 112.492 179.903 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.7 -25.16 4.61 Favored Glycine 0 C--N 1.333 0.39 0 C-N-CA 120.235 -0.983 . . . . 0.0 112.172 -179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.6 mp -151.39 61.24 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.536 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 178.698 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.656 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -140.77 110.89 6.6 Favored 'General case' 0 C--N 1.331 -0.203 0 N-CA-C 113.899 1.074 . . . . 0.0 113.899 -178.062 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.667 HG12 ' HB2' ' A' ' 21' ' ' ARG . 9.6 p -80.75 127.2 39.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 177.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.592 ' HB3' HD13 ' A' ' 19' ' ' ILE . 1.2 p90 -153.21 154.48 34.78 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.342 0.592 . . . . 0.0 111.832 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.46 ' CD2' ' HB3' ' A' ' 72' ' ' GLU . 15.4 m80 -119.91 142.03 49.08 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.253 -0.885 . . . . 0.0 110.121 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.445 ' N ' ' CD1' ' A' ' 63' ' ' PHE . 2.7 m-85 -103.49 141.93 35.14 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 120.912 0.386 . . . . 0.0 111.118 -179.432 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 25.8 mmm180 -109.56 125.43 52.52 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.772 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.525 HG22 ' H ' ' A' ' 67' ' ' GLN . 57.1 m -101.06 126.34 35.23 Favored Pre-proline 0 C--O 1.235 0.318 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -51.79 -24.76 19.08 Favored 'Trans proline' 0 C--N 1.35 0.614 0 C-N-CA 122.934 2.422 . . . . 0.0 112.76 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.525 ' H ' HG22 ' A' ' 65' ' ' THR . 31.6 tt0 -67.08 -13.75 62.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.766 0.317 . . . . 0.0 110.907 179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.02 41.6 2.23 Favored Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.295 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 62.7 mm-40 -125.96 156.07 40.36 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.84 0.352 . . . . 0.0 111.124 -179.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.632 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.2 tt -125.73 113.29 17.11 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.684 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.462 HG12 ' N ' ' A' ' 72' ' ' GLU . 48.4 t -103.54 156.7 5.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.83 179.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.607 ' O ' HD13 ' A' ' 73' ' ' ILE . 12.5 pt-20 -135.96 141.8 44.5 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.403 -0.362 . . . . 0.0 111.122 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.607 HD13 ' O ' ' A' ' 72' ' ' GLU . 40.2 mm -145.46 125.75 6.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.44 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.91 ' HB2' HD23 ' A' ' 78' ' ' LEU . 59.6 m-20 -91.31 99.68 12.61 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.251 0.548 . . . . 0.0 111.306 -179.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.656 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -66.05 -12.71 58.28 Favored Glycine 0 N--CA 1.449 -0.442 0 CA-C-N 115.485 -0.779 . . . . 0.0 112.756 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.5 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 38.7 ttm180 -98.53 -34.53 10.56 Favored 'General case' 0 N--CA 1.452 -0.326 0 N-CA-C 111.94 0.348 . . . . 0.0 111.94 -178.752 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.747 ' C ' HD22 ' A' ' 78' ' ' LEU . . . -101.21 -7.06 23.43 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 113.224 0.824 . . . . 0.0 113.224 -178.492 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.91 HD23 ' HB2' ' A' ' 74' ' ' ASP . 3.7 mm? -126.17 44.47 2.85 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.915 0.388 . . . . 0.0 111.506 -179.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.601 HG22 ' O ' ' A' ' 57' ' ' GLY . 36.1 t -66.47 117.95 8.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.778 179.539 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.867 ' HB3' ' HA ' ' A' ' 39' ' ' ARG . . . -63.88 110.61 2.15 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.816 0.341 . . . . 0.0 110.704 179.833 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . . . . . . . . . 77.2 mtt-85 -117.23 155.32 49.9 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.283 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -81.39 11.67 2.98 Favored 'Trans proline' 0 C--N 1.346 0.41 0 C-N-CA 122.864 2.376 . . . . 0.0 113.091 -179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 51.6 mm-40 -58.92 -44.41 91.31 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-O 121.045 0.45 . . . . 0.0 110.729 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.505 ' O ' ' HB2' ' A' ' 85' ' ' ARG . 95.2 mt-10 -107.81 -50.54 3.04 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.673 179.38 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.505 ' HB2' ' O ' ' A' ' 84' ' ' GLU . 39.8 ttm180 167.49 132.26 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.45 179.824 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.707 HD13 ' HB3' ' A' ' 39' ' ' ARG . 54.8 mt . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.93 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.407 ' NE ' ' N ' ' A' ' 9' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.829 0.347 . . . . 0.0 110.867 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 29.1 t-80 65.58 74.34 0.38 Allowed 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.686 -179.858 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.4 tt0 -179.7 81.95 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.764 -179.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.586 ' N ' HD12 ' A' ' 12' ' ' LEU . 5.2 mp -100.76 26.31 6.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.254 -0.43 . . . . 0.0 111.266 179.914 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.479 ' HA ' HG11 ' A' ' 34' ' ' VAL . 44.3 mm -91.24 143.07 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.926 179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.49 -18.45 50.85 Favored Glycine 0 CA--C 1.518 0.271 0 C-N-CA 120.614 -0.803 . . . . 0.0 112.964 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.74 HD13 ' OG1' ' A' ' 65' ' ' THR . 0.4 OUTLIER -110.38 158.62 18.25 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.921 0.391 . . . . 0.0 111.153 179.802 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 48.5 t -74.13 158.49 34.11 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.158 -179.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.472 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 p -138.83 110.22 5.23 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.094 -179.774 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 59.1 ttt-85 -86.18 138.83 31.59 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.792 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.527 HD13 ' HB3' ' A' ' 61' ' ' PHE . 51.0 mm -94.69 110.43 23.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.283 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.851 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -80.05 -28.36 39.28 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.113 0.482 . . . . 0.0 110.695 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.653 ' HB3' HG12 ' A' ' 60' ' ' VAL . 29.7 tpt180 -168.0 144.86 4.13 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.531 179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.41 ' OG ' HG13 ' A' ' 27' ' ' ILE . 30.9 t -140.0 164.48 29.89 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.813 -0.63 . . . . 0.0 111.294 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.488 ' HB ' ' HB ' ' A' ' 58' ' ' ILE . 8.4 p -63.39 -45.28 98.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.24 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.495 ' CD2' ' HB3' ' A' ' 26' ' ' ASP . 40.0 t60 -106.47 137.22 44.85 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.963 0.411 . . . . 0.0 110.836 -179.701 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.423 ' HA ' ' HB3' ' A' ' 28' ' ' GLN . 59.4 ttt-85 -58.89 -38.51 79.02 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 112.502 0.556 . . . . 0.0 112.502 -178.565 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.495 ' HB3' ' CD2' ' A' ' 24' ' ' HIS . 38.7 t70 -55.48 -22.87 22.77 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.842 0.353 . . . . 0.0 111.4 -179.311 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.423 ' HA ' HD12 ' A' ' 30' ' ' ILE . 24.4 pt -114.06 -13.18 11.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.459 0 CA-C-N 116.123 -0.489 . . . . 0.0 111.65 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HB3' ' HA ' ' A' ' 25' ' ' ARG . 5.7 tm0? -75.49 139.08 42.0 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 120.951 0.405 . . . . 0.0 111.234 -179.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.418 ' N ' ' NE2' ' A' ' 28' ' ' GLN . . . 76.34 10.62 85.48 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.888 -0.673 . . . . 0.0 113.255 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.423 HD12 ' HA ' ' A' ' 27' ' ' ILE . 25.4 mt -104.04 126.5 58.65 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 CA-C-N 116.93 0.365 . . . . 0.0 111.427 -179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.9 p -93.56 152.4 19.06 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 109.976 179.277 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.426 ' C ' ' HD2' ' A' ' 33' ' ' ARG . . . -167.27 -165.32 24.47 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 119.986 -1.102 . . . . 0.0 112.91 -179.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.035 ' O ' HG23 ' A' ' 44' ' ' ILE . 8.9 mpt_? -109.24 172.05 7.08 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.098 0.475 . . . . 0.0 111.429 -179.608 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.517 ' O ' ' HB3' ' A' ' 45' ' ' GLU . 13.7 p -102.17 155.58 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.976 0 N-CA-C 115.767 1.766 . . . . 0.0 115.767 -174.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 1.102 HG22 ' CB ' ' A' ' 45' ' ' GLU . 12.9 t -135.52 -51.97 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.564 0 CA-C-O 121.52 0.676 . . . . 0.0 109.654 175.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.429 ' O ' HD22 ' A' ' 42' ' ' LEU . 36.5 t70 -160.98 161.29 31.51 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 114.814 -1.085 . . . . 0.0 111.043 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -119.21 106.19 12.1 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.808 178.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.484 HG22 ' H ' ' A' ' 40' ' ' ASN . 43.9 m -102.68 149.35 24.54 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.053 0.454 . . . . 0.0 111.176 -179.053 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.413 ' NH1' ' HA ' ' A' ' 82' ' ' PRO . 40.2 ptt180 -52.66 -22.88 5.62 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.527 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.515 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -137.0 13.58 3.09 Favored 'General case' 0 C--N 1.33 -0.241 0 N-CA-C 112.744 0.646 . . . . 0.0 112.744 -179.501 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.515 HG23 ' O ' ' A' ' 40' ' ' ASN . 15.7 p -158.05 155.91 30.12 Favored 'General case' 0 CA--C 1.52 -0.203 0 CA-C-O 121.358 0.599 . . . . 0.0 111.828 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.619 ' C ' HD13 ' A' ' 42' ' ' LEU . 2.7 tm? -132.63 111.43 11.19 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.309 -0.859 . . . . 0.0 109.717 179.988 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.724 ' HB3' ' HB ' ' A' ' 35' ' ' VAL . 39.5 ttt85 -91.6 124.37 35.71 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.247 -179.415 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.035 HG23 ' O ' ' A' ' 33' ' ' ARG . 65.5 mt -99.37 117.58 44.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 N-CA-C 113.407 0.891 . . . . 0.0 113.407 -177.788 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 1.102 ' CB ' HG22 ' A' ' 35' ' ' VAL . 20.9 tt0 -128.14 137.02 51.93 Favored 'General case' 0 C--O 1.254 1.318 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 177.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.595 ' SD ' ' HB2' ' A' ' 33' ' ' ARG . 4.0 mpp? -101.88 132.91 47.39 Favored 'General case' 0 C--O 1.234 0.274 0 O-C-N 125.595 1.809 . . . . 0.0 110.243 179.808 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.2 m-20 -46.02 -27.04 0.83 Allowed 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.074 -0.512 . . . . 0.0 111.712 -179.847 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -63.28 -11.66 23.47 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.265 179.786 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.16 23.53 9.64 Favored Glycine 0 N--CA 1.448 -0.504 0 C-N-CA 120.957 -0.64 . . . . 0.0 112.443 -179.731 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.468 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 78.2 mtp180 -104.51 158.94 16.14 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.521 0.2 . . . . 0.0 110.528 179.645 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 56.2 mt-10 -148.97 144.3 26.7 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.185 0.517 . . . . 0.0 111.919 -179.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.681 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.22 138.2 3.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.284 179.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.1 t -91.84 147.17 23.18 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.017 0.437 . . . . 0.0 112.153 -179.086 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.624 HG21 HD12 ' A' ' 44' ' ' ILE . 49.0 t -152.4 121.62 3.35 Favored Pre-proline 0 CA--C 1.536 0.417 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.022 179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.413 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 27.2 Cg_exo -64.14 120.15 7.4 Favored 'Trans proline' 0 C--N 1.35 0.647 0 C-N-CA 122.855 2.37 . . . . 0.0 113.022 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.522 ' HB3' ' HB2' ' A' ' 42' ' ' LEU . 20.5 ptmt -100.81 -2.36 32.44 Favored 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 112.218 0.451 . . . . 0.0 112.218 179.604 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.942 ' HA2' HG21 ' A' ' 79' ' ' VAL . . . -49.34 -24.51 5.21 Favored Glycine 0 C--N 1.332 0.326 0 C-N-CA 120.317 -0.944 . . . . 0.0 112.633 -179.308 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.823 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -147.07 58.77 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 N-CA-C 109.098 -0.705 . . . . 0.0 109.098 178.946 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.673 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -149.27 114.71 5.55 Favored 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -178.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.851 HG13 ' HB3' ' A' ' 20' ' ' ALA . 7.9 p -82.79 131.49 33.61 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 116.145 -0.48 . . . . 0.0 109.894 177.883 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.527 ' HB3' HD13 ' A' ' 19' ' ' ILE . 0.9 OUTLIER -153.47 151.64 30.07 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.226 0.536 . . . . 0.0 111.984 -179.707 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.409 ' CE1' ' HG3' ' A' ' 72' ' ' GLU . 76.1 m-70 -114.7 138.88 50.17 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.474 -179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.498 ' HB2' ' HB ' ' A' ' 71' ' ' VAL . 2.3 m-85 -97.64 118.86 35.1 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 120.896 0.379 . . . . 0.0 110.788 179.642 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.413 ' NE ' ' CD2' ' A' ' 70' ' ' LEU . 20.9 mmt85 -99.18 123.75 43.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.563 -179.922 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.74 ' OG1' HD13 ' A' ' 15' ' ' LEU . 65.5 m -99.69 127.67 33.37 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.502 -0.317 . . . . 0.0 110.668 179.899 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.9 Cg_exo -47.23 -30.88 11.45 Favored 'Trans proline' 0 C--N 1.349 0.554 0 C-N-CA 122.724 2.283 . . . . 0.0 112.411 179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.5 ' H ' HG22 ' A' ' 65' ' ' THR . 8.3 tt0 -62.12 -16.48 52.79 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.246 -0.433 . . . . 0.0 110.901 179.634 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.16 43.7 1.85 Allowed Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.852 -0.689 . . . . 0.0 112.436 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.436 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 4.2 mm-40 -118.2 153.73 33.38 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.85 0.357 . . . . 0.0 110.972 179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.636 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -124.32 110.21 14.3 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.715 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.498 ' HB ' ' HB2' ' A' ' 63' ' ' PHE . 56.0 t -111.17 157.62 11.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.822 179.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.614 ' O ' HD13 ' A' ' 73' ' ' ILE . 40.2 tt0 -132.71 145.63 51.2 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.04 0.448 . . . . 0.0 111.683 -179.512 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.614 HD13 ' O ' ' A' ' 72' ' ' GLU . 45.1 mm -148.67 119.23 1.25 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.158 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.88 179.36 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.472 ' H ' HD12 ' A' ' 78' ' ' LEU . 60.6 m-20 -89.46 99.77 12.7 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.146 0.498 . . . . 0.0 112.125 -178.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.673 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -68.93 -11.91 64.07 Favored Glycine 0 N--CA 1.447 -0.57 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.025 178.424 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.513 ' HD3' HG23 ' A' ' 58' ' ' ILE . 16.1 tpp85 -77.12 -67.02 0.75 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 121.023 0.44 . . . . 0.0 112.071 -178.241 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -99.61 -54.85 2.82 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 113.292 0.849 . . . . 0.0 113.292 -178.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.472 HD12 ' H ' ' A' ' 74' ' ' ASP . 71.2 mt -49.52 -23.56 1.66 Allowed 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.832 -178.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.942 HG21 ' HA2' ' A' ' 57' ' ' GLY . 9.8 p -57.57 101.52 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.924 0.392 . . . . 0.0 111.037 179.761 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -57.05 154.43 9.81 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.917 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.768 ' O ' ' N ' ' A' ' 84' ' ' GLU . 54.0 mtp85 -117.0 157.86 45.51 Favored Pre-proline 0 N--CA 1.468 0.434 0 CA-C-O 119.058 -0.496 . . . . 0.0 110.118 -179.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.612 ' C ' ' H ' ' A' ' 84' ' ' GLU . 59.1 Cg_exo -30.49 -35.53 0.04 OUTLIER 'Trans proline' 0 C--N 1.366 1.484 0 C-N-CA 122.74 2.293 . . . . 0.0 110.168 178.41 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . 0.552 ' N ' ' O ' ' A' ' 81' ' ' ARG . 56.5 mt-10 -69.03 24.23 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 112.935 -1.938 . . . . 0.0 109.258 174.423 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.768 ' N ' ' O ' ' A' ' 81' ' ' ARG . 55.9 mt-10 -39.19 -17.01 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 123.741 0.816 . . . . 0.0 112.837 -173.747 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.521 ' N ' ' O ' ' A' ' 83' ' ' GLU . 63.3 mtt85 -74.31 66.73 1.34 Allowed 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 173.395 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.483 ' N ' ' O ' ' A' ' 84' ' ' GLU . 50.3 mm . . . . . 0 N--CA 1.454 -0.242 0 CA-C-N 115.009 -0.996 . . . . 0.0 111.536 -175.699 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 75.4 mtt-85 . . . . . 0 C--O 1.232 0.169 0 CA-C-O 120.801 0.334 . . . . 0.0 110.987 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.1 m-70 63.42 87.14 0.11 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.087 -179.855 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 8.5 mp0 -105.21 32.0 4.52 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.768 179.971 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.512 HD22 ' OE1' ' A' ' 37' ' ' GLU . 61.0 tp -82.87 -22.01 34.14 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.273 -179.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.496 HG22 ' N ' ' A' ' 14' ' ' GLY . 43.1 mm -82.39 158.22 3.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-O 120.843 0.354 . . . . 0.0 111.166 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.496 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 100.51 -8.97 58.75 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.88 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.563 ' O ' HD12 ' A' ' 15' ' ' LEU . 2.0 pp -109.9 166.1 11.19 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-O 120.857 0.361 . . . . 0.0 111.317 -179.818 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 50.4 m -91.51 158.52 16.42 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.805 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.743 HG23 ' CE1' ' A' ' 63' ' ' PHE . 4.4 p -131.29 139.39 51.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.93 0.395 . . . . 0.0 111.387 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 65.1 mtt85 -133.59 120.08 20.26 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.66 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.5 mp -91.69 137.04 22.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.865 0.365 . . . . 0.0 111.346 -179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.706 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -98.22 -35.36 10.38 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.857 179.787 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.799 ' HB3' HG12 ' A' ' 60' ' ' VAL . 13.1 tpt180 -148.34 145.64 28.2 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.51 179.374 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.526 ' OG ' HG21 ' A' ' 19' ' ' ILE . 55.5 m -139.63 164.17 30.63 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.435 -179.709 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.498 HG13 ' CD2' ' A' ' 24' ' ' HIS . 10.0 p -76.07 -29.22 19.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.777 179.465 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.498 ' CD2' HG13 ' A' ' 23' ' ' VAL . 88.1 m-70 -111.32 137.34 49.19 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.675 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 78.6 ttt180 -67.33 -24.72 65.77 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.486 ' OD1' ' HB3' ' A' ' 24' ' ' HIS . 11.9 p-10 -77.63 -0.73 27.68 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 112.027 0.381 . . . . 0.0 112.027 -179.254 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.438 HG12 ' HB2' ' A' ' 24' ' ' HIS . 22.6 pt -131.38 -19.52 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 112.048 0.388 . . . . 0.0 112.048 -179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 41.0 tt0 -60.81 143.55 54.43 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.896 0.379 . . . . 0.0 111.132 -179.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.42 18.27 58.14 Favored Glycine 0 C--N 1.331 0.288 0 C-N-CA 120.861 -0.685 . . . . 0.0 112.896 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.4 mm -100.93 109.07 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 CA-C-O 120.852 0.358 . . . . 0.0 111.194 -179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 78.6 p -92.95 166.38 12.41 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.547 179.719 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 171.23 -161.7 34.29 Favored Glycine 0 N--CA 1.45 -0.395 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.762 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.984 ' O ' HG23 ' A' ' 44' ' ' ILE . 0.1 OUTLIER -98.57 170.47 8.79 Favored 'General case' 0 C--O 1.22 -0.459 0 CA-C-O 120.93 0.395 . . . . 0.0 111.292 -179.902 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.702 ' C ' ' H ' ' A' ' 45' ' ' GLU . 12.8 p -102.75 155.12 5.21 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.935 0 N-CA-C 115.589 1.7 . . . . 0.0 115.589 -174.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 1.038 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.2 OUTLIER -130.47 -50.23 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.596 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 175.52 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.424 ' OD1' ' N ' ' A' ' 37' ' ' GLU . 46.5 t0 -160.73 167.29 27.18 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.282 -179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.512 ' OE1' HD22 ' A' ' 12' ' ' LEU . 85.7 tt0 -128.36 127.66 43.08 Favored 'General case' 0 N--CA 1.464 0.242 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.153 178.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.417 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 84.8 m -123.19 154.37 38.81 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-O 121.117 0.484 . . . . 0.0 111.954 -179.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.647 ' HB3' ' HG2' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -40.83 -35.49 0.51 Allowed 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 115.368 -0.833 . . . . 0.0 112.877 -179.841 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.402 ' N ' ' HG2' ' A' ' 39' ' ' ARG . 0.1 OUTLIER -145.61 25.69 1.32 Allowed 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 112.15 0.426 . . . . 0.0 112.15 -179.295 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.401 HG23 ' O ' ' A' ' 40' ' ' ASN . 5.5 p -154.87 147.08 23.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.153 0.501 . . . . 0.0 111.303 179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.994 HD11 ' CE2' ' A' ' 61' ' ' PHE . 39.6 mt -117.88 156.85 27.7 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.519 -0.764 . . . . 0.0 111.71 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 1.038 ' C ' HG23 ' A' ' 35' ' ' VAL . 0.5 OUTLIER -129.69 119.03 22.84 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.867 -1.06 . . . . 0.0 108.72 178.71 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 0.984 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.5 mt -103.61 103.93 15.91 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 N-CA-C 112.458 0.54 . . . . 0.0 112.458 -178.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.971 ' N ' HG22 ' A' ' 35' ' ' VAL . 43.0 tt0 -115.83 137.86 51.7 Favored 'General case' 0 C--O 1.256 1.402 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.723 ' HG3' ' HE ' ' A' ' 33' ' ' ARG . 3.7 mpp? -106.06 135.88 46.74 Favored 'General case' 0 N--CA 1.454 -0.229 0 O-C-N 125.681 1.863 . . . . 0.0 110.317 -179.838 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 47.4 p-10 -48.08 -25.45 1.44 Allowed 'General case' 0 N--CA 1.462 0.172 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.657 -179.869 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.65 -11.22 33.07 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.42 -0.355 . . . . 0.0 111.088 179.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.44 23.85 9.25 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.342 -179.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.471 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 99.1 mtt180 -104.64 158.6 16.39 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.6 0.238 . . . . 0.0 110.437 179.703 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 54.8 mt-10 -152.39 139.25 18.97 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.795 0.331 . . . . 0.0 111.523 -179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.672 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.6 tt -156.7 119.92 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.174 179.451 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -79.15 154.35 29.38 Favored 'General case' 0 CA--C 1.529 0.156 0 CA-C-O 120.938 0.399 . . . . 0.0 111.993 -179.412 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.434 HG13 HD12 ' A' ' 27' ' ' ILE . 48.5 t -150.76 121.92 3.88 Favored Pre-proline 0 CA--C 1.535 0.384 0 CA-C-N 115.95 -0.568 . . . . 0.0 111.023 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.41 115.46 2.6 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.819 2.346 . . . . 0.0 113.111 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.668 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 20.2 ptmt -100.82 -1.5 34.67 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 116.222 -0.445 . . . . 0.0 112.076 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.775 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.27 -23.07 2.69 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.326 -0.94 . . . . 0.0 112.789 -178.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.775 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.2 mp -150.68 60.1 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.384 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 178.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.03 112.78 5.39 Favored 'General case' 0 CA--C 1.531 0.231 0 N-CA-C 113.98 1.104 . . . . 0.0 113.98 -178.351 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.799 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.9 p -75.31 135.71 26.59 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 178.039 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.994 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.2 p90 -154.37 161.18 41.88 Favored 'General case' 0 C--N 1.332 -0.194 0 C-N-CA 120.399 -0.521 . . . . 0.0 111.542 -179.328 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.424 ' ND1' ' HG2' ' A' ' 72' ' ' GLU . 50.7 t60 -124.47 126.29 45.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.422 -179.202 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.743 ' CE1' HG23 ' A' ' 17' ' ' VAL . 3.5 m-30 -94.37 147.21 23.45 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.732 179.398 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.41 ' NH1' ' HB3' ' A' ' 70' ' ' LEU . 32.1 mmt180 -135.89 125.1 24.58 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.879 179.646 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.605 HG22 ' H ' ' A' ' 67' ' ' GLN . 89.5 m -99.66 127.85 32.94 Favored Pre-proline 0 C--N 1.329 -0.315 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.558 179.807 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -53.09 -24.39 25.32 Favored 'Trans proline' 0 C--N 1.349 0.596 0 C-N-CA 122.722 2.281 . . . . 0.0 112.448 -179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.605 ' H ' HG22 ' A' ' 65' ' ' THR . 26.0 mt-30 -66.11 -12.47 55.81 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.252 -0.431 . . . . 0.0 111.053 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.09 36.2 3.46 Favored Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.829 -0.7 . . . . 0.0 112.238 -179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 49.2 mt-10 -126.12 151.94 46.56 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.805 0.336 . . . . 0.0 111.046 -179.94 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.748 HD22 ' C ' ' A' ' 70' ' ' LEU . 0.0 OUTLIER -122.68 144.98 48.79 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.84 -179.891 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 60.8 t -143.96 104.98 0.89 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.879 -179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.424 ' HG2' ' ND1' ' A' ' 62' ' ' HIS . 49.1 mt-10 -89.35 144.72 25.86 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.875 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.622 ' HB ' ' CE1' ' A' ' 61' ' ' PHE . 54.2 mt -149.25 134.32 10.42 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-O 120.868 0.366 . . . . 0.0 110.622 179.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.715 ' O ' HD23 ' A' ' 78' ' ' LEU . 1.5 m-20 -93.94 99.9 12.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.841 -179.177 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -56.95 -13.2 8.07 Favored Glycine 0 C--O 1.225 -0.455 0 C-N-CA 121.102 -0.57 . . . . 0.0 112.699 178.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.43 ' HD2' ' O ' ' A' ' 76' ' ' ARG . 5.5 tmm_? -92.1 -34.29 14.42 Favored 'General case' 0 N--CA 1.451 -0.418 0 CA-C-O 121.199 0.524 . . . . 0.0 109.859 -179.812 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.453 ' HB3' ' HB2' ' A' ' 74' ' ' ASP . . . -93.54 0.11 56.51 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.531 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.715 HD23 ' O ' ' A' ' 74' ' ' ASP . 4.2 mm? -109.14 38.02 2.41 Favored 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.134 0.492 . . . . 0.0 110.808 179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.527 HG22 ' N ' ' A' ' 80' ' ' ALA . 10.8 p -47.95 162.28 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.398 0 CA-C-N 115.641 -0.709 . . . . 0.0 111.107 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.527 ' N ' HG22 ' A' ' 79' ' ' VAL . . . -47.45 162.59 0.06 Allowed 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 120.923 0.392 . . . . 0.0 111.591 -179.007 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.647 ' HG2' ' HB3' ' A' ' 39' ' ' ARG . 40.4 mmt-85 -58.44 115.36 11.26 Favored Pre-proline 0 N--CA 1.455 -0.177 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.3 -179.088 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -82.44 -14.18 9.41 Favored 'Trans proline' 0 N--CA 1.462 -0.348 0 C-N-CA 122.366 2.044 . . . . 0.0 112.863 -179.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -110.37 -25.13 10.25 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.746 -179.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.426 ' HB2' ' HB3' ' A' ' 81' ' ' ARG . 88.7 mt-10 -92.8 10.45 30.87 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.594 -179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.407 ' HG2' ' N ' ' A' ' 86' ' ' ILE . 38.9 ttm180 65.9 159.61 0.12 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.777 0.323 . . . . 0.0 110.762 -179.89 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.524 HD12 ' CB ' ' A' ' 80' ' ' ALA . 37.7 mm . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.163 -179.749 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.416 ' HG2' ' N ' ' A' ' 10' ' ' HIS . 46.9 ttt85 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 120.689 0.281 . . . . 0.0 110.705 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . 0.416 ' N ' ' HG2' ' A' ' 9' ' ' ARG . 9.7 p80 -51.41 162.7 0.32 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.119 -179.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.402 ' HG2' HG12 ' A' ' 13' ' ' ILE . 35.9 tt0 -114.86 -66.15 1.12 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.62 -179.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.439 ' O ' ' HG ' ' A' ' 12' ' ' LEU . 22.9 tp 55.17 23.1 5.09 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.012 179.6 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 48.7 mm -91.52 160.31 2.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.33 -0.395 . . . . 0.0 111.375 -179.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 80.19 15.58 78.35 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.956 -0.64 . . . . 0.0 112.843 179.851 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.458 ' CD2' HG23 ' A' ' 65' ' ' THR . 39.3 mt -110.29 153.46 24.83 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.759 0.314 . . . . 0.0 111.398 -179.632 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 49.6 m -76.17 154.27 35.53 Favored 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 177.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.492 ' CG2' ' CE1' ' A' ' 63' ' ' PHE . 6.2 p -147.11 135.41 15.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 C-N-CA 120.47 -0.492 . . . . 0.0 112.255 -178.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.478 ' HA ' ' HA ' ' A' ' 31' ' ' SER . 12.2 ptp180 -137.0 141.4 42.54 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.551 179.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 60' ' ' VAL . 19.6 mt -103.1 139.65 23.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.251 -179.73 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -96.98 -31.73 12.37 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.021 0.438 . . . . 0.0 110.943 179.745 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.599 ' HB2' HG12 ' A' ' 60' ' ' VAL . 53.5 mtp85 -154.56 131.98 11.23 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.49 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.514 ' OG ' HG13 ' A' ' 27' ' ' ILE . 54.9 p -139.0 164.31 30.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.273 -0.421 . . . . 0.0 111.483 -179.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.487 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.6 p -52.87 -46.73 52.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.894 -0.594 . . . . 0.0 111.483 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.487 ' N ' HG13 ' A' ' 23' ' ' VAL . 90.7 m-70 -97.77 135.13 39.98 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.834 0.349 . . . . 0.0 110.899 -179.846 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 45.7 ttt85 -68.33 -19.55 64.67 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.008 -0.542 . . . . 0.0 111.623 -179.701 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . 0.408 ' OD1' HG23 ' A' ' 27' ' ' ILE . 57.2 p30 -81.26 0.87 34.89 Favored 'General case' 0 C--N 1.327 -0.391 0 N-CA-C 112.022 0.378 . . . . 0.0 112.022 -179.456 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.514 HG13 ' OG ' ' A' ' 22' ' ' SER . 16.5 pt -135.12 0.39 1.08 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 3.0 pt20 -87.19 152.23 22.5 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.843 0.354 . . . . 0.0 111.25 -179.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.06 18.03 56.61 Favored Glycine 0 C--N 1.33 0.246 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.887 179.545 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . . . . . . . . . 49.0 mm -103.21 119.86 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.361 0 CA-C-O 120.874 0.369 . . . . 0.0 111.456 -179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.478 ' HA ' ' HA ' ' A' ' 18' ' ' ARG . 52.9 m -92.99 149.9 20.91 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.261 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -170.82 -161.99 22.39 Favored Glycine 0 N--CA 1.448 -0.511 0 C-N-CA 120.02 -1.086 . . . . 0.0 113.671 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.079 ' HB3' ' O ' ' A' ' 45' ' ' GLU . 9.2 mmm180 -104.14 172.51 6.76 Favored 'General case' 0 C--O 1.218 -0.594 0 CA-C-O 121.487 0.66 . . . . 0.0 112.506 -179.401 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.623 ' C ' ' H ' ' A' ' 45' ' ' GLU . 11.1 p -102.37 153.47 5.36 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 114.67 1.359 . . . . 0.0 114.67 -176.648 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 1.035 HG23 ' C ' ' A' ' 43' ' ' ARG . 0.1 OUTLIER -136.32 -50.99 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.513 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 174.811 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.443 ' HB3' ' HD2' ' A' ' 43' ' ' ARG . 38.6 t70 -160.91 167.22 27.05 Favored 'General case' 0 CA--C 1.529 0.171 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.533 -179.367 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -125.86 124.85 41.8 Favored 'General case' 0 C--N 1.332 -0.175 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 178.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.427 ' HB ' ' O ' ' A' ' 41' ' ' THR . 89.6 m -116.25 156.76 26.01 Favored 'General case' 0 C--O 1.232 0.132 0 CA-C-O 121.106 0.479 . . . . 0.0 111.759 -179.028 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 80' ' ' ALA . 40.2 ptt180 -40.43 -47.37 2.59 Favored 'General case' 0 N--CA 1.463 0.189 0 CA-C-N 115.442 -0.799 . . . . 0.0 112.119 -179.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.445 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -135.37 28.6 3.36 Favored 'General case' 0 C--N 1.325 -0.47 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.689 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.445 HG23 ' O ' ' A' ' 40' ' ' ASN . 10.1 p -155.91 154.06 30.63 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.132 0.491 . . . . 0.0 111.326 179.787 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.954 HD11 ' CE2' ' A' ' 61' ' ' PHE . 44.0 mt -119.83 162.81 18.48 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.671 -0.695 . . . . 0.0 111.351 -179.87 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 1.035 ' C ' HG23 ' A' ' 35' ' ' VAL . 5.4 mtt85 -134.11 118.62 17.92 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.435 179.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.013 HG23 ' O ' ' A' ' 33' ' ' ARG . 69.1 mt -106.17 106.64 20.96 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -178.064 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 1.079 ' O ' ' HB3' ' A' ' 33' ' ' ARG . 38.0 tt0 -126.34 138.67 53.6 Favored 'General case' 0 C--O 1.251 1.158 0 CA-C-O 120.881 0.372 . . . . 0.0 110.317 178.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.697 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 5.6 ptp -116.07 141.95 47.45 Favored 'General case' 0 C--O 1.239 0.544 0 O-C-N 124.846 1.341 . . . . 0.0 110.405 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -42.03 -28.57 0.18 Allowed 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.384 -178.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.1 m-20 -58.8 -14.27 8.35 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 120.89 0.376 . . . . 0.0 110.554 179.082 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 97.31 18.2 29.34 Favored Glycine 0 N--CA 1.448 -0.555 0 CA-C-N 116.103 -0.498 . . . . 0.0 111.879 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.467 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 4.9 mmp_? -105.41 120.79 42.47 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 120.458 0.171 . . . . 0.0 111.1 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . 0.47 ' HA ' ' HA ' ' A' ' 45' ' ' GLU . 0.5 OUTLIER -120.44 147.51 45.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.111 179.982 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.548 HG23 ' HB ' ' A' ' 44' ' ' ILE . 11.5 tt -159.23 122.56 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.398 -179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.0 t -76.24 154.32 35.31 Favored 'General case' 0 N--CA 1.464 0.231 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.765 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.434 HG21 HD12 ' A' ' 44' ' ' ILE . 42.0 t -151.3 121.26 3.61 Favored Pre-proline 0 CA--C 1.536 0.434 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.456 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.459 ' HD2' HD12 ' A' ' 27' ' ' ILE . 37.1 Cg_exo -61.37 117.23 4.01 Favored 'Trans proline' 0 C--N 1.35 0.655 0 C-N-CA 122.995 2.463 . . . . 0.0 113.421 -179.662 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.623 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.94 -2.58 31.5 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.238 -0.437 . . . . 0.0 112.152 179.4 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.82 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -49.11 -24.99 5.12 Favored Glycine 0 C--N 1.332 0.341 0 C-N-CA 120.332 -0.937 . . . . 0.0 112.53 -179.042 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.82 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -151.22 60.92 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.449 -0.523 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.193 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.695 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -150.54 120.64 7.22 Favored 'General case' 0 CA--C 1.53 0.207 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 -178.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.699 ' O ' HG23 ' A' ' 19' ' ' ILE . 8.8 p -80.29 140.15 17.14 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.131 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 177.799 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.954 ' CE2' HD11 ' A' ' 42' ' ' LEU . 2.3 p90 -156.05 168.18 28.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.963 0.411 . . . . 0.0 111.915 -179.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 44.2 m-70 -137.35 128.77 28.19 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.674 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.492 ' CE1' ' CG2' ' A' ' 17' ' ' VAL . 3.5 m-85 -94.4 133.87 37.51 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.142 179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.426 ' HD3' ' N ' ' A' ' 64' ' ' ARG . 0.6 OUTLIER -109.52 145.5 36.19 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.68 179.369 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.522 ' HB ' ' HB2' ' A' ' 69' ' ' GLU . 32.4 m -113.75 130.45 23.78 Favored Pre-proline 0 C--N 1.33 -0.264 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.561 179.775 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_exo -47.98 -31.1 15.11 Favored 'Trans proline' 0 C--N 1.349 0.565 0 C-N-CA 122.79 2.327 . . . . 0.0 112.902 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.415 ' H ' HG22 ' A' ' 65' ' ' THR . 32.0 tt0 -69.21 -12.4 61.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.982 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.17 46.63 1.42 Allowed Glycine 0 N--CA 1.45 -0.4 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.72 179.801 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.522 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.3 mt-10 -120.87 151.23 39.91 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-O 120.774 0.321 . . . . 0.0 110.772 179.507 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.635 ' C ' HD13 ' A' ' 70' ' ' LEU . 3.0 tm? -127.15 121.36 31.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.029 0.443 . . . . 0.0 110.808 -179.868 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.536 ' N ' HD13 ' A' ' 70' ' ' LEU . 48.7 t -115.28 148.01 18.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.285 179.411 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 89.7 mt-10 -132.24 141.77 49.16 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.005 0.431 . . . . 0.0 111.702 -179.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.671 HG23 HD23 ' A' ' 78' ' ' LEU . 59.3 mt -149.06 151.43 13.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.783 -0.644 . . . . 0.0 110.008 179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.693 ' OD2' ' HB3' ' A' ' 77' ' ' ALA . 9.7 p-10 -109.12 99.72 8.98 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.003 0.43 . . . . 0.0 111.855 -179.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -65.42 -12.37 55.69 Favored Glycine 0 N--CA 1.45 -0.422 0 CA-C-N 115.808 -0.633 . . . . 0.0 112.611 178.963 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.593 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 98.5 mtt180 -93.41 -43.16 8.89 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-O 120.898 0.38 . . . . 0.0 111.755 -178.718 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.693 ' HB3' ' OD2' ' A' ' 74' ' ' ASP . . . -101.14 -7.39 23.2 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -178.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.671 HD23 HG23 ' A' ' 73' ' ' ILE . 26.4 tp -119.85 40.47 3.4 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 120.748 0.309 . . . . 0.0 111.187 -179.708 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 79' ' ' VAL . 7.8 p -59.12 100.88 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-O 120.895 0.379 . . . . 0.0 110.674 179.621 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . 0.6 ' HB3' ' O ' ' A' ' 39' ' ' ARG . . . -58.69 124.78 20.88 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.279 -179.569 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.593 ' HD2' ' O ' ' A' ' 81' ' ' ARG . 0.0 OUTLIER -95.76 155.25 38.68 Favored Pre-proline 0 C--N 1.327 -0.37 0 CA-C-O 121.057 0.456 . . . . 0.0 111.566 179.997 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 65.5 Cg_endo -90.0 -155.02 0.05 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 123.041 2.494 . . . . 0.0 112.333 -179.679 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.4 mt-10 -55.43 -17.72 5.6 Favored 'General case' 0 CA--C 1.53 0.21 0 CA-C-O 120.692 0.282 . . . . 0.0 111.317 179.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.49 ' HG2' ' O ' ' A' ' 84' ' ' GLU . 39.7 tt0 -78.13 10.55 2.86 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.416 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.466 ' CG ' ' O ' ' A' ' 84' ' ' GLU . 5.9 ptp85 49.49 -177.66 0.01 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-O 120.844 0.354 . . . . 0.0 111.427 -179.733 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.437 ' N ' ' HG2' ' A' ' 81' ' ' ARG . 31.7 mt . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.265 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.435 ' HD3' ' C ' ' A' ' 9' ' ' ARG . 2.1 tmt_? . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.862 0.363 . . . . 0.0 110.277 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 3.2 p80 -112.38 -29.81 7.39 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.472 -179.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 42.58 30.53 0.23 Allowed 'General case' 0 N--CA 1.464 0.256 0 CA-C-N 116.455 -0.338 . . . . 0.0 111.719 179.797 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.873 HD23 ' O ' ' A' ' 12' ' ' LEU . 6.2 tt -77.14 -28.93 54.39 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.88 0.371 . . . . 0.0 110.674 179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 14' ' ' GLY . 54.8 mt -56.46 154.58 1.71 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.125 180.0 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.716 ' H ' HG13 ' A' ' 34' ' ' VAL . . . 91.28 -19.79 44.67 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.807 -0.711 . . . . 0.0 113.184 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.914 ' O ' HG12 ' A' ' 34' ' ' VAL . 87.0 mt -73.78 164.67 26.34 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.939 0.399 . . . . 0.0 111.4 -179.629 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.417 ' OG ' ' NH1' ' A' ' 18' ' ' ARG . 50.7 p -91.01 156.1 18.2 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.516 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.419 HG22 ' HB3' ' A' ' 63' ' ' PHE . 33.7 t -147.18 133.17 12.62 Favored 'Isoleucine or valine' 0 C--O 1.232 0.18 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 -179.337 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.417 ' NH1' ' OG ' ' A' ' 16' ' ' SER . 10.2 mpt_? -112.0 129.83 56.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.481 178.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.531 HD13 ' HB3' ' A' ' 61' ' ' PHE . 45.9 mm -90.4 117.1 33.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.982 -179.988 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.644 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -89.16 -36.6 15.59 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.072 0.463 . . . . 0.0 110.971 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.712 ' HB2' HG12 ' A' ' 60' ' ' VAL . 39.5 mmt180 -156.44 139.04 15.02 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.452 179.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 86.1 p -139.13 164.09 30.7 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.102 -179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.428 HG13 ' N ' ' A' ' 24' ' ' HIS . 8.0 p -59.7 -43.09 90.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.142 179.883 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.428 ' N ' HG13 ' A' ' 23' ' ' VAL . 90.4 m-70 -102.42 133.99 46.45 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.774 179.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 38.8 ptt85 -70.37 -24.15 62.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.299 -179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -65.11 -23.04 67.03 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.088 -179.901 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.711 ' HA ' HD12 ' A' ' 30' ' ' ILE . 22.9 pt -112.39 -20.6 6.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.473 -179.87 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 52.5 tt0 -58.1 153.38 14.87 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.517 -179.498 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 63.32 15.14 56.41 Favored Glycine 0 N--CA 1.452 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 113.376 179.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.711 HD12 ' HA ' ' A' ' 27' ' ' ILE . 47.1 mt -104.14 128.46 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.362 0 CA-C-N 116.953 0.377 . . . . 0.0 111.382 179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 48.4 t -96.46 160.72 14.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.267 179.409 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -173.41 -161.97 24.57 Favored Glycine 0 N--CA 1.449 -0.442 0 C-N-CA 120.152 -1.023 . . . . 0.0 112.741 -179.843 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.122 ' O ' HG23 ' A' ' 44' ' ' ILE . 1.9 ttm105 -120.94 170.47 9.47 Favored 'General case' 0 CA--C 1.539 0.525 0 CA-C-O 120.83 0.348 . . . . 0.0 110.536 -179.735 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.914 HG12 ' O ' ' A' ' 15' ' ' LEU . 14.9 p -102.85 153.83 5.48 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 -175.348 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.763 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.8 p -138.31 -49.31 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.183 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.227 175.903 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.456 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 37.3 t70 -159.32 165.74 32.72 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.783 -179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . . . . . . . . . 50.5 mt-10 -124.87 134.53 52.67 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.612 179.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.455 HG22 ' H ' ' A' ' 40' ' ' ASN . 41.2 m -120.37 148.73 43.38 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 120.959 0.409 . . . . 0.0 110.671 -179.72 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.409 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 25.3 ptt-85 -54.29 -21.7 9.96 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.83 -179.63 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.506 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -134.43 9.98 3.74 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.417 0.525 . . . . 0.0 112.417 -179.661 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.506 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.2 p -158.13 161.94 37.96 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 121.317 0.58 . . . . 0.0 111.66 179.729 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.685 HD23 ' HD2' ' A' ' 56' ' ' LYS . 2.6 tm? -123.84 124.18 42.08 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.342 -0.844 . . . . 0.0 109.809 179.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.643 ' HB3' ' CG1' ' A' ' 35' ' ' VAL . 25.2 ttm-85 -99.62 128.49 45.73 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 -179.654 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.122 HG23 ' O ' ' A' ' 33' ' ' ARG . 55.5 mt -108.61 120.31 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 N-CA-C 114.16 1.17 . . . . 0.0 114.16 -176.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.763 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 37.8 tt0 -131.13 141.4 50.11 Favored 'General case' 0 C--O 1.258 1.507 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 175.634 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.549 ' HA ' ' CG ' ' A' ' 33' ' ' ARG . 6.4 ptp -119.32 135.17 54.84 Favored 'General case' 0 C--O 1.241 0.613 0 CA-C-N 114.242 -1.345 . . . . 0.0 111.072 179.861 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 56.1 m-20 -42.45 -26.1 0.1 Allowed 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.211 -0.904 . . . . 0.0 112.443 -179.204 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 55.9 m-20 -58.68 -15.47 11.99 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.88 0.372 . . . . 0.0 110.423 179.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 100.72 17.21 24.21 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 121.215 -0.517 . . . . 0.0 112.11 -179.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.511 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 5.0 mmp_? -105.33 161.68 14.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.739 0.304 . . . . 0.0 111.151 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 55.6 mt-10 -151.14 146.77 26.36 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.171 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.499 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.6 tp -158.68 152.85 6.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.504 179.699 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 12.0 t -103.7 148.54 25.93 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 112.067 0.395 . . . . 0.0 112.067 -179.239 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.48 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 48.2 t -152.39 126.03 4.3 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.149 179.582 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.447 ' HD2' ' CD1' ' A' ' 27' ' ' ILE . 24.0 Cg_exo -64.56 118.03 5.04 Favored 'Trans proline' 0 C--N 1.348 0.55 0 C-N-CA 122.816 2.344 . . . . 0.0 113.061 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.685 ' HD2' HD23 ' A' ' 42' ' ' LEU . 0.0 OUTLIER -100.62 -1.69 34.71 Favored 'General case' 0 N--CA 1.465 0.285 0 N-CA-C 112.236 0.458 . . . . 0.0 112.236 179.475 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.822 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.57 -25.75 4.83 Favored Glycine 0 C--N 1.332 0.352 0 C-N-CA 120.32 -0.943 . . . . 0.0 112.384 -178.711 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.822 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.4 mp -151.99 61.12 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.452 -0.373 0 N-CA-C 109.428 -0.582 . . . . 0.0 109.428 178.799 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.696 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -141.13 110.58 6.35 Favored 'General case' 0 CA--C 1.532 0.253 0 N-CA-C 113.791 1.034 . . . . 0.0 113.791 -178.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.712 HG12 ' HB2' ' A' ' 21' ' ' ARG . 10.8 p -77.77 126.76 38.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 116.466 -0.333 . . . . 0.0 110.211 178.09 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.531 ' HB3' HD13 ' A' ' 19' ' ' ILE . 4.4 p90 -153.87 151.2 29.22 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.203 0.525 . . . . 0.0 111.539 -179.705 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.45 ' CE1' ' HG2' ' A' ' 72' ' ' GLU . 46.9 m170 -117.2 136.91 52.71 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.077 179.783 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.562 ' CZ ' HG21 ' A' ' 71' ' ' VAL . 4.5 p90 -108.52 139.6 43.04 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 121.075 0.464 . . . . 0.0 111.105 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . . . . . . . . . 46.9 mmm-85 -108.25 142.03 39.13 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.835 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.67 ' HA ' HD22 ' A' ' 15' ' ' LEU . 87.6 m -107.14 129.97 23.54 Favored Pre-proline 0 C--N 1.329 -0.298 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.423 179.758 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.6 Cg_exo -44.47 -32.3 5.39 Favored 'Trans proline' 0 C--N 1.349 0.603 0 C-N-CA 122.777 2.318 . . . . 0.0 112.765 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.475 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -61.12 -16.65 46.63 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.133 179.827 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.03 45.45 1.6 Allowed Glycine 0 N--CA 1.45 -0.405 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.286 -179.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -126.08 152.36 45.96 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.846 0.355 . . . . 0.0 111.193 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.633 HD23 ' C ' ' A' ' 70' ' ' LEU . 5.4 tt -127.06 126.36 42.92 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.582 179.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.628 ' N ' HD23 ' A' ' 70' ' ' LEU . 48.4 t -126.41 153.51 35.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.997 179.935 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.45 ' HG2' ' CE1' ' A' ' 62' ' ' HIS . 39.3 mt-10 -119.48 140.74 49.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.3 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.402 HG23 ' HG ' ' A' ' 78' ' ' LEU . 55.7 mt -138.37 124.05 24.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.274 179.487 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.453 ' O ' ' HB3' ' A' ' 78' ' ' LEU . 1.5 m-20 -90.02 99.27 12.32 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 121.119 0.485 . . . . 0.0 111.583 -179.265 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.696 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.78 -12.26 20.15 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.762 -0.654 . . . . 0.0 113.091 179.06 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.505 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 26.1 ptt-85 -94.44 -48.91 5.92 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 117.282 0.541 . . . . 0.0 111.924 -178.404 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . 0.412 ' N ' ' HG3' ' A' ' 76' ' ' ARG . . . -101.83 -20.97 14.69 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 113.55 0.944 . . . . 0.0 113.55 -178.497 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.887 HD13 ' O ' ' A' ' 78' ' ' LEU . 3.0 tm? -78.11 -29.48 48.96 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -178.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.436 HG21 ' HA2' ' A' ' 57' ' ' GLY . 59.3 t -54.63 99.96 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.927 0.394 . . . . 0.0 111.222 -179.724 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -109.98 109.96 20.73 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.182 179.68 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.45 ' O ' ' HG3' ' A' ' 81' ' ' ARG . 37.8 ptt180 -117.37 94.74 46.04 Favored Pre-proline 0 C--N 1.329 -0.302 0 CA-C-O 120.789 0.328 . . . . 0.0 111.647 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.464 ' HD2' ' O ' ' A' ' 85' ' ' ARG . 88.3 Cg_endo -76.07 -125.0 0.01 OUTLIER 'Trans proline' 0 CA--C 1.538 0.702 0 C-N-CA 122.507 2.138 . . . . 0.0 111.636 179.46 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 50.3 mt-10 -110.35 -25.56 10.03 Favored 'General case' 0 C--O 1.231 0.104 0 O-C-N 122.041 -0.412 . . . . 0.0 111.934 -179.636 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -87.0 -50.31 6.74 Favored 'General case' 0 C--N 1.326 -0.424 0 CA-C-O 120.889 0.376 . . . . 0.0 111.354 -179.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . 0.464 ' O ' ' HD2' ' A' ' 82' ' ' PRO . 47.5 ttt85 -174.83 -74.0 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.04 179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.409 ' CD1' ' HA ' ' A' ' 39' ' ' ARG . 28.4 mm . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.369 -0.378 . . . . 0.0 110.202 178.643 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 59.6 ttp85 . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.764 0.316 . . . . 0.0 110.904 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -64.62 174.29 1.83 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.966 -179.943 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.5 tt0 -115.34 135.47 54.1 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.792 -179.926 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.847 HD23 ' O ' ' A' ' 12' ' ' LEU . 5.4 tt -79.0 -33.21 45.19 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.473 -179.814 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.518 HG22 ' N ' ' A' ' 14' ' ' GLY . 45.4 mm -66.53 159.91 4.29 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.266 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.795 179.709 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.518 ' N ' HG22 ' A' ' 13' ' ' ILE . . . 79.91 -0.26 83.26 Favored Glycine 0 CA--C 1.519 0.282 0 C-N-CA 120.658 -0.782 . . . . 0.0 112.568 -179.523 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.67 ' CD2' HG23 ' A' ' 65' ' ' THR . 61.9 mt -94.58 166.18 12.16 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.92 0.39 . . . . 0.0 110.988 -179.737 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.57 ' HA ' ' HD3' ' A' ' 33' ' ' ARG . 47.5 t -91.78 158.02 16.58 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.388 179.455 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.731 HG13 ' CE1' ' A' ' 63' ' ' PHE . 38.3 t -125.45 149.33 30.08 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.859 -179.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.428 ' HD2' ' HB2' ' A' ' 31' ' ' SER . 26.2 mmm180 -136.42 114.5 11.46 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.671 ' N ' HD12 ' A' ' 19' ' ' ILE . 1.4 mp -91.93 134.01 31.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.794 179.743 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.464 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -109.65 -31.78 7.35 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.137 -179.975 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.421 ' HB2' HG12 ' A' ' 60' ' ' VAL . 81.9 mtm180 -155.26 138.51 15.7 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.466 179.705 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.44 ' HB3' ' CD1' ' A' ' 27' ' ' ILE . 48.6 m -139.24 164.22 30.39 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.896 0.379 . . . . 0.0 111.328 -179.887 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.48 HG13 ' N ' ' A' ' 24' ' ' HIS . 7.2 p -61.31 -46.12 97.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 115.995 -0.548 . . . . 0.0 111.407 179.946 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.48 ' N ' HG13 ' A' ' 23' ' ' VAL . 43.8 m170 -105.45 137.3 43.49 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.134 -179.824 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . 0.46 ' HD3' ' N ' ' A' ' 25' ' ' ARG . 0.1 OUTLIER -69.79 -19.88 63.48 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.204 179.957 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -64.31 -18.12 64.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 111.296 179.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.557 ' C ' HD12 ' A' ' 27' ' ' ILE . 2.3 pp -135.12 14.56 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 CA-C-N 116.416 -0.356 . . . . 0.0 111.518 179.592 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 51.5 tt0 -83.44 146.7 28.27 Favored 'General case' 0 N--CA 1.455 -0.185 0 CA-C-N 116.379 -0.373 . . . . 0.0 111.131 -179.94 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 62.12 16.12 52.27 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.759 179.802 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.473 ' O ' HD13 ' A' ' 19' ' ' ILE . 49.9 mm -103.01 117.78 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 CA-C-O 120.764 0.316 . . . . 0.0 111.07 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.428 ' HB2' ' HD2' ' A' ' 18' ' ' ARG . 72.0 p -92.72 170.34 9.79 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.556 179.847 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -178.63 -170.59 40.87 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 119.95 -1.119 . . . . 0.0 113.479 -179.945 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.074 ' O ' HG23 ' A' ' 44' ' ' ILE . 9.2 tpp85 -98.96 170.46 8.71 Favored 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 110.161 -0.311 . . . . 0.0 110.161 -179.781 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.608 ' C ' ' H ' ' A' ' 45' ' ' GLU . 7.3 p -103.1 153.73 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.749 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.988 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.714 ' HB ' ' CB ' ' A' ' 45' ' ' GLU . 2.7 p -137.94 -49.38 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.059 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.453 ' N ' ' CG1' ' A' ' 35' ' ' VAL . 2.3 p30 -159.4 167.11 29.6 Favored 'General case' 0 C--N 1.34 0.161 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.269 179.05 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.527 ' OE2' HD13 ' A' ' 12' ' ' LEU . 48.9 mt-10 -129.4 131.96 46.91 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-O 120.687 0.279 . . . . 0.0 111.074 179.837 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.433 ' HB ' HG22 ' A' ' 41' ' ' THR . 30.2 m -120.38 146.17 46.44 Favored 'General case' 0 N--CA 1.455 -0.225 0 N-CA-C 110.003 -0.369 . . . . 0.0 110.003 179.528 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . 0.411 ' O ' HG13 ' A' ' 79' ' ' VAL . 47.6 mmt-85 -55.8 -13.72 1.93 Allowed 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 112.278 0.473 . . . . 0.0 112.278 -179.264 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -135.08 4.0 3.2 Favored 'General case' 0 C--N 1.331 -0.21 0 N-CA-C 113.012 0.745 . . . . 0.0 113.012 -179.664 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.468 ' CA ' ' HG2' ' A' ' 56' ' ' LYS . 13.4 t -158.54 159.72 35.86 Favored 'General case' 0 C--O 1.232 0.166 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.604 179.571 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.853 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -113.92 144.91 42.28 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.284 178.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.63 ' C ' HG12 ' A' ' 35' ' ' VAL . 8.9 tpt180 -124.83 122.22 36.79 Favored 'General case' 0 N--CA 1.443 -0.809 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.835 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.074 HG23 ' O ' ' A' ' 33' ' ' ARG . 51.5 mt -103.38 124.29 57.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -176.578 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.714 ' CB ' ' HB ' ' A' ' 35' ' ' VAL . 25.9 tt0 -131.09 138.76 49.7 Favored 'General case' 0 C--O 1.26 1.645 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 175.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.714 ' HA ' ' HG2' ' A' ' 33' ' ' ARG . 31.7 mtm -108.4 132.21 53.99 Favored 'General case' 0 C--O 1.233 0.237 0 O-C-N 125.391 1.682 . . . . 0.0 110.86 -179.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 37.3 t70 -45.94 -27.9 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.615 -179.716 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -62.49 -12.35 21.69 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.135 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 101.18 23.57 9.6 Favored Glycine 0 N--CA 1.449 -0.469 0 C-N-CA 120.91 -0.662 . . . . 0.0 112.238 -179.751 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.463 ' HB2' ' HB2' ' A' ' 46' ' ' MET . 52.8 mtp85 -104.67 161.09 14.44 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.544 0.211 . . . . 0.0 110.655 179.845 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -152.04 141.56 21.68 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 121.111 0.481 . . . . 0.0 111.75 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.587 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.2 tp -159.09 142.03 5.47 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.622 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 9.9 t -96.31 154.54 17.2 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.909 0.385 . . . . 0.0 112.022 -179.199 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.507 HG13 ' HD2' ' A' ' 55' ' ' PRO . 56.0 t -146.53 139.32 14.22 Favored Pre-proline 0 CA--C 1.534 0.35 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.069 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.507 ' HD2' HG13 ' A' ' 54' ' ' VAL . 84.9 Cg_endo -81.09 114.97 2.93 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 122.802 2.335 . . . . 0.0 113.021 -179.497 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.732 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 21.0 ptmt -100.99 -1.68 33.73 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -179.786 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.813 ' C ' HD12 ' A' ' 58' ' ' ILE . . . -48.42 -26.71 5.23 Favored Glycine 0 C--N 1.331 0.26 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.819 -178.412 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.813 HD12 ' C ' ' A' ' 57' ' ' GLY . 3.3 mp -152.48 61.44 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 N-CA-C 109.535 -0.543 . . . . 0.0 109.535 178.692 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.674 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -148.3 117.12 6.69 Favored 'General case' 0 C--N 1.33 -0.242 0 N-CA-C 113.698 0.999 . . . . 0.0 113.698 -178.654 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.464 HG13 ' HB3' ' A' ' 20' ' ' ALA . 10.3 p -79.86 137.95 20.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.112 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.087 178.046 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.853 ' CE2' HD11 ' A' ' 42' ' ' LEU . 8.9 p90 -156.07 168.13 28.25 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.93 0.395 . . . . 0.0 111.337 -179.413 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . . . . . . . . . 60.9 m-70 -135.17 129.62 34.08 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.747 -179.601 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . 0.731 ' CE1' HG13 ' A' ' 17' ' ' VAL . 3.0 m-85 -93.69 117.74 30.48 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.562 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.514 ' NH1' ' HB2' ' A' ' 64' ' ' ARG . 0.1 OUTLIER -92.94 146.58 23.52 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.814 179.961 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.67 HG23 ' CD2' ' A' ' 15' ' ' LEU . 61.9 m -121.04 124.25 27.49 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.788 179.844 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -47.35 -34.03 17.98 Favored 'Trans proline' 0 C--N 1.351 0.663 0 C-N-CA 122.705 2.27 . . . . 0.0 112.443 179.91 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.433 ' H ' HG22 ' A' ' 65' ' ' THR . 73.3 mt-30 -62.37 -15.8 50.75 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.061 179.668 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.26 46.15 1.48 Allowed Glycine 0 N--CA 1.449 -0.453 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.598 -179.998 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.495 ' HB2' ' HB ' ' A' ' 65' ' ' THR . 86.1 mt-10 -123.45 155.11 38.09 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 120.812 0.339 . . . . 0.0 110.852 179.715 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.436 HD13 ' NH1' ' A' ' 64' ' ' ARG . 60.8 tp -126.96 119.95 27.93 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.257 -179.767 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.694 HG12 HD11 ' A' ' 73' ' ' ILE . 43.8 t -116.25 141.24 34.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.306 179.428 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.779 ' C ' HD12 ' A' ' 73' ' ' ILE . 16.6 pt-20 -131.38 134.24 46.08 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 121.022 0.439 . . . . 0.0 112.063 -179.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.779 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.6 mp -140.8 128.02 22.2 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.629 179.002 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.857 ' HB3' HD23 ' A' ' 78' ' ' LEU . 65.9 t0 -88.11 99.89 12.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.134 0.492 . . . . 0.0 111.786 -179.075 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.674 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -59.15 -12.29 15.84 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.674 -0.694 . . . . 0.0 112.666 178.657 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.608 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 47.3 ttt85 -82.88 -66.97 0.83 Allowed 'General case' 0 N--CA 1.451 -0.375 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -178.351 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -101.22 -42.69 6.24 Favored 'General case' 0 C--N 1.323 -0.574 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -178.15 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.857 HD23 ' HB3' ' A' ' 74' ' ' ASP . 4.3 mm? -54.26 -20.39 6.94 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 -178.635 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.411 HG13 ' O ' ' A' ' 39' ' ' ARG . 60.4 t -59.6 100.98 0.1 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.414 0 CA-C-O 120.864 0.364 . . . . 0.0 110.95 179.775 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -96.67 111.29 23.5 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.027 179.911 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.409 ' HG3' ' O ' ' A' ' 81' ' ' ARG . 15.6 ptp180 -100.03 103.89 25.46 Favored Pre-proline 0 C--N 1.328 -0.353 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.985 179.941 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.3 Cg_endo -80.5 52.87 4.51 Favored 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.565 2.177 . . . . 0.0 112.773 -179.632 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -110.02 -40.94 4.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.159 0.504 . . . . 0.0 110.654 179.542 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -107.31 -50.06 3.15 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.598 179.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 56.0 ttp180 179.77 152.35 0.43 Allowed 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.011 -0.541 . . . . 0.0 110.744 179.8 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 51.2 mm . . . . . 0 C--N 1.33 -0.28 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.983 -179.951 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . . . . . . . . . 53.9 mtp85 . . . . . 0 C--O 1.232 0.14 0 CA-C-O 120.705 0.288 . . . . 0.0 111.115 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' HIS . . . . . . . . . . . . . 22.1 m80 -110.64 141.91 43.23 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.919 0.39 . . . . 0.0 110.923 179.903 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 94.6 mt-10 62.44 120.92 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.007 179.892 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.738 HD12 HD12 ' A' ' 15' ' ' LEU . 61.0 tp -82.3 -25.31 34.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.998 179.901 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ILE . . . . . 0.521 HD12 ' O ' ' A' ' 35' ' ' VAL . 46.5 mm -66.6 137.1 25.51 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.028 -179.98 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 102.78 11.68 34.36 Favored Glycine 0 N--CA 1.453 -0.23 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.809 179.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.738 HD12 HD12 ' A' ' 12' ' ' LEU . 86.0 mt -110.14 166.15 11.19 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.845 0.355 . . . . 0.0 110.871 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.407 ' HB2' ' HB2' ' A' ' 64' ' ' ARG . 62.6 m -94.47 158.26 15.63 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.653 179.911 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.438 ' CG2' HG22 ' A' ' 34' ' ' VAL . 36.2 t -129.09 154.72 40.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 121.12 0.486 . . . . 0.0 111.567 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.435 ' N ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -144.58 95.61 2.73 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.725 -0.67 . . . . 0.0 109.736 179.526 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.646 ' CD1' HG11 ' A' ' 54' ' ' VAL . 50.5 mt -78.1 136.02 24.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.937 -179.153 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.738 ' HB3' HG13 ' A' ' 60' ' ' VAL . . . -106.28 -26.91 11.32 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.343 178.997 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.949 ' HB3' HG12 ' A' ' 60' ' ' VAL . 46.7 ttt85 -147.54 144.03 28.22 Favored 'General case' 0 N--CA 1.452 -0.362 0 CA-C-N 115.721 -0.672 . . . . 0.0 110.374 179.081 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.482 ' OG ' HG21 ' A' ' 19' ' ' ILE . 44.0 m -139.8 164.5 29.8 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.295 -179.555 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.652 HG22 ' CD1' ' A' ' 58' ' ' ILE . 47.2 t -58.91 -57.42 11.36 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.271 179.824 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . 0.563 ' H ' HD11 ' A' ' 27' ' ' ILE . 5.1 t-80 -102.27 137.44 40.52 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.643 -179.516 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' ARG . . . . . . . . . . . . . 85.9 mtm180 -52.51 -23.66 6.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.688 -179.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -74.68 -11.7 60.24 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.545 -179.705 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . 0.756 HD12 ' HD2' ' A' ' 55' ' ' PRO . 11.0 pt -122.52 3.46 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.319 0 N-CA-C 111.991 0.367 . . . . 0.0 111.991 -179.839 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.423 ' HG3' ' HA ' ' A' ' 21' ' ' ARG . 50.8 tt0 -87.07 152.45 22.35 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 121.02 0.438 . . . . 0.0 111.439 -179.787 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 61.73 18.13 55.85 Favored Glycine 0 N--CA 1.452 -0.254 0 C-N-CA 121.071 -0.585 . . . . 0.0 113.125 179.37 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' ILE . . . . . 0.643 HD12 ' HA ' ' A' ' 27' ' ' ILE . 38.2 mt -103.46 129.26 55.68 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.464 0 CA-C-O 120.878 0.371 . . . . 0.0 111.485 -179.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 79.8 p -101.14 159.38 15.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.084 179.381 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . -172.88 -161.7 23.72 Favored Glycine 0 N--CA 1.45 -0.373 0 C-N-CA 119.966 -1.111 . . . . 0.0 113.314 -179.745 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 1.088 ' O ' HG23 ' A' ' 44' ' ' ILE . 50.7 mtp180 -116.59 173.23 6.74 Favored 'General case' 0 C--O 1.221 -0.407 0 CA-C-O 121.379 0.609 . . . . 0.0 111.768 -179.608 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . 0.645 HG23 ' O ' ' A' ' 15' ' ' LEU . 43.0 t -99.83 151.65 4.89 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 -175.43 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.873 HG23 ' OE1' ' A' ' 45' ' ' GLU . 9.8 p -138.31 -47.77 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.198 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.222 177.2 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' ASP . . . . . 0.435 ' N ' HG13 ' A' ' 35' ' ' VAL . 51.6 t0 -159.09 162.44 36.54 Favored 'General case' 0 C--N 1.34 0.195 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.318 179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' GLU . . . . . 0.579 ' HG2' HD23 ' A' ' 12' ' ' LEU . 8.8 mp0 -129.09 129.93 45.85 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.642 0.258 . . . . 0.0 110.867 179.708 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' THR . . . . . 0.432 ' O ' ' HD3' ' A' ' 56' ' ' LYS . 39.9 m -121.54 149.25 43.38 Favored 'General case' 0 C--N 1.332 -0.19 0 CA-C-N 116.546 -0.297 . . . . 0.0 110.332 179.691 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' ARG . . . . . . . . . . . . . 58.1 mtm-85 -56.67 -17.32 8.39 Favored 'General case' 0 C--N 1.328 -0.359 0 N-CA-C 112.324 0.49 . . . . 0.0 112.324 -179.465 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ASN . . . . . 0.507 ' O ' HG23 ' A' ' 41' ' ' THR . 0.1 OUTLIER -134.39 9.5 3.72 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 112.676 0.621 . . . . 0.0 112.676 -179.764 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' THR . . . . . 0.507 HG23 ' O ' ' A' ' 40' ' ' ASN . 19.8 p -158.42 155.01 27.83 Favored 'General case' 0 CA--C 1.521 -0.17 0 CA-C-O 121.358 0.599 . . . . 0.0 112.2 179.278 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.728 HD11 ' CE2' ' A' ' 61' ' ' PHE . 12.8 mt -111.66 132.66 54.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.499 178.758 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ARG . . . . . 0.844 ' C ' HG12 ' A' ' 35' ' ' VAL . 9.0 ttt85 -110.14 125.69 53.28 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 178.979 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' ILE . . . . . 1.088 HG23 ' O ' ' A' ' 33' ' ' ARG . 59.8 mt -112.76 119.13 59.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 N-CA-C 114.629 1.344 . . . . 0.0 114.629 -175.871 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' GLU . . . . . 0.873 ' OE1' HG23 ' A' ' 35' ' ' VAL . 79.3 tt0 -131.06 141.25 50.17 Favored 'General case' 0 C--O 1.256 1.431 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 175.435 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.601 ' HB3' ' HB2' ' A' ' 33' ' ' ARG . 6.2 ptp -118.97 135.35 54.65 Favored 'General case' 0 C--O 1.24 0.592 0 O-C-N 125.108 1.505 . . . . 0.0 110.31 179.058 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -42.03 -26.69 0.1 Allowed 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.583 -0.735 . . . . 0.0 112.54 -178.729 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 24.9 m-20 -58.82 -14.92 10.15 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.929 0.395 . . . . 0.0 110.403 178.993 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 98.77 17.21 28.84 Favored Glycine 0 N--CA 1.449 -0.48 0 CA-C-N 115.988 -0.551 . . . . 0.0 111.938 -179.686 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' ARG . . . . . 0.52 ' HB2' ' CG ' ' A' ' 46' ' ' MET . 79.4 mtp180 -105.64 125.92 51.55 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.87 0.367 . . . . 0.0 111.619 -179.883 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -119.52 145.37 46.39 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.939 179.823 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ILE . . . . . 0.419 HG23 ' HB ' ' A' ' 44' ' ' ILE . 8.7 tp -159.25 148.9 7.27 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.731 179.968 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 8.8 t -98.72 154.2 18.15 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.781 0.324 . . . . 0.0 111.646 -179.535 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' VAL . . . . . 0.745 HG21 HD12 ' A' ' 44' ' ' ILE . 47.4 t -148.36 129.68 7.21 Favored Pre-proline 0 CA--C 1.535 0.394 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.177 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.756 ' HD2' HD12 ' A' ' 27' ' ' ILE . 27.4 Cg_exo -63.75 126.29 17.15 Favored 'Trans proline' 0 C--N 1.349 0.567 0 C-N-CA 122.955 2.437 . . . . 0.0 113.312 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' LYS . . . . . 0.687 ' HB3' ' HG ' ' A' ' 42' ' ' LEU . 0.0 OUTLIER -101.11 -1.65 33.51 Favored 'General case' 0 CA--C 1.532 0.285 0 CA-C-N 115.926 -0.579 . . . . 0.0 112.208 -179.93 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . 0.485 ' O ' HG21 ' A' ' 79' ' ' VAL . . . -47.96 -48.09 25.18 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 120.593 -0.813 . . . . 0.0 113.646 -177.547 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' ILE . . . . . 0.849 ' HA ' ' HA ' ' A' ' 76' ' ' ARG . 2.1 pp -148.36 60.76 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.398 0 CA-C-O 121.287 0.565 . . . . 0.0 109.954 179.859 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . 0.672 ' O ' ' HA3' ' A' ' 75' ' ' GLY . . . -131.21 111.9 12.33 Favored 'General case' 0 C--N 1.327 -0.398 0 N-CA-C 114.004 1.112 . . . . 0.0 114.004 -178.064 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.949 HG12 ' HB3' ' A' ' 21' ' ' ARG . 8.2 p -71.31 121.84 22.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 N-CA-C 109.676 -0.491 . . . . 0.0 109.676 177.801 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . 0.728 ' CE2' HD11 ' A' ' 42' ' ' LEU . 6.0 p90 -141.68 145.62 35.13 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 121.136 0.494 . . . . 0.0 111.926 -178.826 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' HIS . . . . . 0.73 ' HB3' HD21 ' A' ' 70' ' ' LEU . 55.7 m-70 -114.42 133.53 55.66 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.603 -179.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -101.7 116.66 33.24 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.859 0.361 . . . . 0.0 111.497 -179.883 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.676 ' HD3' HD23 ' A' ' 70' ' ' LEU . 22.6 mmt85 -84.85 136.33 33.7 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.747 179.256 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' THR . . . . . 0.493 HG22 ' H ' ' A' ' 67' ' ' GLN . 86.5 m -115.34 125.72 28.55 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.622 179.804 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -41.68 -28.41 0.67 Allowed 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 123.174 2.583 . . . . 0.0 113.272 -179.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' GLN . . . . . 0.493 ' H ' HG22 ' A' ' 65' ' ' THR . 4.1 tp-100 -60.36 -17.21 41.91 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.765 0.317 . . . . 0.0 110.756 179.963 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 103.1 28.2 6.25 Favored Glycine 0 N--CA 1.448 -0.552 0 C-N-CA 120.996 -0.621 . . . . 0.0 112.116 179.918 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' GLU . . . . . 0.416 ' CG ' ' HB ' ' A' ' 65' ' ' THR . 16.7 pt-20 -126.65 156.09 41.55 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.761 0.315 . . . . 0.0 111.031 179.848 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' LEU . . . . . 0.73 HD21 ' HB3' ' A' ' 62' ' ' HIS . 2.7 tm? -125.45 125.88 44.04 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.014 0.435 . . . . 0.0 111.254 -179.926 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.624 HG12 HD11 ' A' ' 73' ' ' ILE . 43.6 t -101.02 144.71 12.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.699 -0.682 . . . . 0.0 110.176 179.477 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.763 ' C ' HD12 ' A' ' 73' ' ' ILE . 0.7 OUTLIER -120.4 132.25 55.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.981 0.42 . . . . 0.0 111.52 -179.536 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.763 HD12 ' C ' ' A' ' 72' ' ' GLU . 2.8 mp -139.43 107.36 3.08 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.85 -0.614 . . . . 0.0 110.058 179.533 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ASP . . . . . 0.791 ' HB2' HD13 ' A' ' 78' ' ' LEU . 57.4 m-20 -69.11 99.74 1.16 Allowed 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.178 0.513 . . . . 0.0 111.754 -179.112 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' GLY . . . . . 0.672 ' HA3' ' O ' ' A' ' 59' ' ' ALA . . . -54.65 -11.51 2.82 Favored Glycine 0 C--O 1.227 -0.299 0 CA-C-N 115.483 -0.781 . . . . 0.0 113.219 178.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' ARG . . . . . 0.849 ' HA ' ' HA ' ' A' ' 58' ' ' ILE . 75.7 mtp180 -78.81 -64.33 1.21 Allowed 'General case' 0 N--CA 1.455 -0.184 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 -177.815 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' ALA . . . . . . . . . . . . . . . -100.85 0.31 38.34 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 114.156 1.169 . . . . 0.0 114.156 -177.403 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' LEU . . . . . 0.791 HD13 ' HB2' ' A' ' 74' ' ' ASP . 7.1 mp -97.8 3.76 49.91 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 112.57 0.581 . . . . 0.0 112.57 -179.47 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.485 HG21 ' O ' ' A' ' 57' ' ' GLY . 41.0 t -76.01 110.37 11.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 C-N-CA 120.822 -0.351 . . . . 0.0 110.93 179.544 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' ALA . . . . . . . . . . . . . . . -102.11 110.42 22.38 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.036 179.898 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' ARG . . . . . 0.422 ' CB ' ' HB2' ' A' ' 84' ' ' GLU . 99.2 mtt180 -85.72 152.88 57.59 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.06 -179.77 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -81.23 -92.78 0.0 OUTLIER 'Trans proline' 0 C--N 1.346 0.436 0 C-N-CA 122.667 2.245 . . . . 0.0 113.346 -179.513 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -50.81 -25.64 4.71 Favored 'General case' 0 C--N 1.332 -0.194 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.224 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' GLU . . . . . 0.422 ' HB2' ' CB ' ' A' ' 81' ' ' ARG . 8.6 mp0 -74.09 -16.63 61.02 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.121 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' ARG . . . . . . . . . . . . . 84.0 mtm180 62.45 171.15 0.13 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.979 179.864 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 49.2 mm . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.862 -179.974 . . . . . . . . 0 0 . 1 stop_ save_